"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's",47,"Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ms. Keri Mattox. You may begin."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",227,"Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceuticals. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at www.endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would like to turn the call over to Rajiv."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. Let me now turn to our fourth quarter and f",1399,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. 
Let me now turn to our fourth quarter and full year 2015 earnings presentation. On Slide 2, you will see our agenda for today's call. We will start with an overview of Endo's consummation in 2015 and we'll move to review the highlights of our fourth quarter and full year 2015 financial results, walking through our U.S. Branded, U.S. Generics and international businesses. We will then turn to our full year 2016 outlook and financial guidance. After our prepared remarks, we look forward to taking your questions. 
Moving on to Slide 4. 2015 was a year of transformative growth for Endo as we work towards our goal of improving lives while creating value. We made significant progress in our U.S. Branded pharmaceuticals business segment, completing the acquisition of Auxilium and revitalizing our product portfolio and R&D pipeline. We also secured FDA approval for BELBUCA and extended our Voltaren gel licensing agreement. In addition, we received a favorable IP rolling for OPANA ER and are continuing to advance that product with the recently submitted data package to the FDA that we feel could support an abused [indiscernible] formulation label expansion. The FDA has accepted the submission and set an action date of July 29, 2016. Collectively, these efforts and our continued execution across our full branded portfolio of products resulted in full year 4% underlying revenue growth for 2015.
Next, 2015 was a year of transformation and achieving critical mass for our U.S. Generics business. In September, we acquired Par Pharmaceuticals, expanding our portfolio with higher barrier to entry and alternative dosage products, tripling our R&D pipeline and creating a path for U.S. Generics company. After beginning full-scale integration in the fall, we've continued to optimize our generics business operations and product portfolio, ultimately driving 11% underlying revenue growth in 2015 in this segment. Our international segment was also rebased in 2015, positioning our emerging-market businesses strongly for growth in 2016 and beyond. For example, in our Litha business, we focused on [indiscernible] pharmaceuticals, acquiring a product at R&D portfolio from Aspen and divesting non-core aspects like devices and vaccines. Overall, we drove 6% underlying revenue growth in our international segment in 2015.
Finally, we continue to evolve in those corporate structure and strategy. We diversified our AMS business to further sharpen our focus on specialty pharmaceuticals. We continue to build out and enhance our R&D infrastructure. We generated strong underlying cash flow from operations in line with expectations. In short, we have established a platform that, even if we pursue no additional M&A, positions us for future double-digit underlying growth and expanding margins. 2015 was indeed an important and transformative year in Endo's evolution. 
Moving to Slide 5. You will see that evolution reflected in our solid financial performance in the fourth quarter and full year. Suky will provide more details about our results in just a few minutes. 
Next on Slide 6, let's talk about U.S. Branded pharmaceuticals. In 2015, our rebuilt brand portfolio drove underlying revenue growth in the mid-single digits. Key drivers of the growth included XIAFLEX, which continued to perform in line with our expectations. We have also officially launched BELBUCA and expect that product to be an important growth driver moving forward. The kickoff for this differentiated [indiscernible] 3 product took place at our national sales meeting earlier this month, and I can personally attest to the excitement and enthusiasm of our significantly expanded pain field force. All of us at Endo believe that this first and only currently approved buprenorphine bottle film for chronic pain offer an important new treatment option for patients. Also in December, we executed a new agreement to extend our commercialization for the market-leading Voltaren Gel through 2023 and secured rights to any future Authorized Generic for that product. 
Moving on to Slide 7 that's look at a snapshot of all XIAFLEX performed for the year. Well XIAFLEX U.S. revenues represented approximately 12% of our branded full year reported revenues and only 5% of overall Endo full year reported revenues, the product continues to be a very attractive growth opportunity and we are excited about the potential in its currently approved indications as well as in the R&D pipeline. Overall, XIAFLEX for Peyronie's Disease saw a strong 72% full year demand growth with vials [indiscernible] nearly 30,000 in 2015. We continue to expand our position base and are increasing our efforts to broaden clinical events. We believe that PD patient base can also expand. Our broad DPC campaigns including a comprehensive awareness program, which leverage spokesperson, Dr. Jerry [indiscernible] a long-time ESPN commentator and MD are formally kicking off next week. IN Dupuytren's contracture, we saw steady 12% full year demand growth in 2015, which is especially encouraging given that we are 5 years post launch. Our continuing efforts in this indication are focused on expanding the physician user base, educating patients about effective and nonsurgical option and with a multicore-enabled expansion building the average number of vials per patient over time.
Next let's talk about our U.S. Generics business on Slide 8. Overall, we were able to drive an underlying growth rate in the double digit for the full year despite increasing pricing pressures across the sector. We are very pleased with the strong contribution provided by the legacy Par business in the fourth quarter, which exceeded our international -- our internal expectations. The legacy Qualitest businesses, while diversified and historically insulated from the challenging pricing environment, did experience some volume loss and pricing pressure in the fourth quarter due to increased competition in multiplayer categories. While we have seen volume declines in some areas of this business, it is important to note that 80% of Qualitest's extended unit loss in the full year 2015 versus prior year was driven by only a handful of products that correspond to approximately 20% of Qualitest reported net sales in 2014. 
The fourth quarter also saw a more mild cold flu season that we believe contributed to lower-than-expected overall generic sales performance. As you will note, actual full year underlying generics growth was lower than prelminary estimates shared earlier this year. This was due to fourth quarter actual sales of our legacy Qualitest portfolio. Versus our preliminary expectations, the shortfall was driven by a number of nonrecurring net charges that were recorded as part of our year-end processes. While these types of customary charges -- while these types of charges are customary in any given quarter, we did see a higher level in the fourth quarter of 2015. Also, the shortfall was driven by a combination of higher-than-anticipated rebates and chargebacks that came through on fourth quarter sales identified during our year-end closed processes in January and February. These shortfalls were offset by better-than-expected results in our branded business bringing the total company performance in line with our 2015 preliminary expectations, once again highlighting the value of our diversified revenue mix. We will talk more about expectations for the generics pricing climate in 2016 and beyond when we discuss our full year guidance later in this call.
Next on Slide 9, you will see that 2015 was a year of rebasing for growth and increasing profitability for our International Pharmaceutical segment. Now that continues to be a steady high-margin contributor with recent launches providing potential upside for the business over time. In the fourth quarter, the impact of these launches were offset by the loss of exclusivity on select products, leading to some modest noncash impairments. Our [indiscernible] business continues to grow, driven by products across this broad portfolio. It was also a year of transformation for Litha with the Aspen portfolio acquisition and the divestiture of noncore product lines, which closed earlier this month. That business is now more sharply and strategically focused on higher-growth and higher-margin pharmaceutical products. I should note that similar to what we've seen across the sector and broader markets, a stronger U.S. dollar did impact our reported performance for the quarter and full year. 
On Slide 10, you will see our reported segment revenues continued to grow in 2015. 
Now for a more comprehensive look at our financial results, let me turn the call over to Suky. Suky?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increase",1218,"Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increased revenues, adjusted margins growing faster than revenue, progress on our tax planning strategies and adjusted earnings per share growth. 
Moving to Slide 12, let's take a more detailed look at our underlying cash flow from operations in 2015, which remained strong throughout the year. We view this as a quality measure of our overall results and our ability to deliver a long-term shareholder value. What you will see on this slide is that our 2015 reported cash flow from operations was impacted by a number of noncore cash outlays that are centered around product liabilities and nonrecurring costs related to M&A transaction completed in 2015. If you to neutralize these items, cash flow from operations have a high correlation to adjusted net income. We expect this profile to continue into 2016. As a note, you will see -- also see more information on our cash conversion cycle related to working capital in the appendix of today's slide presentation.
Next on Slide 13, we'd like to provide you more background around the mesh product liability accrual in the fourth quarter and how that is projected to impact future financial results. The environment around mesh product liability has evolved rapidly with an influx of claims having been presented to the company in late 2015. We believe these additional claims are primarily the result of increased advertising by plaintiff's attorneys, a lack of meaningful settlements by other mesh manufacturers and higher value verdicts awarded against other manufacturers. That said, we've taken the approach to strategically settle higher-value and quality case inventories with key plaintiff lawyer in certain individual cases. Also we plan to shift our strategy to vigorously defend and, if appropriate, litigate remaining cases and seek relief from the federal court in the ongoing mesh multidistrict litigation. I note that our approval is based on claims that are settled or are considered improbable and [indiscernible]. We currently are aware of approximately 8,000 purported claims that have not been accrued for, because based on the analysis by the company and outside legal counsel, we believe this portfolio could be of lower value and lower quality as almost all of the claims are lacking medical records and/Or basic demographic information. We've also recently become aware of what we believe may be fraudulent or other wrongful activities relating to the generation of certain mesh claims. While we do not yet know the scope of such activities we plan to fully investigate them and, if appropriate, will vigorously pursue all available remedies against each responsible party and cooperate with law enforcement authorities, other mesh manufacturers and the court.
Importantly, we have seen a rate of purported cases decrease substantially in the early part of 2016 as we continue to make progress in narrowing the mesh liability tale. We are also reducing the potential for product liability related to future mesh implants through our decision to shut down our [indiscernible] Women's Health business, which we announced earlier today. 
Now turning to the accrual. Our pretax product liability accruals as of the end of the third quarter was approximately $1.4 billion. In the fourth quarter, about $150 million was paid out in Qualified Settlement Funds or QSFs. During the fourth quarter of 2015, we recorded an $834 million pretax charge to increase the estimated product liability accrual for mesh cases. Reflected in this increase as a conservative measure based on the lack of any meaningful reduction factor observed today, we have removed the reduction or kickout factor resulting in a $401 million impact. The total increase also reflects a $433 million impact primarily related to the execution of additional mesh or settlement agreements in 2016. It is important to note that we believe these recently settled cases represent a higher value and quality portfolio cases with a higher mix of explant surgeries or revisions and are not representative of overall settlement per case averages. At the end of the fourth quarter 2015, the amount funded in the QSF was $579 million. This brings us to a total remaining mesh liability, pretax cash call of approximately $1.5 billion. Our total remaining mesh liability post-tax cash call based on the current accrual is projected to be approximately $575 million through 2017 with about $150 million to $250 million paid in 2016 and approximately $325 million to $425 million paid in 2017. The overall pretax cash call is mitigated by an expected tax rate refund of approximately $700 million that is expected in the first half of 2016. With these post-tax cash call projections and a robust underlying cash generation, we have the confidence that we can continue to delever into the 3 to 4x range in the second half of 2016 and expect further delevering into 2017. 
Next, on Slide 14, let's talk briefly about the announcement we made this morning regarding ASTORA Women's Health business. As you know, we successfully divested the AMS Men's Health business and launched a strategic sale process for AMS Women's Health, now ASTORA Women's Health, in 2015. That process did result in formal base for ASTORA. However, Endo has now determined that the best strategy is to wind down ASTORA business operations. This decision was a difficult one as it impacts our dedicated employees, the physician community and, importantly, the patients for whom ASTORA products are important treatment options. Key factors that drove our decision include the evolving product liability landscape around vaginal mesh has been challenging and continues to evolve for all manufacturers including ASTORA. And second by shutting down the business as opposed to selling it, we're able to reduce the potential for product liability related to future mesh implants, which would not have been achievable in the event of a sale of the ASTORA business. So we will now work to support physician transition plans to alternate products. We expect to cease business operations for ASTORA by March 31, 2016. On other balance sheet matters, as noted in our press release, we took noncash impairment charges totaling approximately $140 million in the quarter. These charges are on a total goodwill and intangible balance of $15 billion as of December 31, 2015. The majority or about $86 million of the charges were related to Paladin and is driven by the loss of exclusivity of certain products. As we noted at Q3, we finalized our goodwill testing in Q4 and guided that there could be modest changes to impairments in the fourth quarter.
I would like to emphasize that 2015 was another year of transformation for Endo and one that positions us for future growth and profitability. Specifically, it was a year where we further diversified and expanded our revenue base. We delivered solid underlying growth in a challenging market. We expanded margins, improved our underlying after-tax cash flow conversion, we built a strong branded and generics product pipeline, we improved our operating model and execution and made continued progress on narrowing the tale of the company's mesh-related product liability. 
Now let me turn the call back over to Rajiv to discuss our key priorities and growth drivers for 2016. Rajiv?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which ha",1349,"Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which has been so supportive of ASTORA and its products. 
Now moving to Slide 16. As we enter 2016, we have set out a number of strategic and operational priorities. First, we are focused on value creation including a strong commercial launch of BELBUCA, continued growth of XIAFLEX in DC and PD and the seamless integration and continued growth for our generics business. Second, we are executing using our differentiated operating model. We are advancing our derisked R&D pipeline and moving key XIAFLEX programs into clinical trials this year, and we are continuing [indiscernible] R&D pipeline momentum and productivity. Third, Endo is achieving sustainable growth. As Suky mentioned, we expect to delever back down to the 3 to 4x net debt to adjusted EBITDA range this year. And in our continuing efforts to diversify our revenue base, we expect to drive underlying growth in our emerging markets with our rebase [indiscernible] and Litha businesses. 
Next on Slide 17, we are very pleased to have launched BELBUCA last week. We believe BELBUCA is well differentiated as it combines Schedule 3 status, proven efficacy and established safety and tolerability profile  of buprenorphine with a novel delivery system that adds convenience and flexibility for patients. To support our accounts into the nearly $5 billion, long-acting opioid market, we've more than doubled our pain field force and have been working to ensure broad patient access. We believe BELBUCA is strongly positioned for growth and are projecting sales to be greater than $250 million in 2019, which, while significant, represents only a small proportion of the existing current market. 
Turning to Slide 18. You will see the scope and size of the chronic pain burden that we are looking to address with BELBUCA. More than 30% of all Americans or about 100 million people are suffering from chronic pain. This is more than diabetes, coronary heart disease and cancer combined. 
On Slide 19, let's discuss where we are positioning BELBUCA within the chronic pain treatment paradigm. We see a prime opportunity for BELBUCA to serve those patients who are transitioning from short-acting opioids to a long-acting opioid treatment. We also see potential for BELBUCA and its differentiated product profile to make an impact by capturing patient searching from other long-acting opioids or pursue a opiod-na√Øve and are going directly to a long-acting opioid product. In short, we believe the opportunity for BELBUCA is exciting and significant, and our early feedback from customers under launch has been very positive. 
Next on Slide 20, let's talk about our progress with XIAFLEX. XIAFLEX continues to perform in line with our internal growth expectations. We continue to aspire to be a $1 billion franchise around this molecule. We are projecting continued momentum into 2016 and double-digit growth for this product over our planning horizon. This growth will be fueled in part by our multipronged sales and marketing campaigns designed to increase physician and patient awareness. In terms of the R&D pipeline, XIAFLEX continues to exceed our internal and initial expectations and are continuing to move new programs into the clinic this year. 
Next on Slide 21, you will see the considerable market expansion opportunity for XIAFLEX. While it was launched more than 5 years ago and has seen steady growth and increasing traction over time, we believe there's a significant opportunity for us to grow market share for XIAFLEX for Dupuytren's contracture using our DPC campaigns and to continue building traction for the multi- [indiscernible] indication. in Peyronie's disease, we are seeking to expand the market through an unbranded disease awareness campaign. While a large number of diagnosed patients are currently untreated, XIAFLEX is showing very strong penetration amongst those patients that are treated. We believe that by continuing to capture those patient treatments and expanding the base of patients seeking a treatment option, we can continue the robust double-digit growth in this indication.
In summary, across our branded business in 2016, we expect to drive growth with BELBUCA, XIAFLEX and other products including our long-acting TRT portfolio with some offset by continued erosion in our legacy products. As a result, we project low single-digit underlying growth for this business. 
Moving to Slide 22. Our focus on value creation also includes our U.S. Generics business. This 2015 and 2016 breakout of our pro forma generics revenue illustrates key segments of our Par business as well as how those segments are growing. Most importantly, the segments that are growing substantially are also those that represent our highest value products. In fact, we project that in 2016, more than 40% of our generics revenues will come from revenues in our highest value and highest growth categories. First, new launches and alternative dosages will be a key growth driver this year as it includes the introduction of first-to-file products like the generic versions of Zetia and [indiscernible] XR, which we expect to bring to market at the end of 2016. This category also includes differentiated higher barrier to entry and higher-margin products like patches, powders, ophthalmics and other alternative dosages. 
Next sterile injectables have tripled in net sales since Par acquired JHP in 2014, and these products have high barriers to entry, high margins and strong competitive positioning and growth potential. We project significant continued double-digit growth with gross margins well above the company average for this segment in 2016. In summary, across our generics business in 2016, we project underlying growth in the mid to high teens. 
Moving to Slide 23. You will see that the effect of our collective efforts and our acquisition of Par in 2015 are not only increasing the size of our portfolio and generics pipeline but also growing revenue and improving our gross margins. We expect to meaningfully continue this expansion into 2016 and beyond.
Next on Slide 24, let's talk about our differentiated operating model, specifically, our derisked XIAFLEX R&D pipeline. As I mentioned earlier, we anticipate that we will initiate new clinical programs in this year. Beyond that, we see a broad range of potential aesthetic and therapeutic indications with significant unmet needs with large patients populations and market potential that we believe will drive the long-term value of XIAFLEX. 
Moving to Slide 25. Let me take a moment to provide you with an overview of our recently initiated Phase IIb clinical trial in cellulite. Cellulite affects nearly all women and there is little evidence that current treatments are an effective. 
Moving to Slide 26. Our differentiated operating model and derisked R&D approach also drives our generics activities. Par brought with its own industry strongest Paragraph IV first-to-file and first-to-market R&D capabilities. Those capabilities are fueling projected stream of potential high-value, high-margin product launches in 2016 to 2019 time frame. Specifically, we project more than 100 potential product launches over the horizon including 20 first-to-files. 
Next on Slide 27. Let's talk about our emerging market international business as another driver for sustainable growth. Overall, we expect our international business segments including Paladin in the more established Canadian markets will demonstrate a high single-digit underlying growth rate in 2016 driven by a emerging markets businesses. That said, we believe international reported revenues will decline in 2016 due to a stronger dollar versus 2015, increased generic competition for the Paladin portfolio and divestitures of low margin device and vaccine products from the [indiscernible] portfolio. However, importantly, we expect that our 2016 operating income from this business segment will be line with 2015 due to our successful rebasing of our emerging markets businesses.
You will see here the expected impact of this rebasing on [indiscernible] and Litha revenues and operating margins in 2016. We expect a significantly improved margin profile in international segments and low double-digit underlying growth across SOMAR and Litha this year. 
With that, let me turn the call back over to Suky to talk about our full financial guidance for 2016. Suky?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products i",648,"Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products including Voltaren Gel, LIDODERM AG, FROVA, Valganciclovir and low-dose hydrocodone APAP. Second, while our diversified portfolio insulated us for most of 2015, as Rajiv mentioned, we do expect pricing headwinds in U.S. Generics to continue across the sector and for there to be a more challenging pricing environment for commoditized products. And third, we assume current exchange rates for foreign currency conversions. 
So on Slide 30, you will see the highlights of our full year 2016 financial guidance are as follows. We expect total net revenues to be in the range of $4.32 billion to $4.52 billion. We project adjusted gross margins of 63% to 65% this year which is in line with 2015 despite a higher mix of generics revenue in 2016. This is primarily driven by the continued growth of XIAFLEX, the launch of BELBUCA and our continued shift towards high-value products in our generics business. Each of our segments is expected to maintain or improve their gross margin profile in 2016 versus 2015. Despite increases in branded promotional spending across XIAFLEX and BELBUCA and higher R&D expenses to support the branded and generics pipeline, total expenses are growing below the rate of sales as we leverage G&A and capture the full synergies for the Par transaction. This translates into a projected adjusted operating expense to revenue ratio of 19.5% to 20%, which is more than 150 basis point improvement versus 2015. Under these assumptions, we expect adjusted EBITDA margins in the mid-40s, which is better than our 2015 EBITDA margin profile. Adjusted interest expense is expected to be approximately $455 million. This estimate includes approximately $34 million of the amortization of deferred financing fees in 2016 and also assumes debt paydown of about $500 million in 2016 versus ending gross debt balances in 2015. 
Given our continued progress on building out our infrastructure in Dublin, leveraging deal attributes and executing on our tax strategy, as observed through 2015, we expect an adjusted effective tax rate of 9% to 11% for the full year 2016. These moving parts translate to an adjusted diluted earnings per share range of $5.85 to $6.20 with approximately 224 million weighted average diluted shares outstanding. 
As expected, our results will be lumpy through the year, driven by a number of factors including the early investment and corresponding ramp of BELBUCA, the timing of potential market events around key products in the branded and generics portfolio that Rajiv mentioned earlier, the cyclical nature of some of our businesses including fluctuations and stocking levels and the anticipated launch of our generic versions of Seroquel XR and Zetia in the fourth quarter of 2016. 
Using the midpoint of our revenue and EPS ranges, we expect about 54% of revenues and about 57% of EPS to be in the second half of 2016. This weighting is heavily influenced with the expected timing of the Zetia and SEROQUEL launches. Again, using the midpoint of our revenue and EPS ranges, we expect about 22% of revenues and 18% of EPS to be in the first quarter of 2016. This is driven by normal cyclical trends and destocking the we historically see in the first quarter. Also, investment for BELBUCA in the first quarter more than offset revenues for that product as we will book revenues based on demand until we see a normalized pattern of shipments versus demand trends. 
So in summary, we believe that 2016 financial profile will be a continuation of 2015, which was marked by solid underlying revenue growth, margin expansion, an attractive tax rate and strong underlying cash flow conversion. 
Now to close out the call, let me turn the call back over to Rajiv. Rajiv?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified",196,"Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified and strongly positioned businesses. Our focus is on value creation, which we plan to drive through our priorities including a strong commercial launch of BELBUCA, continued growth of XIAFLEX and continued growth for the Par portfolio. We utilize a differentiated operating model that is based on a diversified product portfolio and a strong derisked R&D pipeline across our businesses. And finally, we are achieving sustainable growth with a projected double-digit underlying growth rate, increasing operating margins, strong cash flow conversion and the ability to delever rapidly. 2015 was a year of transformation and continued evolution for Endo. We see 2016 as a year of execution, of delivering on the promise and potential of our business and of creating significant value for our shareholders. We look forward to achieving these goals through your continued support. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd now like to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please.",23,"Thank you, Rajiv. We'd now like to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our first question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Rajiv or maybe this is for Paul, can you just expect that some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite an expectation of greater appro",78,"Rajiv or maybe this is for Paul, can you just expect that some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite an expectation of greater approvals? So can you I guess help us understand the Qualitest impact for 4Q, how is that likely to continue and then what erosion are you expecting for the business for this year?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So, and what I will do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what you're seeing from the consortia and how that's changing our view on pricing in the sec",50,"So, and what I will do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what you're seeing from the consortia and how that's changing our view on pricing in the sector."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So the first thing I would say is into the fourth quarter when we give preliminary results all around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commodi",202,"So the first thing I would say is into the fourth quarter when we give preliminary results all around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commoditized parts of our business. And then as we closed out our final processes for the year, we did recognize higher level of chargebacks and rebate coming through, specifically around our more commoditized portfolio as well as our pain franchise. That in tandem with one-time charges that occurred in the fourth quarter led to a lower-than-expected fourth quarter. I should say that those one-time charges we do not expect to continue in forward-looking quarterly results, but there is some underlying pressure around pricing that will extend in 2016. Having said that, all of that is baked into our forward-looking estimates for 2016. And as Rajiv noted earlier in the scripted remarks, we've seen very strong generics growth in the midteens to high teens, primarily driven by the injectables business, continued growth across the base as well as our launches on the certain products. 
Paul, if you want to add anything more on the price erosion please."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I think that's right. I think Suky really hit the nail in the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortium is really resulted back in Q2 of last year when you saw [indiscernible] and one-stop a",169,"I think that's right. I think Suky really hit the nail in the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortium is really resulted back in Q2 of last year when you saw [indiscernible] and one-stop and in full operation. But I think on a go-forward basis, to Suky's point, we are prepared for it as part of our 2016 forecast. And really when you look at the commodities business, it's going to be very, very challenging to take price decreases like we had historically seen over the past couple of years, but that again is all planned for. Our focus is clearly on our pipeline. It's all on execution. Rajiv touched on it in his opening comments that this year is going to be a year of execution. We've got to get our products out of the FDA. That's our defense. That's our strategy on a go-forward basis. It's our portfolio and getting our products approved."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Can I just confirm that there's no pricing increases built into the 2016 guidance?",15,"Can I just confirm that there's no pricing increases built into the 2016 guidance?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio that we can selectively and very appropriat",62,"So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio that we can selectively and very appropriately increase. But to answer your question on the generic commodities business, it's a volume gain for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Our next question comes from the line of Louise Chen from Guggenheim.",12,"Our next question comes from the line of Louise Chen from Guggenheim."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So first question I had here was on gross margin expansion and operating leverage in '16, how should we think about that in light of your results in the fourth quarter. And then second question is on the generics business, how should we think about the un",57,"So first question I had here was on gross margin expansion and operating leverage in '16, how should we think about that in light of your results in the fourth quarter. And then second question is on the generics business, how should we think about the underlying growth outside of SEROQUEL Zetia and the sales progression quarter-over-quarter?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question.",24,"Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was with a higher mix generics products versus branded. We might see some dilution into our gross margin. As we actually work through our p",281,"Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was with a higher mix generics products versus branded. We might see some dilution into our gross margin. As we actually work through our plan and our portfolio prioritization, we're actually moving to a higher mix of a higher value products, which is ultimately expanding our margins. So as Paul talked about or as Rajiv talked about in his scripted remarks, the growth of the injectable franchise is one that is characterized for the gross margin profile well above the overall company average as we think about the launches of some of our day certain products. Those are also products that have gross margin profiles well ahead of the overall gross margin average. And than when you add in continued growth of XIAFLEX as well as BELBUCA, both of which have gross margin profiles above the company average, you start to form a picture where we're going to see this gross margin expansion into 2016 and one that we're very pleased and confident in. And then from an operating margin perspective, as I said, we're going to spend more against advertising and promoting -- promotion against XIAFLEX and BELBUCA. We are going to spend more this year around R&D for generics and for branded, full stop. However, we are getting operating leverage through G&A as well as through the full realization of the Par synergies sometime in mid-2016. So not only do we get all operating margin expansion -- gross margin expansion, we're going to see operating margin expansion as well and also on top of a very favorable tax rate."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. And just to address your growth question Louise, let me take a crack at it and then Paul will add. While you mentioned in SEROQUEL keep in mind that, that what Par has over the '16 to '19 time frame is 100 possible product launches, right",178,"Thank you, Suky. And just to address your growth question Louise, let me take a crack at it and then Paul will add. While you mentioned in SEROQUEL keep in mind that, that what Par has over the '16 to '19 time frame is 100 possible product launches, right, so certainly [indiscernible] circle standout because of the magnitude. But as we talked about in the past, those are also partner products, right? So as you look at all the entire horizon, you will have many, many more launches, most of which are not partnered where the bottom line equates entirely to Endo, right? So from that standpoint, we do see new launches being the primary driver of growth business in '16 as well as into the future. I would also say that the injectables business has been a great performer for Par. It's tripled in size JHP was acquired by Par and we expect to see the momentum continue in '16 as well as beyond. And I don't know Paul if you'd like to add anything to that."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Sure thanks, Rajiv. I think that's right. I mean when we look at 2016, I mean we all know that Zetia and [indiscernible] are clearly large drivers coming at the end of Q4. And not apologizing for that. Those are hard to develop products, hard to part",268,"Yes. Sure thanks, Rajiv. I think that's right. I mean when we look at 2016, I mean we all know that Zetia and [indiscernible] are clearly large drivers coming at the end of Q4. And not apologizing for that. Those are hard to develop products, hard to partner products and we're very proud of that relationship. That said, we have about 20 products that we should be launching in 2016, albeit maybe not major, major drivers. But in the generic industry, and you never actually know what product can outperform, and some example, when we look at what we achieved in 2015 that are carrying us into 2016, we had a handful of carryover products like [indiscernible] and these are relatively smaller type products that ultimately have limited competition. They're going to carry us into the first part of 2016. Again, hard to make. But from a brand sales standpoint, maybe not at the largest products but good drivers. When we look a little bit at the  [indiscernible] portfolio, we are real proud of what we have in Rochester. I think it's a great time to have sterile facility in U.S. soil. It continues to be a barrier to entry. Products like Vasostrict tests continue to outperform, and that's on the branded site. But additionally, we have a handful of generic products that have had limited competition, products like [indiscernible] and ethacrynic acid. These are all products that have been genericized but limited competition. And again these factored in with some of our overlap and carryover products from last year should give us a good basis for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Liav Abraham with Citi.",10,"And our next question comes from Liav Abraham with Citi."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking? Or do you anticipate any more? And if so, how meaningful could they be? And then secondly related to that, how do yo",59,"Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking? Or do you anticipate any more? And if so, how meaningful could they be? And then secondly related to that, how do you expect this liability to impact your cash flows going forward?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","We have discussed mesh over the course of the last 2 years, and I think as you know, with this mass [indiscernible] litigation situations, it is a very difficult to produce yet. That being said, what I would say is that we have come a long way. And althou",435,"We have discussed mesh over the course of the last 2 years, and I think as you know, with this mass [indiscernible] litigation situations, it is a very difficult to produce yet. That being said, what I would say is that we have come a long way. And although the environment has continued to be more challenging than we have initial settlements, which by the way, I'm glad we did, but the reality is that the rest of industry at that time didn't follow with additional settlements as we would have expected and there was increased advertising, which has kind of led to this additional [indiscernible] of claims in the back end of 2015. Now as we look at what we have done here though, I do feel good that the current settlement that we just announced this morning are ones that are focused on the high-value claims. And effectively, what is left is what we believe to be a much lower value set of portfolio cases, many of them could be serious. And in addition, this is -- there is an evidence of potential fraud amongst some of these cases as well. So as we look at what remains, we do think it is a portfolio we can be a lot more aggressive in terms of how we approach it, either in terms of taking some cases into trial as well as potentially through an investigation fraud seeking to dismiss some incompetence of [indiscernible]. And also keep in mind we have now put a significant time between us and the public health notice that the FDA should in 2011. That again should also be factored that drives to reduce the number of revenue cases. And then finally, our decision to shut down the ASTORA business also will contribute to reducing potential for future liability. So I think as we stand here today, we do feel good about where we've taken the mesh liability despite the additional increment that you saw in 2015. We do expect to resolve the remainder of it over the course of the next couple of years and then there's no guarantee that an accrual may or may not change. But I would say is that we are confident given what we know now about where we have a broader situation. And then fundamentally we're a different company now, right? And so we have on an adjusted basis more than $2.5 billion or roughly around $2.5 billion of adjusted EBITDA, which allows us the ability to manage this over time it makes it a lot more manageable call on our cash."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, and Liav this is Suky. So good morning. So relative to your question on how it impacts cash flow, so as we pointed out in the slides, at the end of fourth quarter, we got a pretax remaining cash call of about $1.5 billion after we make these addition",208,"Yes, and Liav this is Suky. So good morning. So relative to your question on how it impacts cash flow, so as we pointed out in the slides, at the end of fourth quarter, we got a pretax remaining cash call of about $1.5 billion after we make these additional accruals. So again, pretax remaining cash call of $1.5 billion. We expect in 2016 to pay somewhere around $850 million to $900 million of that $1.5 billion on a pretax basis. But after you consider the tax refund that we'll be getting as far part of our restructuring of the AMS sale, our post tax obligation for mesh in 2016 will be somewhere between $150 million to $250 million, so quite manageable in the backdrop of $2 billion plus EBITDA in 2016. As we move to 2017, as we put in the slide, we expect the post-tax cash call there for the residual of that liability that I talked about to be somewhere between 350 and 450, and again that is going to be in the base of EBITDA from 2016 of $2 billion-plus to one that's growing double digits into 2017, so again, very manageable cash call in the backdrop of very robust underlying cash flow generation."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term.",45,"A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. I think the answer to the first question is very simple. It's $359 million of sales of Par in the quarter, and then Suky, do you want to?",29,"Sure. I think the answer to the first question is very simple. It's $359 million of sales of Par in the quarter, and then Suky, do you want to?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, the one thing I'd say that is that $359 million was a little bit better than our expectation primarily driven by the injectables business. We're also seeing good performance in the base business. As Paul talked about a little bit earlier, that should",232,"Yes, the one thing I'd say that is that $359 million was a little bit better than our expectation primarily driven by the injectables business. We're also seeing good performance in the base business. As Paul talked about a little bit earlier, that should carry over into 2016 as well. I will also say as we move forward into '16, Paul is looking at this portfolio as one portfolio, so we will not break out Par versus legacy Qualitest sales. We treat this as one business and that's how we'll report on it. The charges in the fourth quarter were about $30 million that we consider to be one-time and nonrecurring. It's really 3 factors that make this up. Well, there's a number of factors, 3 of which are examples are around trade disputes in the fourth quarter. We have some changes in estimates around gross connects. And third, we have some charges higher-than-expected around the harmonization of our methodologies around gross connects as we integrated Par and Qualitest. Again, we do not expect those to reoccur on a quarterly basis going forward. Your last question, Greg, around the tax rate, again, very pleased where the tax rate is migrating. We expect our effective P&L tax rate in '17 and beyond to be in the low double digits to low teens, but there is, again, continued opportunity to improve that over time."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Annabel Samimy with Stifel.",10,"And our next question comes from Annabel Samimy with Stifel."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just wanted to understand a little bit the underlying growth in generics, and obviously the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the",59,"Just wanted to understand a little bit the underlying growth in generics, and obviously the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the underlying growth of Par right now? And how can we think about that going forward?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Annabel, this is Rajiv, let me start and then Paul will add. I think I don't know if you were a little late in the call, you may have been able to heard about the growth drivers for '16. So there are 2 primary drivers for '16, and frankly, these will be t",224,"Annabel, this is Rajiv, let me start and then Paul will add. I think I don't know if you were a little late in the call, you may have been able to heard about the growth drivers for '16. So there are 2 primary drivers for '16, and frankly, these will be the drivers for Paul as well. One are new launches. So obviously in '16, you have the impact of Zetia the SEROQUEL but just beyond that, there are 100 potential launches that Par has in the time period of '16 through '19. So that is firstly the biggest driver of growth. It's all about volume and launches of those products. And the secretary of growth is the injectables, the sale injectables portfolio, which will be a robust contributor in 2016 as well as beyond. Now outside of that, we have in the combined business approximately 8,000 SKUs, right? Now part of that, Paul will continue to optimize, but among the remainder, there will be certain molecules that do well for us and certain ones that won't, right? So that's the benefit of having a diversified portfolio, but net-net when you put all these 3 factors together, on the back of those launched products and the sterile injectables business, we feel very good about the trajectory in '16 as well as beyond that."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Is there some underlying growth that we can assume for the generics business at this point?",16,"Is there some underlying growth that we can assume for the generics business at this point?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. We've talked about mid to high teens for the generics business for 2016.",14,"Yes. We've talked about mid to high teens for the generics business for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Shibani Malhotra with Nomura Securities.",14,"And our next question comes from the line of Shibani Malhotra with Nomura Securities."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","This is Austin Nelson for Shibane. The first question a couple. In one of the slides, there's a point that the Opana ER [indiscernible] label settlement has been resubmitted to the FDA. Wondering if you could give any color around your expectations on whe",124,"This is Austin Nelson for Shibane. The first question a couple. In one of the slides, there's a point that the Opana ER [indiscernible] label settlement has been resubmitted to the FDA. Wondering if you could give any color around your expectations on when we could hear from the FDA. And then if Endo does receive [indiscernible] labeling, would you explain that the old formulation generics will be removed from the market for safety? And then the other question was on the expectation for net debt-to-EBITDA guidance get back down to the mid-3 to 3 to 4x range, did that include only restricted cash? Or does not include cash that will be accrued for the accrual but not actually paid out in the year?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So let me get the OPANA question and Suky can talk on that question. The Opana ER submission has gone into a monumental effort. This business does not only inclusion of data from our installation study but also a lot of [indiscernible] data. FDA has set a",132,"So let me get the OPANA question and Suky can talk on that question. The Opana ER submission has gone into a monumental effort. This business does not only inclusion of data from our installation study but also a lot of [indiscernible] data. FDA has set an action date of July 29, 2016, for the file. So that is a time frame in which we expect to hear back from them. Now even if we are successful in getting the relabeling, if you could certainly serve to help remove all the generics on the market with the exception of impact that is impact licensed to the product, and therefore, to do so will require a longer path including citizen [indiscernible], which we certainly would undertake but it would not be immediate. Suky?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, good morning, Austin. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is ex",50,"Yes, good morning, Austin. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is excluded from that calculation."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellam with Piper Jaffray.",14,"And our next question comes from the line of David Amsellam with Piper Jaffray."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A couple of questions on generics. So you mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition for that pr",105,"A couple of questions on generics. So you mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition for that product -- that competition down the road? So that's number one. And then on the SEROQUEL and Zetia generics, given these are partnered, can you help give us a sense of how the margins on these will look like during the exclusivity period committed to margins, gross margins for the overall generics business given that you've got shared economics there?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thanks, David. So on the Vasostrict question, so we're not going to break out our guidance on a product line level and now the product revenue for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important product for as in 2",63,"Thanks, David. So on the Vasostrict question, so we're not going to break out our guidance on a product line level and now the product revenue for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important product for as in 2015. So maybe Paul you can comment on your views on possible future of competition for Vasostrict."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So Vasostrict remember is an NDA, so that was filed as 505b2, so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very hard and close with the patent tr",76,"So Vasostrict remember is an NDA, so that was filed as 505b2, so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very hard and close with the patent trade office. Again, but at this point, there are certain things that are unknown. But again, we are looking to protect that product as you would expect from an NDA standpoint."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Zetia and SEROQUEL.",3,"Zetia and SEROQUEL."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","On the Zetia and SEROQUEL question, we have 2 partners, but during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would jus",64,"On the Zetia and SEROQUEL question, we have 2 partners, but during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would just say it's more of a 50-50 like type relationship. Post-day 181, I would say it behaves more like a standard 3-player partnership."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, David just to put a little bit more on what Paul just gave there. So SEROQUEL, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average",50,"Yes, David just to put a little bit more on what Paul just gave there. So SEROQUEL, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average during the exclusivity period."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just two questions here. First on BELBUCA. Can you just talk about the launch expectations? I know you talked about 2019, but just about 2016, what type of ramp should we think about here as we're thinking about the initial modeling? And the second questi",155,"Just two questions here. First on BELBUCA. Can you just talk about the launch expectations? I know you talked about 2019, but just about 2016, what type of ramp should we think about here as we're thinking about the initial modeling? And the second question is a bigger picture one. I guess over the last 18 months, company has done 2 large acquisitions with Auxilium and Par. You pursued probably a third one with [indiscernible]. As I think about the next 12 months and the evolution of the company, is this just a fundamentally different environment from an M&A perspective where we're not going to see big deal that are much less likely? Or do you see what's happening in the market now just a temporary pause or slowdown and, eventually, we're going to see a high level of consolidation that hasn't been playing over the last few years kind of returning to the sector?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure, thanks, Chris. So on BELBUCA, we're very pleased the we are able to launch the product as we have predicted in the month of February. I  was personally at a national sales meeting. We're very excited and expanded the pain field force [indiscernible]",277,"Sure, thanks, Chris. So on BELBUCA, we're very pleased the we are able to launch the product as we have predicted in the month of February. I  was personally at a national sales meeting. We're very excited and expanded the pain field force [indiscernible] feedback product has been very good and all of our managed care conversations are going well, right? That being said, it's early days from a managed care contracting standpoint. It's also early days in terms of the actual launch of the product. And also as we have indicated before, while every [indiscernible] in this product, which is why we put out an aspirational number for 2019 of $250 million, we do expect the ramp to be somewhat gradual in the first 12 months, and that is reflecting unknown. For instance, this is a different format of [indiscernible] patch, which while there are many advantages, patients and physicians need to get used to it. For those patients that are on other LAOs that are being transitioned to BELBUCA that needs to be down titration and up titration, so these things will take time for physicians to get used to. And also, as you well know from a market access standpoint, while commercial covered lives you can contract early in the launch, when it comes to Medicaid Part D coverage, which is roughly about 1/3 of the coverage in this market, and that usually waits for a full cycle. So we certainly would look to 2017 to have a much more substantial ramp than in 2016. But all the early signs are well within our expectations of what we expect to see for the product."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","On your question on M&A, let me answer from an Endo perspective and see if we need further clarification on it. For us as you pointed out, 2015 was a very, very transformational year in terms of transaction. So in particular, we concluded Auxilium, the Pa",449,"On your question on M&A, let me answer from an Endo perspective and see if we need further clarification on it. For us as you pointed out, 2015 was a very, very transformational year in terms of transaction. So in particular, we concluded Auxilium, the Par transaction and at a small level Aspen transaction in South Africa, which essentially gave us new platforms, right, and a sense of critical mass, particularly in our generics business. In many ways, we accomplished what we set out to accomplish, which is to get a set of assets, which even if we do no further M&A gives us a part double-digit growth. And then you couple that with the market environment where the debt markets will be [indiscernible] equity markets. But for as leaving the market conditions aside, 2016 really is about execution, which is why we've talked so much about BELBUCA, about XIAFLEX, the Par integration, those are the things that are going to make us successful. So from that perspective, M&A is not a key priority for us in 2016. I have said in the Par, we said we will continue to monitor opportunities. But really strictly, I think the [indiscernible] opportunities that make sense for us in 2016 will be the small in-licensing or product acquisition here or there either for our branded business or international, but we're talking -- we have a very small call on our cash for doing those types of things and the opportunity come across them. In terms of larger transactions, it is not in the anticipation to look for larger acquisitions in 2016. I have, however, said that even if there are -- if there is a larger merger, which could be value-creating that is done on the basis of a relative value of 2 companies and those are the types of things that we certainly will evaluate if they come our way. But certainly, it is not high on our list of priorities in terms of acquisitions as we look out over '16. Now back to your question about the nature of what's going on in the industry, I would say certainly the debt markets and equity markets have led to somewhat of a pause. But overall, if we look over the last 20, 30 years, this is a still highly fragmented industry. There are lots of -- it's a been a deal-rich industry for a long period of time. Obviously, those deals are cyclical and my suspicion is that deals will continue to be an important part of this industry as we look forward. But 2016 is certainly likely to be -- to see a pause at least from our perspective."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman of UBS.",13,"And our next question comes from the line of Marc Goodman of UBS."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A few things. First, there were a couple of products LIDODERM and Voltaren Gel that seemed to do much better than we wouldn't expect it. Can you talk if there is an inventory build there or what was going on? Second of all you talked about 2017 kind of im",217,"A few things. First, there were a couple of products LIDODERM and Voltaren Gel that seemed to do much better than we wouldn't expect it. Can you talk if there is an inventory build there or what was going on? Second of all you talked about 2017 kind of implying kind of a $7 number, which now with Voltaren Gel back seems a little low number and especially given the way you're talking about tax rate now relative to before I would think that number of $7 is [indiscernible] needs to be brought up. So maybe you could talk about that a little. And third, I'm just trying to understand on the generics business, the pricing that you're talking about. There's one aspect of it, which is the commodity pricing, but then there's the other aspect, which is the pain products, which have been really important for you. And I guess the question is, we heard from other company in the space and they were complaining about new players coming back last year and they were complaining about pricing in that market and they were having some troubles there, and yet Endo was not complaining at all at that time. And now there seems to be a delayed impact. So I'm trying to understand why is that."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So let me get your question in order. With respect to V Gel, it was a really good year last year. We had I think double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I think we've been successful i",468,"Sure. So let me get your question in order. With respect to V Gel, it was a really good year last year. We had I think double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I think we've been successful in holdings some of our contracts through '15 probably better than we had expected on the branded LIDODERM. But as we enter into '16, we do expect to see some drop-off of those contracts that we would never be seen when we see our 2016 results, but it's already factored into our guidance. 2017 Marc, we're not going to comment on 2017. Clearly, we made that commentary against the backdrop of the Par transaction. First of all, I'm delighted to say what we committed to the outside world when we did the Par transaction, which was an accretion number for 2016, that is going out in our guidance as well as the implied multiple that we put out there for the Par transaction, which was 10 to 11x for synergy EBITDA multiple that is also following through in the 2016 numbers. As you said, there are lots of other puts and takes in our business. Certainly, V Gel is one. We are very excited about the extension of the agreement. There's always the possibility and potential of generic on V Gel, which we also have to keep in mind, which it somewhat offset a new agreement with the [indiscernible] that we have the right to [indiscernible] Authorized Generic and a lot of 2017 will also depend on how we're doing on BELBUCA and XIAFLEX. So we are very optimistic as we look at the '16 and beyond time horizon for Endo. That being said, we're not going to provide any specific further guidance on '17. On the generics question, I'll start and I'll bounce it to Paul. I think what I would say is if you separate the commodity -- the traditional commodity products from the pain products, and as you pointed out pain has been a traditional area of strength to us, we have -- we've often taken the approach of focusing on value versus pure volume on the pain business, right? So although we've taken some substantial volume declines in our pain portfolio, they are somewhat anticipated based on the price increases we took and, of course, we've taken. So net-net from a value standpoint, we're actually pleased with how the pain portfolio has performed. But is there a pricing pressure in pain as well as the commodity portfolio? The answer is yes because there are smaller players who tend to be aggressive even in the pain arena now, more so than they have been in the past. I don't know Paul if you have any comments."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. I think that's right. I mean at the end of the day you have product yield. You also have timing issues with consortiums and our contracts with certain trade partners, I think that was part of what we've also saw, right, against seeing the full impact",137,"Yes. I think that's right. I mean at the end of the day you have product yield. You also have timing issues with consortiums and our contracts with certain trade partners, I think that was part of what we've also saw, right, against seeing the full impact of Red Oak really kicking in Q2. So you have the timing -- you've got a timing issue that we were focused on. So to your point, to Rajiv's point, clearly, yes, there are more competitors in the narcotic space, and we're seeing that. But we had our select wins, right, across the board. So to Rajiv's point, select wins, yes, we may have sacrificed certain pricing, sorry, certain volume shortfalls. But ultimately, I think the timing of the consortium is probably the main issue that we saw in 2015."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just first on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking? Or is this a sort of the seasonal nature of the product where it's a little bit stronger in the 4Q coupled with heightened demand? And secondly, as",81,"Just first on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking? Or is this a sort of the seasonal nature of the product where it's a little bit stronger in the 4Q coupled with heightened demand? And secondly, as we think about some of the consumer initiatives to drive awareness of the product in '16 on the SG&A side, when can you expect to start to see that translate on the increased volume side?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel. Now that being said, we have indicated in the third quarter that it was a little bit lower than that, so t",202,"Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel. Now that being said, we have indicated in the third quarter that it was a little bit lower than that, so there's probably a little bit of stocking impact going into the fourth quarter but nothing out of the ordinary. As we pointed out, especially the back end of the fourth quarter tends to be a heavy period because there are many patients who like to [indiscernible] the surgeries during that holiday period, so that is also a contributor. I think as we enter 2016, we are excited about everything, all the changes we put in place both internal as well as some of the new programs that we have put in place like the [indiscernible] program that I referred to in Peyronie's disease, and so many of those are just kicking off. So realistically for them to have a real impact, I think you're looking at probably the third quarter before we can really report back on successes of these programs but early indicators of all of them have been very positive."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit VanjanI with Oppenheimer.",13,"And our next question comes from the line of Rohit VanjanI with Oppenheimer."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones? Secondly on XIAFLEX",95,"I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones? Secondly on XIAFLEX, can you outline the number of shift files in each indication for [indiscernible]? And then going back to the mesh claims, I think you said there were 8,000 mesh claims that hadn't been accrued for. What is the potential value of those 8,000 claims?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the f",148,"Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the facts are very honestly across this portfolio. Most of these cases don't even have medical records. As I pointed out, today, as evidence of fraud at least on some subset but we are investigating vigorously. So as a result, we're not in a position to [indiscernible] sign other than to say we do expect at this point in time patient advise that we are receiving from our outside counsel the value of these cases are lower than the ones that we have to settle there now. And Q4 launches, Paul, do you have any other, the data on that one?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So Q4, the products that we're probably most proud of coming out of Q4 was, again, the [indiscernible] solution product. That is an [indiscernible] product from GSK, also a product called apramipexole [ph] is another product that we executed on with for t",79,"So Q4, the products that we're probably most proud of coming out of Q4 was, again, the [indiscernible] solution product. That is an [indiscernible] product from GSK, also a product called apramipexole [ph] is another product that we executed on with for the fourth quarter. We did indicated that we do have some delays on the [indiscernible] patch. That was a product that we are hoping to get out in Q4, so that product will be delayed into 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had this [indiscernible] under 8,000. And in DC, we had about 8,400 shipped vials.",31,"And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had this [indiscernible] under 8,000. And in DC, we had about 8,400 shipped vials."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with William James Raymond James.",16,"And our next question comes from the line of Elliot Wilbur with William James Raymond James."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","First question for Rajiv. With the launch of BELBUCA and the doubling in the pain sales force and I guess the reoptimization around product promotion last quarter, can you just may be provide us with an update on current field force size configuration and",169,"First question for Rajiv. With the launch of BELBUCA and the doubling in the pain sales force and I guess the reoptimization around product promotion last quarter, can you just may be provide us with an update on current field force size configuration and was doing what in terms of detail allocation just relatively? And then the follow-up to that, with some of these efforts now, you have a collection of small niche branded assets that you really aren't receiving any direct promotion or attention, and clearly, couple of products picked up from Par. So just wondered what your thinking is around this portfolio of products STENDRA, [indiscernible] FORTESTA and [indiscernible] and then what not, whether or not these be in fact candidates for divestiture. And the just a follow-up for Suky, doesn't really sound like there's been changes to your long-term tax rate expectations. Maybe you could just walk us through a couple of things that are impacting 2016 accrual rate versus the expected long-term taxa accrual rate."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me cut to your first question and then Suky can talk about tax. And so in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varyin",308,"Let me cut to your first question and then Suky can talk about tax. And so in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varying sizes as before varying sizes in our branded business, the largest of which is our pain field force, which is size to be competitive with other pain players. And in that field force, we detailed BELBUCA, Opana ER and Voltaren Gel. So those are the 3 products that are detailed. And then on occasion, we do some reminder calls on some of them. In our specialty business, there are 2 field forces. One is focused on urology and that field force carries in the first position as XIAFLEX for Peyronie's disease and also carries our long-acting testosterone replacement therapies, which are [indiscernible] and TESTOPEL. We have a second special field force, which is smaller one, which is focus on XIAFLEX for Dupuytren's contracture and Supprelin LA, which is our product for central precocious puberty. We also have a smaller field force, which we inherited from Par, which I must say we are all very impressed with the early performance. They are focused on selling [indiscernible] , which is a product that came from the Par transaction, but we're also using that field force as a mechanism to provide some initial launch support, additional launch support for BELBUCA over time will take on the promotion of some of these smaller brands. So net-net, at this point, we're very pleased with the promotional mix that we have in our field force. They are even now older and more established products are continuing to be important to us so we are not looking to sell or divest any of them."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, so around the tax rate in 2016 the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue source. So that's why you see a step up from between '15 to '16. Having said that, the low double-digit high-single",183,"Yes, so around the tax rate in 2016 the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue source. So that's why you see a step up from between '15 to '16. Having said that, the low double-digit high-single digit estimate that we have for '16 is well below our initial expectations that we set for '16 when we closed Par, where we said that we thought that the tax rate might be closer to the midteens. So we actually are seeing some progress versus our original expectations. As you think about 2017 moving on, we would characterize that as sort of low teens type of tax rate. The reason why that migrates up a little bit is you continue to drip off deal attributes that were created over the last couple of years, but otherwise, the underlying fundamentals of the tax rate are still very attractive. And as I said, for '17 and beyond, there's still a number of opportunities and strategies that we can deploy it to bring that down over time."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And your next question comes from the line of David Risinger with Morgan Stanley.",14,"And your next question comes from the line of David Risinger with Morgan Stanley."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So I have 2 questions. First, with respect to the Qualitest outlook just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to in the ballpark of what was -- of what the number was in the fourth quarter of '15",117,"So I have 2 questions. First, with respect to the Qualitest outlook just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to in the ballpark of what was -- of what the number was in the fourth quarter of '15? And then turning to Slide 13 in the deck, Suky, I was hoping that you could just take us through the walk-through from the $1.5 billion in the pretax cash call and then the $575 million in the post-tax cash call. I know that you mentioned a $700 million tax refund, but obviously, there's another number in there to bring that figure down to $575 million."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So let me address your first question, which is, first of all, keep in mind that as Suky pointed out, there was nonrecurring impacts in the fourth quarter that impacted Qualitest, but should not see a go forward impact. And secondly back to the comment th",153,"So let me address your first question, which is, first of all, keep in mind that as Suky pointed out, there was nonrecurring impacts in the fourth quarter that impacted Qualitest, but should not see a go forward impact. And secondly back to the comment that Suky me, we are providing guidance for Qualitest distinct from Par. Simply at this point, Paul has a combined portfolio. It's negotiating customer contracts across a combined portfolio. We will make some portfolio optimization decisions as we go into the year in terms of what products you prioritize with customers and that may impact our products, quality of products. And so as a result, we do not expect to provide any guidance for the legacy quarter of this portfolio going forward other than what we already commented on. I would say for the combined business, we expect to see mid to high teens underlying growth for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, and good morning, David. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million, the first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016,",139,"Yes, and good morning, David. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million, the first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016, we expect that to be somewhere around $850 million to $900 million. And then you back out the tax refund of approximately $700 million from that, that's one component. And then in 2017, we expect the pretax cash call to be somewhere between $600 million to $650 million. If you apply a U.S. tax shield against that of approximately 35%, you get down to your post tax cash call somewhere around $400 million. When you put those 2 pieces together, that should get you into the $575 million range."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with North Bend capital markets.",16,"And our next question comes from the line of David Buck with North Bend capital markets."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's your expectation embedded in the guidance for pricing for brands in 2016? And the",88,"For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's your expectation embedded in the guidance for pricing for brands in 2016? And then for Suky, just a quick one, can you talk a little bit about the gap between EBITDA of about $2 billion plus for this year and what we should be thinking about for GAAP cash flow from operations including the mesh liability payments."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thanks, David so on the branded pricing. Our experience in 2015 and 2016 actually are not dramatically different. It's relative to what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price i",183,"Thanks, David so on the branded pricing. Our experience in 2015 and 2016 actually are not dramatically different. It's relative to what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price increases. They typically range from the low single digit -- actually 0 in certain cases to potentially up to 20%, 25%. The high end of that range is typically for our mature products that already have multiple generics on the market. Our portfolio is generally contracted, which means that our price increases are capped. So even if we are taking price increases are higher, that means mid-single-digit, the realized price increases for us in our branded business is somewhere in the low to mid-single digits. So that levels our experience in 2015. Our price increases that we took in our branded portfolio are already public for 2016. And they're in the same range that I just described and we would expect a similar time of lower to mid-single-digit impact on our branded business this year as well. That's all incorporated into our guidance."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. And regarding David, good morning, your question around cash flow for next year, the way to think about is, first of all, we would expect underlying cash flow from operations as we depicted for 2015 to have a very high correlation to adjusted net inc",235,"Yes. And regarding David, good morning, your question around cash flow for next year, the way to think about is, first of all, we would expect underlying cash flow from operations as we depicted for 2015 to have a very high correlation to adjusted net income. But to give you some of the moving parts for next year to help model, if you started with the midpoint of our revenue range and assume the mid-40s EBITDA margin, you get roughly into the $2 billion, $2 plus billion EBITDA range, from there, your movements on cash, you got interest expense, which we've talked about, you've got cash taxes in the mid-single digits on the underlying business. You've got a mesh post tax cash call of about $150 million to $250 million as we've talked about. Working capital on a day sales basis is going to be relatively steady throughout the year. However, because of the fourth quarter launches of Seroquel and Zetia, we do expect there to be a call on cash in the fourth quarter of somewhere between $200 million to $300 million. That will normalize in the first quarter of '17 as that launch pulls through. We have CapEx of about $150 million and contingent consideration of about $150 million. So if you put all those pieces together, that should get you pretty close to where we see our cash flow for the year."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group.",15,"And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Going back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well, and in particular, how you look at the brand s",96,"Going back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well, and in particular, how you look at the brand sales of $379 million for the quarter? Are there any moving parts there to consider [indiscernible] total in there, is that discontinued operations? I'd say quarter-on-quarter, 3Q to 4Q, from the products you give us, that explains about half of the quarter-to-quarter increase. So what other contributors were there on the branded side?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So on the Par number, we're just verifying this, but I believe that number is a generics only number and excludes the brands. And then your second question, Andrew, with respect to...",32,"So on the Par number, we're just verifying this, but I believe that number is a generics only number and excludes the brands. And then your second question, Andrew, with respect to..."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Yes, with respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million, the products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem",82,"Yes, with respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million, the products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem to have stepped up 3Q to 4Q. Some of that is a full quarter of the Par brands. But were there any other factors, products that were -- had a balance in 4Q in brands?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So as you say and [indiscernible] some of the smaller brands so we had success, for example, with [indiscernible] in the fourth quarter as contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a decent fou",97,"Sure. So as you say and [indiscernible] some of the smaller brands so we had success, for example, with [indiscernible] in the fourth quarter as contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a decent fourth quarter. Sumavel was a contributor. So it's a series of the smaller brands. And again, it goes to show the value of our more diversified established and other products, part of our branded business and then many of them do contribute. I mean when you add them all together, it is a material contribution."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","STENDRA was out for 2016.",5,"STENDRA was out for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. STENDRA is out for 2016.",6,"Yes. STENDRA is out for 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes one thing I would add for 2015 fourth quarter in LIDODERM, we did see a benefit one-time benefit of some return adjustments that won't repeat in first quarter of 2016.",31,"Yes one thing I would add for 2015 fourth quarter in LIDODERM, we did see a benefit one-time benefit of some return adjustments that won't repeat in first quarter of 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao with Barclays.",4,"Douglas Tsao with Barclays."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple. Paul, maybe on the delay for Exelon [ph], what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky in terms of the visibility of the mesh liability sort of [indiscernible] sort of the lower quality",86,"Just a couple. Paul, maybe on the delay for Exelon [ph], what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky in terms of the visibility of the mesh liability sort of [indiscernible] sort of the lower quality of some of the [indiscernible] cases just curious in terms of the historical precedent into a some of those, perhaps, moving up into a higher quality sort of claim as things like medical records perhaps become available to you?"
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I would say on the [indiscernible] patch, we're probably looking at late to second half of 2016.",17,"I would say on the [indiscernible] patch, we're probably looking at late to second half of 2016."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","With respect to mesh and Doug, consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken based on advice of outside advisers as well as looking through the po",199,"With respect to mesh and Doug, consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken based on advice of outside advisers as well as looking through the portfolio of plaintiff's attorneys in terms of those are more likely to have [indiscernible] claims and effectively focus on the high value. As we said, as we look at all the remainder, while there is information, there is also other piece of information we have such as the potential fraudulent claims that leads us to believe that these are of lower value, right? And this is consistent with the advice that we've gotten from our outside advisers as well. And we also believe that it is to our benefit and to our advantage to be more aggressive with this remaining portfolio including potentially taking some file if we need to. So our current [indiscernible] I believe based on the factors that we have that we do believe that they are lower value cases, we will deal with them over time and there is no anticipation of any other settlements in the near term."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva.",25,"And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as look for outlook for 2016, we are very pleased with the solid performance that we had in 2015. We believe that th",183,"Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as look for outlook for 2016, we are very pleased with the solid performance that we had in 2015. We believe that the fundamentals of the business as a very strong, strong underlying growth that will sustain ourselves into 2016 into the medium term that we've talked about in the past. We are positioned for growth in 2016. We have some strong growth drivers like XIAFLEX, BELBUCA and our generics portfolio that we continue to put a laserlike focus on. We're progressing the XIAFLEX pipeline, creating some real momentum around that new indication, potential new indications like cellulite. Clearly, our focus this year is on execution and on generating strong underlying free cash flow, which have allowed us to continue to delever despite the incremental accrual that we talked about with respect to mesh liability. With that, I thank you for your time and look forward to joining all of you on our next quarterly call. Thank you."
28071,325746146,943427,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone have a great day."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today",47,"Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to introduce your host for today's conference, Ms. Keri Mattox. You may begin."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",228,"Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceutical. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at www.endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. Let me now turn to our fourth quarter and f",1407,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. 
Let me now turn to our fourth quarter and full year 2015 earnings presentation. On Slide 2, you will see our agenda for today's call. We will start with an overview of Endo's transformation in 2015, and we'll move to review the highlights of our fourth quarter and full year 2015 financial results, walking through our U.S. Branded, U.S. Generics and international businesses. We will then turn to our full year 2016 outlook and financial guidance. After our prepared remarks, we look forward to taking your questions. 
Moving on to Slide 4. 2015 was a year of transformative growth for Endo, as we worked towards our goal of improving lives while creating value. We made significant progress in our U.S. Branded Pharmaceuticals business segment, completing the acquisition of Auxilium and revitalizing our product portfolio and R&D pipeline. We also secured FDA approval for BELBUCA and extended our Voltaren Gel licensing agreement. In addition, we received a favorable IP ruling for OPANA ER and are continuing to advance that product with the recently submitted data package to the FDA that we feel could support an abuse deterrent formulation label expansion. The FDA has accepted that submission and set an action date of July 29, 2016. Collectively, these efforts and our continued execution across our full branded portfolio of products resulted in full year 4% underlying revenue growth for 2015.
Next, 2015 was a year of transformation and achieving critical mass for our U.S. Generics business. In September, we acquired Par Pharmaceutical, expanding our portfolio with higher barrier to entry and alternative dosage products, tripling our R&D pipeline and creating a top 4 U.S. Generics company. After beginning full-scale integration in the fall, we've continued to optimize our generics business operations and product portfolio, ultimately driving 11% underlying revenue growth in 2015 in this segment. Our international segment was also rebased in 2015, positioning our emerging-market businesses strongly for growth in 2016 and beyond. For example, in our Litha business, we focused on core pharmaceuticals, acquiring a product and R&D portfolio from Aspen and divesting noncore assets like devices and vaccines. Overall, we drove 6% underlying revenue growth in our international segment in 2015.
Finally, we continue to evolve in those corporate structure and strategy. We divested our AMS Men's health business to further sharpen our focus on specialty pharmaceuticals. We continue to build out and enhance our Irish infrastructure. We generated strong underlying cash flow from operations, in line with expectations. In short, we have established a platform that, even if we pursue no additional M&A, positions us for future double-digit underlying growth and expanding margins. 2015 was indeed an important and transformative year in Endo's evolution. 
Moving to Slide 5. You will see that evolution reflected in our solid financial performance in the fourth quarter and full year. Suky will provide more details about our results in just a few minutes. 
Next on Slide 6, let's talk about U.S. Branded Pharmaceuticals. In 2015, our rebuilt branded portfolio drove underlying revenue growth in the mid-single digits. Key drivers of that growth included XIAFLEX, which continued to perform in line with our expectations. We have also officially launched BELBUCA and expect that product to be an important growth driver moving forward. The kickoff for this differentiated Schedule III product took place at our national sales meeting earlier this month, and I can personally attest to the excitement and enthusiasm of our significantly expanded pain field force. All of us at Endo believe that this first and only currently approved buprenorphine buccal film for chronic pain does offer an important new treatment option for patients. Also in December, we executed a new agreement to extend our commercialization for the market-leading Voltaren Gel through 2023 and secured rights to any future Authorized Generic for that product. 
Moving on to Slide 7. Let's look at a snapshot of how XIAFLEX performed for the year. While XIAFLEX U.S. revenues represent approximately 12% of our branded full year reported revenues and only 5% of overall Endo full year reported revenues, the product continues to be a very attractive growth opportunity, and we are excited about the potential in its currently approved indications as well as in the R&D pipeline. Overall, XIAFLEX for Peyronie's disease saw a strong 72% full year demand growth with vials totaling nearly 30,000 in 2015. We continue to expand our physician base and are increasing our efforts to broaden clinical awareness. We believe that PD, patient base can also expand. Our broad DTC campaigns, including a comprehensive disease awareness program with celebrity spokesperson, Dr. Jerry Punch, a long-time ESPN commentator and MD, are formally kicking off next week. In Dupuytren's contracture, we saw a steady 12% full year demand growth in 2015, which is especially encouraging given that we are 5 years post launch. Our continuing efforts in this indication are focused on expanding the physician user base, educating patients about an effective nonsurgical option and with the multi-cord label expansion building the average number of vials per patient over time.
Next, let's talk about our U.S. Generics business on Slide 8. Overall, we were able to drive an underlying growth rate in the double digits for the full year despite increasing pricing pressures across the sector. We are very pleased with the strong contribution provided by the legacy Par business in the fourth quarter, which exceeded our international -- our internal expectations. The legacy Qualitest businesses, while diversified and historically insulated from the challenging pricing environment, did experience some volume loss and pricing pressure in the fourth quarter due to increased competition in multi-player categories. While we have seen volume declines in some areas of this business, it is important to note that 80% of Qualitest's extended unit loss in the full year 2015 versus prior year was driven by only a handful of products that correspond to approximately 20% of Qualitest reported net sales in 2014. 
The fourth quarter also saw a more mild cold flu season, that we believe contributed to lower-than-expected overall generic sales performance. As you will note, actual full year underlying generics growth was lower than preliminary estimates shared earlier this year. This was due to fourth quarter actual sales of our legacy Qualitest portfolio. Versus our preliminary expectations, part of the shortfall was driven by a number of nonrecurring net charges that were recorded as part of our year-end processes. While these types of customary charges -- while these types of charges are customary in any given quarter, we did see a higher level in the fourth quarter of 2015. Also the shortfall was driven by a combination of higher-than-anticipated rebates and chargebacks that came through on fourth quarter sales identified during our year-end closed processes in January and February. These shortfalls were offset by better-than-expected results in our branded business bringing the total company performance in line with our 2015 preliminary expectations, once again highlighting the value of our diversified revenue mix. We will talk more about our expectations for the generics pricing climate in 2016 and beyond when we discuss our full year guidance later in this call.
Next on Slide 9, you will see that 2015 was a year of rebasing for growth and increasing profitability for our International Pharmaceutical segment. Paladin continues to be a steady high-margin contributor with recent launches providing potential upside for the business over time. In the fourth quarter, the impact of these launches were offset by the loss of exclusivity on select products, leading to some modest noncash impairments. Our Somar business continues to grow, driven by products across this broad portfolio. It was also a year of transformation for Litha with the Aspen portfolio acquisition and our divestiture of noncore product lines, which closed earlier this month. That business is now more sharply and strategically focused on higher-growth and higher-margin pharmaceutical products. I should note that similar to what we've seen across the sector and broader markets, a stronger U.S. dollar did impact our reported performance for the quarter and full year. 
On Slide 10, you will see our reported segment revenues continued to grow in 2015. 
Now for a more comprehensive look at our financial results, let me turn the call over to Suky. Suky?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by a diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increa",1218,"Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by a diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increased revenues, adjusted margins growing faster than revenue, progress on our tax planning strategies and adjusted earnings per share growth. 
Moving to Slide 12. Let's take a more detailed look at our underlying cash flow from operations in 2015, which remained strong throughout the year. We view this as a quality measure of our overall results and our ability to deliver a long-term shareholder value. What you will see on this slide is that our 2015 reported cash flow from operations was impacted by a number of noncore cash outlays that are centered around product liabilities and nonrecurring costs related to M&A transactions completed in 2015. If you neutralize these items, cash flow from operations have a high correlation to adjusted net income. We expect this profile to continue into 2016. As a note, you will see -- also see more information on our cash conversion cycle related to working capital in the appendix of today's slide presentation.
Next on Slide 13, we would like to provide you more background around the mesh product liability accrual in the fourth quarter and how that is projected to impact future financial results. The environment around mesh product liability has evolved rapidly with an influx of claims having been presented to the company in late 2015. We believe these additional claims are primarily the result of increased advertising by plaintiff's attorneys, a lack of meaningful settlements by other mesh manufacturers and higher value verdicts awarded against other manufacturers. That said, we've taken the approach to strategically settle higher-value and quality case inventories with key plaintiff's lawyers in certain individual cases. Also we plan to shift our strategy to vigorously defend and, if appropriate, litigate remaining cases and seek relief from the federal court in the ongoing mesh multi-district litigation. I note that our accrual is based on claims that are settled or are considered probable an estimate. We currently are aware of approximately 8,000 purported claims that have not been accrued for, because based on the analysis by the company and outside legal counsel, we believe this portfolio could be of lower value and lower quality as almost all of the claims are lacking medical records and/or basic demographic information. We've also recently become aware of what we believe may be fraudulent or other wrongful activities relating to the generation of certain mesh claims. While we do not yet know the scope of such activities, we plan to fully investigate them and, if appropriate, will vigorously pursue all available remedies against each responsible party and cooperate with law enforcement authorities, other mesh manufacturers and the court.
Importantly, we have seen the rate of purported cases decrease substantially in the early part of 2016, as we continue to make progress in narrowing the mesh liability tail. We are also reducing the potential for product liability related to future mesh implants through our decision to shut down our ASTORA Women's Health business, which we announced earlier today. 
Now turning to the accrual. Our pretax product liability accrual as of the end of the third quarter was approximately $1.4 billion. In the fourth quarter, about $150 million was paid out in Qualified Settlement Funds or QSFs. During the fourth quarter of 2015, we recorded an $834 million pretax charge to increase the estimated product liability accrual for mesh cases. Reflected in this increase as a conservative measure based on the lack of any meaningful reduction factor observed to date, we have removed the reduction or kick-out factor, resulting in a $401 million impact. Total increase also reflects a $433 million impact, primarily related to the execution of additional mesh or settlement agreements in 2016. It is important to note that we believe these recently settled cases represent a higher value and quality portfolio cases with a higher mix of explant surgeries or revisions and are not representative of overall settlement per case averages. At the end of the fourth quarter 2015, the amount funded in the QSF was $579 million. This brings us to a total remaining mesh liability, pretax cash call of approximately $1.5 billion. Our total remaining mesh liability post-tax cash call based on the current accrual is projected to be approximately $575 million through 2017 with about $150 million to $250 million paid in 2016 and approximately $325 million to $425 million paid in 2017. The overall pretax cash call is mitigated by an expected tax refund of approximately $700 million that is expected in the first half of 2016. With these post-tax cash call projections and a robust underlying cash generation, we have the confidence that we can continue to delever into the 3 to 4x range in the second half of 2016 and expect further delevering into 2017. 
Next, on Slide 14, let's talk briefly about the announcement we made this morning regarding ASTORA Women's Health business. As you know, we successfully divested the AMS Men's Health business and launched a strategic sale process for AMS Women's Health, now ASTORA Women's Health, in 2015. That process did result in formal base for ASTORA. However, Endo has now determined that the best strategy is to wind down ASTORA business operations. This decision was a difficult one as it impacts our dedicated employees, the physician community and importantly, the patients for whom ASTORA products are important treatment options. Key factors that drove our decision include the evolving product liability landscape around vaginal mesh has been challenging and continues to evolve for all manufacturers, including ASTORA. And second, by shutting down the business as opposed to selling it, we're able to reduce the potential for product liability related to future mesh implants, which would not have been achievable in the event of a sale of the ASTORA business. So we will now work to support physician transition plans to alternate products. We expect to cease business operations for ASTORA by March 31, 2016. On other balance sheet matters, as noted in our press release, we took noncash impairment charges totaling approximately $140 million in the quarter. These charges are on a total goodwill and intangible balance of $15 billion as of December 31, 2015. The majority or about $86 million of the charges were related to Paladin and is driven by the loss of exclusivity of certain products. As we noted at Q3, we finalized our goodwill testing in Q4 and guided that there could be modest changes to impairments in the fourth quarter.
I would like to emphasize that 2015 was another year of transformation for Endo, and one that positions us for future growth and profitability. Specifically, it was a year where we further diversified and expanded our revenue base. We delivered solid underlying growth in a challenging market. We expanded margins, improved our underlying after-tax cash flow conversion, we built a strong branded and generics product pipeline, we improved our operating model and execution and made continued progress on narrowing the tail of the company's mesh-related product liability. 
Now let me turn the call back over to Rajiv to discuss our key priorities and growth drivers for 2016. Rajiv?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which ha",1351,"Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which has been so supportive of ASTORA and its products. 
Now moving to Slide 16. As we enter 2016, we have set out a number of strategic and operational priorities. First, we are focused on value creation, including a strong commercial launch of BELBUCA, continued growth of XIAFLEX in DC and PD and the seamless integration and continued growth for our generics business. Second, we are executing using our differentiated operating model. We are advancing our derisked R&D pipeline and moving key XIAFLEX programs into clinical trials this year, and we are continuing to pause R&D pipeline momentum and productivity. Third, Endo is achieving sustainable growth. As Suky mentioned, we expect to delever back down to the 3 to 4x net debt to adjusted EBITDA range this year. And in our continuing efforts to diversify our revenue base, we expect to drive underlying growth in our emerging markets with our rebased Somar and Litha businesses. 
Next on Slide 17, we are very pleased to have launched BELBUCA last week. We believe BELBUCA is well differentiated as it combines Schedule III status, proven efficacy and established safety and tolerability profile of buprenorphine with a novel delivery system that adds convenience and flexibility for patients. To support our accounts into the nearly $5 billion, long-acting opioid market, we've more than doubled our pain field force and have been working to ensure broad patient access. We believe BELBUCA is strongly positioned for growth and are projecting sales to be greater than $250 million in 2019, which, while significant, represents only a small proportion of the existing current market. 
Turning to Slide 18. You will see the scope and size of the chronic pain burden that we are looking to address with BELBUCA. More than 30% of all Americans or about 100 million people are suffering from chronic pain. This is more than diabetes, coronary heart disease and cancer combined. 
On Slide 19, let's discuss where we are positioning BELBUCA within the chronic pain treatment paradigm. We see a prime opportunity for BELBUCA to serve those patients who are transitioning from short-acting opioids to a long-acting opioid treatment. We also see potential for BELBUCA and its differentiated product profile to make an impact by capturing patient searching from other long-acting opioids or those who are opioid-naive and are going directly to a long-acting opioid product. In short, we believe the opportunity for BELBUCA is exciting and significant, and our early feedback from customers on the launch has been very positive. 
Next on Slide 20, let's talk about our progress with XIAFLEX. XIAFLEX continues to perform in line with our internal growth expectations. We continue to aspire to build a $1 billion franchise around this molecule. We are projecting continued momentum into 2016 and double-digit growth for this product over our planning horizon. This growth will be fueled in part by our multi-pronged sales and marketing campaigns designed to increase physician and patient awareness. In terms of the R&D pipeline, XIAFLEX continues to exceed our internal -- initial expectations and are continuing to move new programs into the clinic this year. 
Next on Slide 21, you will see the considerable market expansion opportunity for XIAFLEX. While it was launched more than 5 years ago and has seen steady growth and increasing traction over time, we believe there's a significant opportunity for us to grow market share for XIAFLEX for Dupuytren's contracture using our DPC campaigns and to continue building traction for the multi-cord indication. In Peyronie's disease, we are seeking to expand the market through an unbranded disease awareness campaign. While a large number of diagnosed patients are currently untreated, XIAFLEX is showing very strong penetration amongst those patients that are treated. We believe that by continuing to capture those patient treatments and expanding the base of patients seeking a treatment option, we can continue the robust double-digit growth in this indication.
In summary, across our branded business in 2016, we expect to drive growth with BELBUCA, XIAFLEX and other products, including our long-acting TRT portfolio with some offset by continued erosion in our legacy products. As a result, we project low single-digit underlying growth for this business. 
Moving to Slide 22. Our focus on value creation also includes our U.S. Generics business. This 2015 and 2016 breakout of our pro forma generics revenue illustrates key segments of our Par business as well as how those segments are growing. Most importantly, the segments that are growing substantially are also those that represent our highest value products. In fact, we project that in 2016, more than 40% of our generics revenues will come from revenues in our highest value and highest growth categories. First, new launches and alternative dosages will be a key growth driver this year as it includes the introduction of first-to-file products like the generic versions of Zetia and Seroquel XR, which we expect to bring to market at the end of 2016. This category also includes differentiated higher barrier to entry and higher-margin products like patches, powders, ophthalmics and other alternative dosages. 
Next, sterile injectables have tripled in net sales since Par acquired JHP in 2014, and these products have high barriers to entry, high margins and strong competitive positioning and growth potential. We project significant continued double-digit growth with gross margins well above the company average for this segment in 2016. In summary, across our generics business in 2016, we project underlying growth in the mid to high teens. 
Moving to Slide 23. You will see that the effect of our collective efforts and our acquisition of Par in 2015 are not only increasing the size of our portfolio and generics pipeline, but also growing revenue and improving our gross margins. We expect to meaningfully continue this expansion into 2016 and beyond.
Next on Slide 24. Let's talk about our differentiated operating model, specifically our derisked XIAFLEX R&D pipeline. As I mentioned earlier, we anticipate that we will initiate new clinical programs this year. Beyond that, we see a broad range of potential aesthetic and therapeutic indications with significant unmet needs with large patient populations and market potentials that we believe will drive the long-term value of XIAFLEX. 
Moving to Slide 25. Let me take a moment to provide you with an overview of our recently initiated Phase IIb clinical trial in Cellulite. Cellulite affects nearly all women and there is little evidence that current treatments are effective. 
Moving to Slide 26. Our differentiated operating model and derisked R&D approach also drives our generics activities. Par brought with its own the industry's strongest Paragraph IV first-to-file and first-to-market R&D capabilities. Those capabilities are fueling a projected stream of potential high-value, high-margin product launches in 2016 to 2019 time frame. Specifically, we project more than 100 potential product launches over that horizon, including 20 first-to-files. 
Next on Slide 27. Let's talk about our emerging market international business as another driver for sustainable growth. Overall, we expect our international business segment, including Paladin in the more established Canadian market will demonstrate a high single-digit underlying growth rate in 2016, driven by emerging markets businesses. That said, we believe international reported revenues will decline in 2016 due to a stronger dollar versus 2015, increased generic competition for the Paladin portfolio and divestitures of low margin device and vaccine products from the Litha portfolio. However, importantly, we expect that our 2016 operating income from this business segment will be in line with 2015 due to our successful rebasing of our emerging markets businesses.
You will see here the expected impact of this rebasing on Somar and Litha revenues and operating margins in 2016. We expect a significantly improved margin profile in international segment and low double-digit underlying growth across Somar and Litha this year. 
With that, let me turn the call back over to Suky to talk about our full financial guidance for 2016. Suky?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products,",651,"Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products, including Voltaren Gel, LIDODERM AG, FROVA, Valganciclovir and low-dose hydrocodone APAP. Second, while our diversified portfolio insulated us for most of 2015, as Rajiv mentioned, we do expect pricing headwinds in U.S. Generics to continue across the sector and for there to be a more challenging pricing environment for commoditized products. And third, we assume current exchange rates for foreign currency conversions. 
So on Slide 30, you will see the highlights of our full year 2016 financial guidance are as follows. We expect total net revenues to be in the range of $4.32 billion to $4.52 billion. We project adjusted gross margins of 63% to 65% this year, which is in line with 2015 despite a higher mix of generics revenue in 2016. This is primarily driven by the continued growth of XIAFLEX, the launch of BELBUCA and our continued shift towards high-value products in our generics business. Each of our segments is expected to maintain or improve their gross margin profile in 2016 versus 2015. Despite increases in branded promotional spending across XIAFLEX and BELBUCA and higher R&D expenses to support the branded and generics pipelines, total expenses are growing below the rate of sales as we leverage G&A and capture the full synergies from the Par transaction. This translates into a projected adjusted operating expense to revenue ratio of 19.5% to 20%, which is more than 150 basis point improvement versus 2015. Under these assumptions, we expect adjusted EBITDA margins in the mid-40s, which is better than our 2015 EBITDA margin profile. Adjusted interest expense is expected to be approximately $455 million. This estimate includes approximately $34 million of amortization of deferred financing fees in 2016 and also assumes debt pay down of about $500 million in 2016 versus ending gross debt balances in 2015. 
Given our continued progress on building out our infrastructure in Dublin, leveraging deal attributes and executing on our tax strategy, as observed through 2015, we expect an adjusted effective tax rate of 9% to 11% for the full year of 2016. These moving parts translate to an adjusted diluted earnings per share range of $5.85 to $6.20 with approximately 224 million weighted average diluted shares outstanding. 
As expected, our results will be lumpy through the year, driven by a number of factors, including the early investment and corresponding ramp of BELBUCA; the timing of potential market events around key products in the branded and generics portfolio that Rajiv mentioned earlier; the cyclical nature of some of our businesses, including fluctuations and stocking levels; and the anticipated launch of our generic versions of Seroquel XR and Zetia in the fourth quarter of 2016. 
Using the midpoint of our revenue and EPS ranges, we expect about 54% of revenues and about 57% of EPS to be in the second half of 2016. This weighting is heavily influenced by the expected timing of the Zetia and SEROQUEL launches. Again, using the midpoint of our revenue and EPS ranges, we expect about 22% of revenues and 18% of EPS to be in the first quarter of 2016. This is driven by normal cyclical trends and destocking that we historically see in the first quarter. Also investment for BELBUCA in the first quarter more than offsets revenues for that product as we will book revenues based on demand until we see a normalized pattern of shipments versus demand trends. 
So in summary, we believe that 2016 financial profile will be a continuation of 2015, which was marked by solid underlying revenue growth, margin expansion and attractive tax rate and strong underlying cash flow conversion. 
Now to close out the call, let me turn it -- the call back over to Rajiv. Rajiv?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified",198,"Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified and strongly positioned businesses. Our focus is on value creation, which we plan to drive through our priorities, including a strong commercial launch of BELBUCA, continued growth for XIAFLEX and continued growth for the Par portfolio. We utilize a differentiated operating model that is based on a diversified product portfolio and a strong derisked R&D pipeline across our businesses. And finally, we are achieving sustainable growth with a projected double-digit underlying growth rate, increasing operating margins, strong cash flow conversion and the ability to delever rapidly. 2015 was a year of transformation and continued evolution for Endo. We see 2016 as a year of execution, of delivering on the promise and potential of our business and of creating significant value for our shareholders. We look forward to achieving these goals and -- through your continued support. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please.",23,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our first question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Rajiv or maybe this is for Paul. Can you just expand on some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite with an expectation of greater ap",81,"Rajiv or maybe this is for Paul. Can you just expand on some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite with an expectation of greater approvals. So can you, I guess, help us understand the Qualitest impact from 4Q? How is that likely to continue? And then what type of erosion are you expecting in the business for this year?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. And Randall, what I'll do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what he is seeing from the consortia and how that's changing our view on pricing in",51,"Sure. And Randall, what I'll do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what he is seeing from the consortia and how that's changing our view on pricing in this sector."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So the first thing I would say is into the fourth quarter when we give preliminary results around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commoditize",204,"So the first thing I would say is into the fourth quarter when we give preliminary results around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commoditized parts of our business. And then as we closed out our final processes for the year, we did recognize higher level of chargebacks and rebates coming through, specifically around our more commoditized portfolio as well as our pain franchise. That in tandem with onetime charges that occurred in the fourth quarter led to a lower-than-expected fourth quarter. I should say that those onetime charges we do not expect to continue in forward-looking quarterly results, but there is some underlying pressure around pricing that will extend in 2016. Having said that, all of that is baked into our forward-looking estimates for 2016. And as Rajiv noted earlier in scripted remarks, we still see very strong generics growth in the mid-teens to high teens, primarily driven by our injectables business, continued growth across the base as well as our launches on day certain products. I don't know, Paul, if you want to add anything more on the price erosion, please."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I think that's right. I think Suky really hit the nail on the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortium is really resulted back in Q2 of last year when you saw Redoak and one-stop in full op",167,"I think that's right. I think Suky really hit the nail on the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortium is really resulted back in Q2 of last year when you saw Redoak and one-stop in full operation. I think on a go-forward basis, to Suky's point, we are prepared for it. It's part of our 2016 forecast. And really when you look at the commodities business, it's going to be very, very challenging to take price decreases like we had historically seen over, maybe, the past couple of years, but that again is all planned for. Our focus is clearly on our pipeline. It's all-on execution. Rajiv touched on it in his opening comments that this year is going to be a year of execution. We've got to get our products out of the FDA. That's our defense. That's our strategy on a go-forward basis. It's our portfolio and getting our products approved."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Can you just...",4,"Can you just..."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Operator -- go ahead Randall?",5,"Operator -- go ahead Randall?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Can you just confirm that there is no pricing increases built into the 2016 guidance?",15,"Can you just confirm that there is no pricing increases built into the 2016 guidance?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio, that we can selectively and very appropria",62,"So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio, that we can selectively and very appropriately increase. But to answer your question on the generic commodities business, it's a volume gain for 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Our next question comes from the line of Louise Chen from Guggenheim.",12,"Our next question comes from the line of Louise Chen from Guggenheim."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So first question I had here was on gross margin expansion and operating leverage in '16. How should we think about that in light of your results in the fourth quarter? And then second question is on the generics business. How should we think about the un",57,"So first question I had here was on gross margin expansion and operating leverage in '16. How should we think about that in light of your results in the fourth quarter? And then second question is on the generics business. How should we think about the underlying growth outside of Seroquel, Zetia and the sales progression quarter-over-quarter?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question.",24,"Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was with a higher mix of generics products versus branded. We might see some dilution into our gross margin. As we actually work through ou",282,"Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was with a higher mix of generics products versus branded. We might see some dilution into our gross margin. As we actually work through our plan and our portfolio prioritization, we're actually moving to a higher mix of higher value products, which is ultimately expanding our margins. So as Paul talked about or as Rajiv talked about in his scripted remarks, the growth of the injectable franchise is one that is characterized with the gross margin profile well above the overall company average as we think about the launches of some of our day certain products. Those are also products that have gross margin profiles well ahead of the overall gross margin average. And then when you add in continued growth of XIAFLEX as well as BELBUCA, both of which have gross margin profiles above the company average, you start to form a picture of where we're going to see this gross margin expansion into 2016 and one that we're very pleased and confident in. And then from an operating margin perspective, as I said, we are going to spend more against advertising and promoting -- promotion against XIAFLEX and BELBUCA. We are going to spend more this year around R&D for generics and for branded, full stop. However, we are getting operating leverage through G&A as well as through the full realization of the Par synergies sometime in mid-2016. So not only do we get operating margin expansion -- gross margin expansion, we're going to see operating margin expansion as well and also on top of a very favorable tax rate."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. And just to touch on your growth question, Louise, let me take a crack at it and then Paul will add. While you mentioned Zetia and Seroquel, keep in mind that what Par has over the '16 to '19 time frame is 100 possible product launches, r",184,"Thank you, Suky. And just to touch on your growth question, Louise, let me take a crack at it and then Paul will add. While you mentioned Zetia and Seroquel, keep in mind that what Par has over the '16 to '19 time frame is 100 possible product launches, right? So certainly, Zetia and Seroquel standout because of the magnitude. But as we talked about in the past, those are also partner products, right? So as you look at all this entire horizon, you will have many, many more launches, most of which are not partnered where the bottom line is -- equates entirely to Endo, right? So from that standpoint, we do see new launches being the primary driver of growth in this business in '16 as well as into the future. I would also say that the injectables business has been a great performer for Par. It's tripled in size since JHP was acquired by Par, and we expect to see that momentum continue in '16 as well as beyond. I don't know, Paul, if you'd like to add anything to that."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Thanks, Rajiv. And I think that's right. I mean, when we look at 2016 -- I mean, we all know that Zetia and quetiapine are clearly large drivers coming at the end of Q4. And not apologizing for that, those are hard to develop products, hard to",271,"Yes, sure. Thanks, Rajiv. And I think that's right. I mean, when we look at 2016 -- I mean, we all know that Zetia and quetiapine are clearly large drivers coming at the end of Q4. And not apologizing for that, those are hard to develop products, hard to partner products and we're very proud of that relationships. That said, we have about 20 products that we should be launching in 2016, albeit maybe not major, major drivers. But in the generic industry, you never actually know what product can outperform. And as some examples, when we look at what we achieved in 2015 that are carrying us into 2016, we had a handful of carryover products like pramipexole, dutasteride, tamsulosin. These are relatively smaller type products that ultimately have limited competition. They're going to carry us into the first part of 2016. Again, hard to make, but from a brand sales standpoint, maybe not of the largest products, but good drivers. When we look a little bit at the sterile portfolio, we are real proud of what we have in Rochester. I think it's a great time to have sterile facility in U.S. soil. It continues to be a barrier to entry. Products like Vasostrict have continued to outperform, and that's on the branded side. But additionally, we have a handful of generic products that have had limited competition, products like [indiscernible] and ethacrynic acid. These are all products that have been genericized, but limited competition. And again, these factored in with some of our overlap and carryover products from last year should give us a good basis for 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Liav Abraham with Citi.",10,"And our next question comes from Liav Abraham with Citi."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking or do you anticipate any more? And if so, how meaningful could they be? And then secondly, related to that, how do yo",63,"Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking or do you anticipate any more? And if so, how meaningful could they be? And then secondly, related to that, how do you expect this liability to impact your cash flows going forward? That's it for now."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. We have discussed mesh over the course of the last 2 years, and I think as you know, with this mass tort litigation situations, it is very difficult to predict the end, right? That being said, what I would say is that we have come a long way. And al",448,"Sure. We have discussed mesh over the course of the last 2 years, and I think as you know, with this mass tort litigation situations, it is very difficult to predict the end, right? That being said, what I would say is that we have come a long way. And although the environment has continued to be more challenging than we had thought, I mean, with the initial settlements, which, by the way, I'm glad we did, but the reality is that the rest of industry at that time didn't follow with additional settlements as we would have expected, right, and there was increased advertising, which is kind of what's led to this additional bolus of claims in the back end of 2015. Now as we look at what we have done here though, I do feel good that the current settlements that we just announced this morning are ones that are focused on the high-value claims. And effectively, what is left is what we believe to be a much lower value set of portfolio cases, many of them could be spurious. And in addition, this is -- there's an evidence of potential fraud amongst some of these cases as well, right? So as we look at what remains, we do think it is a portfolio we can be a lot more aggressive in terms of how we approach it, either in terms of taking some cases to trial as well as potentially through an investigation of this fraud, seeking to dismiss a chunk of it as well, right? So -- and also keep in mind, we've now put a significant time between us and the public health notice that the FDA issued in 2011. That again should also be another factor that drives to reduce the number of new cases. And then finally, our decision to shut down the ASTORA business also will contribute to reducing the potential for future liability. So I think as we stand here today, we do feel good about where we've taken the mesh liability despite the additional increment that we saw in 2015. We do expect to resolve the remainder of it over the course of the next couple of years. There's no guarantee that accrual may or may not change. What I would say is that we are confident given what we know now about where we have a broader situation. And then fundamentally, we're a different company now, right? So we have, on adjusted basis, more than $2.5 billion or roughly around $2.5 billion of adjusted EBITDA, which allows us the ability to manage this over time and makes it a lot more manageable -- or on our cash."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. And Liav, this is Suky. Relative to your question on how it impacts cash flow -- so as we pointed out in the slides, at the end of fourth quarter, we've got a pretax remaining cash call of about $1.5 billion after we make these additional accruals. S",205,"Yes. And Liav, this is Suky. Relative to your question on how it impacts cash flow -- so as we pointed out in the slides, at the end of fourth quarter, we've got a pretax remaining cash call of about $1.5 billion after we make these additional accruals. So again, pretax remaining cash call of $1.5 billion. We expect in 2016 to pay somewhere around $850 million to $900 million of that $1.5 billion on a pretax basis. But after you consider the tax refund that we'll be getting as part of our structuring of the AMS sale, our post-tax obligation for mesh in 2016 will be somewhere between $150 million to $250 million, so quite manageable in the backdrop of $2 billion plus EBITDA in 2016. As we move to 2017, as we've put in the slide, we expect the post-tax cash call there for the residual of that liability that I talked about to be somewhere between $350 million and $450 million, and again, that's going to be on the base of EBITDA from 2016 of $2 billion plus to one that's growing double digits into 2017. So again, very manageable cash call in the backdrop of very robust underlying cash flow generation."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly, Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term?",45,"A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly, Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. I think the answer to the first question is very simple. It was $359 million of sales of Par in the fourth quarter. And then Suky, do you want to...",31,"Sure. I think the answer to the first question is very simple. It was $359 million of sales of Par in the fourth quarter. And then Suky, do you want to..."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. The one thing I would say, that $359 million was a little bit better than our expectation, primarily driven by the injectables business. We're also seeing good solid performance in the base business. As Paul talked about a little bit earlier, that sh",235,"Yes. The one thing I would say, that $359 million was a little bit better than our expectation, primarily driven by the injectables business. We're also seeing good solid performance in the base business. As Paul talked about a little bit earlier, that should carry over into 2016 as well. I will also say as we move forward into '16, Paul is looking at this portfolio as one portfolio, so we will not break out Par versus legacy Qualitest sales. We treat this as one business and that's how we'll report on it. The charges in the fourth quarter were about $30 million that we consider to be onetime and nonrecurring. It's really 3 factors that make this up. Well, there's a number of factors, 3 of which are examples -- are around trade disputes in the fourth quarter. We have some changes in estimates around gross connects. And third, we had some charges higher than expected around the harmonization of our methodologies around gross connects as we integrated Par and Qualitest. Again, we do not expect those to reoccur on a quarterly basis going forward. Your last question, Greg, around the tax rate, again, very pleased where the tax rate is migrating. We expect our effective P&L tax rate in '17 and beyond to be in the low double digits to low teens, but there is, again, continued opportunity to improve that over time."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Annabel Samimy with Stifel.",10,"And our next question comes from Annabel Samimy with Stifel."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just wanted to understand a little bit the underlying growth in generics and I guess, the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the u",60,"Just wanted to understand a little bit the underlying growth in generics and I guess, the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the underlying growth of Par right now? And how can we think about that going forward?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Annabel, this is Rajiv. Let me start and then Paul -- I think I don't know if you were -- so you were a little late for the call. You may not have heard us talking about the growth drivers for '16. So there are 2 primary drivers for '16 and frankly, these",234,"Annabel, this is Rajiv. Let me start and then Paul -- I think I don't know if you were -- so you were a little late for the call. You may not have heard us talking about the growth drivers for '16. So there are 2 primary drivers for '16 and frankly, these will be the drivers with Paul as well. One are new launches, right? So obviously, in '16, you have the impact of Zetia and Seroquel. But just beyond that, there are 100 potential launches that Par has in the time period of '16 through '19. So that is firstly the biggest driver of growth. It's all about volume and launches of those products. And the second area of growth is the injectables, the cell injectables portfolio, which is -- which will be a robust contributor to 2016 as well as beyond. Now outside of that, we have, in the combined business, plus or minus 1,000 SKUs, right? Now part of that, Paul will continue to optimize. But among the remainder, there will be certain molecules that do well for us and certain ones that won't, right? So that's the benefit of having a diversified portfolio. But net-net, when you put all these 3 factors together, on the back of those launched products and the sterile injectables business, we feel very good about the trajectory in '16 as well as beyond that."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Is there some underlying growth that we can assume for the generics business at this point?",16,"Is there some underlying growth that we can assume for the generics business at this point?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So we -- yes, we've talked about mid- to high teens for the generics business for now for 2016.",19,"So we -- yes, we've talked about mid- to high teens for the generics business for now for 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Shibani Malhotra with Nomura Securities.",14,"And our next question comes from the line of Shibani Malhotra with Nomura Securities."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","This is Austin Nelson on for Shibani. The first question, I mean, a couple with -- In one of the slides, there is a point that the OPANA ER abuse deterrent label settlement has been resubmitted to the FDA. I'm wondering if you can give any color around yo",135,"This is Austin Nelson on for Shibani. The first question, I mean, a couple with -- In one of the slides, there is a point that the OPANA ER abuse deterrent label settlement has been resubmitted to the FDA. I'm wondering if you can give any color around your expectations on when we could hear from the FDA. And then if Endo does receive abuse deterrent labeling, would you expect that the old formulation generics will be removed from the market for safety? And then the other question was on the expectation for net debt to EBITDA guidance, get back down into the mid-3 to 3 to 4x range, did that include only restricted cash? Or does that include cash that will be accrued for the accrual but not actually paid out in the year?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So on the -- let me get the OPANA question and Suky can talk for the debt question. The OPANA ER submission has gone -- it was a monumental effort. It is because this is not only the inclusion of data from our own stipulation [ph] study but also a lot of",149,"So on the -- let me get the OPANA question and Suky can talk for the debt question. The OPANA ER submission has gone -- it was a monumental effort. It is because this is not only the inclusion of data from our own stipulation [ph] study but also a lot of FP data. The FP [ph] has set an action date of July 29, 2016, for the file. So that is the time frame in which we expect to hear back from them. Now even if we are successful in getting the relabeling, if the -- if they could certainly serve to help remove all the generics on the market with the exception of Impax that has impaired license to the product, and therefore, to do so would require a longer path, including a citizen's petition, which we certainly would undertake but it would not be immediate. Suky?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is, the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is excluded from that calc",47,"Yes. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is, the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is excluded from that calculation."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellam with Piper Jaffray.",14,"And our next question comes from the line of David Amsellam with Piper Jaffray."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So a couple of questions on generics. So you had mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition for",105,"So a couple of questions on generics. So you had mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition for that product, competition down the road? So that's number one. And then on the Seroquel and Zetia generics, given these are partnered, can you help give us a sense of how the margins on these will look like during the exclusivity period compared to margins, gross margins for the overall generics business given that you've got shared economics there?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. thanks, David. So on the Vasostrict question, so we are not going to break out our guidance at a product line level of -- and now the product revenues for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important driver",68,"Yes. thanks, David. So on the Vasostrict question, so we are not going to break out our guidance at a product line level of -- and now the product revenues for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important driver for us in 2016. But maybe, Paul, you can comment a bit on your views on possible future competition for Vasostrict."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Thanks. So Vasostrict, remember, is an NDA, right, so that was filed as a 505(b)(2), so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very",81,"Yes, sure. Thanks. So Vasostrict, remember, is an NDA, right, so that was filed as a 505(b)(2), so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very hard and close with the patent trade office. Again, but at this point, there are certain things that are unknown. But again, we are looking to protect that product as you would expect from an NDA standpoint."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Zetia and Seroquel.",3,"Zetia and Seroquel."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","On the Zetia and SEROQUEL question, we have 2 partners. But during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would say",64,"On the Zetia and SEROQUEL question, we have 2 partners. But during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would say it's more of a 50-50 like type relationship. Post day 181, I would say it behaves more like a standard 3-player partnership."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. David, just to put a little bit more on what Paul just gave there. So Seroquel, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average",50,"Yes. David, just to put a little bit more on what Paul just gave there. So Seroquel, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average during the exclusivity period."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Great. Just 2 questions here. Just first, on BELBUCA, can you just talk about the launch expectations? I know you've talked about 2019, but just as we go out to 2016, what type of ramp should we think about here as we're thinking about the initial modelin",163,"Great. Just 2 questions here. Just first, on BELBUCA, can you just talk about the launch expectations? I know you've talked about 2019, but just as we go out to 2016, what type of ramp should we think about here as we're thinking about the initial modeling? And the second question is the bigger picture one. I guess, over the last 18 months, the company has done 2 large acquisitions with Auxilium and Par. You pursued probably a third one with Salix. As I think about the next 12 months and the evolution of the company, is this just a fundamentally different environment from an M&A perspective where we're not going to fuse big deals or they're much less likely? Or do you see what's happening in the market now, just a temporary pause or slowdown and that eventually, we're going to see the high level of consolidation that has been playing over the last few years kind of returning to the sector?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Thanks, Chris. So on BELBUCA, we're very pleased that we're able to launch the product as we have predicted. In the month of February, I was personally at a national sales meeting. We are very excited and expanded the pain field [indiscernible] also",745,"Sure. Thanks, Chris. So on BELBUCA, we're very pleased that we're able to launch the product as we have predicted. In the month of February, I was personally at a national sales meeting. We are very excited and expanded the pain field [indiscernible] also, the feedback for the product has been very good, and all of our managed care conversations are going well, right? That being said, it's early days from a managed care contracting standpoint. It's also early days in terms of the actual launch of the product. And as we had indicated before, while we're -- every component [ph] in this product, which is why we've put out an aspirational number for 2019 of $250 million, we do expect the ramp to be somewhat gradual in the first 12 months, and that's just reflecting unknowns, right? So this is a different format of buccal patch, which, while there are many advantages, patients and physicians need to get used to it. For those patients that are on other LAOs that are being transitioned to BELBUCA that needs to be -- down titration and up titration. So these things will take time for physicians to get used to. And also, as you well know, from a market access standpoint, while commercial covered lives, you can contract early in a launch, when it comes to Medicaid Part D coverage, which is roughly about 1/3 of the coverage in this market, that usually waits for a full cycle, right? So we certainly would look to 2017 to have a more -- much more substantial ramp than in 2016. But all the early signs are well within our expectations of what we expect to see for the product. On your question on M&A, let me answer from an Endo perspective and then -- and see if we have any further clarification on it. For us, as you pointed out, 2015 was a very, very transformational year in terms of transactions, right? So we -- in particular, we concluded Auxilium, the Par transaction and at a small level, Aspen transaction in South Africa, which essentially gave us new platforms, right, and a sense of critical mass, particularly in our generics business. In many ways, we accomplished what we set out to accomplish, which is to get a set of assets, which, even if we do no further M&A, gives us a path to double-digit growth. And then you couple that with a market environment where the debt markets are weak as are the equity markets. But for us, leaving the market conditions aside, 2016 really is about execution, which is why we've talked so much about BELBUCA, about XIAFLEX, the Par integration. Those are the things that are going to make us successful. So from that perspective, M&A is not a key priority for us in 2016. I have said -- in the past, I've said we will continue to monitor opportunities. But really strictly, I think the past opportunities that make sense for us in 2016 will be the small in-licensing or product acquisition here or there either for our branded business or international, but we're talking -- we have a very small call on our cash for doing those types of things if the opportunity come across them. In terms of larger transactions, it is not in our anticipation to do -- to look for large acquisitions in 2016. I have, however, said that if there are -- if there is a larger merger, which could be value-creating that is done on the basis of the relative value of 2 companies, and those are the types of things that we certainly will evaluate if they come our way. But certainly, it is not high on our list of priorities in terms of acquisitions as we look out over '16. Now back to your question about the nature of what's going on in the industry, I would say, certainly, the debt markets and equity markets have led to somewhat of a pause. But overall, if we look over the last 20, 30 years, this is a still highly fragmented industry. There are lots of -- it's been a deal-rich industry for a long period of time. Obviously, those deals are cyclical, and my suspicion is that deals will continue to be an important part of this industry as we look forward. But 2016 is certainly likely to be -- to see a pause, at least from our perspective."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A few things. First, there were a couple of products, LIDODERM and Voltaren Gel, that seemed to do much better than we would have expected. Can you just talk if there was an inventory build there or what was going on? Second of all, you've talked about 20",220,"A few things. First, there were a couple of products, LIDODERM and Voltaren Gel, that seemed to do much better than we would have expected. Can you just talk if there was an inventory build there or what was going on? Second of all, you've talked about 2017 kind of implying a $7 number, which now, with Voltaren Gel back, seems a little low number and especially given the way you're talking about tax rate now. Relative to before, I would think that, that number of $7 is too low and needs to be brought up. So maybe you can talk about that a little. And then third, I'm just trying to understand, on the generics business, the pricing that you're talking about. There's one aspect of it, which is the commodity pricing, but then there's the other aspect, which is the pain products, which have been really important for you. And I guess, the question is, we've heard from other companies in the space, and they were complaining about new players coming back last year and they were complaining about pricing in that market and they were having some troubles there, and yet Endo was not complaining at all at that time. And now there seems to be a delayed impact. So I'm trying to understand why is that."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Let me -- let's see if we can hit your questions in order. With respect to the V Gel, it was a very good year last year. We had, I think, double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I thin",486,"Sure. Let me -- let's see if we can hit your questions in order. With respect to the V Gel, it was a very good year last year. We had, I think, double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I think we have been -- that we've been successful in holding some of our contracts through '15, probably even better than we had expected on the branded LIDO. But as we enter into '16, we do expect to see some drop-off of those contracts and that would be seen when we see our 2016 results, but it's already factored into our guidance. 2017, Marc, we're not going to comment on 2017. Clearly, we made that commentary in the back -- against the backdrop of the Par transaction. First of all, I'm delighted to say what we committed to the outside world when we did the Par transaction, which was an accretion number for 2016, that is going out in our guidance as well as the implied multiple that we put out there for the Par transaction, which was 10 to 11x for synergy EBITDA multiple that is also following through in the 2016 numbers. As you said, there are lots of other puts and takes in our business. Certainly, V Gel is one. We are very excited about the extension of the agreement. There's always the possibility and potential of a generic on V Gel, which we also have to keep in mind, which, it somewhat offset  in our new agreement by the fact that we have the right to an Authorized Generic. And a lot of 2017 will also depend on how we're doing on BELBUCA and XIAFLEX. So we are very optimistic as we look at the '16 and beyond time horizon for Endo. That being said, we're not going to provide any specific further guidance on '17. On the generics question, I'll start and I'll bounce it to Paul. I think what I would say is if you could separate the commodity -- the traditional commodity products from the pain products, and as you pointed out, pain has been a traditional area of strength to us, we have often taken the approach of focusing on value versus pure volume on the pain business, right? So although we've taken some substantial volume declines in our pain portfolio, they are somewhat anticipated based on the price increases we took and of course, we've taken. So net-net, from a value standpoint, we're actually pleased with how the pain portfolio has performed. But is there a pricing pressure in pain as well as the commodity portfolio? The answer is yes because there are smaller players who tend to be aggressive even in the pain arena now, more so than they have been in the past. I don't know, Paul, if you have any comments about that."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, I think that's right. I mean, at the end of the day, you have product and you also have timing issues with consortiums. And our contracts with certain trade partners, I think that was part of what we've -- also saw, right, against seeing the full imp",140,"Yes, I think that's right. I mean, at the end of the day, you have product and you also have timing issues with consortiums. And our contracts with certain trade partners, I think that was part of what we've -- also saw, right, against seeing the full impact of Red Oak really kicking in, in Q2. So you have the timing -- you've got a timing issue that we were focused on. So to your point, to Rajiv's point, clearly, yes, there are more competitors in the narcotics space and we're seeing that. But we had our select wins, right, across the board. So to Rajiv's point, select wins, yes, we may have sacrificed certain pricing -- sorry, certain volume shortfalls. But ultimately, I think the timing of the consortium is probably the main issue that we saw in 2015."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just on -- first, on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking or is this a sort of just the seasonal nature of the product where it's a little bit stronger in the 4Q coupled with heightened demand? And s",84,"Just on -- first, on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking or is this a sort of just the seasonal nature of the product where it's a little bit stronger in the 4Q coupled with heightened demand? And secondly, as we think about some of the consumer initiatives to drive awareness of the product in '16 on the SG&A side, when can you expect to start to see that translate on the increased volume side?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel[Audio Gap]so expect to save. Now that being said, we had indicated in the third quarter that it would b",212,"Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel
[Audio Gap]
so expect to save. Now that being said, we had indicated in the third quarter that it would be a little bit lower than that. So that -- there's probably a little bit of stocking impact going in the fourth quarter but nothing out of the ordinary. As you pointed out, especially the back end of the fourth quarter tends to be a heavy period because there are many patients who like to schedule their surgeries during that holiday period, so that is also a contributor. I think as we enter 2016, we are excited about everything, all the changes we put in place, both internal as well as some of the new programs that we have put in place like the disease awareness program that I referred to in Peyronie's disease. So many of those are just now kicking off. So realistically, for them to have a real impact, I think you're looking at probably the third quarter before we can really report back on successes of these programs, but early indicators of all of them have been very positive."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones. Secondly, on XIAFLE",96,"I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones. Secondly, on XIAFLEX, can you outline the number of shift files in each indication, Peyronie's and Dupuytren's? And then going back to the mesh claims, I think you said there were 8,000 mesh claims that hadn't been accrued for. What is the potential value of those 8,000 claims?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the f",153,"Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the facts are very unclear across this portfolio. Most of these cases, we don't even have medical records. As I pointed out, there is evidence of fraud, at least on some subset, that we are investigating vigorously. So as a result, we're not in a position to assign an altitude, [ph] other than to say that we do expect, at this point in time, based on advice that we are receiving from outside counsel, the value of these cases are lower than the ones that we have to settle there now. And Q4 launches, Paul, do you have any other -- the data on that one?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So Q4, the products that we're probably most proud of coming out of Q4 was, again, the dutasteride/tamsulosin product. That is a Jalyn product from GSK. Also, a product called pramipexole is another product that we executed on for the fourth quarter. We d",75,"So Q4, the products that we're probably most proud of coming out of Q4 was, again, the dutasteride/tamsulosin product. That is a Jalyn product from GSK. Also, a product called pramipexole is another product that we executed on for the fourth quarter. We did indicated that we do have some delays on the rivastigmine patch. That was a product we are hoping to get out in Q4, so that product will be delayed into 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had -- just had under 8,000. And in DC, we had about 8,400 shipped vials.",32,"And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had -- just had under 8,000. And in DC, we had about 8,400 shipped vials."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","First question for Rajiv. With the launch of BELBUCA and the doubling of the pain sales force and also, I guess, the reoptimization around product promotion last quarter, could you maybe just provide us with an update on current sales force size configura",167,"First question for Rajiv. With the launch of BELBUCA and the doubling of the pain sales force and also, I guess, the reoptimization around product promotion last quarter, could you maybe just provide us with an update on current sales force size configuration and who's doing what in terms of detail allocation just relatively? And then the follow-up to that, with some of these efforts now, you have a collection of small niche-branded assets that you really aren't receiving any direct promotional attention, including a couple of products picked up from Par. So just wondering what your thinking is around this portfolio of products, STENDRA, Testim, FORTESTA and TESTO and whatnot, whether or not these would, in fact, be candidates for divestiture. And then just a follow-up for Suky, it doesn't really sound like there's been change to your long-term tax rate expectations. Maybe you could just walk us through a couple of things that are impacting 2016 accrual rate versus the expected long-term tax accrual rate."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me cut to your first question and then Suky can talk about tax. So in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varying si",314,"Let me cut to your first question and then Suky can talk about tax. So in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varying sizes, as I've [indiscernible] before, of varying sizes in our branded business, the largest of which is our pain field force, which is sized to be competitive with other pain players. And in that field force, we detailed BELBUCA, OPANA ER and Voltaren Gel. So those are the 3 products that are detailed. And then on occasion, we do some reminder calls on SUMAVEL. In our specialty business, there are 2 field forces, one is focused on urology, and that field force carries in the first position as XIAFLEX for Peyronie's disease and also carries our long-acting testosterone replacement therapies, which are AVEED and TESTOPEL. We have a second specialty field force, which is a smaller one that is focused on XIAFLEX for Dupuytren's contracture and SUPPRELIN LA, which is our product for central precocious puberty. We also have a smaller field force, which we inherited from Par, which, I must say, we are all very impressed with their early performance. They are focused on selling the -- selling NASCOBAL, which is a product that came over from the Par transaction, but we are also using that field force as a mechanism to provide some initial launch support -- additional launch support for BELBUCA. And over time, we'll take on the promotion of some of these smaller brands. So net-net, at this point, we're very pleased with the promotional mix that we have in our field force. Their even now older and more established products are continuing to be important to us, so we are not looking to sell or divest any of them."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. So around the tax rate in 2016, the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue sourced. So that's why you see a step-up from between '15 and '16. Having said that, the low double digit, high si",183,"Yes. So around the tax rate in 2016, the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue sourced. So that's why you see a step-up from between '15 and '16. Having said that, the low double digit, high single digit estimate that we have for '16 is well below our initial expectations that we set for '16 when we closed Par, where we said that we thought that the tax rate might be closer to the midteens. So we actually are seeing some progress versus our original expectations. As you think about 2017 moving on, we would characterize that as sort of low teens type of tax rate. The reason why that migrates up a little bit is you continue to drip off deal attributes that were created over the last couple of years. But otherwise, the underlying fundamentals of the tax rate are still very attractive. And as I said, for '17 and beyond, there's still a number of opportunities and strategies that we can deploy to bring that down over time."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Risinger with Morgan Stanley.",14,"And our next question comes from the line of David Risinger with Morgan Stanley."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So I have 2 questions. First, with respect to the Qualitest outlook, just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to in the ballpark of what was -- or of what the number was in the fourth quarter of",118,"So I have 2 questions. First, with respect to the Qualitest outlook, just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to in the ballpark of what was -- or of what the number was in the fourth quarter of '15? And then turning to Slide 13 in the deck, Suky, I was hoping that you could just take us through the walk-through from the $1.5 billion in the pretax cash call and then the $575 million in the post-tax cash call. I know that you mentioned a $700 million tax refund, but obviously, there's another number in there to bring that figure down to $575 million."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So David, let me address your first question, which is, first of all, keep in mind that, as Suky pointed out, there was some nonrecurring impacts in the fourth quarter that impacted Qualitest but should not see any roll forward impact. And secondly, I thi",162,"So David, let me address your first question, which is, first of all, keep in mind that, as Suky pointed out, there was some nonrecurring impacts in the fourth quarter that impacted Qualitest but should not see any roll forward impact. And secondly, I think to -- back to the comment that Suky made, where we're not providing guidance for Qualitest distinct from Par. Simply provided, at this point, Paul has a combined portfolio. It's negotiating customer contracts across a combined portfolio. He will make some portfolio optimization decisions as he goes into the year in terms of what products he prioritizes with customers. And that may impact our products, it may impact quality of products. So as a result, we do not expect to provide any guidance for the legacy Qualitest portfolio going forward other than what we already commented on. I would say that, for the combined business, we expect to see mid to high teens underlying growth for 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million, the first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016, we expect that to be som",135,"Yes. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million, the first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016, we expect that to be somewhere around $850 million to $900 million, and then you back out the tax refund of approximately $700 million from that. That's one component. And then in 2017, we expect the pretax cash call to be somewhere between $600 million to $650 million. If you apply a U.S. tax shield against that of approximately 35%, you get down to your post-tax cash call of somewhere around $400 million. When you put those 2 pieces together, that should get you into the $575 million range."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's your expectation embedded in the guidance for pricing for brands in 2016? And the",88,"For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's your expectation embedded in the guidance for pricing for brands in 2016? And then for Suky, just a quick one, can you talk a little bit about the gap between EBITDA of about $2 billion plus for this year and what we should be thinking about for GAAP cash flow from operations, including the mesh liability payments?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thanks, David. So on the branded pricing, our experience in 2015 and 2016 actually are not dramatically different. It's well within what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price",188,"Thanks, David. So on the branded pricing, our experience in 2015 and 2016 actually are not dramatically different. It's well within what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price increases. They typically range in -- from the low single -- actually, 0 in certain cases to potentially up to 20%, 25%. The high end of that range is typically for our mature products that already have multiple generics on the market. Our portfolio is generally contracted, which means that our price increases are capped. So even if we are taking -- price increases are higher, then that means mid-single digits, the realized price increases for us in our branded business is somewhere in the low to mid-single digits. So that level is our experience in 2015. Our price increases that we took in our branded portfolio are already public for 2016. And they're in the same range that I just described, and we would expect a similar type of low to mid-single-digit impact on our branded business this year as well. That's all incorporated into our guidance."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. And regarding your question around cash flow for next year, the way to think about it is, first of all, we would expect underlying cash flow from operations as we depicted for 2015 to have a very high correlation to adjusted net income. But to give y",231,"Yes. And regarding your question around cash flow for next year, the way to think about it is, first of all, we would expect underlying cash flow from operations as we depicted for 2015 to have a very high correlation to adjusted net income. But to give you some of the moving parts for next year to help model, if you started with the midpoint of our revenue range and assume the mid-40s EBITDA margin, you get roughly into the $2 billion, $2-plus billion EBITDA range. From there, your movements on cash, you got interest expense, which we've talked about, you've got cash taxes in the mid-single digits on the underlying business. You've got a mesh post-tax cash call of about $150 million to $250 million as we've talked about. Working capital on a day sales basis is going to be relatively steady throughout the year. However, because of the fourth quarter launches of Seroquel and Zetia, we do expect there to be a call on cash in the fourth quarter of somewhere between $200 million to $300 million. That will normalize in the first quarter of '17 as that launch pulls through. We have CapEx of about $150 million and contingent consideration of about $150 million. So if you put all those pieces together, that should get you pretty close to where we see our cash flow for the year."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group.",15,"And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","If we go back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well and in particular, how you look at the brand",101,"If we go back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well and in particular, how you look at the brand sales of $379 million for the quarter? Are there any moving parts there to consider? Is STENDRA still in there or is that in discontinued operations? I'd say quarter-on-quarter, 3Q to 4Q, from the products you give us, that explains about half of the quarter-to-quarter increase. So what other contributors were there on the branded side?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So on the Par number, we're just verifying this, but I believe that number is a generics-only number and excludes the brands. And then the -- your second question, Andrew, with respect to...",33,"So on the Par number, we're just verifying this, but I believe that number is a generics-only number and excludes the brands. And then the -- your second question, Andrew, with respect to..."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Yes. With respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million. The products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem",82,"Yes. With respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million. The products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem to have stepped up 3Q to 4Q. Some of that is a full quarter of the Par brands. But were there any other factors, products that were -- had a bounce in 4Q in brands?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So the -- as you point -- as you say, Andrew, some of the smaller brands -- so we had success, for example, with AVEED in the fourth quarter as contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a decen",102,"Sure. So the -- as you point -- as you say, Andrew, some of the smaller brands -- so we had success, for example, with AVEED in the fourth quarter as contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a decent fourth quarter. SUMAVEL was a contributor. So it's a series of these smaller brands. And again, it goes to show the value of our more diversified, established and other products, part of our branded business and many of them do contribute. I mean, when you add them all together, it is a material contribution."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, and I'll just add...",5,"Yes, and I'll just add..."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","[indiscernible] STENDRA was out for 2016?",6,"[indiscernible] STENDRA was out for 2016?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, STENDRA is out for 2016.",6,"Yes, STENDRA is out for 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. One thing I would add for 2015 fourth quarter in LIDODERM, we did see a benefit, onetime benefit of some returns, reserves adjustments that won't repeat in first quarter of 2016.",32,"Yes. One thing I would add for 2015 fourth quarter in LIDODERM, we did see a benefit, onetime benefit of some returns, reserves adjustments that won't repeat in first quarter of 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao with Barclays.",4,"Douglas Tsao with Barclays."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple. Paul, maybe on the delay for Exelon, what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky, in terms of the visibility on the mesh liability, sort of cited sort of the lower quality of some of t",85,"Just a couple. Paul, maybe on the delay for Exelon, what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky, in terms of the visibility on the mesh liability, sort of cited sort of the lower quality of some of the outstanding cases, just curious in terms of the historical precedent in terms of some of those, perhaps, moving up into a higher-quality sort of claim as things like medical records perhaps become available to you?"
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I would say, on the Exelon patch, Doug, we're probably looking at late to second half of 2016.",18,"I would say, on the Exelon patch, Doug, we're probably looking at late to second half of 2016."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Okay. With respect to mesh and Doug, I think consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken, based on advice of outside advisers as well as looking",203,"Okay. With respect to mesh and Doug, I think consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken, based on advice of outside advisers as well as looking through the portfolio of plaintiffs, attorneys in terms of those who are more likely to have credible claims and effectively focus on the high value, right? As we've said, as we look out over the remainder, while there is information, there is also other piece of information we have such as the potential fraudulent claims that leads us to believe that these are of lower value, right? And this is consistent with the advice that we've gotten from our outside advisers as well. And we also believe that it is to our benefit and to our advantage to be more aggressive with this remaining portfolio, including potentially taking some to trial if we need to. So our current -- I believe based on the factors that we have, we do believe that they are lower-value cases. We will deal with them over time, and there is no anticipation of any other settlements in the near term."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva.",25,"And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as the outlook for 2016, we are very pleased with the solid performance that we had in 2015. We believe that the fun",182,"Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as the outlook for 2016, we are very pleased with the solid performance that we had in 2015. We believe that the fundamentals of the business are very strong, strong underlying growth that will sustain ourselves into 2016 into the medium term that we've talked about in the past.
We are positioned for growth in 2016. We have some strong growth drivers like XIAFLEX, BELBUCA and our generics portfolio that we continue to put a laser-like focus on. We're progressing the XIAFLEX pipeline, creating some real momentum around the new indication, potential new indications like cellulite.
Clearly, our focus this year is on execution and on generating strong underlying free cash flow, which would allow us to continue to delever despite the incremental accrual that we talked about with respect to the mesh liability.
With that, I thank you for your time and look forward to joining all of you on our next quarterly call. Thank you."
28071,325746146,943718,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today",47,"Good day, ladies and gentlemen, and welcome to the Endo International Fourth Quarter and Full Year 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to introduce your host for today's conference, Ms. Keri Mattox. You may begin."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",228,"Good morning, and thank you for joining us to discuss our fourth quarter and full year 2015 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceutical. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at www.endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. Let me now turn to our fourth quarter and f",1404,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier this morning. 
Let me now turn to our fourth quarter and full year 2015 earnings presentation. On Slide 2, you will see our agenda for today's call. We will start with an overview of Endo's transformation in 2015, and we'll move to review the highlights of our fourth quarter and full year 2015 financial results, walking through our U.S. Branded, U.S. Generics and International businesses. We will then turn to our full year 2016 outlook and financial guidance. After our prepared remarks, we look forward to taking your questions. 
Moving on to Slide 4. 2015 was a year of transformative growth for Endo, as we worked towards our goal of improving lives while creating value. We made significant progress in our U.S. Branded Pharmaceuticals business segment, completing the acquisition of Auxilium and revitalizing our product portfolio and R&D pipeline. We also secured FDA approval for BELBUCA and extended our Voltaren Gel licensing agreement. In addition, we received a favorable IP ruling for OPANA ER and are continuing to advance that product with the recently submitted data package to the FDA that we feel could support an abuse-deterrent formulation label expansion. The FDA has accepted that submission and set an action date of July 29, 2016. Collectively, these efforts and our continued execution across our full branded portfolio of products resulted in full year 4% underlying revenue growth for 2015.
Next, 2015 was a year of transformation and achieving critical mass for our U.S. Generics business. In September, we acquired Par Pharmaceutical, expanding our portfolio with higher barrier to entry and alternative-dosage products, tripling our R&D pipeline and creating a top 4 U.S. generics company. After beginning full-scale integration in the fall, we've continued to optimize our generics business operations and product portfolio, ultimately driving 11% underlying revenue growth in 2015 in this segment. Our International segment was also rebased in 2015, positioning our emerging-market businesses strongly for growth in 2016 and beyond. For example, in our Litha business, we focused on core pharmaceuticals, acquiring a product and R&D portfolio from Aspen and divesting noncore assets like devices and vaccines. Overall, we drove 6% underlying revenue growth in our international segment in 2015.
Finally, we continue to evolve in both corporate structure and strategy. We divested our AMS men's health business to further sharpen our focus on specialty pharmaceuticals. We continued to build out and enhance our Irish infrastructure. We generated strong underlying cash flow from operations, in line with expectations. In short, we have established a platform that, even if we pursue no additional M&A, positions us for future double-digit underlying growth and expanding margins. 2015 was indeed an important and transformative year in Endo's evolution. 
Moving to Slide 5. You will see that evolution reflected in our solid financial performance in the fourth quarter and full year. Suky will provide more details about our results in just a few minutes. 
Next on Slide 6, let's talk about U.S. Branded Pharmaceuticals. In 2015, our rebuilt branded portfolio drove underlying revenue growth in the mid-single digits. Key drivers of that growth included XIAFLEX, which continued to perform in line with our expectations. We have also officially launched BELBUCA and expect that product to be an important growth driver moving forward. The kickoff for this differentiated Schedule III product took place at our national sales meeting earlier this month, and I can personally attest to the excitement and enthusiasm of our significantly expanded pain field force. All of us at Endo believe that this first and only currently approved buprenorphine buccal film for chronic pain does offer an important new treatment option for patients. Also in December, we executed a new agreement to extend our commercialization for the market-leading Voltaren Gel through 2023 and secured rights to any future Authorized Generic for that product. 
Moving on to Slide 7. Let's look at a snapshot of how XIAFLEX performed for the year. While XIAFLEX U.S. revenues represent approximately 12% of our branded full year reported revenues and only 5% of overall Endo full year reported revenues, the product continues to be a very attractive growth opportunity, and we are excited about the potential in its currently approved indications as well as in the R&D pipeline. Overall, XIAFLEX for Peyronie's disease saw a strong 72% full year demand growth with vials totaling nearly 30,000 in 2015. We continue to expand our physician base and are increasing our efforts to broaden clinical awareness. We believe the PD patient base can also expand. Our broader DTC campaigns, including a comprehensive disease awareness program with celebrity spokesperson, Dr. Jerry Punch, a long-time ESPN commentator and MD, are formally kicking off next week. In Dupuytren's contracture, we saw a steady 12% full year demand growth in 2015, which is especially encouraging given that we are 5 years post launch. Our continuing efforts in this indication are focused on expanding the physician user base, educating patients about an effective nonsurgical option, and with the multi-cord label expansion, building the average number of vials per patient over time.
Next, let's talk about our U.S. Generics business on Slide 8. Overall, we were able to drive an underlying growth rate in the double digits for the full year despite increasing pricing pressures across the sector. We are very pleased with the strong contribution provided by the legacy Par business in the fourth quarter, which exceeded our international -- our internal expectations. The legacy Qualitest businesses, while diversified and historically insulated from the challenging pricing environment, did experience some volume loss and pricing pressure in the fourth quarter due to increased competition in multi-player categories. While we have seen volume declines in some areas of this business, it is important to note that 80% of Qualitest's extended unit loss in the full year 2015 versus prior year was driven by only a handful of products that correspond to approximately 20% of Qualitest reported net sales in 2014. 
The fourth quarter also saw a more mild cold/flu season, that we believe contributed to lower-than-expected overall generic sales performance. As you will note, actual full year underlying generics growth was lower than preliminary estimates shared earlier this year. This was due to fourth quarter actual sales of our legacy Qualitest portfolio. Versus our preliminary expectations, part of the shortfall was driven by a number of nonrecurring net charges that were recorded as part of our year-end processes. While these types of customary charges -- while these types of charges are customary in any given quarter, we did see a higher level in the fourth quarter of 2015. Also the shortfall was driven by a combination of higher-than-anticipated rebates and chargebacks that came through on fourth quarter sales identified during our year-end close processes in January and February. These shortfalls were offset by better-than-expected results in our branded business, bringing the total company performance in line with our 2015 preliminary expectations, once again highlighting the value of our diversified revenue mix. We will talk more about our expectations for the generics pricing climate in 2016 and beyond when we discuss our full year guidance later in this call.
Next on Slide 9, you will see that 2015 was a year of rebasing for growth and increasing profitability for our International Pharmaceutical segment. Paladin continues to be a steady high-margin contributor, with recent launches providing potential upside for the business over time. In the fourth quarter, the impact of these launches were offset by the loss of exclusivity on select products, leading to some modest noncash impairments. Our Somar business continues to grow, driven by products across this broad portfolio. It was also a year of transformation for Litha with the Aspen portfolio acquisition and our divestiture of noncore product lines, which closed earlier this month. That business is now more sharply and strategically focused on higher-growth and higher-margin pharmaceutical products. I should note that, similar to what we've seen across the sector and broader markets, a stronger U.S. dollar did impact our reported performance for the quarter and full year. 
On Slide 10, you will see our reported segment revenues continued to grow in 2015. 
Now for a more comprehensive look at our financial results, let me turn the call over to Suky. Suky?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by a diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increa",1215,"Thank you, Rajiv, and good morning, everyone. As Rajiv mentioned, the full year 2015 financial results were solid and characterized by a diversified and profitable business. On Slide 11, you will see that we achieved robust performance in 2015 with increased revenues, adjusted margins growing faster than revenue, progress on our tax planning strategies and adjusted earnings per share growth. 
Moving to Slide 12. Let's take a more detailed look at our underlying cash flow from operations in 2015, which remained strong throughout the year. We view this as a quality measure of our overall results and our ability to deliver long-term shareholder value. What you will see on this slide is that our 2015 reported cash flow from operations was impacted by a number of noncore cash outlays that are centered around product liabilities and nonrecurring costs related to M&A transactions completed in 2015. If you neutralize these items, cash flow from operations have a high correlation to adjusted net income. We expect this profile to continue into 2016. As a note, you will see -- also see more information on our cash conversion cycle related to working capital in the appendix of today's slide presentation.
Next on Slide 13, we would like to provide you more background around the mesh product liability accrual in the fourth quarter and how that is projected to impact future financial results. The environment around mesh product liability has evolved rapidly, with an influx of claims having been presented to the company in late 2015. We believe these additional claims are primarily the result of increased advertising by plaintiff's attorneys, a lack of meaningful settlements by other mesh manufacturers and higher-value verdicts awarded against other manufacturers. That said, we've taken the approach to strategically settle higher-value and quality case inventories with key plaintiff's lawyers in certain individual cases. Also we plan to shift our strategy to vigorously defend and, if appropriate, litigate remaining cases and seek relief from the federal court in the ongoing mesh multi-district litigation. I note that our accrual is based on claims that are settled or are considered probable in estimate [ph]. We currently are aware of approximately 8,000 purported claims that have not been accrued for, because based on the analysis by the company and outside legal counsel, we believe this portfolio could be of lower value and lower quality as almost all of the claims are lacking medical records and/or basic demographic information. We've also recently become aware of what we believe may be fraudulent or other wrongful activities relating to the generation of certain mesh claims. While we do not yet know the scope of such activities, we plan to fully investigate them and, if appropriate, will vigorously pursue all available remedies against each responsible party and cooperate with law enforcement authorities, other mesh manufacturers and the court.
Importantly, we have seen the rate of purported cases decrease substantially in the early part of 2016 as we continue to make progress in narrowing the mesh liability tail. We are also reducing the potential for product liability related to future mesh implants through our decision to shut down our ASTORA Women's Health business, which we announced earlier today. 
Now turning to the accrual. Our pretax product liability accrual as of the end of the third quarter was approximately $1.4 billion. In the fourth quarter, about $150 million was paid out in Qualified Settlement Funds or QSFs. During the fourth quarter of 2015, we recorded an $834 million pretax charge to increase the estimated product liability accrual for mesh cases. Reflected in this increase as a conservative measure, based on the lack of any meaningful reduction factor observed to date, we have removed the reduction or kick-out factor, resulting in a $401 million impact. Total increase also reflects a $433 million impact, primarily related to the execution of additional master settlement agreements in 2016. It is important to note that we believe these recently settled cases represent a higher value and quality portfolio cases with a higher mix of explant surgeries or revisions and are not representative of overall settlement per-case averages. At the end of the fourth quarter 2015, the amount funded in the QSF was $579 million. This brings us to a total remaining mesh liability, pretax cash call, of approximately $1.5 billion. Our total remaining mesh liability post-tax cash call based on the current accrual is projected to be approximately $575 million through 2017, with about $150 million to $250 million paid in 2016 and approximately $325 million to $425 million paid in 2017. The overall pretax cash call is mitigated by an expected tax refund of approximately $700 million that is expected in the first half of 2016. With these post-tax cash call projections and a robust underlying cash generation, we have the confidence that we can continue to delever into the 3 to 4x range in the second half of 2016 and expect further delevering into 2017. 
Next, on Slide 14, let's talk briefly about the announcement we made this morning regarding ASTORA Women's Health business. As you know, we successfully divested the AMS men's health business and launched a strategic sale process for AMS Women's Health, now ASTORA Women's Health, in 2015. That process did result in formal bids for ASTORA. However, Endo has now determined that the best strategy is to wind down ASTORA business operations. This decision was a difficult one as it impacts our dedicated employees, the physician community and importantly, the patients for whom ASTORA products are important treatment options. Key factors that drove our decision include the evolving product liability landscape around vaginal mesh has been challenging and continues to evolve for all manufacturers, including ASTORA. And second, by shutting down the business as opposed to selling it, we're able to reduce the potential for product liability related to future mesh implants, which would not have been achievable in the event of a sale of the ASTORA business. So we will now work to support physician transition plans to alternate products. We expect to cease business operations for ASTORA by March 31, 2016. On other balance sheet matters, as noted in our press release, we took noncash impairment charges totaling approximately $140 million in the quarter. These charges are on a total goodwill and intangible balance of $15 billion as of December 31, 2015. The majority or about $86 million of the charges were related to Paladin and is driven by the loss of exclusivity of certain products. As we noted at Q3, we finalized our goodwill testing in Q4 and guided that there could be modest changes to impairments in the fourth quarter.
I would like to emphasize that 2015 was another year of transformation for Endo, and one that positions us for future growth and profitability. Specifically, it was a year where we further diversified and expanded our revenue base. We delivered solid underlying growth in a challenging market. We expanded margins, improved our underlying after-tax cash flow conversion, we built a strong branded and generics product pipeline, we improved our operating model and execution and made continued progress on narrowing the tail of the company's mesh-related product liability. 
Now let me turn the call back over to Rajiv to discuss our key priorities and growth drivers for 2016. Rajiv?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which ha",1345,"Thank you, Suky. Let me first echo your comments about our dedicated ASTORA employees and management team and take a moment to thank them for their contributions and commitment to the business. We would also like to thank the physician community, which has been so supportive of ASTORA and its products. 
Now moving to Slide 16. As we enter 2016, we have set out a number of strategic and operational priorities. First, we are focused on value creation, including a strong commercial launch of BELBUCA, continued growth of XIAFLEX in DC and PD and the seamless integration and continued growth for our generics business. Second, we are executing using our differentiated operating model. We are advancing our derisked R&D pipeline and moving key XIAFLEX programs into clinical trials this year, and we are continuing past [ph] R&D pipeline momentum and productivity. Third, Endo is achieving sustainable growth. As Suky mentioned, we expect to delever back down to the 3 to 4x net debt to adjusted EBITDA range this year. And in our continuing efforts to diversify our revenue base, we expect to drive underlying growth in our emerging markets with our rebased Somar and Litha businesses. 
Next on Slide 17, we are very pleased to have launched BELBUCA last week. We believe BELBUCA is well differentiated as it combines Schedule III status, proven efficacy and established safety and tolerability profile of buprenorphine with a novel delivery system that adds convenience and flexibility for patients. To support our launch into the nearly $5 billion, long-acting opioid market, we've more than doubled our pain field force and have been working to ensure broad patient access. We believe BELBUCA is strongly positioned for growth and are projecting sales to be greater than $250 million in 2019, which, while significant, represents only a small proportion of the existing current market. 
Turning to Slide 18. You will see the scope and size of the chronic pain burden that we are looking to address with BELBUCA. More than 30% of all Americans or about 100 million people are suffering from chronic pain. This is more than diabetes, coronary heart disease and cancer combined. 
On Slide 19, let's discuss where we are positioning BELBUCA within the chronic pain treatment paradigm. We see a prime opportunity for BELBUCA to serve those patients who are transitioning from short-acting opioids to a long-acting opioid treatment. We also see potential for BELBUCA and its differentiated product profile to make an impact by capturing patients searching from other long-acting opioids or those who are opioid-naive and are going directly to a long-acting opioid product. In short, we believe the opportunity for BELBUCA is exciting and significant, and our early feedback from customers on the launch has been very positive. 
Next on Slide 20, let's talk about our progress with XIAFLEX. XIAFLEX continues to perform in line with our internal growth expectations. We continue to aspire to build a $1 billion franchise around this molecule. We are projecting continued momentum into 2016 and double-digit growth for this product over our planning horizon. This growth will be fueled in part by our multi-pronged sales and marketing campaigns designed to increase physician and patient awareness. In terms of the R&D pipeline, XIAFLEX continues to exceed our internal -- initial expectations and are continuing to move new programs into the clinic this year. 
Next on Slide 21, you will see the considerable market expansion opportunity for XIAFLEX. While it was launched more than 5 years ago and has seen steady growth and increasing traction over time, we believe there's a significant opportunity for us to grow market share for XIAFLEX for Dupuytren's contracture using our DTC campaigns and to continue building traction for the multi-cord indication. In Peyronie's disease, we are seeking to expand the market through an unbranded disease awareness campaign. While a large number of diagnosed patients are currently untreated, XIAFLEX is showing very strong penetration amongst those patients that are treated. We believe that by continuing to capture those patient treatments and expanding the base of patients seeking a treatment option, we can continue the robust double-digit growth in this indication.
In summary, across our branded business in 2016, we expect to drive growth with BELBUCA, XIAFLEX and other products, including our long-acting TRT portfolio, with some offset by continued erosion in our legacy products. As a result, we project low single-digit underlying growth for this business. 
Moving to Slide 22. Our focus on value creation also includes our U.S. Generics business. This 2015 and 2016 breakout of our pro forma generics revenue illustrates key segments of our Par business as well as how those segments are growing. Most importantly, the segments that are growing substantially are also those that represent our highest-value products. In fact, we project that in 2016, more than 40% of our generics revenues will come from revenues in our highest-value and highest-growth categories. First, new launches and alternative dosages will be a key growth driver this year as it includes the introduction of first-to-file products like the generic versions of Zetia and Seroquel XR, which we expect to bring to market at the end of 2016. This category also includes differentiated higher-barrier-to-entry and higher-margin products like patches, powders, ophthalmics and other alternative dosages. 
Next, sterile injectables have tripled in net sales since Par acquired JHP in 2014, and these products have high barriers to entry, high margins and strong competitive positioning and growth potential. We project significant continued double-digit growth, with gross margins well above the company average for this segment in 2016. In summary, across our generics business in 2016, we project underlying growth in the mid to high teens. 
Moving to Slide 23. You will see that the effect of our collective efforts and our acquisition of Par in 2015 are not only increasing the size of our portfolio and generics pipeline, but also growing revenue and improving our gross margins. We expect to meaningfully continue this expansion into 2016 and beyond.
Next on Slide 24. Let's talk about our differentiated operating model, specifically our derisked XIAFLEX R&D pipeline. As I mentioned earlier, we anticipate that we will initiate new clinical programs this year. Beyond that, we see a broad range of potential aesthetic and therapeutic indications with significant unmet needs with large patient populations and market potential that we believe will drive the long-term value of XIAFLEX. 
Moving to Slide 25. Let me take a moment to provide you with an overview of our recently initiated Phase IIb clinical trial in cellulite. Cellulite affects nearly all women and there is little evidence that current treatments are effective. 
Moving to Slide 26. Our differentiated operating model and derisked R&D approach also drives our generics activities. Par brought with it some of the industry's strongest Paragraph IV, first-to-file and first-to-market R&D capabilities. Those capabilities are fueling a projected stream of potential high-value, high-margin product launches in 2016 to 2019 time frame. Specifically, we project more than 100 potential product launches over that horizon, including 20 first-to-files. 
Next on Slide 27. Let's talk about our emerging market international business as another driver for sustainable growth. Overall, we expect our International business segment, including Paladin in the more established Canadian market, will demonstrate a high single-digit underlying growth rate in 2016, driven by emerging markets businesses. That said, we believe international reported revenues will decline in 2016 due to a stronger dollar versus 2015, increased generic competition for the Paladin portfolio and divestitures of low-margin device and vaccine products from the Litha portfolio. However, importantly, we expect that our 2016 operating income from this business segment will be in line with 2015 due to our successful rebasing of our emerging markets businesses.
You will see here the expected impact of this rebasing on Somar and Litha revenues and operating margins in 2016. We expect a significantly improved margin profile in International segment and low double-digit underlying growth across Somar and Litha this year. 
With that, let me turn the call back over to Suky to talk about our full financial guidance for 2016. Suky?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products,",650,"Thank you, Rajiv. On Slide 29, we have outlined the key considerations built into our 2016 financial guidance. First, our guidance incorporates a risk-adjusted range of scenarios around potential 2016 generic and competitive entrants for select products, including Voltaren Gel, LIDODERM AG, FROVA, Valganciclovir and low-dose hydrocodone APAP. Second, while our diversified portfolio insulated us for most of 2015, as Rajiv mentioned, we do expect pricing headwinds in U.S. Generics to continue across the sector and for there to be a more challenging pricing environment for commoditized products. And third, we assume current exchange rates for foreign currency conversions. 
So on Slide 30, you will see the highlights of our full year 2016 financial guidance are as follows. We expect total net revenues to be in the range of $4.32 billion to $4.52 billion. We project adjusted gross margins of 63% to 65% this year, which is in line with 2015 despite a higher mix of generics revenue in 2016. This is primarily driven by the continued growth of XIAFLEX, the launch of BELBUCA and our continued shift towards high-value products in our generics business. Each of our segments is expected to maintain or improve their gross margin profile in 2016 versus 2015. Despite increases in branded promotional spending across XIAFLEX and BELBUCA and higher R&D expenses to support the branded and generics pipelines, total expenses are growing below the rate of sales as we leverage G&A and capture the full synergies from the Par transaction. This translates into a projected adjusted operating expense to revenue ratio of 19.5% to 20%, which is more than 150 basis point improvement versus 2015. Under these assumptions, we expect adjusted EBITDA margins in the mid-40s, which is better than our 2015 EBITDA margin profile. Adjusted interest expense is expected to be approximately $455 million. This estimate includes approximately $34 million of amortization of deferred financing fees in 2016 and also assumes debt pay-down of about $500 million in 2016 versus ending gross debt balances in 2015. 
Given our continued progress on building out our infrastructure in Dublin, leveraging deal attributes and executing on our tax strategy, as observed through 2015, we expect an adjusted effective tax rate of 9% to 11% for the full year of 2016. These moving parts translate to an adjusted diluted earnings per share range of $5.85 to $6.20 with approximately 224 million weighted average diluted shares outstanding. 
As expected, our results will be lumpy through the year, driven by a number of factors, including the early investment and corresponding ramp of BELBUCA; the timing of potential market events around key products in the branded and generics portfolio that Rajiv mentioned earlier; the cyclical nature of some of our businesses, including fluctuations in stocking levels; and the anticipated launch of our generic versions of Seroquel XR and Zetia in the fourth quarter of 2016. 
Using the midpoint of our revenue and EPS ranges, we expect about 54% of revenues and about 57% of EPS to be in the second half of 2016. This weighting is heavily influenced by the expected timing of the Zetia and Seroquel launches. Again, using the midpoint of our revenue and EPS ranges, we expect about 22% of revenues and 18% of EPS to be in the first quarter of 2016. This is driven by normal cyclical trends and destocking that we historically see in the first quarter. Also investment for BELBUCA in the first quarter more than offsets revenues for that product as we will book revenues based on demand until we see a normalized pattern of shipments versus demand trends. 
So in summary, we believe the 2016 financial profile will be a continuation of 2015, which was marked by solid underlying revenue growth, margin expansion, an attractive tax rate and strong underlying cash flow conversion. 
Now to close out the call, let me turn it -- the call back over to Rajiv. Rajiv?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified",197,"Thank you, Suky. Moving to Slide 31. In summary, we see the Endo story as one marked by significant growth, increased profitability and value creation in 2016 and beyond. We are building a leading global specialty pharmaceutical company with 3 diversified and strongly positioned businesses. Our focus is on value creation, which we plan to drive through our priorities, including a strong commercial launch of BELBUCA, continued growth for XIAFLEX and continued growth for the Par portfolio. We utilize a differentiated operating model that is based on a diversified product portfolio and a strong derisked R&D pipeline across our businesses. And finally, we are achieving sustainable growth with a projected double-digit underlying growth rate, increasing operating margins, strong cash flow conversion and the ability to delever rapidly. 2015 was a year of transformation and continued evolution for Endo. We see 2016 as a year of execution, of delivering on the promise and potential of our business and of creating significant value for our shareholders. We look forward to achieving these goals and to your continued support. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please.",23,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question please."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our first question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Rajiv, or maybe this is better for Paul. Can you just expand on some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite with an expectation of gr",82,"Rajiv, or maybe this is better for Paul. Can you just expand on some of the pricing headwinds that you're seeing and factoring in? Most of your larger peers are talking about a similar erosion level this year to last year despite with an expectation of greater approvals. So can you, I guess, help us understand the Qualitest impact from 4Q? How is that likely to continue? And then what type of erosion are you expecting in the business for this year?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. And what I'll do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what he is seeing from the consortia and how that's changing our view on pricing in this sec",50,"Sure. And what I'll do is maybe I'll just pass it to Suky for just a comment on the financial aspect and then Paul can comment on the more qualitative aspects and what he is seeing from the consortia and how that's changing our view on pricing in this sector."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So the first thing I would say is into the fourth quarter when we give preliminary results around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commoditize",205,"So the first thing I would say is into the fourth quarter when we give preliminary results around 2015, that did imply some softness in 2015 fourth quarter around generics. We did start to see the early signs of some volume erosion in our more commoditized parts of our business. And then as we closed out our final processes for the year, we did recognize higher level of chargebacks and rebates coming through, specifically around our more commoditized portfolio as well as our pain franchise. That, in tandem with onetime charges that occurred in the fourth quarter, led to a lower-than-expected fourth quarter. I should say that those onetime charges we do not expect to continue in forward-looking quarterly results, but there is some underlying pressure around pricing that will extend in 2016. Having said that, all of that is baked into our forward-looking estimates for 2016. And as Rajiv noted earlier in scripted remarks, we still see very strong generics growth in the mid-teens to high teens, primarily driven by our injectables business, continued growth across the base as well as our launches on day [ph] certain products. I don't know, Paul, if you want to add anything more on the price erosion, please."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I think that's right. I think Suky really hit the nail on the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortiums is really resulted back in Q2 of last year when you saw Red Oak and OneStop in full o",169,"I think that's right. I think Suky really hit the nail on the head. When you look at consortiums, et cetera, really it started back -- the full impact of the consortiums is really resulted back in Q2 of last year when you saw Red Oak and OneStop in full operation. I think on a go-forward basis, to Suky's point, we are prepared for it. It's part of our 2016 forecast. And really when you look at the commodities business, it's going to be very, very challenging to take price increases like we had historically seen over, maybe, the past couple of years, but that again is all planned for. Our focus is clearly on our pipeline. It's all on execution. Rajiv touched on it in his opening comments that this year is going to be a year of execution. We've got to get our products out of the FDA. That's our defense. That's our strategy on a go-forward basis. It's our portfolio and getting our products approved."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Can you just...",4,"Can you just..."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Operator -- go ahead Randall?",5,"Operator -- go ahead Randall?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Can you just confirm that there is no pricing increases built into the 2016 guidance?",15,"Can you just confirm that there is no pricing increases built into the 2016 guidance?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio, that we can selectively and very appropria",62,"So from that standpoint on the generic side, we have not taken any real price increases that are material. Clearly, the plan is driven on volume. Maybe we have to point out a few brands, the injectable portfolio, that we can selectively and very appropriately increase. But to answer your question on the generic commodities business, it's a volume gain for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Our next question comes from the line of Louise Chen from Guggenheim.",12,"Our next question comes from the line of Louise Chen from Guggenheim."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So first question I had here was on gross margin expansion and operating leverage in '16. How should we think about that in light of your results in the fourth quarter? And then second question is on the generics business. How should we think about the un",57,"So first question I had here was on gross margin expansion and operating leverage in '16. How should we think about that in light of your results in the fourth quarter? And then second question is on the generics business. How should we think about the underlying growth outside of Seroquel, Zetia and the sales progression quarter-over-quarter?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question.",24,"Let me have Suky cover the gross margin question, Louise, and then Paul and I will come back and talk about the generics question."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was, with a higher mix of generics products versus branded, we might see some dilution into our gross margin. As we actually work through o",282,"Yes. So actually a little bit better than expected from the closing of Par. Our initial expectation going into 2016 was, with a higher mix of generics products versus branded, we might see some dilution into our gross margin. As we actually work through our plan and our portfolio prioritization, we're actually moving to a higher mix of higher-value products, which is ultimately expanding our margins. So as Paul talked about or as Rajiv talked about in his scripted remarks, the growth of the injectable franchise is one that is characterized with a gross margin profile well above the overall company average as we think about the launches of some of our day [ph] certain products. Those are also products that have gross margin profiles well ahead of the overall gross margin average. And then when you add in continued growth of XIAFLEX as well as BELBUCA, both of which have gross margin profiles above the company average, you start to form a picture of where we're going to see this gross margin expansion into 2016 and one that we're very pleased and confident in. And then from an operating margin perspective, as I said, we are going to spend more against advertising and promoting -- promotion against XIAFLEX and BELBUCA. We are going to spend more this year around R&D for generics and for branded, full stop. However, we are getting operating leverage through G&A as well as through the full realization of the Par synergies sometime in mid-2016. So not only do we get operating margin expansion -- gross margin expansion, we're going to see operating margin expansion as well and also on top of a very favorable tax rate."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. And just to touch on your growth question, Louise, let me take a crack at it and then Paul will add. While you mentioned Zetia and Seroquel, keep in mind that what Par has over the '16 to '19 time frame is 100 possible product launches, r",185,"Thank you, Suky. And just to touch on your growth question, Louise, let me take a crack at it and then Paul will add. While you mentioned Zetia and Seroquel, keep in mind that what Par has over the '16 to '19 time frame is 100 possible product launches, right? So certainly, Zetia and Seroquel stand out because of their magnitude. But as we talked about in the past, those are also partnered products, right? So as you look out over this entire horizon, you will have many, many more launches, most of which are not partnered where the bottom line is -- equates entirely to Endo, right? So from that standpoint, we do see new launches being the primary driver of growth in this business in '16 as well as into the future. I would also say that the injectables business has been a great performer for Par. It's tripled in size since JHP was acquired by Par, and we expect to see that momentum continue in '16 as well as beyond. I don't know, Paul, if you'd like to add anything to that."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Thanks, Rajiv. And I think that's right. I mean, when we look at 2016 -- I mean, we all know that Zetia and quetiapine are clearly large drivers coming at the end of Q4. And not apologizing for that, those are hard-to-develop products, hard-to-",269,"Yes, sure. Thanks, Rajiv. And I think that's right. I mean, when we look at 2016 -- I mean, we all know that Zetia and quetiapine are clearly large drivers coming at the end of Q4. And not apologizing for that, those are hard-to-develop products, hard-to-partner products and we're very proud of those relationships. That said, we have about 20 products that we should be launching in 2016, albeit maybe not major, major drivers. But in the generic industry, you never actually know what product can outperform. And as some examples, when we look at what we achieved in 2015 that are carrying us into 2016, we had a handful of carryover products like pramipexole, dutasteride, tamsulosin. These are relatively smaller-type products that ultimately have limited competition. They're going to carry us into the first part of 2016. Again, hard to make, but from a brand sales standpoint, maybe not of [ph] the largest products, but good drivers. When we look a little bit at the sterile portfolio, we are real proud of what we have in Rochester. I think it's a great time to have a sterile facility on U.S. soil. It continues to be a barrier to entry. Products like Vasostrict have continued to outperform, and that's on the branded side. But additionally, we have a handful of generic products that have had limited competition, products like dexmetatopadine [ph] and ethacrynic acid. These are all products that have been genericized, but limited competition. And again, these, factored in with some of our overlap and carryover products from last year, should give us a good basis for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Liav Abraham with Citi.",10,"And our next question comes from Liav Abraham with Citi."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking or do you anticipate any more? And if so, how meaningful could they be? And then secondly, related to that, how do yo",63,"Just a couple of questions on the mesh liability. Can you confirm that this is pretty much the end of these charges that you'll be taking or do you anticipate any more? And if so, how meaningful could they be? And then secondly, related to that, how do you expect this liability to impact your cash flows going forward? That's it for now."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. We have discussed mesh over the course of the last 2 years, and I think as you know, with these mass tort litigation situations, it is very difficult to predict the end, right? That being said, what I would say is that we have come a long way. And a",446,"Sure. We have discussed mesh over the course of the last 2 years, and I think as you know, with these mass tort litigation situations, it is very difficult to predict the end, right? That being said, what I would say is that we have come a long way. And although the environment has continued to be more challenging than we had thought, I mean, with the initial settlements, which, by the way, I'm glad we did, but the reality is that the rest of industry at that time didn't follow with additional settlements as we would have expected, right, and there was increased advertising, which is kind of what's led to this additional bolus of claims in the back end of 2015. Now as we look at what we have done here though, I do feel good that the current settlements that we just announced this morning are ones that are focused on the high-value claims. And effectively, what is left is what we believe to be a much lower-value set of portfolio cases, many of them could be spurious. And in addition, this is -- there's an evidence of potential fraud amongst some of these cases as well, right? So as we look at what remains, we do think it is a portfolio we can be a lot more aggressive in terms of how we approach it, either in terms of taking some cases to trial as well as potentially through an investigation of this fraud, seeking to dismiss a chunk of it as well, right? So -- and also keep in mind, we've now put a significant time between us and the public health notice that the FDA issued in 2011. That again, should also be another factor that drives to reduce the number of new cases. And then finally, our decision to shut down the ASTORA business also will contribute to reducing the potential for future liability. So I think as we stand here today, we do feel good about where we've taken the mesh liability despite the additional increment that we saw in 2015. We do expect to resolve the remainder of it over the course of the next couple of years. There's no guarantee that accrual may or may not change. What I would say is that we are confident, given what we know now, about where we have brought the situation. And then fundamentally, we're a different company now, right? So we have, on adjusted basis, more than $2.5 billion or roughly around $2.5 billion of adjusted EBITDA, which allows us the ability to manage this over time and makes it a lot more manageable call on our cash."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. And Liav, this is Suky. Relative to your question on how it impacts cash flow -- so as we pointed out in the slides, at the end of fourth quarter, we've got a pretax remaining cash call of about $1.5 billion after we make these additional accruals. S",206,"Yes. And Liav, this is Suky. Relative to your question on how it impacts cash flow -- so as we pointed out in the slides, at the end of fourth quarter, we've got a pretax remaining cash call of about $1.5 billion after we make these additional accruals. So again, pretax remaining cash call of $1.5 billion. We expect in 2016 to pay somewhere around $850 million to $900 million of that $1.5 billion on a pretax basis. But after you consider the tax refund that we'll be getting as part of our structuring of the AMS sale, our post-tax obligation for mesh in 2016 will be somewhere between $150 million to $250 million, so quite manageable in the backdrop of $2 billion plus of EBITDA in 2016. As we move to 2017, as we've put in the slide, we expect the post-tax cash call there for the residual of that liability that I talked about to be somewhere between $350 million and $450 million, and again, that's going to be on the base of EBITDA from 2016 of $2 billion plus, to one that's growing double digits into 2017. So again, very manageable cash call in the backdrop of very robust underlying cash flow generation."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Gregg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Gregg Gilbert with Deutsche Bank."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly, Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term?",45,"A couple of quick ones. First, can you quantify Par sales in the fourth quarter? Secondly, can you quantify the generic charges in the fourth quarter? And lastly, Suky, can you help us understand whether the 9% to 11% tax rate is sustainable longer term?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. I think the answer to the first question is very simple. It was $359 million of sales of Par in the fourth quarter. And then Suky, do you want to...",31,"Sure. I think the answer to the first question is very simple. It was $359 million of sales of Par in the fourth quarter. And then Suky, do you want to..."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. The one thing I would say, that $359 million was a little bit better than our expectation, primarily driven by the injectables business. We're also seeing good solid performance in the base business. As Paul talked about a little bit earlier, that sh",237,"Yes. The one thing I would say, that $359 million was a little bit better than our expectation, primarily driven by the injectables business. We're also seeing good solid performance in the base business. As Paul talked about a little bit earlier, that should carry over into 2016 as well. I will also say as we move forward into '16, Paul is looking at this portfolio as one portfolio, so we will not break out Par versus legacy Qualitest sales. We treat this as one business and that's how we'll report on it. The charges in the fourth quarter were about $30 million that we consider to be onetime and nonrecurring. It's really 3 factors that make this up. Well, there's a number of factors, 3 of which are examples -- are around trade disputes in the fourth quarter. We have some changes in estimates around gross to nets. And third, we had some charges higher than expected around the harmonization of our methodologies around gross to nets as we integrated Par and Qualitest. Again, we do not expect those to reoccur on a quarterly basis going forward. Your last question, Gregg, around the tax rate, again, very pleased where the tax rate is migrating. We expect our effective P&L tax rate in '17 and beyond to be in the low double digits to low teens, but there is, again, continued opportunity to improve that over time."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from Annabel Samimy with Stifel.",10,"And our next question comes from Annabel Samimy with Stifel."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just wanted to understand a little bit the underlying growth in generics in, I guess, the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the u",60,"Just wanted to understand a little bit the underlying growth in generics in, I guess, the first part of your call. Obviously, we see that there was a hit from the commoditized business. What component of the Par business is commoditized? And what is the underlying growth of Par right now? And how can we think about that going forward?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Annabel, this is Rajiv. Let me start and then Paul -- I think I don't know if you were a little late for the call. You may not have heard us talking about the growth drivers for '16. So there are 2 primary drivers for '16 and frankly, these will be the dr",230,"Annabel, this is Rajiv. Let me start and then Paul -- I think I don't know if you were a little late for the call. You may not have heard us talking about the growth drivers for '16. So there are 2 primary drivers for '16 and frankly, these will be the drivers with Par as well. One are new launches, right? So obviously, in '16, you have the impact of Zetia and Seroquel. But just beyond that, there are 100 potential launches that Par has in the time period of '16 through '19. So that is firstly the biggest driver of growth. It's all about volume and launches of those products. And the second area of growth is the injectables, the sterile injectables portfolio, which is -- which will be a robust contributor to 2016 as well as beyond. Now outside of that, we have, in the combined business, plus or minus 1,000 SKUs, right? Now part of that, Par will continue to optimize. But among the remainder, there will be certain molecules that do well for us and certain ones that won't, right? So that's the benefit of having a diversified portfolio. But net-net, when you put all these 3 factors together, on the back of those launched products and the sterile injectables business, we feel very good about the trajectory in '16 as well as beyond that."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Is there some underlying growth that we can assume for the generics business at this point?",16,"Is there some underlying growth that we can assume for the generics business at this point?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So we -- yes, we've talked about mid- to high teens for the generics business for now for 2016.",19,"So we -- yes, we've talked about mid- to high teens for the generics business for now for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Shibani Malhotra with Nomura Securities.",14,"And our next question comes from the line of Shibani Malhotra with Nomura Securities."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","This is Austin Nelson on for Shibani. The first question, I mean, a couple with [ph] -- in one of the slides, there is a point that the OPANA ER abuse-deterrent label settlement has been resubmitted to the FDA. I'm wondering if you can give any color arou",132,"This is Austin Nelson on for Shibani. The first question, I mean, a couple with [ph] -- in one of the slides, there is a point that the OPANA ER abuse-deterrent label settlement has been resubmitted to the FDA. I'm wondering if you can give any color around your expectations on when we could hear from the FDA. And then if Endo does receive abuse-deterrent labeling, would you expect that the old formulation generics will be removed from the market for safety? And then the other question was on the expectation for net debt to EBITDA guidance, get back down into the mid-3 to 4x range, did that include only restricted cash? Or does that include cash that will be accrued for the accrual but not actually paid out in the year?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So on the -- let me get the OPANA question and Suky can talk for the debt question. The OPANA ER submission has gone in, and it was a monumental effort just because this is not only the inclusion of data from our insufflation study but also a lot of epi d",146,"So on the -- let me get the OPANA question and Suky can talk for the debt question. The OPANA ER submission has gone in, and it was a monumental effort just because this is not only the inclusion of data from our insufflation study but also a lot of epi data. The FDA has set an action date of July 29, 2016, for the file. So that is the time frame in which we expect to hear back from them. Now even if we are successful in getting the relabeling, if the -- it would certainly serve to help remove all the generics on the market with the exception of Impax that has the impaired license to the product, and therefore, to do so would require a longer path, including a citizen's petition, which we certainly would undertake but it would not be immediate. Suky?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is excluded from that calcu",47,"Yes. Relative to your question on EBITDA -- sorry, on our net debt leverage calculation, the way we think about that is the only cash we put in there is unrestricted cash. So restricted cash that is meant for the mesh liability is excluded from that calculation."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellem with Piper Jaffray.",14,"And our next question comes from the line of David Amsellem with Piper Jaffray."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So a couple of questions on generics. So you had mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition -- f",108,"So a couple of questions on generics. So you had mentioned Vasostrict earlier in the call. Can you talk about how much of the Par sales mix consisted of Vasostrict in the fourth quarter and what your thoughts are on the potential for that competition -- for that product to have competition down the road? So that's number one. And then on the Seroquel and Zetia generics, given these are partnered, can you help give us a sense of how the margins on these will look like during the exclusivity period compared to margins, gross margins for the overall generics business given that you've got shared economics there?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks, David. So on the Vasostrict question, so we are not going to break out our guidance at a product-line level of -- and now the product revenues for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important driver",67,"Yes. Thanks, David. So on the Vasostrict question, so we are not going to break out our guidance at a product-line level of -- and now the product revenues for the fourth quarter. But certainly, suffice it to say that Vasostrict is a very important driver for us in 2016. But maybe, Paul, you can comment a bit on your views on possible future competition for Vasostrict."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Thanks. So Vasostrict, remember, is an NDA, right, so that was filed as a 505(b)(2), so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very",81,"Yes, sure. Thanks. So Vasostrict, remember, is an NDA, right, so that was filed as a 505(b)(2), so it's not a generic product. Our goal will be to have proper and appropriate protection on a go-forward basis. That's something that we're working very, very hard and close with the patent trade office. Again, but at this point, there are certain things that are unknown. But again, we are looking to protect that product, as you would expect, from an NDA standpoint."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Zetia and Seroquel.",3,"Zetia and Seroquel."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","On the Zetia and SEROQUEL question, we have 2 partners. But during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would say",64,"On the Zetia and SEROQUEL question, we have 2 partners. But during the exclusivity period, there are certain mechanics that are contractual obligation. I would say that it behaves more like a balanced partnership for the exclusivity period. So I would say it's more of a 50-50 like type relationship. Post day 181, I would say it behaves more like a standard 3-player partnership."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. David, just to put a little bit more on what Paul just gave there. So Seroquel, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average",50,"Yes. David, just to put a little bit more on what Paul just gave there. So Seroquel, we would expect to be slightly above the overall company average during the exclusivity period. And Zetia, we would expect to be in line with the overall generics average during the exclusivity period."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Great. Just 2 questions here. Just first, on BELBUCA, can you just talk about the launch expectations? I know you've talked about 2019, but just as we go out to 2016, what type of ramp should we think about here as we're thinking about the initial modelin",162,"Great. Just 2 questions here. Just first, on BELBUCA, can you just talk about the launch expectations? I know you've talked about 2019, but just as we go out to 2016, what type of ramp should we think about here as we're thinking about the initial modeling? And the second question is the bigger-picture one. I guess, over the last 18 months, the company has done 2 large acquisitions with Auxilium and Par. You pursued probably a third one with Salix. As I think about the next 12 months and the evolution of the company, is this just a fundamentally different environment from an M&A perspective where we're not going to these big deals or they're much less likely? Or do you see what's happening in the market now, just a temporary pause or slowdown and that eventually, we're going to see the high level of consolidation that has been playing over the last few years kind of returning to the sector?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Thanks, Chris. So on BELBUCA, we're very pleased that we're able to launch the product as we have predicted. In the month of February, I was personally at a national sales meeting. We are very excited and expanded the pain field force, also the feed",741,"Sure. Thanks, Chris. So on BELBUCA, we're very pleased that we're able to launch the product as we have predicted. In the month of February, I was personally at a national sales meeting. We are very excited and expanded the pain field force, also the feedback for the product has been very good, and all of our managed care conversations are going well, right? That being said, it's early days from a managed care contracting standpoint. It's also early days in terms of the actual launch of the product. And as we had indicated before, while we have every confidence in this product, which is why we've put out an aspirational number for 2019 of $250 million, we do expect the ramp to be somewhat gradual in the first 12 months, and that's just reflecting unknowns, right? So this is a different format, a buccal patch, which, while there are many advantages, patients and physicians need to get used to it. For those patients that are on other LAOs that are being transitioned to BELBUCA there needs to be down titration and up titration. So these things will take time for physicians to get used to. And also, as you well know, from a market access standpoint, while commercial covered lives, you can contract early in a launch, when it comes to Medicare Part D coverage, which is roughly about 1/3 of the coverage in this market, that usually waits for a full cycle, right? So we certainly would look to 2017 to have a more -- much more substantial ramp than in 2016. But all the early signs are well within our expectations of what we expect to see for the product. On your question on M&A, let me answer from an Endo perspective and then -- and see if we have any further clarification on it. For us, as you pointed out, 2015 was a very, very transformational year in terms of transactions, right? So we -- in particular, we concluded Auxilium, the Par transaction, and at a smaller level, Aspen transaction in South Africa, which essentially gave us new platforms, right, and a sense of critical mass, particularly in our generics business. In many ways, we accomplished what we set out to accomplish, which is to get a set of assets, which, even if we do no further M&A, gives us a path to double-digit growth. And then you couple that with a market environment where the debt markets are weak, as are the equity markets. But for us, leaving the market conditions aside, 2016 really is about execution, which is why we've talked so much about BELBUCA, about XIAFLEX, the Par integration. Those are the things that are going to make us successful. So from that perspective, M&A is not a key priority for us in 2016. I have said -- in the past, I've said we will continue to monitor opportunities. But realistically, I think the types of opportunities that make sense for us in 2016 will be the small in-licensing or product acquisition here or there either for our branded business or international, but we're talking -- we have a very small call on our cash for doing those types of things if the opportunity come across them. In terms of larger transactions, it is not our anticipation to do -- to look for large acquisitions in 2016. I have, however, said that if there are -- if there is a larger merger, which could be value-creating that is done on the basis of the relative value of 2 companies, those are the types of things that we certainly will evaluate if they come our way. But certainly, it is not high on our list of priorities in terms of acquisitions as we look out over '16. Now back to your question about the nature of what's going on in the industry. I would say, certainly, the debt markets and equity markets have led to somewhat of a pause. But overall, if we look over the last 20, 30 years, this is a still highly fragmented industry. There are lots of -- it's been a deal-rich industry for a long period of time. Obviously, those deals are cyclical, and my suspicion is that deals will continue to be an important part of this industry as we look forward. But 2016 is certainly likely to be -- to see a pause, at least from our perspective."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","A few things. First, there were a couple of products, LIDODERM and Voltaren Gel, that seemed to do much better than we would have expected. Can you just talk if there was an inventory build there or what was going on? Second of all, you've talked about 20",219,"A few things. First, there were a couple of products, LIDODERM and Voltaren Gel, that seemed to do much better than we would have expected. Can you just talk if there was an inventory build there or what was going on? Second of all, you've talked about 2017 kind of implying a $7 number, which now, with Voltaren Gel back, seems a little low. And especially given the way you're talking about tax rate now, relative to before, I would think that, that number of $7 is too low and needs to be brought up. So maybe you can talk about that a little. And then third, I'm just trying to understand, on the generics business, the pricing that you're talking about. There's one aspect of it, which is the commodity pricing, but then there's the other aspect, which is the pain products, which have been really important for you. And I guess, the question is, we've heard from other companies in the space, and they were complaining about new players coming back last year and they were complaining about pricing in that market and they were having some troubles there, and yet Endo was not complaining at all at that time. And now there seems to be a delayed impact. So I'm trying to understand why is that."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Let me -- let's see if we can hit your questions in order. With respect to the V Gel, it was a very good year last year. We had, I think, double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I thin",484,"Sure. Let me -- let's see if we can hit your questions in order. With respect to the V Gel, it was a very good year last year. We had, I think, double-digit prescription volume growth, and that was the driver of V Gel for the year. In the LIDODERM, I think we have been -- that we've been successful in holding some of our contracts through '15, probably even better than we had expected on the branded LIDO. But as we enter into '16, we do expect to see some drop-off of those contracts and that would be seen when we see our 2016 results, but it's already factored into our guidance. 2017, Marc, we're not going to comment on 2017. Clearly, we made that commentary in the back -- against the backdrop of the Par transaction. First of all, I'm delighted to say what we committed to the outside world when we did the Par transaction, which was an accretion number for 2016, that is borne out in our guidance, as well as the implied multiple that we put out there for the Par transaction, which was 10 to 11x post-synergy EBITDA multiple, that is also following through in the 2016 numbers. As you said, there are lots of other puts and takes in our business. Certainly, V Gel is one. We are very excited about the extension of the agreement. There's always the possibility and potential of a generic on V Gel, which we also have to keep in mind, which -- it's somewhat offset in our new agreement by the fact that we have the right to an Authorized Generic. And a lot of 2017 will also depend on how we're doing on BELBUCA and XIAFLEX. So we are very optimistic as we look at the '16-and-beyond time horizon for Endo. That being said, we're not going to provide any specific further guidance on '17. On the generics question, I'll start and I'll bounce it to Paul. I think what I would say is if you could separate the commodity -- the traditional commodity products from the pain products, and as you pointed out, pain has been a traditional area of strength to us, we have often taken the approach of focusing on value versus pure volume on the pain business, right? So although we've taken some substantial volume declines in our pain portfolio, they are somewhat anticipated based on the price increases we took and of course, we've taken. So net-net, from a value standpoint, we're actually pleased with how the pain portfolio has performed. But is there a pricing pressure in pain as well as the commodity portfolio? The answer is yes because there are smaller players who tend to be aggressive even in the pain arena now, more so than they have been in the past. I don't know, Paul, if you have any comments about that."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, I think that's right. I mean, at the end of the day, you have product and you also have timing issues with consortiums. And our contracts with certain trade partners, I think that was part of what we've also saw, right, again, seeing the full impact",139,"Yes, I think that's right. I mean, at the end of the day, you have product and you also have timing issues with consortiums. And our contracts with certain trade partners, I think that was part of what we've also saw, right, again, seeing the full impact of Red Oak really kicking in, in Q2. So you have the timing -- you've got a timing issue that we were focused on. So to your point, to Rajiv's point, clearly, yes, there are more competitors in the narcotics space, and we're seeing that. But we had our select wins, right, across the board. So to Rajiv's point, select wins, yes, we may have sacrificed certain pricing -- sorry, certain volume shortfalls. But ultimately, I think the timing of the consortium is probably the main issue that we saw in 2015."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just on -- first, on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking or is this sort of just the seasonal nature of the product, where it's a little bit stronger in 4Q, coupled with heightened demand? And secon",82,"Just on -- first, on XIAFLEX, a little stronger than we were forecasting into the quarter. Was there any stocking or is this sort of just the seasonal nature of the product, where it's a little bit stronger in 4Q, coupled with heightened demand? And secondly, as we think about some of the consumer initiatives to drive awareness of the product in '16 on the SG&A side, when can you expect to start to see that translate on the increased volume side?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel[Audio Gap][indiscernible]. Now that being said, we had indicated in the third quarter that it would be",209,"Sure. Jason, so we ended XIAFLEX in terms of inventories roughly where you would expect. It is not a product that has a lot of stock in the channel
[Audio Gap]
[indiscernible]. Now that being said, we had indicated in the third quarter that it would be a little bit lower than that. So that -- there's probably a little bit of stocking impact going into the fourth quarter, but nothing out of the ordinary. As you pointed out, especially the back end of the fourth quarter tends to be a heavy period because there are many patients who like to schedule their surgeries during that holiday period, so that is also a contributor. I think as we enter 2016, we are excited about everything, all the changes we put in place, both internal as well as some of the new programs that we have put in place like the disease awareness program that I referred to in Peyronie's disease. So many of those are just now kicking off. So realistically, for them to have a real impact, I think you're looking at probably the third quarter before we can really report back on successes of these programs, but early indicators of all of them have been very positive."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones. Secondly, on XIAFLE",96,"I just had a couple. So I think on the last earnings call, you wrote or you said that you expect 5 to 7 new generic product launches in Q4. I was wondering if you got those product launches and maybe what were some of the biggest ones. Secondly, on XIAFLEX, can you outline the number of shipped vials in each indication, Peyronie's and Dupuytren's? And then going back to the mesh claims, I think you said there were 8,000 mesh claims that hadn't been accrued for. What is the potential value of those 8,000 claims?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the f",153,"Sure. So let me start on the mesh while we get some of the data for your first question. So on mesh, while we identified this possible portfolio of 8,000 cases, the reason that we are not moving forward with any settlements for that portfolio is, a, the facts are very unclear across this portfolio. Most of these cases, we don't even have medical records. As I pointed out, there is evidence of fraud, at least on some subset, that we are investigating vigorously. So as a result, we're not in a position to assign a value to it, other than to say that we do expect, at this point in time, based on advice that we are receiving from outside counsel, the value of these cases are lower than the ones that we have just settled now. And Q4 launches, Paul, do you have any other -- the data on that one?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So Q4, the products that we're probably most proud of coming out of Q4 was, again, the dutasteride/tamsulosin product. That is a Jalyn product from GSK. Also, a product called pramipexole is another product that we executed on for the fourth quarter. We d",75,"So Q4, the products that we're probably most proud of coming out of Q4 was, again, the dutasteride/tamsulosin product. That is a Jalyn product from GSK. Also, a product called pramipexole is another product that we executed on for the fourth quarter. We did indicate that we do have some delays on the rivastigmine patch. That was a product we were hoping to get out in Q4, so that product will be delayed into 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had -- just had under 8,000. And in DC, we had about 8,400 shipped vials.",32,"And then on your question on the shipped vials in the fourth quarter. So in Peyronie's, we had -- just had under 8,000. And in DC, we had about 8,400 shipped vials."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","First question for Rajiv. With the launch of BELBUCA and the doubling of the pain sales force and also, I guess, the reoptimization around product promotion last quarter, could you maybe just provide us with an update on current sales force size, configur",167,"First question for Rajiv. With the launch of BELBUCA and the doubling of the pain sales force and also, I guess, the reoptimization around product promotion last quarter, could you maybe just provide us with an update on current sales force size, configuration and who's doing what in terms of detail allocation just relatively? And then the follow-up to that, with some of these efforts now, you have a collection of small, niche, branded assets that really aren't receiving any direct promotional attention, including a couple of products picked up from Par. So just wondering what your thinking is around this portfolio of products, STENDRA, Testim, FORTESTA and TESTO and whatnot, whether or not these would, in fact, be candidates for divestiture. And then just a follow-up for Suky, it doesn't really sound like there's been change to your long-term tax rate expectations. Maybe you could just walk us through a couple of things that are impacting 2016 accrual rate versus the expected long-term tax accrual rate."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Let me cut to your first question and then Suky can talk about tax. So in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varying si",316,"Let me cut to your first question and then Suky can talk about tax. So in terms of field force size, we are not disclosing the size of our field force for competitive reasons. What I would say is that -- so we have essentially 3 field forces of varying sizes, as I've -- actually 4 of varying sizes in our branded business, the largest of which is our pain field force, which is sized to be competitive with other pain players. And in that field force, we detail BELBUCA, OPANA ER and Voltaren Gel. So those are the 3 products that are detailed. And then on occasion, we do some reminder calls on SUMAVEL. In our specialty business, there are 2 field forces. One is focused on urology, and that field force carries in the first position as XIAFLEX for Peyronie's disease and also carries our long-acting testosterone replacement therapies, which are AVEED and TESTOPEL. We have a second specialty field force, which is a smaller one that is focused on XIAFLEX for Dupuytren's contracture and SUPPRELIN LA, which is our product for central precocious puberty. We also have a smaller field force, which we inherited from Par, which, I must say, we are all very impressed with their early performance. They are focused on selling the -- selling NASCOBAL, which is a product that came over from the Par transaction, but we are also using that field force as a mechanism to provide some initial launch support -- additional launch support for BELBUCA, and over time, will take on the promotion of some of these smaller brands. So net-net, at this point, we're very pleased with the promotional mix that we have in our field force. The -- even our older and more established products are continuing to be important to us, so we are not looking to sell or divest any of them."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. So around the tax rate in 2016, the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue source. So that's why you see a step-up from between '15 and '16. Having said that, the low double digit, high sin",183,"Yes. So around the tax rate in 2016, the movement from 2015 is primarily driven by the addition of the Par income, which is all U.S. revenue source. So that's why you see a step-up from between '15 and '16. Having said that, the low double digit, high single digit estimate that we have for '16 is well below our initial expectations that we set for '16 when we closed Par, where we said that we thought that the tax rate might be closer to the mid-teens. So we actually are seeing some progress versus our original expectations. As you think about 2017 moving on, we would characterize that as sort of low teens type of tax rate. The reason why that migrates up a little bit is you continue to drip off deal attributes that were created over the last couple of years. But otherwise, the underlying fundamentals of the tax rate are still very attractive. And as I said, for '17 and beyond, there's still a number of opportunities and strategies that we can deploy to bring that down over time."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Risinger with Morgan Stanley.",14,"And our next question comes from the line of David Risinger with Morgan Stanley."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","So I have 2 questions. First, with respect to the Qualitest outlook, just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to or in the ballpark of what was -- or of what the number was in the fourth quarter",119,"So I have 2 questions. First, with respect to the Qualitest outlook, just so that we understand how to model it, should we be thinking about a 20% decline in '16, similar to or in the ballpark of what was -- or of what the number was in the fourth quarter of '15? And then turning to Slide 13 in the deck, Suky, I was hoping that you could just take us through the walk-through from the $1.5 billion in the pretax cash call and then the $575 million in the post-tax cash call. I know that you mentioned a $700 million tax refund, but obviously, there's another number in there to bring that figure down to $575 million."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So David, let me address your first question, which is, first of all, keep in mind that, as Suky pointed out, there was some nonrecurring impacts in the fourth quarter that impacted Qualitest which should not see any roll forward impact. And secondly, I t",161,"So David, let me address your first question, which is, first of all, keep in mind that, as Suky pointed out, there was some nonrecurring impacts in the fourth quarter that impacted Qualitest which should not see any roll forward impact. And secondly, I think to -- back to the comment that Suky made, where we're not providing guidance for Qualitest distinct from Par, simply because, at this point, Paul has a combined portfolio. He's negotiating customer contracts across a combined portfolio. He will make some portfolio optimization decisions as he goes into the year in terms of what products he prioritizes with customers. And that may impact Par products, it may impact Qualitest products. So as a result, we do not expect to provide any guidance for the legacy Qualitest portfolio going forward other than what we already commented on. I would say that, for the combined business, we expect to see mid to high teens underlying growth for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million. The first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016, we expect that to be som",135,"Yes. Relative to your question on the mesh post-tax liability for 2013, how do we get from $1.5 billion down to $575 million. The first thing I would do is break it down into what the pretax cash calls are in '16 and '17. In 2016, we expect that to be somewhere around $850 million to $900 million, and then you back out the tax refund of approximately $700 million from that. That's one component. And then in 2017, we expect the pretax cash call to be somewhere between $600 million to $650 million. If you apply a U.S. tax shield against that of approximately 35%, you get down to your post-tax cash call of somewhere around $400 million. When you put those 2 pieces together, that should get you into the $575 million range."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's the expectation embedded in the guidance for pricing for brands in 2016? And then",88,"For Rajiv, can you talk a little bit about the branded pricing experience that you had in the fourth quarter and full year 2015? What was realized branded pricing and what's the expectation embedded in the guidance for pricing for brands in 2016? And then for Suky, just a quick one. Can you talk a little bit about the gap between EBITDA of about $2 billion plus for this year and what we should be thinking about for GAAP cash flow from operations, including the mesh liability payments?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Thanks, David. So on the branded pricing, our experience in 2015 and 2016 actually are not dramatically different. It's well within what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price",188,"Thanks, David. So on the branded pricing, our experience in 2015 and 2016 actually are not dramatically different. It's well within what we've -- how we've always characterized our branded pricing strategy, which is that we take appropriate prices, price increases. They typically range in -- from the low single -- actually, 0 in certain cases, to potentially up to 20%, 25%. The high end of that range is typically for our mature products that already have multiple generics on the market. Our portfolio is generally contracted, which means that our price increases are capped. So even if we are taking price increases that are higher than that mid-single digits, the realized price increases for us in our branded business is somewhere in the low to mid-single digits. So that level is our experience in 2015. Our price increases that we took in our branded portfolio are already public for 2016. And they're in the same range that I just described, and we would expect a similar type of low to mid-single digit impact on our branded business this year as well. That's all incorporated into our guidance."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. And regarding your question around cash flow for next year, the way to think about it is, first of all, we would expect underlying cash flow from operations, as we depicted for 2015, to have a very high correlation to adjusted net income. But to give",231,"Yes. And regarding your question around cash flow for next year, the way to think about it is, first of all, we would expect underlying cash flow from operations, as we depicted for 2015, to have a very high correlation to adjusted net income. But to give you some of the moving parts for next year to help model, if you started with the midpoint of our revenue range and assume the mid-40s EBITDA margin, you get roughly into the $2 billion, $2-plus billion EBITDA range. From there, your movements on cash, you got interest expense, which we've talked about, you've got cash taxes in the mid-single digits on the underlying business. You've got a mesh post-tax cash call of about $150 million to $250 million, as we've talked about. Working capital on a day sales basis is going to be relatively steady throughout the year. However, because of the fourth quarter launches of Seroquel and Zetia, we do expect there to be a call on cash in the fourth quarter of somewhere between $200 million to $300 million. That will normalize in the first quarter of '17 as that launch pulls through. We have CapEx of about $150 million and contingent consideration of about $150 million. So if you put all those pieces together, that should get you pretty close to where we see our cash flow for the year."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group.",15,"And our next question comes from the line of Andrew Finkelstein with Susquehanna Financial Group."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","If we go back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well, and in particular, how you look at the bran",101,"If we go back, you mentioned that the Par contribution was $359 million. Could you clarify whether that was the contribution of Par to the generic segment or whether that included the brand contribution as well, and in particular, how you look at the brand sales of $379 million for the quarter? Are there any moving parts there to consider? Is STENDRA still in there or is that in discontinued operations? I'd say, quarter-on-quarter, 3Q to 4Q, from the products you give us, that explains about half of the quarter-to-quarter increase. So what other contributors were there on the branded side?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","So on the Par number, we're just verifying this, but I believe that number is a generics-only number and excludes the brands. And then the -- your second question, Andrew, with respect to...",33,"So on the Par number, we're just verifying this, but I believe that number is a generics-only number and excludes the brands. And then the -- your second question, Andrew, with respect to..."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Yes. With respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million. The products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem",82,"Yes. With respect to the brand segment overall, $379 million for the quarter, about $305 million in 3Q, so up about $75 million. The products you break out, if I did my math, explain about $38 million of the increase. So some of the smaller products seem to have stepped up 3Q to 4Q. Some of that is a full quarter of the Par brands. But were there any other factors, products that were -- had a bounce in 4Q in brands?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Sure. So the -- as you point -- as you say, Andrew, some of the smaller brands -- so we had success, for example, with AVEED in the fourth quarter as a contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a dec",103,"Sure. So the -- as you point -- as you say, Andrew, some of the smaller brands -- so we had success, for example, with AVEED in the fourth quarter as a contributor. STENDRA, although we announced our decision on it in the third quarter, actually had a decent fourth quarter. SUMAVEL was a contributor. So it's a series of these smaller brands. And again, it goes to show the value of our more diversified, established and other products, part of our branded business, and many of them do contribute. I mean, when you add them all together, it is a material contribution."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, and I'll just add...",5,"Yes, and I'll just add..."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","I was going to ask you if STENDRA was out for 2016.",12,"I was going to ask you if STENDRA was out for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes, STENDRA is out for 2016.",6,"Yes, STENDRA is out for 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Yes. One thing I would add for 2015 fourth quarter, in LIDODERM, we did see a benefit, onetime benefit of some returns, reserves adjustments that won't repeat in first quarter of 2016.",32,"Yes. One thing I would add for 2015 fourth quarter, in LIDODERM, we did see a benefit, onetime benefit of some returns, reserves adjustments that won't repeat in first quarter of 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao with Barclays.",4,"Douglas Tsao with Barclays."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Analysts","Just a couple. Paul, maybe on the delay for Exelon, what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky, in terms of the visibility on the mesh liability, sort of cited sort of the lower quality of some of t",85,"Just a couple. Paul, maybe on the delay for Exelon, what's your visibility in terms of the timing of the launch there? And then just for Rajiv and Suky, in terms of the visibility on the mesh liability, sort of cited sort of the lower quality of some of the outstanding cases, just curious in terms of the historical precedent in terms of some of those, perhaps, moving up into a higher-quality sort of claim as things like medical records perhaps become available to you?"
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","I would say, on the Exelon patch, Doug, we're probably looking at late the second half of 2016.",18,"I would say, on the Exelon patch, Doug, we're probably looking at late the second half of 2016."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Okay. With respect to mesh, and Doug, I think consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken, based on advice of outside advisers as well as lookin",202,"Okay. With respect to mesh, and Doug, I think consistent with the answer I gave to a previous version of this question, we are taking a different approach to what remains here, right? So we have taken, based on advice of outside advisers as well as looking through the portfolio of plaintiff's attorneys, in terms of those who are more likely to have credible claims, and effectively focus on the high value, right? As we've said, as we look out over the remainder, while there is [indiscernible] information, there is also other pieces of information we have such as the potential fraudulent claims that leads us to believe that these are of lower value, right? And this is consistent with the advice that we've gotten from our outside advisers as well. And we also believe that it is to our benefit and to our advantage to be more aggressive with this remaining portfolio, including potentially taking some to trial if we need to. So our current beliefs based on the factors that we have, we do believe that they are lower-value cases. We will deal with them over time, and there is no anticipation of any other settlements in the near term."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva.",25,"And I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Rajiv De Silva."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Executives","Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as the outlook for 2016. We are very pleased with the solid performance that we had in 2015. We believe that the fun",182,"Well, thank you very much, everyone, for joining us for today's call. Just to summarize where we are with respect to 2015 earnings as well as the outlook for 2016. We are very pleased with the solid performance that we had in 2015. We believe that the fundamentals of the business are very strong, strong underlying growth that will sustain us into 2016 into the medium term that we've talked about in the past.
We are positioned for growth in 2016. We have some strong growth drivers like XIAFLEX, BELBUCA and our generics portfolio that we continue to put a laser-like focus on. We're progressing the XIAFLEX pipeline, creating some real momentum around the new indications, potential new indications like cellulite.
Clearly, our focus this year is on execution and on generating strong underlying free cash flow, which would allow us to continue to delever despite the incremental accrual that we talked about with respect to the mesh liability.
With that, I thank you for your time and look forward to joining all of you on our next quarterly call. Thank you."
28071,325746146,943866,"Endo International plc, Q4 2015 Earnings Call, Feb 29, 2016",2016-02-29,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Ker",56,"Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Keri Matrox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin your conference."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmace",228,"Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceuticals. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements made by in the management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings",702,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings presentation. 
On the next 2 slides, you will see a brief agenda and an outline of key themes for today's call. To begin, I will provide a snapshot of our first quarter financial results, which, despite some headwinds, were largely in line with our expectations. However, these headwinds have created substantial challenges to overcome in the remainder of the year. We are providing revised full year 2016 guidance today to reflect these challenges. We will spend some additional time discussing the state of our business, key drivers for this rebasing and our action plans moving forward. 
Specifically, there are 3 factors to call out that we will discuss in more detail on today's call: deeper-than-expected erosion in the legacy Qualitest business; delays in FDA actions related to our 505(b)(2) products; and earlier-than-expected generic entrant for Voltaren Gel. Importantly, we will also talk about why we believe that our core growth drivers will continue to provide opportunities to execute against our strategic plan and allow us to return to organic growth, improve margins and delever in the medium term. 
Before we begin, I would like to take this opportunity to welcome our 2 new board members on behalf of our board and the company. We are delighted that Doug and Todd have accepted our invitation to join. We look forward to their contributions. 
Moving to Slide 6. You will see the Q1 snapshot of reported segment revenues. In our branded business, we saw solid continued growth for XIAFLEX, which performed well despite the expected historical trend of Q1 seasonality. This growth was offset in part by a decline in Voltaren Gel due to the product's loss of exclusivity in March and continued pressure on the European markets. In our generic segment, the base business erosion continued into the first quarter and was significantly deeper than we expected at approximately 30%. This was driven by continued pricing and competitive pressures on our commoditized MPM products. The erosion was partially offset by strong performance from our sterile injectables portfolio including Vasostrict and the overall performance of the legacy Par portfolio. We will return to these themes when we discuss full year guidance. 
The international business performed as expected with a modest decline in reported revenues. However, our emerging markets businesses continued to show both constant exchange rate revenue growth and underlying growth as well as margin expansion. 
On Slide 7, you will see our first quarter segment revenues as well as reported and underlying growth. 
Next on Slide 8, we provided our first quarter financial results. 
Moving on to Slide 10. Let's talk about the state of our business and the context in which we are viewing the remainder of 2016. To best understand where Endo is now, it's important to also understand where we've been and what we've built. When I joined the company in 2013, we chartered a new strategic cause and outlined some very clear goals, as seen here in the left column. Over the next 3 years, we set out to achieve these goals and position Endo for growth. That strategy is still core to Endo and how we run our business. However, what has become clear is that 2016 specialty pharmaceutical landscape and market forces require an evolution of that strategy. 
So let's talk about our path forward. Our goal has not changed. We continue to aspire to build a leading global specialty pharmaceutical company. What has changed rapidly is the landscape and market environment within which we are operating, particularly in generics. What does this mean going forward? It means we're reshaping the path forward for Endo. We are rebasing expectations for the business and are evolving our current strategy to meet challenges and capitalize on opportunities. Ultimately, we are positioning the company for long-term organic and diversified growth, margin improvement and delevering. 
So let me now turn the call over to Paul to discuss key factors and drivers related to generics. Paul?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying an actual sales. The",1670,"Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying an actual sales. The variances between the sales totals resulted from a greater-than-anticipated erosion and base business of approximately 30%, driven particularly by the legacy Qualitest portfolio. While we expected base erosion to be higher in the first quarter than the full year, the actual erosion was much deeper across our pain portfolio and other commoditized products than originally anticipated. By contrast, the legacy Par portfolio is performing on track with internal expectations. Our sterile injectables product portfolio continued its strong performance with 86% growth over Q1 2015. Our new launches, an alternative dosage product portfolio performance, was stable and largely unchanged year-over-year. 
So let's discuss the factors that impacted these Q1 results that we believe will shape our full year generics performance. Moving to Slide 14. There are rapidly changing market conditions that have affected the broader generic sector and Par. First, we've seen a steep and rapid price erosion caused by payer consolidation that has been more even profound than anticipated. Its effect has exceeded what might have been expected from an ordinary downturn in the industry's traditional pricing cycle. The impact has been particularly acute in the more commodity like product categories as such as our pain and controlled substances portfolio and our immediate-release solid oral dosage forms. 
Second, coupled with this consolidation and new payer environment, competitors are taking aggressive pricing actions to gain market share. Examples include both the 300 and 325 milligrams strength of hydrocodone APAP, butalbital, morphine sulfate and oxycodone. 
Third, there's been a rapid erosion of the pain segment, driven by 3 things: one, continued market contraction; two, increased competitive capacity in pressure; and three, while still early to judge the full impact, we believe the recently issued CDC guidelines will continue to put pressure on an already soft pain market. As you may know, approximately 40% of the legacy Qualitest portfolio was comprised of pain products, so this sector specific weakness has had a disproportionate effect on our generics business. Fourth, there's been a recent end market acceleration of FDA approval for generic products. While we'll ultimately expect this to also benefit the Par portfolio in our own pending submissions over time, the approvals in launches seen in late Q1 and in April of this year have resulted in greater competitive pressure for our products. Fifth and finally, the latest and expected FDA actions related to our 505(b)(2) products means that we have yet to see the anticipated removal of unapproved competitive products from the market. Correspondingly, we have yet to achieve the market exclusivity that we expected for these products. It's important to note that we still expect these FDA actions but now on a delayed time line. The removal of relevant unapproved products may not occur before first half of 2017 versus our original expectation of early 2016. 
Now that we've talked about what's happened in the generics market, let's also take a few minutes to review when some of these events surfaced, thereby impacting our generic business. In 2016, it's important to note that the U.S. generic landscape has continued to shift, with significant events and updates as recently as late March and April. In fact, it was not until late March that we confirmed the delays on the regulatory actions related to our 505(b)(2) products that I just mentioned. Then in April alone, we see at least 5 competitive product approvals and additional market entrants. Finally, we've also just completed our consortium bid cycle with a more negative output in increased pricing pressure than we anticipated. 
Moving to Slide 16. I do want to take a few moments to discuss our ongoing integration of the Qualitest and Par businesses. Last fall and Q1 of this year, we were conducting an integration of 2 complex generic businesses. What became very clear to those of us who have been in the generic industry for sometimes is that the legacy Par operating model is better positioned to address the challenges of today's evolving market. As a result, we set out to shift the legacy Qualitest portfolio strategy from a high-volume approach to the high-value operating value long practiced by legacy Par. As part of the integration activities, we're also transitioning the legacy Qualitest systems and processes to the Par business platform. The legacy Par systems offer more real-time and product level data, allowing for faster analysis and reaction within a challenging and changing market. While many of these improvements were already planned at Qualitest, the integration of our business will accelerate the benefits. 
Next on Slide 17. Let's talk about what we're doing to address these challenges and best position our generic business moving forward, our action plan. First, we are continuing to maximize our key growth drivers such as our sterile injectables portfolio, led by Vasostrict and approximately 30 new products that we expect to launch this year. Next, our platform for long-term organic growth is our R&D pipeline. We are continuing to advance these more than 250 projects post reprice our expectations and anticipate filing 25 to 30 new submissions in 2016 alone. We're also accelerating the implementation of an optimization and restructuring of our product portfolio and manufacturing facility network. I'll talk more about this restructuring shortly. Additionally, we are accelerating the move of legacy Qualitest business onto the Par platform. This is already substantially complete as our commercial insight and forecasting capabilities have been fully transitioned. Finally, critical to our action plan is our ability to execute. This is not the first turbulent market environment that the Par has successfully navigated. Our team is seasoned, capable and prudent. 
Moving to Slide 18. Now permit me to provide some additional detail on the restructuring I mentioned earlier. Most importantly, this restructuring is an acceleration of our ongoing integration and broader optimization efforts designed to prioritize and grow high-value durable assets. It is entirely consistent with our integration activities to date. The restructuring will affect our manufacturing sites in Charlotte and in Huntsville and will result in more than 60 product discontinuations. In addition, we are pruning less value-driven R&D projects so that we can prioritize our investments on differentiated and high-value projects. We expect that the restructuring will be completed by the third quarter of 2017 and will result in a total of approximately $60 million in annualized net run rate savings by Q4 of 2017. We expect to see about $10 million of that gross margin improvement this year. As a result, shortly, we will begin the process of informing employees of these changes. As part of that effort, approximately 740 employees will be impacted under phase transition. For Endo, the Par management team; and for me personally, this is both an extremely [indiscernible] and disappointing to our company. We value our people, and for those who will be affected, we thank you all for what you've contributed to Endo. We'll be providing resources to help manage through this difficult transition. 
And while change is never easy, it is necessary to better position our generics position to successfully compete in the U.S. generics market. So on Slide 19. Let's talk about our full year revenue outlook for the generic segments. We are previously expected a mid-teen underlying growth rate for the business given the erosion now forecasted across the sector and particularly for our base business in the delay in and regulatory action related to our 505(b)(2) products offset by the strong growth projected for sterile injectables and new launches and alternative dosage portfolios, we now expect underlying growth for our generics business to be in the low single digit percentage range. We do expect that erosion on our base business to moderate back to rates typical for the generic industry beyond 2016. The erosion in 2016 is expected to be more acute than historical trends due to our relative pricing and share levels in the pain markets prior to the observed and expected erosion. 
Moving to Slide 20. You'll see a look at our Q1 2016 reported generic net sales annualized versus our full year 2016 guidance midpoint. You can see the projected decline due to non-face business competitive entries in base erosion which we expect to be approximately 5 years per quarter through the end of the year. Our new product launches are a significant driver of growth as illustrated by the green block and bringing to our projected generic net sales midpoint for the year. 
Now let's look at our 2016 launches on Slide 21. We are in a track to launch 30 new products this year Four of these are first-to-file products including our generic Seroquel and generic Zetia products that will launch in the fourth quarter of 2016. Another 2 launch products are alternate dosages and another 9 are sterile injectables. Importantly, and as an illustration of our value-focused strategy platform, nearly 1/3 of our projected launches are products that will be exclusive or faced only one generic competitor. Finally, let's close this generics discussion with a quick review of our robust R&D pipeline on Slide 22. 
As I mentioned earlier, we have more than 250 projects in our reprioritized R&D pipeline. We anticipate launching more than 100 of them between 2016 and 2019, representing a total current market value of nearly $30 billion. Our pipeline is robust, diversified and populated by higher barrier-to-entry in higher margin generic products. We believe that positions us strongly for future growth. I am confident in our platform and I believe that our pipeline is truly differentiated. I know that our team has the experience and the ability to address these challenges and to deliver future generics growth and margin expansion. 
With that, let me turn the call back over to Rajiv for a discussion on our branded business. Rajiv?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President of U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportuni",822,"Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President of U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportunities. Brian has been a critical part of the efforts to reposition our company over the last 3 years. We will miss him at Endo and wish him well in his future endeavors. 
Moving to Slide 24. Let's talk about factors affecting our U.S. Branded business. First, there has been a recent generic entrant for our Voltaren Gel product. This generic came into the market earlier than we expected and it has affected our 2016 outlook for V Gel. Second, we have seen increasing pressure on our branded pain segment. These include additional competitive entries as well as continual increasing number of public policy and regulatory reactions such as the recent CDC guidelines around opioid prescribing end-use. Additionally, there are reimbursement restrictions now in place for LIDODERM further limiting the use of that branded product. Against this backdrop, we do continue to see significant growth potential in our differentiated products BELBUCA. However, it has progressed at a slower pace than we initially expected due to pain market pressures. That said, we continue to believe in the future of this product at the scheduled 3 alternatives in the opioid category. 
On Slide 25, you will see the opportunity for BELBUCA, the [indiscernible] only buprenorphine Buccal Film for chronic pain management which we launched in late February this year. There are about 90 million total prescriptions written for the treatment of chronic pain below 160 milligrams multi [indiscernible] or MSCs. BELBUCA is at positioned to help patients both from short-acting opioids as well as long-acting opioids. Given the size of both these segments, even with the relatively small share of the available prescription base, BELBUCA could become a very meaningful product in this category. 
It is also important to note that even in these early days, BELBUCA is not only capturing switches from LAOs but also from SAOs and new therapy stocks. Further, we have seen an increasing number of repeat prescription week all week. Its differential profile is resonating well with the [indiscernible] and patients across the spectrum, and our early feedback on access, ease of use, efficacy and side effect profile have all been positive. 
Along these lines, let's look at Slide 26, to talk more about early progress on the BELBUCA launch. There are 3 areas that we are focused on in terms of early launch, traction and feedback. While I won't talk through each bullet here, we did want to provide a comprehensive look at where we are making progress and where we see opportunities to further accelerate BELBUCA launch traction. 
Next on Slide 27, let's talk about XIAFLEX. the XIAFLEX continues its double-digit demand growth profile and we are making good progress in growing that business. We see a significant opportunity to expand both our share of the current treatment market as well as the size of the overall markets for both Dupuytren's contracture and Peyronie's disease. Across both of the DC and PD indications, we have new initiatives focused on driving growth. We are working to broaden our active injector base and have improved targeting to reach the most appropriate positions. Our DTC and print ad campaign efforts are also showing signs of real traction. For example, visitors to the ""Ask About the Curve"" websites spend about 10x longer on the site than an average website visit, and about 1 in 10 visitors click through to find the Peyronie's disease specialist in that area. 
We have also worked to improve convenience with physicians through our reimbursement support initiatives and our product savings program. Overall, these efforts position XIAFLEX for strong continued growth. We expect mid- to high teens percentage growth in 2016.
Moving to Slide 28. Let's talk about the other driver for XIAFLEX growth over the long term: our robust R&D pipeline. We see significant opportunity and substantial value for XIAFLEX across both therapeutic aesthetic indications and have talked about how the product Could be a $1 billion franchise for Endo by the mid-2020s. That opportunity is driven by the more than 12 potential indications currently in the R&D pipeline and the multiple additional programs in even earlier stages of development. As part of our evolved corporate strategy and initiatives to return to organic growth, we are accelerating our R&D programs with XIAFLEX and plan to move 5 programs into the clinic even earlier than previously expected in 2016. It is a time of significant opportunity for these growth drivers in our branded business. We have taken steps to best seize those opportunities and accelerate their growth while also managing the legacy products within our portfolio. 
With that, let me turn the call over to Suky to discuss our full year 2016 financial guidance. Suky?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo for the rest of 2016. On Slide 30, we",315,"Thank you, Rajiv and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo for the rest of 2016. On Slide 30, we have provided an outline of the key components of change to our rebased revenue guidance that lead to an 11% reduction. As you can see, the largest driver of the change is the greater-than-expected erosion in our generics-based business. As a reminder, we define base generics as extended release, immediate release and pain and controlled substance products. As with the branded business, our rest of the year projections are based on business and commercial assessment and recent trend announced [indiscernible] product-by-product level that also takes into account the outcomes and competitive actions. 
Approximately 55% of the decline is related to price erosion and 45% relates to volume declines. This is an important variable as price declines fall to margin at 100%. I should also note we expect to realize the value of delayed 505(b)(2) actions later in 2017. 
Next on Slide 31, let's look at the drivers for the changes in our projected gross margin for 2016. Our previous guidance was 63% to 65% for the full year. Given the impacts of key events and market factors, we now expect full year gross margin to be in the range of 59% to 60%. Using the midpoint of the previous and revised guidance range, we expect gross margins to decline about 17% versus prior expectations. We are projecting a disproportionally high erosion on gross margin versus revenue due to a number of factors that you will see detailed here in the blue call-out box. Importantly, we do expect to realize gross margin for our 505(b)(2) products in 2017, and we expect to offset the 2016 underabsorption through rationalization efforts into 2017."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Moving to Slide 32. We have provided a bridge from our previous EPS expectations for the full year through our revised guidance. The reduction in EPS reflect the revenue and gross margin drivers that I've just discussed. We've taken actions to help offset",717,"Moving to Slide 32. We have provided a bridge from our previous EPS expectations for the full year through our revised guidance. The reduction in EPS reflect the revenue and gross margin drivers that I've just discussed. We've taken actions to help offset the declines we are projecting. In 2016, we are reducing OpEx across SG&A while remaining focused on prioritized investments against growth drivers and accelerating our branded R&D programs, and we project improvement in our tax rate. Lastly, we are taking actions to improve our gross margin profile through the planned rationalization that's all covered earlier. 
On Slide 33, you will see our 2016 financial outlook by business segment including expected, reported and underlying growth rates and gross margins across the portfolio. The branded business growth rate reflects the loss of exclusivity of V Gel. The generics outlook reflects the declines in the base business and the delayed regulatory actions that were discussed earlier. And international is broadly in line with previous expectations. 
Next on Slide 34, we have outlined our full revised 2016 financial guidance. From a cadence perspective, we continue to see revenues and EPS weighted to the second half of the year, driven by the launches from the Par portfolio and continued grow from XIAFLEX and BELBUCA. We now expect approximately 46% of revenues and 39% of full year EPS in the first half of 2016. This implies a sequential step-down in Q2 due to a number of drivers including the full quarter impact of recently launched generic competitors that we talked about earlier on the call. In addition, we expect a ramp-up in spending int eh second quarter primarily related to our acceleration of R&D programs and commercial efforts in U.S. Branded. We have talked through the moving parts around revenues and gross margin. We expect interest expense to continue to be about $455 million. Our tax rate will be lower due to continued progress around planning strategies and due to a lower mix of U.S. source income while maintaining static debt benefits and acquired attributes. Depending on the nature and timing of potential discrete items, the cadence of tax rate through the year can be lumpy. Consistent with prior commentary we do expect to step up in our tax rate in outer years. We now project that range to be in the high single digits. 
Next on Slide 35. While our first quarter cash flow from operations was negative, it was impacted by a number of items that we consider to be noncore. After considering these items, underlying cash flow from operations continues to be well correlated to adjusted net income. I will also note that our working capital metrics are in line with our expectations. Consistent with prior quarter, we have provided more details around working capital in the appendix of this presentation. 
Moving to Slide 36. It is important to note that we continue to project robust cash from operations prior to legal-related cash flows. I will note that in early Q2, we received the full tax refund that we pointed to earlier in the year. Ultimately, we expect to use remaining cash to pay done approximately $250 million to $300 million in debt in 2016. 
Finally, on Slide 37, let me provide you with a snapshot of our liquidity profile. This is important because our cash position and liquidity ratios remain strong and well within our covenants as defined under our debt agreements. We do not foresee any challenge and remaining well within those limits in 2016 and beyond. We expect our net debt leverage ratio to remain in the high 4x in 2016 with some fluctuations based on quarterly cadence. We continue to remain committed to delevering into 3 to 4x range over time. 
In summary, as we rebase our outlook for our business, which is driven by the factors that Rajiv and Paul spoke to earlier, we remain committed to driving financial discipline including taking actions to improve gross margins, investing in growth drivers, becoming more efficient around G&A, continuing to improve our underlying tax rate, optimizing our cost of capital, driving improvements in working capital and improving after tax cash flows from operations to service our liabilities and for investments and future growth. 
With that, let me turn the call back over to Rajiv."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. On Slide 39, you will see the c",550,"Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. 
On Slide 39, you will see the corporate strategy as we laid it out in 2013 and the actions we took to rebuild the business over the past 3 years. We have successfully changed the structure, the businesses and the growth profile of Endo. Now given the evolving market conditions, it is time for us to continue to evolve our corporate strategy and transform the company for long-term durable growth. 
On Slide 40, let me talk about how we feel Endo is positioned for growth. Our aspiration to build the leading global specialty pharmaceutical company that improves lives and creates value has not changed. We are mindful, though, that we need to set appropriate medium-term goals reflecting current market conditions. This is meant rebasing of our financial guidance for 2016 and the reset of our previous expectations for 2017. However, our goals are clear, return to organic growth at levels above market averages; improved operating margins to be greater than 40%; and delever to between 3 to 4x. Three core areas of focus will enable these goals: growth in our branded business and the XIAFLEX pipeline; growth in our generics business and pipeline; and the ongoing optimization of our existing business.
Moving to Slide 41. There are many key growth drivers that strongly position our U.S. Branded business for long-term growth. We know we have significant end market growth opportunities in both XIAFLEX and BELBUCA. We are continuing to structure our team and our business to achieve that growth potential while also managing our diversified portfolio of legacy products. We are also accelerating our derisked innovative R&D pipeline to advance those programs and the time lines for their potential market entry. 
As we execute this year, we will be achieving key milestones across our U.S. Branded business and we will keep you updated regarding our progress. On Slide 42, let's talk about the the durable portfolio pipeline we have in the U.S. generics business. We are focused on driving growth through our differentiated higher barrier to entry products like sterile injectables and our robust pipeline of more than 250 programs post restructuring. We have a diversified and important lead [indiscernible] based business and a robust highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they execute on these opportunities. 
Let's summarize on Slide 43. We have rebased our business and believe this is a time of significant opportunity for Endo. We have a clear plan to focus on strategic priorities: return to organic growth, margin improvement and delevering. Our key growth -- our key future growth drivers continue to provide promise to deliver against these strategic priorities. And perhaps, most importantly, Endo is a resilient organization and we are all committed to our future. Together, we will execute on our evolved corporate strategy and then achieve our goal to deliver products that improve patients' lives while creating value for our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your first question comes from the line of Randall Stanicky of RBC Capital Markets.",14,"Your first question comes from the line of Randall Stanicky of RBC Capital Markets."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to",69,"Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to approve more drugs, is there a risk that this continues? And is this just in pain or is it more broadly?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will let Paul answer the question.",7,"I will let Paul answer the question."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean clearly, we're disappointed, right? We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say that it",263,"I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean clearly, we're disappointed, right? We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say that it was tempered by some successes on the sterile side from the Par portfolio. So from that standpoint, it was a positive effect. When we look at those big [indiscernible] in terms of specifically in the legacy Qualitest portfolio, we had challenges both in pain and related solid oral dosage in the immediate release portfolio. And what we're seeing was it was a combination of new competitors coming into the market that were established as well as just first-time players as well. So it's a combination of some smaller generic competitors entering the market that ultimately pushed the price down. And a lot of these occurrences were coming in the late March and April time frame. So in essence, it was several factors in terms of competition as well as loss of business. And clearly, on the FDA side, in terms of new competitors coming in and new approvals rather, I think what it could do if we're really starting to hit, we are going to see more players in some of these commodity-based products. But at the same time we have 150 products at the FDA. So you should also assume that we will also get the positive impact of a quicker approval. So at the end of the day, we will get our fair share wins."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Paul, on that, on Slide 20, you called out I think it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is [indiscernible] certain versus assumed or [indiscernible] approvals?",38,"Paul, on that, on Slide 20, you called out I think it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is [indiscernible] certain versus assumed or [indiscernible] approvals?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Right, right. So we've talked a little bit about this. Around 75% is the new launches.",16,"Right, right. So we've talked a little bit about this. Around 75% is the new launches."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Jason Gerberry from Leerink Partners.",13,"Your next question comes from the line of Jason Gerberry from Leerink Partners."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved but t",81,"I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved but that the FDA didn't remove certain unauthorized products from the market. So how many products are we talking about? If you could provide a little bit more detail there, that would be great."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we",157,"Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we were successful on a timely fashion. It's getting harder because the FDA is looking towards drug shortages and really having a high confidence that we're going to be able to supply the entire market. So these 2 particular products that we were talking about, that's what we're faced, we're partnering with the FDA to show that we have the ability and get confidence that we can supply the entire market. We're hoping that was going to happen in early 2016. I think the benefit of having these unapproved sources exit the market will be realized in 2017. It's not that it won't happen. It's just really pushing into next year."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage targets to mid-3s now beyond I guess late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit n",66,"If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage targets to mid-3s now beyond I guess late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit now. You've got mesh. But can you just walk us through some of the puts and takes there?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So we're not going to give guidance on 2017 at this time. There a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to dele",298,"Yes, sure. So we're not going to give guidance on 2017 at this time. There a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to delever. We do see ourselves pushing that target from 3 to 4x from 2016 into 2017 or beyond. There are a number of moving parts that will help with that. Without getting specific guidance, some of the things I pointed to earlier is late in this year, we will build about $200 million of working capital. As far as the Seroquel and Zetia launch, that will be recovered in the first half of 2017 as we actually collect the cash on that revenue both in 2016. As we move into next year, we expect mesh gross payments to moderate down slightly. This year, we would see those mesh payments as being somewhere between $800 million to $900 million. Next year, we would predict that, that would be somewhere around $600 million. So we should see a step-down in gross mesh payments into next year. And then the other big drivers are on capital expenditures. We do see a step-up this year as part of the integration of [indiscernible] Qualitest primarily around the implementation of ERP systems that should moderate down in 2017. And then we could see a slight step-up in the contingent consideration line that I've outlined here for '16 primarily due to the 505(b)(2) products that Paul has spoken to as well [indiscernible] so there's a couple of moving parts that can kind of help you shape where '17 cash might be. But again, we do expect, over time, to delever back with that 3 to 4x range."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of David Amsellem from Piper Jaffray.",13,"Your next question comes from the line of David Amsellem from Piper Jaffray."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","You might have mentioned this, apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that pro",46,"You might have mentioned this, apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that product?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Dave, this is Paul. Regarding Vasostrict, right now we are well protected with our API source. From that standpoint, we feel as though we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO in or",94,"So Dave, this is Paul. Regarding Vasostrict, right now we are well protected with our API source. From that standpoint, we feel as though we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO in order to get patent status which would then have our legal team immediately list the patent to the orange book. That has not happened yet. It's in progress, but at this point in time, our defense is really our API source that should get us through at least 2017."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So no competition in the guidance this year.",8,"So no competition in the guidance this year."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","No. No competition in the guidance.",6,"No. No competition in the guidance."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Chris Schott from JPMorgan.",12,"Your next question comes from the line of Chris Schott from JPMorgan."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I guess the first one, it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence I guess this round of cuts captures an accurate view of the busin",159,"I guess the first one, it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence I guess this round of cuts captures an accurate view of the business going forward. I guess, has there been any change in approach to how conservative or not you're being with the guidance this time around? I guess just addressing investors' concerns that things continue to just deteriorate in the business, just I mean high level just to address that question. The second one, I was just talking about the generic outlook in '17. Just from our perspective, what do you think it's going to take to stabilize the legacy Qualitest business? And just how are you thinking about the growth in the portfolio overall once we get through this difficult 2016 and start to think about the longer-term portfolio?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Chris, let me just start and I will have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We had several things that have not gone our way, and many of those things -- actually all of those things have p",462,"So Chris, let me just start and I will have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We had several things that have not gone our way, and many of those things -- actually all of those things have played out over the course of the last 4 to 6 weeks, right, in the second half of March and in early April. But I'll point to the 3 things that have happened, right, the 3 materials that have happened. First one is the earlier-than-expected launch of the Voltaren generic. So we clearly didn't see it coming as early as it did. We have forecasted it towards the very, very back end of this year at worst and best case into 2017. Now that being said, we knew that there was going to be a generic for Voltaren Gel at some point, right? And in fact, the newly revised agreement with GSK and Novartis give us the right to an authorized generic. So we will have a tail of that product going through 2017 and beyond. So yes, there was bad news. It was earlier than expected, but it's not something that fundamentally impacts the longer-term growth trajectory. The second event that Paul referred towards is the delay in the 505(b)(2) programs. And again, expectation, while it is bad news for 2016 is that it does, in fact, manifest itself in 2017 and will in fact benefit '17 as well as '18 depending on when the FDA have really [indiscernible]. So then it comes down to the Qualitest base business [indiscernible] going to let Paul pick it up. Basically, what we've seen is a real reset in Q1, and Paul talked about the impact of the consortiums, the confluence of competitors that came in, for example, of bigger products like the 325 milligram [indiscernible] product, which is Qualitest's largest product that happened post -- mid-March. All of those things have happened in a way that has reset that business. And the way that we have thought about the guidance is that we've clearly taken a view of saying, how do we predict this erosion continuing to this year. So we do see continuation through this year. But by the same token, and Paul will elaborate on this, [indiscernible] as we go into 2017, continuous erosion in this base business will moderate to what you would typically see in a commoditized generic business, and the future really is about the pipeline and segments like this, the sterile injectable segment. So with that, let me just turn it to sort of Paul. Maybe you could talk a bit about our confidence about the remainder of the year and the moving parts going into '17."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is that, historically, we had successes with the Qualitest portfolio, but we've got a call [indiscer",357,"So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is that, historically, we had successes with the Qualitest portfolio, but we've got a call [indiscernible] it is a mature portfolio that is susceptible to competition. With that, we are transferring the strategy from that high-volume throughput that historically had successes on economies of scale to the more Par legacy success model of high-value products where we're having more technically challenging products, things that are more difficult to make. Now the first thing we have to do, we talked about the restructuring, right? So we need to take the portfolio, we've got to rightsize it, we've got to be real smart about product selection and what we're going to continue to set in the market. We're making some very, very difficult decisions impacting some very talented people in our Charlotte -- in our Huntsville facility. That's been very difficult for all of us. That's the starting point, to focus on the restructuring plan, and it gets back down to our core values of operational execution, something that we are really driving home at Par. Rajiv talked about it already. The pipeline is where we're going to be able to reset ourselves. Ultimately, 75% of our value coming is from 2 products. Fourth quarter, we've talked quite a bit about [indiscernible] Zetia, I'm not going to spend a lot of time there. But we have to execute on the entire portfolio. And at the same time, we've got to continue to repopulate the products as we launch them. So that, coupled with, again, got to get the 505(b)(2), and we have other 505(b)(2)s across the portfolio. It's not just the 2 that we're referring to, but we need to execute. We have a path forward, we have a good strategy. I think these are areas that are going to help us ultimately stabilize our base. And at the same time, we can't lose focus on our service levels and our quality and continue with diversification of our portfolio."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Greg Fraser from Deutsche Bank.",13,"Your next question comes from the line of Greg Fraser from Deutsche Bank."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Craig Dilbert. On the product rationalization efforts, do you expect those will try to help gross margins during 2016? Or were those benefits -- or the benefits from those efforts to be realized more in 2017 and beyond? And then I",89,"It's Greg Fraser on for Craig Dilbert. On the product rationalization efforts, do you expect those will try to help gross margins during 2016? Or were those benefits -- or the benefits from those efforts to be realized more in 2017 and beyond? And then I guess I had a quick one on the amendment to the central agreement with CPG that's mentioned in the press release. Can you give us more color on that change and what you know about CPG's intention with respect to that thought?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So I'll take the first one, Rajiv, on the gross margin and restructuring. So the question on gross margin for 2016 will be about $10 million.",27,"So I'll take the first one, Rajiv, on the gross margin and restructuring. So the question on gross margin for 2016 will be about $10 million."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, we've outlined that in the gross margin waterfall that you see in our presentation, Greg. In addition, we expect that benefit, net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realization of $6",48,"Yes, we've outlined that in the gross margin waterfall that you see in our presentation, Greg. In addition, we expect that benefit, net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realization of $60 million by 2018."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And that's on a cumulative basis.",7,"And that's on a cumulative basis."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And Greg, just to answer your question on the TPG stance, and so when TPG first took shares, when we acquired Par, there was substantial agreement that prevented TPG from increasing their stake in the company. So in this instance, concurrent to Todd comin",99,"And Greg, just to answer your question on the TPG stance, and so when TPG first took shares, when we acquired Par, there was substantial agreement that prevented TPG from increasing their stake in the company. So in this instance, concurrent to Todd coming on our board, our board put a decision to release TPG from the stance agreement subject to certain limits and those outlined in the 8-K that we filed with the [indiscernible] agreement, but effectively, it allows TPG to purchase up to another $250 million worth of shares subject to a cap add 10% of ownership."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Operator, can we have the next question please?",8,"Operator, can we have the next question please?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Liav Abraham from Citi.",9,"Your next question comes from Liav Abraham from Citi."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics specifically in the legacy Par business? And that was my first question. And then secondly, just a quick questi",76,"The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics specifically in the legacy Par business? And that was my first question. And then secondly, just a quick question on the tax rate, can you just remind us on the accounting of your tax rate? Is this a GAAP tax rate or a cash tax rate? And what is your cash tax rate?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","This is Paul. In terms of legacy Par, in terms of the pricing pressure for the most part, it's flat, maybe low single digits in terms of price. But for the most part, it's flat. And again, we're able to defend it because for the most part, that base busin",70,"This is Paul. In terms of legacy Par, in terms of the pricing pressure for the most part, it's flat, maybe low single digits in terms of price. But for the most part, it's flat. And again, we're able to defend it because for the most part, that base business comprises quite a bit of modified release, sustained release. We've got the injectables as well, so a little less competition."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. Moving to the tax question. Our tax rate, adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt or any [indiscernible] and trends for price planning as we",96,"Yes. Moving to the tax question. Our tax rate, adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt or any [indiscernible] and trends for price planning as well as acquired attributes that ultimately results in our adjusted effective tax rate, which is and has been significantly higher than our cash tax rate. Our cash tax rate has been negative for a number of years and is expected to be in the low single digits in our foreseeable future."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Mark Goodwin from UBS.",12,"Your next question comes from the line of Mark Goodwin from UBS."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year as guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be i",156,"Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year as guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be in the first place. I mean are these going to be products like Vasostrict, which seems to be -- obviously going to break $200 million this year, at least that's what it seems. So just give us a sense of that as well as the other 505(b)(2)s that you have. As you say in the pipeline, what we see others launching in '17, are they coming in '18, '19? When do they come? And how big can they be? And then just one quick one, which is you mentioned 60 product discontinuations. What are the sales on those products on an annual basis? And how much is that impacting this year?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict and it's a little bit larger than you had indicated. It's an excess of around $300 million. Now the 505(b)(2)s that we are working with the FDA, we hav",181,"So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict and it's a little bit larger than you had indicated. It's an excess of around $300 million. Now the 505(b)(2)s that we are working with the FDA, we have not, for competitive reasons, disclosed specifically the value. I would say they're not on the magnitude of Vasostrict. They're material but they're nowhere near the magnitude of Vasostrict. I think for competitive reasons, I think at this point, that's far as you can go on, on the 2 products that we're working with, with the agency. Additionally, we do have a 505(b)(2) strategy to take unapproved drugs when they're on requisite clinical trials and bring them to market. And we do have a handful of additional products that are at various stages and across the entire portfolio of either injectables or solid or oral dosage forms. At this point, we're just not advanced enough to get into more detail, and hopefully, in another quarter or 2, we'll be able to provide a little bit more visibility."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, I think, Marc, just to add to that, and this is certainly one of our core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. And certainly, we're encouraged by the s",80,"Yes, I think, Marc, just to add to that, and this is certainly one of our core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. And certainly, we're encouraged by the success that the Par team has had with Vasostrict so far. In terms of the impact of the product rationalization, Suky, do you want to talk about the revenue impact?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. So this year, we would see that revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million. So it steps up by about $70 million in '17. And again, our benefits that we talked about for the",80,"Yes. So this year, we would see that revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million. So it steps up by about $70 million in '17. And again, our benefits that we talked about for the planned rationalization are net of that revenue reduction. So we do still expect to see $60 million margin improvement on a full run rate basis net of the sales reduction."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Great. Operator, can we have the next call please?",9,"Great. Operator, can we have the next call please?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Annabel Samimy with Stifel.",9,"Your next question comes from Annabel Samimy with Stifel."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 [indiscernible] but are we ever going to see the levels that we saw before you've taken this cut down? A",87,"I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 [indiscernible] but are we ever going to see the levels that we saw before you've taken this cut down? And what component of the Qualitest business is commoditized? How much of that 60 -- how much of that product rationalization is part of that commoditized business? And once that gets out, how do you see gross margins are recovering after this?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So Annabel, if I miss something there, just please weigh back in. But overall, we would see was margins, all else being equal, improve into 2017 given the rationalization of our products, sorry our plans, that we talked about as well as because of t",157,"Sure. So Annabel, if I miss something there, just please weigh back in. But overall, we would see was margins, all else being equal, improve into 2017 given the rationalization of our products, sorry our plans, that we talked about as well as because of the reduction in the lower-margin SKUs or products that we're rationalizing. I think other drivers to think about into 2017 as we continue to grow the Par portfolio, which we see as one with products with a margin profile above the existing gross margin average, we could see improvement from that driver. And then in addition, as we see growth from branded within XIAFLEX as well as BELBUCA, we would also see those as potentially expanding margins into 2017. So again, we're not in a position to provide full 2017 or beyond guidance, but we do see a path to recover in gross margins above where 2016 are going to [indiscernible] ."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Are they recovering to the level that they have been at?",11,"Are they recovering to the level that they have been at?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's too early to tell at this time, Annabel.",10,"It's too early to tell at this time, Annabel."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Louise Chen from Guggenheim.",12,"Your next question comes from the line of Louise Chen from Guggenheim."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So just to follow up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is",78,"So just to follow up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is not to be an antagonistic people that people have been asking us. At what point you would consider strategic options for Endo if you can't create shareholder value on your own?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, really. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly. It is disappointing for the company and personally disappointing for myself as well. So we have done an exhaustive assess",487,"Thanks, really. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly. It is disappointing for the company and personally disappointing for myself as well. So we have done an exhaustive assessment over the course of the last few weeks to ensure that we put as much thought as possible into how we assess the remainder of the year. And I would say, our guidance range for the full year is a realistic range, right? So no business is without its risks, and I think you know that. But we have taken a substantial downward division in the base business in generics. We have, and I commented on how we are treating Voltaren Gel. We have also taken the opportunity to address some other parts of our branded business because of the continued pressure in the pain market. We rebase some of those products as well. So we've really taken the opportunity to take a hard look at the forecast in this rebasing. So we don't take this lightly. I mean it's not something that we want to do more than once, right? So that's the post that we've taken. We are confident in this guided range, and we have a team that is going to work extremely hard at executing against this range. But as always [indiscernible] that there is always risk. And then yes one second. So Louise, I was also just going on, and the second question you asked, for us and our Board of Directors, our goal is longer-term shareholder value creation, right? So certainly, that is the last -- what's happened with the business over the course of the last few weeks and months is a disappointment and a setback. But I would point out that our future growth drivers remain unscathed in terms of these particular events that we talked about, right? So we point to XIAFLEX, the XIAFLEX pipeline. We talked to BELBUCA, which even though there is potential delay in terms of the launch trajectory of their product, we continue to believe in the future of that product. And the Par pipeline, which is the primary driver of that acquisition, is as robust as ever, right? It continues to grow. The sterile injectables business is robust and growing, and I have very confidence in Paul and the team in terms of getting the generics business back on track. So from that standpoint, we believe that in the hands of our management team, with the appropriate rebasing that we've done in 2016, that there is a path to returning to organic growth, improving our margins and delevering and, therefore, to creating shareholder value going forward. Having said, we are also being very clear that our board is a shareholder-friendly board. And if there's ever any strategic alternative that presents itself, our board will of course evaluate it."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Andrew Finkelstein from Susquehanna.",12,"Your next question comes from the line of Andrew Finkelstein from Susquehanna."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Could you talk -- I'll give you a couple of things you can focus on, but at a high level, as you talk about the new strategy and even reassessed the environment, I think you highlighted where the growth drivers you currently have. But as you look longer t",157,"Could you talk -- I'll give you a couple of things you can focus on, but at a high level, as you talk about the new strategy and even reassessed the environment, I think you highlighted where the growth drivers you currently have. But as you look longer term, I just want to incubate additional drivers, where are the opportunities in this environment and the types of products that are going to have the right risk reward to pursue? And then as you go about managing that, could you talk about how you're thinking about balancing cash generation in the near term and particularly with regard to leverage ratios versus investments you may want to make and longer-term opportunities? And just specifically on that as you talk about rationalizing some of the legacy products, were these lossmaking? Or is some cash flow being given up? And if so, what's the benefit in doing so at this point?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So let me just take your 3 questions and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline, right? So we've pu",497,"So let me just take your 3 questions and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline, right? So we've pursued the cellular indication. Our Phase IIb trial is in the clinic and [indiscernible] recruiting patients. We feel positive about that, and we've also seen that we have increased confidence in being able to move forward, at least 4 other indications into the clinic, right? and they fall generally into the areas of aesthetics as well as other therapeutic indications around oncology. So the one core priority for us is continued and increased investment in that R&D pipeline. The pain market, clearly, in terms of public policy and relative pressures have increased in their market. As we said before, BELBUCA has a real profile that could really benefit in terms of some of the current concerns around schedule 2 opioid, as we do think there's a future there. But as we look further out into the future, building on our portfolio across our branded business, we could see ourselves in multiple areas that have similar characteristics to other specialty areas where I would say with a smaller focus [indiscernible] some main footprint that we can be successful and following some of the therapeutic areas where XIAFLEX is going to get us to is going to be the best way for us to pursue that. Now leading to your next question, in terms of cash and our priorities for using the cash, as Suky explained what we talked about delevering, we do expect to continue to prioritize delevering and be lowering back to the 3 to 4x is an important goal for us. That is delayed from 2016 into 2017 but continues to be an important goal for us. At the same time, investing in R&D pipeline both in XIAFLEX as well as Par are going to be very important priorities for us, which we will balance as we go, right? So those are going to be the most important uses of cash. And beyond that, obviously, once we get into a position where we have excess cash and have the opportunity to look at perhaps bolt-on acquisitions either for the generics business or the branded business, we will certainly look at those as they come up. [indiscernible] be to do so in the branded space, but that is the way [indiscernible]. We want to make sure that we execute against our growth plan and delever as our primary priorities, and we always keep the option of returning cash to shareholders as an alternative as well. Now let me just turn this to sort of Paul because I want him to talk to you about some of the new areas that we might expand our pipeline into as well as question that you had on product rationalization and the profitability impact of that."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So obviously a very important question, and I want to start by saying this -- the decision in terms of calling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of normal course, it really is an evolution whe",291,"So obviously a very important question, and I want to start by saying this -- the decision in terms of calling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of normal course, it really is an evolution where you need to consistently look at your portfolio. You have to make some tough decisions, you have to take your unprofitable products or products that you're feeling pain and pressure on. That being said we're the fourth largest generic company. We are incredibly relevant. We will continue to be relevant in the industry, and I want to make that statement. When you -- if you want to be able to compete with the 4 large consortiums, add Walmart in, those 5 companies representing in excess of 90% share, you really need a well-balanced portfolio. And what I mean by that is you need your fair share of Paragraph IVs, you need to [indiscernible] technically changing solid oral dosage products. You need injectable products and you do need commodities that are profitable. So that's going to be very important to us in terms of the Qualitest portfolio on a go-forward basis. Now on discontinuation products, hard decisions. By [indiscernible] the portfolio areas that is going to help us, parts that are ultimately being sold at losses and we make the tough decisions, it's going to help us on the cash side. We're going to have a reduction in our operating costs. We'll have a reduction in working capital and we'll also not need to invest as much in certain facilities from a CapEx standpoint. So from that standpoint, generally speaking, high level, those would be areas that we would have savings in."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And I want to just come back to Annabel's question [indiscernible] what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have that",153,"And I want to just come back to Annabel's question [indiscernible] what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have that Rajiv outlined earlier, and given the focus on execution and efficiency that Paul and his team have around our manufacturing network, I think we do see a path to get back into the mid-60s over time. We're not going to time down that at this point yet. We're going to let more '16 play out. And as we move into 2017, we'll have a better view into that, but I do think the growth drivers are at a gross margin that are higher than our overall corporate average. And again, through efficiency that Paul and his team will drive, there could be a pathway there over time."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Douglas Tsao farm Barclays.",12,"Your next question comes from the line of Douglas Tsao farm Barclays."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just first in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA.",24,"Just first in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Let me just address that on Paul's behalf. We're not going to talk about when we might launch our [indiscernible] generic for competitive reasons, and a lot of it is going to depend on how the competitive environment was without one competitor on the mark",66,"Let me just address that on Paul's behalf. We're not going to talk about when we might launch our [indiscernible] generic for competitive reasons, and a lot of it is going to depend on how the competitive environment was without one competitor on the market. So far, we are very happy with the strategies that we have put around mitigating erosion of our branded products."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Okay, and then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective, I mean when do you think we should start to see an inflection in poi",115,"Okay, and then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective, I mean when do you think we should start to see an inflection in point in the script? And then just also, obviously, you noted that [indiscernible] good covered that [indiscernible] exist right now. When do you anticipate further finalizing that? And how are those talks going? And the pricing that you expect to get, is that sort of in line with your expectations that are -- or perhaps a little bit more challenged given the dynamics in the pain market right now?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Great, thanks, Doug. So look, it's still early days on BELBUCA, and the last week, for which we have data I think is the week of April 21, and we had roughly 650 prescriptions, and we continue to see momentum, right? And it's difficult to predict exactly",500,"Great, thanks, Doug. So look, it's still early days on BELBUCA, and the last week, for which we have data I think is the week of April 21, and we had roughly 650 prescriptions, and we continue to see momentum, right? And it's difficult to predict exactly when the inflection point is going to be, but what I can say is that the anecdotal feedback and the qualitative feedback from physicians have been very positive, and I myself have spent time in the field. And the fact that this is a schedule 3 product, despite all the new pressure that is on physicians with the new CDC guidelines and everything else, the message resonates, right? But that being said, from the very beginning, we pointed to something that would likely lead to requiring more time to educate physicians, and that is the tapering and titration required with this product, right? So to the extent that you are trying to move a patient from other therapy on to BELBUCA, you could taper that patient down per our label and then titrate the patient back up. And then for most physicians, what they are trying to do is to figure out their own gut feel for how this works. Clearly, from a promotional standpoint, we have to stand behind what's in the label, but every physician will figure out what he or she is comfortable with. I would also say, another encouraging sign is that repeat prescription from those who prescribed is progressing very well. So we have as many repeat prescriptions now as we have with new RX. These are all good indicators. I'm going to hesitate to give you an exact time frame of when there's going to be an inflection point, but I would point to the second half of this year in terms of when we would expect to see a continued improvement, and I've forgotten the second part of your question, yes it is on the managed care. So it is progressing very well. As we have said before, we have roughly about 2/3 of commercial lives covered at least with default coverage. We made very good progress in terms of converting the default coverage into actual coverage. Many of the plans require -- have confidentiality agreements that prevent us from talking about these things in a public way but one that we can point to where we have permission to talk about is Express Scripts. That has been very good win for us. We're continuing our discussions with other plans. And so far there has -- it's going exactly as we had expected. Now the one piece that we would expect to not get to until 2017 is the Medicare Part D coverage, but that is on par with all of the situations, better product launches midyear. We've also implemented a copay program that basically puts a product on par with comparative products. So from all aspects, from an access standpoint we are making good progress."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Ken Cacciatore from Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore from Cowen and Company."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just kind of reiterating what you all said that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a t",115,"Just kind of reiterating what you all said that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a total restructuring, kind of maximize all aspects of the business. And I guess the question again is why stay standalone? You could take equity in a pro forma company and realize the benefits of a larger entity while the value is extracted. And I guess just for your shareholders, wanting to know are there indeed options on the table and why isn't this very, very high in the list of options?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Ken. So let me refer you back to my previous answer to a similar question, and I'll answer your question. At the end of the day, what is most important for our team and for our board is to ensure that we right the [indiscernible] operationally, ad",197,"Thanks, Ken. So let me refer you back to my previous answer to a similar question, and I'll answer your question. At the end of the day, what is most important for our team and for our board is to ensure that we right the [indiscernible] operationally, address the challenges we have seen and make the progress that we know we can make as a team, right? That being said, we've always been clear that we're a shareholder-friendly management team, we're a shareholder-friendly board and we will always look at strategic options that present themselves. Now one of the things that I've said in the past is, although from a debt market perspective as well as where our own equity is trading, we are not in a position to do substantial acquisitions. But I have pointed out that mergers are certainly options that we would consider if they present themselves. Particularly, we're either on a relative value basis at something that makes sense or we conclude that is in the best interest of our shareholders. So certainly, we will remain open to those options, but our primary focus and priority is on operationally executing against our plan."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Irina Koffler from [indiscernible] .",10,"Your next question comes from Irina Koffler from [indiscernible] ."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback",92,"I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback and delay into 2017? And then going forward, we have to rely on your execution of these programs, and yet we had a delay this year already. So what can you say to give us more conviction in your execution of these products [indiscernible]?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will let Paul answer is. I think I would just point to Vasostrict as an example or why we're so confident in Par's ability to execute. It's been an extraordinary successful product strategy and one where I don't think we've seen the final chapter yet. P",57,"I will let Paul answer is. I think I would just point to Vasostrict as an example or why we're so confident in Par's ability to execute. It's been an extraordinary successful product strategy and one where I don't think we've seen the final chapter yet. Paul continues to work on it, but Paul, why don't you."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA through the 505(b)(2) process. Historically, these are typically older drugs which we have to run regular clinical trials in order to get NDA statu",214,"Again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA through the 505(b)(2) process. Historically, these are typically older drugs which we have to run regular clinical trials in order to get NDA status. When we can change a product and when we can get intellectual property, obviously, we're going to do that aggressively. On certain products, we're able to do that. In certain projects, we are unable to do that. In the case of the products that we are referring to at this point in time, I would tell you that I don't believe that intellectual property is as strategic as we would like it to be. However, there are other things that we would be working towards that, at this point in time, I would not want to disclose for competitive reasons but we are hopeful that this is not going to be a 1 year and out type of 505(b)(2), whereby we spend the requisite PDUFA fees, build up a product and then invite competition. So we do have strategies outside of intellectual property that hopefully will gain us longevity, but we're not talking compound patent IP where you're typically seeing multiple years. That's not what we're talking about here."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from David Risinger from Morgan Stanley.",10,"Your next question comes from David Risinger from Morgan Stanley."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is from the Qualitest business and how much is hitting the Par business? So I'll ma",156,"A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is from the Qualitest business and how much is hitting the Par business? So I'll make up a number. Let's say the hit was $10. Of the $10 hit, was it 2/3 to Qualitest and 1/3 to Par? Was it half and half to each? Just trying to understand that. And then second, with respect to XIAFLEX, how should we think about that product sales sequentially in coming quarters? And then finally, actually, and this one is I guess for Suky, you had mentioned moving parts in 2017. Could you just talk about the big moving parts that are uncertain? I mean obviously, there are some certainty with Zetia and Seroquel, but what are the moving parts for revenue that are uncertain for '17 at this point?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","David, let me hit you with XIAFLEX question then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% we are looking at the U.S. And as we laid out i",153,"David, let me hit you with XIAFLEX question then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% we are looking at the U.S. And as we laid out in our presentation in my comments, our expectation for the full year is product growth should be somewhere in the mid to high teens range, right? Now clearly we are working to accelerate the product, but that is -- if you are aware, our best current thinking is. So if you take a look at the 21% and the full year at mid to high teens, there will be a slight moderation as we head into the next few quarters, but this is still going to be well within the strong double-digit growth profile that we predicted for the product."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And David, your question on the price and the pressure, when we look at the Qualitest portfolio which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in p",91,"And David, your question on the price and the pressure, when we look at the Qualitest portfolio which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in pain. A big portion of our portfolio is directed towards pain. It's not quite the barrier that it once was. And as a result, the pricing pressure that we saw was about 80% tied to legacy Qualitest and about 20% tied to legacy Par."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following [indiscernible] on 2017. So let's talk about what's changed since we last put our expectations for 2017, right? So the 3 main changes have been a resett",343,"And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following [indiscernible] on 2017. So let's talk about what's changed since we last put our expectations for 2017, right? So the 3 main changes have been a resetting of expectations for our Qualitest base business; the delay in the 505(b)(2) program, as we talked about, which is going out of 2016 but will be impacting positively 2017 and 2018 for that matter. And then we talked about V Gel, which we fully expect it to be genericized as we headed into 2017. It just happened much earlier than we expected, and we do have Authorized Generic as an option for us to use going into 2017, right? So the real major downward revision there is the impact of the Qualitest base business. Now there are other moving parts that will impact what our final guidance for 2017 is though, right? We will have to take a view on exactly how BELBUCA is going to do. It all depends on kind of where the inflection point is going to be. Obviously, tailwinds behind XIAFLEX will continue to grow. We will know more by the middle of this year in terms of what's happening in OPANA. We have a July 29 PDUFA date for our ADF [indiscernible] request with the FDA. And we will also know more in terms of some of the other pipeline launches and other programs that Paul's pursuing in the Par business and exactly where they will fall in 2017, right? So those are some of the real moving parts we have. We also signal that we expect to increase our R&D spend, particularly behind the XIAFLEX pipeline. And to the extent that Paul has any new ideas from an R&D standpoint, we will try very hard to meet any additional funding requirements in the Par pipeline as well. So those are some of the moving parts. I don't know, Suky, whether you have anything else that you would point to?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. So just understanding where our exit is in '16 before we make that final call.",41,"I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. So just understanding where our exit is in '16 before we make that final call."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Elliot Wilbur from Raymond James.",13,"Your next question comes from the line of Elliot Wilbur from Raymond James."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","This is Daniel Sanchez on for Elliott Wilbur. Just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities if you were to put the mesh settlement issue behind you and if you think the worst",54,"This is Daniel Sanchez on for Elliott Wilbur. Just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities if you were to put the mesh settlement issue behind you and if you think the worst parts and claims with the highest value are over."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So let me just comment on the overall status of mesh that Suky talk about the financial aspects. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail which is we took the steps to resolve the hi",213,"Sure. So let me just comment on the overall status of mesh that Suky talk about the financial aspects. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail which is we took the steps to resolve the higher quality claims, which is what led to an increase in our accrual that we announced in the fourth quarter call. Since then, the situation has not changed. There is an alleged potential for another 8,000 cases in the tail that we disclosed, but we were also very quick to point out that expectation is that a large proportion of those cases could be of lower quality. We don't have all the facts around them. We'd also point to the fact that there is a potential fraudulent scheme that is running through many of these cases, which we are investigating currently. And unless we pointed out before, this is typically the types of things that you see at the very tail end of a mesh situation. We can't give you a precise projection of what the end date is, but we have confidence that we are seeing the real tail here. I mean Suky, can you talk about the cash expectations in '16?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet. You'll see that in our 10-Q which will be issued in the very near future. Of that $1.9 billion, the amount of restricted cash for our",163,"At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet. You'll see that in our 10-Q which will be issued in the very near future. Of that $1.9 billion, the amount of restricted cash for our cash authority have been put to Qualified Settlement Funds was about $0.5 billion, which leaves a residual $1.4 billion on a gross basis to be paid. We'd expect of that remaining $1.4 billion, about $750 million on a gross basis to be paid between -- for the rest of 2016 and then about $600 million to $650 million into 2017 or the residual of that $1.3 billion balance. So that's where we stand from a cash call basis. As we talked about earlier, we did receive the federal tax refund that we pointed to earlier this year that came in early April. We continue to look at ways to provide a shield around future liabilities."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","And any line of sight as to the magnitude of potential fraud cases? Or is it too early to tell?",20,"And any line of sight as to the magnitude of potential fraud cases? Or is it too early to tell?"
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's an active investigation. We have issued subpoenas in the case and also working with the judge in the MDL cases as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it.",41,"It's an active investigation. We have issued subpoenas in the case and also working with the judge in the MDL cases as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Rohit Vanjani from Oppenheimer.",12,"Your next question comes from the line of Rohit Vanjani from Oppenheimer."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Sorry, I'm [indiscernible] some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate new competitor taking? And then same thing with [indiscernible], are you seeing a",131,"Sorry, I'm [indiscernible] some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate new competitor taking? And then same thing with [indiscernible], are you seeing a new competitor there? And if so, how much did you reduce estimates by? And then secondly, for the generics, can you help me understand the business a little bit there? Do you have contracts primarily at the beginning of the year and that's where you get the renegotiation happening? Or are the majority of the contracts staggered throughout the year? Or are you seeing [indiscernible] where you're choosing not to engage? Or are most of the products sold at [indiscernible] at will where your customer can move pretty freely."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So let me just talk about briefly about [indiscernible] and [indiscernible] and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to the materials for today's call the relative impact on the rebasing of our 2016 guidance. We are not",119,"So let me just talk about briefly about [indiscernible] and [indiscernible] and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to the materials for today's call the relative impact on the rebasing of our 2016 guidance. We are not going to discuss our markets expectations anymore, other than to say there's a single competitor in the market, and we are effectively defending the branded product at the level that we would expect to do. With respect to FROVA, yes, we do have a new competitor that is [indiscernible] and currently, Par has also launched our authorized generic, so that is also in the market. Maybe you can address the the next question."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. In terms of the consortiums, the cycle, I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against. So it's not like you come in, in Q1 and have to deal with 3 of the consortiums",201,"Yes, sure. In terms of the consortiums, the cycle, I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against. So it's not like you come in, in Q1 and have to deal with 3 of the consortiums. [indiscernible] does not actually put out bids. Their expectation is that they're going to be guaranteed best pricing. So their style is a little bit different as opposed to the one-stop program or the revamped program or even the [indiscernible] program Regarding [indiscernible] , that is exactly what it is. So after you go to the consortium bid cycle, that does not mean that you're still not exposed for [indiscernible]. That being said, we defend against [indiscernible], and we have our fair share of wins. We have our fair share of losses. And at the end of the day, I think on a go-forward basis, this in an area that we're fairly strong and in terms of the [indiscernible] to protect ourselves from the legacy Par standpoint and we are, in essence, rightsizing the Qualitest business legacy site in order to be able to defend against [indiscernible] on a go-forward basis."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","We'll time for 1 kind final question. Kevin Kedra from Gabelli.",12,"We'll time for 1 kind final question. Kevin Kedra from Gabelli."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just wondering when you think about strategically how much sense [indiscernible] you keep the generic brand of this is together? Any thoughts about maybe separate those businesses. And then actually I think that'll be good.",35,"Just wondering when you think about strategically how much sense [indiscernible] you keep the generic brand of this is together? Any thoughts about maybe separate those businesses. And then actually I think that'll be good."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Okay, thanks, Kevin. Look, it's a strategic question, and I think one of the things that our company has benefited from over the course of the last 3 years since my arrival when we [indiscernible] accounts on the business is, in fact, the diversity of the",221,"Okay, thanks, Kevin. Look, it's a strategic question, and I think one of the things that our company has benefited from over the course of the last 3 years since my arrival when we [indiscernible] accounts on the business is, in fact, the diversity of the business, right? So the generics business, especially with the addition of Par, I know despite the rebasing that we are taking, it's a highly diversified business with multiple growth drivers. And we've also taken the steps to build critical mass in our branded business, right? But I have been also open that from a forward-looking standpoint, at a certain point in time, when we have critical mass in both our branded business as well as our generics business, this can be bought 2 very viable stand-alone businesses. So from a strategic standpoint, we remain open to thinking about creative ways of creating shareholder value. But as I pointed to earlier in my comments, our primary focus right now is operational execution. We have a full plate in Par in terms of restructuring that needs to be done, focus on the pipeline as well as in the branded business growing XIAFLEX and growing the BELBUCA and investing the pipeline. But certainly, we will keep all strategic options open to us as we think about the future."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","I would now like to turn the call back over to Rajiv De Silva, CEO and President.",17,"I would now like to turn the call back over to Rajiv De Silva, CEO and President."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, and I want to thank all of you for your attention today. There were a lot of very good questions and talk a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. But what I hope that you will t",256,"Thank you, and I want to thank all of you for your attention today. There were a lot of very good questions and talk a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. But what I hope that you will take away from this call today is that despite the rebasing of our 2016 guidance, Endo is a fundamentally different and stronger business than it was in 2013, and it is also a more compelling investment and growth story. In 2013, we had 2 primary and declining assets at that time and a very fragmented base of business at [indiscernible] health care solutions divided in pharmaceuticals. You fast-forward to today, we've rebuilt our branded portfolio and pipeline with the acquisition of Auxilium and in particular XIAFLEX. We've divested noncore businesses. We've achieved scale and differentiation in our generics portfolio with the addition of [indiscernible], and that is what the future is going to be about, particularly as we think to see the rebasing of our legacy Qualitest business, establishing international structure and footprint for both an expansion. We narrowed the mesh detail and we have built a business generating significant EBITDA even after this rebasing and free cash flow that we expect to grow going forward. So no one likes to rebase guidance more than I, but we have now reset our business so that we can move forward and effectively drive growth and value, and we thank you for your continued support. Thank you very much."
28071,331734375,974770,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, this concludes today's conference. Thank you for your participation and have a wonderful day. You may now disconnect.",21,"Ladies and gentlemen, this concludes today's conference. Thank you for your participation and have a wonderful day. You may now disconnect."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Ker",56,"Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin your conference."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmace",226,"Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceuticals. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements made by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings",706,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings presentation. 
On the next 2 slides, you will see a brief agenda and an outline of key themes for today's call. To begin, I will provide a snapshot of our first quarter financial results which, despite some headwinds, were largely in line with our expectations. However, these headwinds have created substantial challenges to overcome in the remainder of the year. We are providing revised full year 2016 guidance today to reflect these challenges. We will spend some additional time discussing the state of our business, key drivers for this rebasing and our action plans moving forward. 
Specifically, there are 3 factors to call out that we will discuss in more detail on today's call: deeper-than-expected erosion in the legacy Qualitest business; delays in FDA actions related to our 505(b)(2) products; and an earlier-than-expected generic entrant for Voltaren Gel. Importantly, we will also talk about why we believe that our core growth drivers will continue to provide opportunities to execute against our strategic plan and allow us to return to organic growth, improve margins and delever in the medium term. 
Before we begin, I would like to take this opportunity to welcome our 2 new board members on behalf of our board and the company. We are delighted that Doug and Todd have accepted our invitation to join. We look forward to their contributions. 
Moving to Slide 6. You will see the Q1 snapshot of reported segment revenues. In our branded business, we saw solid continued growth for XIAFLEX, which performed well despite the expected historical trend of Q1 seasonality. This growth was offset in part by a decline in Voltaren Gel due to that product's loss of exclusivity in March and continued pressure on the pain market. In our generic segment, the base business erosion continued into the first quarter and was significantly deeper than we expected at approximately 30%. This was driven by continued pricing and competitive pressures on our commoditized and pain products. The erosion was partially offset by strong performance from our sterile injectables portfolio, including Vasostrict, and the overall performance of the legacy Par portfolio. We will return to these themes when we discuss full year guidance. 
The international business performed as expected with a modest decline in reported revenues. However, our emerging markets businesses continued to show both constant exchange rate revenue growth and underlying growth as well as margin expansion. 
On Slide 7, you will see our first quarter segment revenues as well as reported and underlying growth. 
Next, on Slide 8, we provided our first quarter financial results. 
Moving on to Slide 10. Let's talk about the state of our business and the context in which we are viewing the remainder of 2016. To best understand where Endo is now, it's important to also understand where we've been and what we've built. When I joined the company in 2013, we chartered a new strategic cause and outlined some very clear goals as seen here in the left column. Over the next 3 years, we set out to achieve these goals and position Endo for growth. That strategy is still core to Endo and to how we run our business. However, what has become clear is that the 2016 specialty pharmaceutical landscape and market forces require an evolution of that strategy. 
So let's talk about our path forward. Our goal has not changed. We continue to aspire to build a leading global specialty pharmaceutical company. What has changed rapidly is the landscape and market environment within which we are operating, particularly in generics. What does this mean going forward? It means we're reshaping the path forward for Endo. We are rebasing expectations for the business and are evolving our current strategy to meet challenges and capitalize on opportunities. Ultimately, we are positioning the company for long-term organic and diversified growth, margin improvement and delevering. 
So let me now turn the call over to Paul to discuss key factors and drivers related to generics. Paul?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying and actual sales. The",1675,"Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying and actual sales. The variances between the sales totals resulted from a greater-than-anticipated erosion and base business of approximately 30%, driven particularly by the legacy Qualitest portfolio. While we expected base erosion to be higher in the first quarter than the full year, the actual erosion was much deeper across our pain portfolio and other commoditized products than originally anticipated. By contrast, the legacy Par portfolio is performing on track with internal expectations. Our sterile injectables product portfolio continued its strong performance with 86% growth over Q1 2015. Our new launches and alternative dosage product portfolio performance was stable and largely unchanged year-over-year. 
So let's discuss the factors that impacted these Q1 results and that we believe will shape our full year generics performance. Moving to Slide 14. There are rapidly changing market conditions that have affected both the broader generic sector and Par. First, we've seen a steep and rapid price erosion caused by payer consolidation that has been more even profound than anticipated. Its effect has exceeded what might have been expected from an ordinary downturn in the industry's traditional pricing cycle. The impact has been particularly acute in the more commodity like product categories, such as our pain and controlled substances portfolio and our immediate-release solid oral dosage forms. 
Second, coupled with this consolidation and new payer environment, competitors are taking aggressive pricing actions to gain market share. Examples include both the 300 and 325 milligrams strength of hydrocodone APAP, butalbital, morphine sulfate and oxycodone. 
Third, there's been a rapid erosion of the pain segment, driven by 3 things: one, continued market contraction; two, increased competitive capacity and pressure; and three, while still too early to judge the full impact, we believe the recently issued CDC guidelines will continue to put pressure on an already soft pain market. As you may know, approximately 40% of the legacy Qualitest portfolio was comprised of pain products, so this sector's specific weakness has had a disproportionate effect on our generics business. Fourth, there's been a recent and marked acceleration of FDA approval for generic products. While we'll ultimately expect this to also benefit the Par portfolio and our own pending submissions over time, the approvals in launches seen in late Q1 and in April of this year have resulted in greater competitive pressure for our products. Fifth and finally, delays in expected FDA actions related to our 505(b)(2) products means that we have yet to see the anticipated removal of unapproved competitive products from the market. Correspondingly, we have yet to achieve the market exclusivity that we expected for these products. It's important to note that we still expect these FDA actions but now on a delayed time line. The removal of relevant unapproved products may not occur before first half of 2017 versus our original expectation of early 2016. 
Now that we've talked about what's happened in the generics market, let's also take a few minutes to review when some of these events surfaced, thereby impacting our generic business. In 2016, it's important to note that the U.S. generic landscape has continued to shift, with significant events and updates as recently as late March and April. In fact, it was not until late March that we confirmed the delays on the regulatory actions related to our 505(b)(2) products that I just mentioned. Then in April alone, we see at least 5 competitive product approvals and additional market entrants. Finally, we've also just completed our consortium bid cycle with a more negative output and an increased pricing pressure than we anticipated. 
Moving to Slide 16. I do want to take a few moments to discuss our ongoing integration of the Qualitest and Par businesses. Last fall and Q1 of this year, we were conducting an integration of 2 complex generic businesses. What became very clear to those of us who have been in the generic industry for some time is that the legacy Par operating model is better positioned to address the challenges of today's evolving market. As a result, we set out to shift the legacy Qualitest portfolio strategy from a high-volume approach to the high-value operating model long practiced by legacy Par. As part of the integration activities, we're also transitioning the legacy Qualitest systems and processes to the Par business platform. The legacy Par systems offer more real-time and product level data, allowing for faster analysis and reaction within a challenging and changing market. While many of these improvements were already planned at Qualitest, the integration of our business will accelerate the benefits. 
Next on Slide 17. Let's talk about what we're doing to address these challenges and best position our generic business moving forward, our action plan. First, we are continuing to maximize our key growth drivers, such as our sterile injectables portfolio, led by Vasostrict and approximately 30 new products we expect to launch this year. Next, our platform for long-term organic growth is our R&D pipeline. We are continuing to advance these more than 250 projects post reprice [indiscernible] and anticipate filing 25 to 30 new submissions in 2016 alone. We are also accelerating the implementation of an optimization and restructuring of our product portfolio and manufacturing facility network. I'll talk more about this restructuring shortly. Additionally, we are accelerating the move of legacy Qualitest business onto the Par platform. This is already substantially complete as our commercial insight and forecasting capabilities have been fully transitioned. Finally, critical to our action plan is our ability to execute. This is not the first turbulent market environment that the Par team has successfully navigated. Our team is seasoned, capable and prudent. 
Moving to Slide 18. Now permit me to provide some additional detail on the restructuring I mentioned earlier. Most importantly, this restructuring is an acceleration of our ongoing integration and broader optimization efforts designed to prioritize and grow high-value durable assets. It is entirely consistent with all our integration activities to date. The restructuring will affect our manufacturing sites in Charlotte and in Huntsville and will result in more than 60 product discontinuations. In addition, we are pruning less value-driven R&D projects so that we can prioritize our investments on differentiated and high-value projects. We expect that the restructuring will be completed by the third quarter of 2017 and will result in a total of approximately $60 million in annualized net run rate savings by Q4 of 2017. We expect to see about $10 million of that gross margin improvement this year. As a result, shortly, we will begin the process and informing employees about these changes. As part of that effort, approximately 740 employees will be impacted under a phased transition. For Endo, the Par management team and for me personally, this is both an extremely disappointing to our company. We value our people, and for those who will be affected, we thank you all for what you've contributed to Endo. We'll be providing resources to help manage through this difficult transition. 
And while change is never easy, it is necessary to better position our generics division to successfully compete in the U.S. generics market. So on Slide 19. Let's talk about our full year revenue outlook for the generic segment. We have previously expected a mid-teens underlying growth rate for the business. Given the erosion now forecasted across the sector and particularly for our base business and the delay in regulatory action related to our 505(b)(2) products, offset by the strong growth projected for our sterile injectables and new launches and alternative dosage portfolios, we now expect underlying growth for our generics business to be in the low single digit percentage range. We do expect that erosion on our base business to moderate back to rates typical for the generic industry beyond 2016. The erosion in 2016 is expected to be more acute than historical trends due to our relative pricing and share levels in the pain markets prior to the observed and expected erosion. 
Moving to Slide 20. You'll see a look at our Q1 2016 reported generic net sales annualized versus our full year 2016 guidance midpoint. You can see the projected decline due to non-face business competitive entries and base erosion, which we expect to be approximately 5 years per quarter through the end of the year. Our new product launches are a significant driver of growth as illustrated by the green block and bring you to our projected generic net sales midpoint for the year. 
Now let's look at our 2016 launches on Slide 21. We are on track to launch nearly 30 new products this year. 4 of these are first-to-file products including our generic Seroquel and generic Zetia products that will launch in the fourth quarter of 2016. Another 2 launch products are alternate dosages and another 9 are sterile injectables. Importantly, and as an illustration of our value-focused strategy and platform, nearly 1/3 of our projected launches are products that will be exclusive or faced only one generic competitor. Finally, let's close this generics discussion with a quick review of our robust R&D pipeline on Slide 22. 
As I mentioned earlier, we have more than 250 projects in our reprioritized R&D pipeline. We anticipate launching more than 100 of them between 2016 and 2019, representing a total current market value of nearly $30 billion. Our pipeline is robust, diversified and populated by higher barrier-to-entry and higher margin generic products. We believe that positions us strongly for future growth. I am confident in our platform and I believe that our pipeline is truly differentiated. I know that our team has the experience and the ability to address these challenges and to deliver future generics growth and margin expansion. 
With that, let me turn the call back over to Rajiv for a discussion on our branded business. Rajiv?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportunitie",825,"Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportunities. Brian has been a critical part of the efforts to reposition our company over the last 3 years. We will miss him at Endo and wish him well in his future endeavors. 
Moving to Slide 24. Let's talk about factors affecting our U.S. Branded business. First, there has been a recent generic entrant for our Voltaren Gel product. This generic came into the market earlier than we expected, and it has affected our 2016 outlook for V Gel. Second, we have seen increasing pressure on our branded pain segment. This includes additional competitive entries as well as a continually increasing number of public policy and regulatory actions, such as the recent CDC guidelines around opioid prescribing end-use. Additionally, there are reimbursement restrictions now in place for LIDODERM further limiting the use of that branded product. Against this backdrop, we do continue to see significant growth potential in our differentiated product, BELBUCA. However, it has progressed at a slower pace than we initially expected due to pain market pressures. That said, we continue to believe in the future of this product as a scheduled 3 alternative in the opioid category. 
On Slide 25, you will see the opportunity for BELBUCA, the first and only buprenorphine Buccal Film for chronic pain management which we launched in late February of this year. There are about 90 million total prescriptions written for the treatment of chronic pain below 160 milligram morphine sulfate equivalents or MSCs. BELBUCA is well positioned to source patients both from short-acting opioids as well as other long-acting opioids. Given the size of both these segments, even with a relatively small share of the available prescription base, BELBUCA could become a very meaningful product in this category. 
It is also important to note that even in these early days, BELBUCA is not only capturing switches from LAOs but also from SAOs and new therapy starts. Further, we have seen an increasing number of repeat prescriptions week over week. Its differentiated profile is resonating well with physicians and patients across the spectrum, and our early feedback on access, ease of use, efficacy and side effect profile have all been positive. 
Along these lines, let's look at Slide 26, to talk more about early progress on the BELBUCA launch. There are 3 areas that we have focused on in terms of early launch, traction and feedback. While I won't talk through each bullet here, we did want to provide a comprehensive look at where we are making progress and where we see opportunities to further accelerate BELBUCA launch traction. 
Next, on Slide 27, let's talk about XIAFLEX. XIAFLEX continues its double-digit demand growth profile, and we are making good progress in growing that business. We see a significant opportunity to expand both our share of the current treatment market as well as the size of the overall markets for both Dupuytren's contracture and Peyronie's disease. Across both of the DC and PD indications, we have new initiatives focused on driving growth. We are working to broaden our active injector base and have improved targeting to reach the most appropriate positions. Our DTC and print ad campaign efforts are also showing signs of real traction. For example, visitors to the ""Ask About the Curve"" website spend about 10x longer on the site than an average website visit, and about 1 in 10 visitors click through to find the Peyronie's disease specialist in the area. 
We have also worked to improve convenience of physicians through our reimbursement support initiatives and our product savings program. Overall, these efforts position XIAFLEX for strong continued growth. We expect mid- to high teens percentage growth in 2016.
Moving to Slide 28. Let's talk about the other driver for XIAFLEX growth over the long term, our robust R&D pipeline. We see significant opportunity and substantial value for XIAFLEX across both therapeutic and aesthetic indications and have talked about how the product could be a $1 billion franchise for Endo by the mid-2020s. That opportunity is driven by the more than 12 potential indications currently in the R&D pipeline and the multiple additional programs in even earlier stages of development. As part of our evolved corporate strategy and initiatives to return to organic growth, we are accelerating our R&D programs for XIAFLEX and plan to move 5 programs into the clinic even earlier than previously expected in 2016. It is a time of significant opportunity for these growth drivers in our branded business. We have taken steps to best seize those opportunities and accelerate their growth, while also managing the legacy products within our portfolio. 
With that, let me turn the call over to Suky to discuss our full year 2016 financial guidance. Suky?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo through the rest of 2016. On Slide 3",320,"Thank you, Rajiv, and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo through the rest of 2016. On Slide 30, we have provided an outline of the key components of change to our rebased revenue guidance that lead to an 11% reduction. As you can see, the largest driver of the change is the greater-than-expected erosion in our generics-based business. As a reminder, we define base generics as extended release, immediate release and pain and controlled substance products. As with the branded business, our rest of the year projections are based on business and commercial assessment and recent trend announcements at a product-by-product level that also takes into account the outcomes of recent bid cycles and competitive actions. 
Approximately 55% of the decline is related to price erosion and 45% relates to volume declines. This is an important variable as price declines fall to margin at 100%. I should also note, we expect to realize the value of delayed 505(b)(2) actions later in 2017. 
Next, on Slide 31, let's look at the drivers for the changes in our projected gross margin for 2016. Our previous guidance was 63% to 65% for the full year. Given the impacts of key events and market factors, we now expect full year gross margin to be in the range of 59% to 60%. Using the midpoint of the previous and revised guidance range, we expect gross margins to decline about 17% versus prior expectations. We are projecting a disproportionally high erosion on gross margin versus revenue due to a number of factors that you will see detailed here in the blue call-out box. Importantly, we do expect to realize gross margin for our 505(b)(2) products in 2017, and we expect to offset the 2016 underabsorption through rationalization efforts into 2017."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Moving to Slide 32. We have provided a bridge from our previous EPS expectations for the full year through our revised guidance. The reduction in EPS reflect the revenue and gross margin drivers that I've just discussed. We've taken actions to help offset",717,"Moving to Slide 32. We have provided a bridge from our previous EPS expectations for the full year through our revised guidance. The reduction in EPS reflect the revenue and gross margin drivers that I've just discussed. We've taken actions to help offset the declines we are projecting. In 2016, we are reducing OpEx across SG&A while remaining focused on prioritized investments against growth drivers and accelerating our branded R&D programs, and we project improvement in our tax rate. Lastly, we are taking actions to improve our gross margin profile through the planned rationalization that Paul covered earlier. 
On Slide 33, you will see our 2016 financial outlook by business segment including expected, reported and underlying growth rates and gross margins across the portfolio. The branded business growth rate reflects the loss of exclusivity of V Gel. The generics outlook reflects the declines in the base business and the delayed regulatory actions that were discussed earlier. And international is broadly in line with previous expectations. 
Next, on Slide 34, we have outlined our full revised 2016 financial guidance. From a cadence perspective, we continue to see revenues and EPS weighted to the second half of the year, driven by the launches from the Par portfolio and continued growth from XIAFLEX and BELBUCA. We now expect approximately 46% of revenues and 39% of full year EPS in the first half of 2016. This implies a sequential step-down in Q2 due to a number of drivers including the full quarter impact of recently launched generic competitors that we talked about earlier on the call. In addition, we expect a ramp-up in spending in the second quarter primarily related to our acceleration of R&D programs and commercial efforts in U.S. Branded. We have talked through the moving parts around revenues and gross margin. We expect interest expense to continue to be about $455 million. Our tax rate will be lower due to continued progress around planning strategies and due to a lower mix of U.S. sourced income while maintaining static debt benefits and acquired attributes. Depending on the nature and timing of potential discrete items, the cadence of tax rate through the year can be lumpy. Consistent with prior commentary, we do expect to step up in our tax rate in outer years. We now project that rate to be in the high single digits. 
Next on Slide 35. While our first quarter cash flow from operations was negative, it was impacted by a number of items that we consider to be noncore. After considering these items, underlying cash flow from operations continues to be well correlated to adjusted net income. I will also note that our working capital metrics are in line with our expectations. Consistent with prior quarter, we have provided more details around working capital in the appendix of this presentation. 
Moving to Slide 36. It is important to note that we continue to project robust cash from operations prior to legal-related cash flows. I will note that in early Q2, we received the full tax refund that we pointed to earlier in the year. Ultimately, we expect to use remaining cash to pay down approximately $250 million to $300 million in debt in 2016. 
Finally, on Slide 37, let me provide you with a snapshot of our liquidity profile. This is important because our cash position and liquidity ratios remained strong and well within our covenants as defined under our debt agreements. We do not foresee any challenge in remaining well within those limits in 2016 and beyond. We expect our net debt leverage ratio to remain in the high 4x in 2016 with some fluctuations based on quarterly cadence. We continue to remain committed to delevering into 3 to 4x range over time. 
In summary, as we rebased our outlook for our business, which is driven by the factors that Rajiv and Paul spoke to earlier, we remain committed to driving financial discipline, including taking actions to improve gross margins, investing in growth drivers, becoming more efficient around G&A, continuing to improve our underlying tax rate, optimizing our cost of capital, driving improvements in working capital and improving after tax cash flows from operations to service our liabilities and for investments in future growth. 
With that, let me turn the call back over to Rajiv."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. On Slide 39, you will see the c",547,"Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. 
On Slide 39, you will see the corporate strategy as we laid it out in 2013 and the actions we took to rebuild the business over the past 3 years. We have successfully changed the structure, the businesses and the growth profile of Endo. Now, given the evolving market conditions, it is time for us to continue to evolve our corporate strategy and transform the company for long-term durable growth. 
On Slide 40, let me talk about how we feel Endo is positioned for growth. Our aspiration to build a leading global specialty pharmaceutical company that improves lives and creates value has not changed. We are mindful, though, that we need to set appropriate medium-term goals reflecting current market conditions. This has meant rebasing of our financial guidance for 2016 and a reset of our previous expectations for 2017. However, our goals are clear, return to organic growth at levels above market averages; improved operating margins to be greater than 40%; and delever to between 3 to 4x. 3 core areas of focus will enable these goals: growth in our branded business and the XIAFLEX pipeline; growth in our generics business and pipeline; and the ongoing optimization of our existing business.
Moving to Slide 41. There are many key growth drivers that strongly position our U.S. Branded business for long-term growth. We know we have significant in-market growth opportunities in both XIAFLEX and BELBUCA. We are continuing to structure our team and our business to achieve that growth potential while also managing our diversified portfolio of legacy products. We are also accelerating our derisked innovative R&D pipeline to advance those programs and the time lines for their potential market entry. 
As we execute this year, we will be achieving key milestones across our U.S. Branded business and we will keep you updated regarding our progress. On Slide 42, let's talk about the durable portfolio and pipeline we have in our U.S. generics business. We are focused on driving growth through our differentiated higher barrier-to-entry products, like sterile injectables, and our robust pipeline of more than 250 programs post restructuring. We have a diversified and importantly reset based business and a robust highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they execute on these opportunities. 
Let's summarize on Slide 43. We have rebased our business and believe this is a time of significant opportunity for Endo. We have a clear plan to focus on strategic priorities: a return to organic growth, margin improvement and delevering. Our key growth -- our key future growth drivers continue to provide promise to deliver against these strategic priorities. And perhaps, most importantly, Endo is a resilient organization, and we are all committed to our future. Together, we will execute on our evolved corporate strategy and then achieve our goal to deliver products that improve patients' lives while creating value for our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your first question comes from the line of Randall Stanicky from RBC Capital Markets.",14,"Your first question comes from the line of Randall Stanicky from RBC Capital Markets."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to",69,"Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to approve more drugs, is there a risk that this continues? And is this just in pain or is it more broadly?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Randall, and then I will have Paul answer the question.",11,"Thanks, Randall, and then I will have Paul answer the question."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean, clearly, we're disappointed, right. We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say tha",264,"So I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean, clearly, we're disappointed, right. We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say that it was tempered by some successes on the sterile side from the Par portfolio. So from that standpoint, it was a positive effect. When we look at those, they bounce in terms of specifically in the legacy Qualitest portfolio. We had challenges both in pain and related solid oral dosage immediate release portfolio. And what we were seeing was it was a combination of new competitors coming into the market that were established as well as just first-time players as well. So it's a combination of some smaller generic competitors entering the market that ultimately pushed the price down. And a lot of these occurrence were coming in the late March and April time frame. So in essence, it was several factors in terms of competition as well as loss of business. And clearly, on the FDA side, in terms of new competitors coming in and new approvals rather, I think what it could do if we're really starting to hit [ph], we are going to see more players in some of these commodity-based products. But at the same time, we have 150 products at the FDA. So you should also assume that we will also get the positive impact of a quicker approval. So at the end of the day, we will get our fair share wins."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Paul, on that, on Slide 20, you called out, I think, it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is date certain versus assumed or hoped  approvals?",38,"Paul, on that, on Slide 20, you called out, I think, it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is date certain versus assumed or hoped  approvals?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. Right, right, right. So we've talked a little bit about this, around 75% is the new launches.",18,"Yes. Right, right, right. So we've talked a little bit about this, around 75% is the new launches."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Jason Gerberry from Leerink Partners.",13,"Your next question comes from the line of Jason Gerberry from Leerink Partners."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved, but",81,"I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved, but that the FDA didn't remove certain unauthorized products from the market. So how many products are we talking about? If you could provide a little bit more detail there, that would be great."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we",159,"Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we were successful on a timely fashion. It's getting harder because the FDA is looking towards drug shortages and really having a high confidence that we're going to be able to supply the entire market. So in these 2 particular products that we are talking about, that's what we're faced. We are partnering with the FDA to show that we have the ability and give confidence that we can supply the entire market. We're hoping that was going to happen in early 2016. I think the benefit of having these unapproved sources exit the market will be realized in 2017. It's not that it won't happen. It's just really pushing into next year."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage target to mid-3s now beyond I guess late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit no",68,"If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage target to mid-3s now beyond I guess late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit now. You've got mesh. But could you just kind of walk us through some of the puts and takes there?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So we're not going to give guidance on 2017 at this time. There are a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to",302,"Yes, sure. So we're not going to give guidance on 2017 at this time. There are a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to delever. We do see ourselves pushing that target from 3 to 4x from 2016 into 2017 or beyond. There are a number of moving parts that will help with that. Without giving specific guidance, some of the things I've pointed to earlier is, late in this year, we will build about $200 million of working capital. As far as the Seroquel and Zetia launch, that will be recovered in the first half of 2017 as we actually collect the cash on that revenue booked in 2016. As we move into next year, we expect mesh gross payments to moderate down slightly. This year, we would see those mesh payments as being somewhere between $800 million to $900 million. Next year, we would predict that, that would be somewhere around $600 million. So we should see a step-down in gross mesh payments into next year. And then the other big drivers are on capital expenditures. We do see a step-up this year as part of the integration of Par and Qualitest primarily around the implementation of ERP systems that should moderate down in 2017. And then we could see a slight step-up in the contingent consideration line that I've outlined here for '16 primarily due to the 505(b)(2) products that Paul has spoken to as well as V Gel. So there's a couple of moving parts that can kind of help you shape where '17 cash might be. But again, we do expect, over time, to delever back into that 3 to 4x range."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of David Amsellem from Piper Jaffray.",13,"Your next question comes from the line of David Amsellem from Piper Jaffray."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","You might have mentioned this, I apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that p",47,"You might have mentioned this, I apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that product?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Dave, this is Paul. Regarding Vasostrict, right now, we are well protected with our API source. From that standpoint, we feel as though that we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO",95,"So Dave, this is Paul. Regarding Vasostrict, right now, we are well protected with our API source. From that standpoint, we feel as though that we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO in order to get patent status, which would then have our legal team immediately list the patent to the Orange Book. That has not happened yet. It's in progress, but at this point in time, our defense is really our API source that should get us through at least 2017."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So no competition in the guidance this year.",8,"So no competition in the guidance this year."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","No. No competition in the guidance.",6,"No. No competition in the guidance."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Chris Schott from JPMorgan.",12,"Your next question comes from the line of Chris Schott from JPMorgan."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I guess the first one is just -- it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence I guess this round of cuts captures an accurate view of",163,"I guess the first one is just -- it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence I guess this round of cuts captures an accurate view of the business going forward. I guess, has there been any change in approach to how conservative or not you're being with the guidance this time around? Or I guess just addressing investors' concerns that things continue to just deteriorate in the business. Can you just, I mean, at high level just address that question. The second one was just talking about the generic outlook in '17. Just from our perspective, what do you think it's going to take to stabilize the legacy Qualitest business? And just how are you thinking about growth in the portfolio overall once we get through this difficult 2016 and start to think about the longer-term portfolio?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Chris, let me just start, and I'm going to have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We've had several things that have not gone our way, and many of those things -- actually all of those thi",476,"So Chris, let me just start, and I'm going to have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We've had several things that have not gone our way, and many of those things -- actually all of those things have played out over the course of the last 4 to 6 weeks, right, in the second half of March and in early April. But I'll point to the 3 things that have happened, right, so the 3 material things that have happened. First one is the earlier-than-expected launch of the Voltaren Gel generic. So we clearly didn't see it coming as early as it did. We had forecasted it towards the very, very back end of this year at worst and best case into 2017. Now that being said, we knew that there was going to be a generic for Voltaren Gel at some point, right, so -- and in fact, the newly revised agreement with GSK and Novartis give us the right to an authorized generic, so we will have a tail of that product going through 2017 and beyond. So yes, that was bad news. It was earlier than expected, but not something that fundamentally impacts our longer-term growth trajectory. The second event that Paul referred to was this delay in the 505(b)(2) programs. And again, our expectation, while it is bad news for 2016 is that it does, in fact, manifest itself from 2017 and will in fact benefit '17 as well as '18 depending on when the FDA have actually asked. So then it comes down to the Qualitest base business, right, and I'm going to let Paul pick it up. But basically what we've seen is a real reset in Q1, and Paul talked about the impact of the consortiums, the confluence of competitors that came in for some of our bigger products, like the 325 milligram Hydro-APAP product, which is Qualitest's largest product that happened post -- mid-March. All of those things have happened in a way that has reset that business. And the way we have thought about the guidance is that we've clearly taken a view of saying, how do we predict this erosion continuing through this year, right. So we do see continued erosion through this year. But by the same token, and Paul will elaborate on this, our view is that as we go into 2017, the continued erosion in this base business will moderate to what you would typically see in a commoditized generic business, and the future really is about the pipeline and segments like the sterile injectable segment, right. So with that, let me just turn it over to Paul. Maybe you can talk a bit about our confidence about the remainder of the year and the moving parts going into '17."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So thanks, Rajiv. So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is, is that, historically, we've had successes with the Qualitest portfolio, but w",361,"So thanks, Rajiv. So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is, is that, historically, we've had successes with the Qualitest portfolio, but we've got a call what it is. It is a mature portfolio that is susceptible to competition. With that, we are transferring the strategy from that high-volume throughput that, historically, had successes on economies of scale to the more Par legacy success model of high-value products, where we're having more technically-challenging products, things that are more difficult to make. Now the first thing we have to do, we talked about the restructuring, right? So we need to take the portfolio. We've got to rightsize it. We've got to be real smart about product selection and what we're going to continue to sell in the market. We're making some very, very difficult decisions impacting some very talented people in our Huntsville facility. That's been very difficult for all of us. So that's the starting point: to focus on the restructuring plan. And it gets back down to our core values of operational execution, something that we are really driving home at Par. Rajiv talked about it already. The pipeline is where we're going to be able to reset ourselves. Ultimately, 75% of our value coming is from 2 products. Fourth quarter, we've talked quite a bit about quetiapine and Zetia. I'm not going to spend a lot of time there. But we have to execute on the entire portfolio, and at the same time, we've got to continue to repopulate the products as we launch them. So that, coupled with -- again, got to get the 505(b)(2)s, and we have other 505(b)(2)s across the portfolio. It's not just the 2 that we're referring to, but we need to execute. We have a path forward. We have a good strategy. I think these are areas that are going to help us ultimately stabilize our base, and at the same time, we can't lose focus on our service levels and our quality and continue with diversification of our portfolio."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Greg Fraser from Deutsche Bank.",13,"Your next question comes from the line of Greg Fraser from Deutsche Bank."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Gregg Gilbert. On the product rationalization efforts, do you expect those as trying to help gross margins during 2016? Or would those benefits -- or the benefits from those efforts be realized more in 2017 and beyond? And then I j",88,"It's Greg Fraser on for Gregg Gilbert. On the product rationalization efforts, do you expect those as trying to help gross margins during 2016? Or would those benefits -- or the benefits from those efforts be realized more in 2017 and beyond? And then I just had a quick one on the amendment to the standstill agreement with TPG that's mentioned in the press release. Can you just give us more color on that change and what you know about TPG's intentions with respect to this thought?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So I'll take the first one, Rajiv, on the gross margin and on the restructuring. So the question on gross margin for 2016 will be about $10 million.",29,"So I'll take the first one, Rajiv, on the gross margin and on the restructuring. So the question on gross margin for 2016 will be about $10 million."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, we've outlined that in the gross margin waterfall that you see in the presentation, Greg. In addition then, we'd expect that benefit -- net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realizat",50,"Yes, we've outlined that in the gross margin waterfall that you see in the presentation, Greg. In addition then, we'd expect that benefit -- net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realization of $60 million by 2018."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And that's on a cumulative basis.",7,"And that's on a cumulative basis."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And Greg, just to answer your question on the TPG standstill, so when TPG first took shares, when we acquired Par, there was a substantial agreement that prevented TPG from increasing their stake in the company. So in this instance, with the -- concurrent",110,"And Greg, just to answer your question on the TPG standstill, so when TPG first took shares, when we acquired Par, there was a substantial agreement that prevented TPG from increasing their stake in the company. So in this instance, with the -- concurrent to Todd Sisitsky coming on our board, our board put the decision to release TPG from that -- from the standstill agreement, subject to certain limits. And that was outlined in the 8-K that we filed with the amendment of the standstill agreement. But effectively, it allows TPG to purchase up to another $250 million worth of shares, subject to a cap at 10% of ownership."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Liav Abraham from Citi.",9,"Your next question comes from Liav Abraham from Citi."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics, specifically in the legacy Par business? That's my first question. And then secondly, just a quick question on",73,"The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics, specifically in the legacy Par business? That's my first question. And then secondly, just a quick question on the tax rate. Can you just remind us the accounting of your tax rate? Is this a GAAP tax rate or a cash tax rate? And what is your cash tax rate?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, we have -- this is Paul. In terms of legacy Par, in terms of the pricing pressure, for the most part, it's flat. Maybe low single digits in terms of price. But for the most part, it's flat. And again, it's -- we're able to defend it because for the m",76,"Yes, we have -- this is Paul. In terms of legacy Par, in terms of the pricing pressure, for the most part, it's flat. Maybe low single digits in terms of price. But for the most part, it's flat. And again, it's -- we're able to defend it because for the most part, that base business comprises quite a bit of modified release, sustained release. We've got the injectables as well, so a little less competition."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. Liav, moving to the tax question. So our tax rate -- adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt, for any IP and trends for price planning as we",100,"Yes. Liav, moving to the tax question. So our tax rate -- adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt, for any IP and trends for price planning as well as for acquired attributes. That ultimately results in our adjusted effective tax rate, which is and has been significantly higher than our cash tax rate. Our cash tax rate has been negative for a number of years and is expected to be in the low single digits in our foreseeable future."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Marc Goodman from UBS.",12,"Your next question comes from the line of Marc Goodman from UBS."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year as guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be i",156,"Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year as guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be in the first place. I mean, are these going to be products like Vasostrict, which seems to be -- obviously, going to break $200 million this year, at least, that's what it seems. So just give us a sense of that as well as the other 505(b)(2)s that you have. As you say in the pipeline, will we see others launching in '17? Are they coming in '18, '19? When do they come? And how big can they be? And then just one quick one, which is you mentioned 60 product discontinuations. What are the sales on those products on an annual basis? And how much is that impacting this year?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict, and it's a little bit larger than you had indicated. It's in excess of around $300 million. Now the 505(b)(2)s that we've -- that we are working with",187,"So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict, and it's a little bit larger than you had indicated. It's in excess of around $300 million. Now the 505(b)(2)s that we've -- that we are working with the FDA, we have not, for competitive reasons, disclosed specifically the value. I would say they're not on the magnitude of Vasostrict. They're material, but nowhere near the magnitude of Vasostrict, I think, for competitive reasons. I think at this point, that was far as we can really go on, on the 2 products that we're working with, with the agency. Additionally, we have -- we do have a 505(b)(2) strategy to take unapproved drugs while they're on requisite clinical trials and bring them to market. And we do have a handful of additional products that are at various stages across the entire portfolio of either injectables or solid oral dosage forms. But at this point, we're just not advanced enough to go into anymore detail. And hopefully, in another quarter or 2, we'll be able to provide a little bit more visibility."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. I think, Marc, just to add to that, and this is certainly one of the core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. We're certainly very encouraged by the s",81,"Yes. I think, Marc, just to add to that, and this is certainly one of the core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. We're certainly very encouraged by the success that the Par team has had with the Vasostrict, so far. In terms of the impact of the product rationalization, Suky, do you want to talk about the revenue impact?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. So this year, we would see that the revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million, so it steps up by about $70 million in '17. And again, our benefits that we talked about for",81,"Yes. So this year, we would see that the revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million, so it steps up by about $70 million in '17. And again, our benefits that we talked about for the planned rationalization are net of that revenue reduction, so we do still expect to see $60 million margin improvement on a full run rate basis, net of the sales reduction."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Annabel Samimy from Stifel.",9,"Your next question comes from Annabel Samimy from Stifel."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 forward. But are we ever going to see the levels that we saw before you've taken this cut down? And what",87,"I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 forward. But are we ever going to see the levels that we saw before you've taken this cut down? And what component of the Qualitest business is commoditized? How much of that $60 million -- how much of the product rationalization is part of that commoditized business? And once that gets out, how do you see gross margins recovering after this?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So for -- Annabel, if I miss something there, just please weigh back in. But overall, we would see the gross margins, all else being equal, improve into 2017, given the rationalization of our products -- sorry, our plans that we talked about as well",161,"Sure. So for -- Annabel, if I miss something there, just please weigh back in. But overall, we would see the gross margins, all else being equal, improve into 2017, given the rationalization of our products -- sorry, our plans that we talked about as well as because of the reduction in the lower-margin SKUs or products that we're rationalizing. I think other drivers to think about into 2017 as we continue to grow the Par portfolio, which we see as one with products with a margin profile above the existing gross margin average, we could see improvement from that driver. And then in addition, as we see growth from branded within XIAFLEX as well as BELBUCA, we would also see those as potentially expanding margins into 2017. So again, we're not in a position to provide a full 2017 or beyond guidance, but we do see a path to recover in gross margins above where 2016 are going to land."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So are they recovering to the level that they had been at?",12,"So are they recovering to the level that they had been at?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's too early to tell at this time, Annabel.",10,"It's too early to tell at this time, Annabel."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Louise Chen from Guggenheim.",12,"Your next question comes from the line of Louise Chen from Guggenheim."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So just to follow-up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is",79,"So just to follow-up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is not meant to be an antagonistic question, but people have been asking us. At what point you would consider strategic options for Endo if you can't create shareholder value on your own?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Louise. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly, right? It is disappointing for the company, and personally, disappointing for myself as well. So we have done an exhausti",501,"Thanks, Louise. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly, right? It is disappointing for the company, and personally, disappointing for myself as well. So we have done an exhaustive assessment over the course of the last few weeks to ensure that we put as much thought as possible into how we assess the remainder of the year. And I would say, our guidance range for the full year is a realistic range, right? So no business is without its risks, and I think you know that. But we have taken a substantial downward division in the base business in generics. We have -- and I commented on how we are treating Voltaren Gel. We've also taken the opportunity to address some other parts of our branded business because of the continued pressure in the pain market that we rebase some of those products as well. So we've really taken the opportunity to take a hard look at the forecast in this rebasing, right? So we don't take this lightly. I mean, it's not something that we want to do more than once, right? So that's the push that we have taken. We are confident in this guidance range, and we have a team that is going to work extremely hard at executing against this range. But as always, since I already point, that there is always risk. And then -- yes, one second. So Louise, I was also just going to answer the second question you asked. So for us and our Board of Directors, our goal is longer-term shareholder value creation, right? So certainly, that is -- the last -- the -- what's happened with the business over the course of the last few weeks and months is a disappointment and a setback. But I would point out that our future growth drivers remain unscathed in terms of these particular events that we talked about, right? So we point to XIAFLEX, the XIAFLEX pipeline. We talked to BELBUCA, which, even though, there is, potentially, a delay in terms of the launch trajectory of their product, we continue to believe in the future of that product. And the Par pipeline, which is the primary driver of that acquisition, is robust as ever, right? It continues to grow. The sterile injectables business is robust and growing, and I have every confidence in Paul and the team in terms of getting the generics business back on track. So from that standpoint, we believe that in the hands of our management team, with the appropriate rebasing that we've done in 2016, that there is a path to returning to organic growth, improving our margins and delevering, and therefore, to creating shareholder value going forward. So having said, we are also being very clear that our board is a shareholder-friendly board. And if there is ever any strategic alternative that presents itself, our board will, of course, evaluate it."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Andrew Finkelstein from Susquehanna.",12,"Your next question comes from the line of Andrew Finkelstein from Susquehanna."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Could you talk -- I'll give you a couple of things you can focus on. But at a high level as you talk about the new strategy and even reassessed the environment, I think you highlighted where are the growth drivers you currently have. But as you look longe",161,"Could you talk -- I'll give you a couple of things you can focus on. But at a high level as you talk about the new strategy and even reassessed the environment, I think you highlighted where are the growth drivers you currently have. But as you look longer term, I just want to incubate additional drivers. Where are the opportunities in this environment and the types of products that are going to have the right risk reward to pursue? And then as you go about managing that, could you talk a little bit about how you're thinking about balancing cash generation in the near term, and particularly, with regard to leverage ratios versus investments you may want to make and longer-term opportunities? And just specifically on that, as you talk about rationalizing some of the legacy products, were these lossmaking? Or is some cash flow being given up? And if so what's the benefit in doing so at this point?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So thank you, Andrew. Let me just take your 3 questions, and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline",511,"So thank you, Andrew. Let me just take your 3 questions, and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline, right? So we've pursued the cellulite indication. Our Phase IIb trial is in the clinic and currently recruiting patients. We feel positive about that. And you've also seen that we have increased confidence in being able to move forward, at least, 4 other indications into the clinic, right? And they fall generally into the areas of aesthetics as well as other therapeutic indications around that oncology nest. So the one core priority for us is continued and increased investment in that R&D pipeline. In the -- the pain market, clearly, in terms of public policy and regulatory pressures, is increasing their market. As we said before, BELBUCA has a real profile that could really benefit in terms of some of the current concerns around Schedule II opioids, so we do think there's a future there. But as we look further out into the future, building on our portfolio across our branded business, we could see ourselves in multiple areas that have similar characteristics to other specialty areas, where I would say with a smaller focus sales on marketing footprint that we can be successful. And following some of the therapeutic areas where XIAFLEX is going to get us to is going to be the best way for us to pursue that. Now leading to your next question, in terms of cash and our priorities for using the cash, as Suky explained when we talked about delevering, we do expect to continue to prioritize delevering and delevering back to the 3 to 4x is a important goal for us. Now that is delayed from 2016 into 2017 but continues to be an important goal for us. At the same time, investing in our R&D pipeline, both in XIAFLEX as well as Par, are going to be very important priorities for us, which we will balance as we go, right? So those are going to be the most important uses of cash. And beyond that, and obviously, once we get into a position where we have excess cash and have the opportunity to look at, perhaps, bolt-on acquisitions either for the generics business or the branded business, we will certainly look at those as they come up. Our preference would be to do so in the branded space, but that is the way out. We want to make sure that we execute against our growth plan and delever as our primary priorities, and we always keep the option of returning cash holder -- cash to shareholders as an alternative as well. Now let me just turn this over to Paul because I want him to talk to you about some of the new areas that we might expand the pipeline into as well as the question that you had on product rationalization and the profitability impact of that."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Okay, thanks. So obviously, a very important question, and I want to start by saying, this -- the decision in terms of the -- calling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of normal course, it rea",301,"Okay, thanks. So obviously, a very important question, and I want to start by saying, this -- the decision in terms of the -- calling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of normal course, it really is an evolution where you need to consistently look at your portfolio. You have to make some tough decisions. You have to take your unprofitable products or products that are -- you're feeling pain and pressure on. That being said, we're the fourth largest generic company. We are incredibly relevant. We will continue to be relevant in the industry, and I want to make that statement. And when you -- if you want to be able to compete with the 4 large consortiums, add Walmart in, those 5 companies representing in excess of 90% share, you really need a well-balanced portfolio. And what I mean by that is you need your fair share of Paragraph IVs. You need heart to make technically-challenging solid oral dosage products. You need injectable products, and you do need commodities that are profitable. So that's going to be very important to us in terms of the Qualitest portfolio on a go-forward basis. Now on discontinuation products, hard decisions. But by calling the portfolio areas that is going to help us, parts that are ultimately being sold at losses, and we make the tough decisions, it's going to help us on the cash side. It's -- we're going to have a reduction on our operating costs. We'll have a reduction on working capital, and we'll also not need to invest as much in certain facilities from a CapEx standpoint. So from that standpoint, generally speaking, high level, those would be areas that we would have savings in."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. And I want to just come back to Annabel's question playing off of what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have t",156,"Yes. And I want to just come back to Annabel's question playing off of what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have that Rajiv outlined earlier and given the focus on execution and efficiency that Paul and his team have around our manufacturing network, I think we do see a path to get back into the mid-60s over time. We're not going to time down that at this point yet. We're going to let more '16 play out. And as we move into 2017, we'll have a better view into that, but I do think the growth drivers are at a gross margin level that are higher than our overall corporate average. And again, through efficiency that Paul and his team will drive, there could be a pathway there over time."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Douglas Tsao farm Barclays.",12,"Your next question comes from the line of Douglas Tsao farm Barclays."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just first, in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA.",24,"Just first, in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will -- let me just address that on Paul's behalf. We're not going to talk about when we might launch our authorized generic for competitive reasons, and a lot of it is going to depend on how the competitive environment evolves without one competitor in",68,"I will -- let me just address that on Paul's behalf. We're not going to talk about when we might launch our authorized generic for competitive reasons, and a lot of it is going to depend on how the competitive environment evolves without one competitor in the market. So far, we are very happy with the strategies that we have put around mitigating erosion of our branded product."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Okay. And then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective. I mean, when do you think we should start to see an inflection point",119,"Okay. And then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective. I mean, when do you think we should start to see an inflection point in the script? And then just also, obviously, you noted that you had a very good coverage -- default coverage exists right now. When do you anticipate sort of finalizing that? And how are those talks going? And the pricing that you expect to get, is that sort of in line with your expectations that are -- or perhaps, a little bit more challenged given the dynamics in the pain market right now?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Great. Thanks, Doug. So look, as I said, it's still early days on BELBUCA, right? And the last week for which we have data, I think, is the week of April 21, and we had roughly 650 prescriptions. And we continue to see momentum, right? And it's difficult",516,"Great. Thanks, Doug. So look, as I said, it's still early days on BELBUCA, right? And the last week for which we have data, I think, is the week of April 21, and we had roughly 650 prescriptions. And we continue to see momentum, right? And it's difficult to predict exactly when the inflection point is going to be, but what I can say is that the anecdotal feedback and the qualitative feedback from physicians have been very positive. And I, myself, have spent time in the field. And the fact that this is a Schedule III product, despite all the new pressure that is on physicians with the new CDC guidelines and everything else, the message resonates, right? But that being said, from the very beginning, we pointed to something that would likely lead to requiring more time to educate physicians, and that is the tapering and titration required with this product, right? So to the extent that you are trying to move a patient from other therapy onto BELBUCA, you had to taper that patient down per our label and then titrate the patient back up. And for most physicians, what they are trying to do is to figure out their own gut feel for how this works. Clearly, from a promotional standpoint, we understand behind what's in the label, but every physician will figure out what he or she is comfortable with. I would also say another encouraging sign is that the repeat prescription from those who prescribed is progressing very well, so we have as many repeat prescriptions now as we have with new RX. So these are all good indicators. I'm going to hesitate to give you an exact time frame of when there's going to be an inflection point, but I would point to the second half of this year in terms of when we would expect to see a continued improvement in it. And I am afraid I've forgotten the second part of your question. Oh, yes, it was on the managed care. So it is progressing very well. As we have said before, we have roughly about 2/3 of commercial lives covered at least with default coverage. We made very good progress in terms of converting the default coverage into actual coverage. Many of the plans require -- have confidentiality agreements that prevent us from talking about these things in a public way. But one that we can point to, where we have permission to talk about, is Express Scripts. That has been a very good win for us. We are continuing our discussions with other plans. And so far, there has -- it's going exactly as we had expected. Now the one piece that we would expect to not get to until 2017 is the Medicare Part D coverage, but that is on par with the -- all of the situations, where our product launches midyear. We've also implemented a copay program that basically puts a product on par with comparative products. So in -- from all aspects, from an access standpoint we are making good progress."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Ken Cacciatore from Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore from Cowen and Company."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just kind of reiterating what you all said that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a t",114,"Just kind of reiterating what you all said that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a total restructuring, kind of maximize all aspects of the business. And I guess the question, again, is why stay standalone? You could take equity in a pro forma company, realize the benefits of a larger entity while the value is extracted. And I guess, just for your shareholders wanting to know, are there indeed options on the table? And why isn't this very, very high in the list of options?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Ken. So let me refer back to my previous answer to a similar question, and I'll answer your question. End of the day, what is most important for our team and for our board is to ensure that we ride the ship operationally, address the challenges th",196,"Thanks, Ken. So let me refer back to my previous answer to a similar question, and I'll answer your question. End of the day, what is most important for our team and for our board is to ensure that we ride the ship operationally, address the challenges that we've seen and make the progress that we know we can make as a team, right? That being said, we've also -- always been clear that we're a shareholder-friendly management team, we're a shareholder-friendly board, and we will always look at strategic options that present themselves. Now one of the things that I have said in the past is, although from a debt market perspective as well as where our own equity is trading, we are not in a position to do substantial acquisitions. But I have pointed out that mergers are certainly options that we would consider if they present themselves. Particularly, we're either on a relative value basis. It's something that makes sense, or we conclude that is the best interest of our shareholders. So certainly, we will remain open to those options, but our primary focus and priority is on operationally executing against our plan."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Irina Koffler from Mizuho.",9,"Your next question comes from Irina Koffler from Mizuho."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going-forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback",90,"I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going-forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback and delay into 2017? And then going forward, we have to rely on your execution of these programs, and yet we had a delay this year already. So what can you say to give us more conviction in your execution of these products?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will let Paul answer it. I think I would just point to Vasostrict as an example of why you should have confidence in Par's ability to execute. It's been an extraordinary successful product strategy and one where I don't think we've seen the final chapte",64,"I will let Paul answer it. I think I would just point to Vasostrict as an example of why you should have confidence in Par's ability to execute. It's been an extraordinary successful product strategy and one where I don't think we've seen the final chapter yet. Paul continues to work on it. But Paul, why don't you answer the rest of the question?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. So again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA, through the 505(b)(2) process. Historically, these are typically older drugs, which we have to run requisite clinical trials in order to g",214,"Yes. So again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA, through the 505(b)(2) process. Historically, these are typically older drugs, which we have to run requisite clinical trials in order to get NDA status. When we can change a product and when we can get intellectual property, obviously, we're going to do that aggressively. On certain products, we're able to do that. In certain projects, we are unable to do that. In the case of the products that we are referring to at this point in time, I would tell you that I don't believe that intellectual property is as strategic as we would like it to be. However, there are other things that we would be working towards that, at this point in time, I would not want to disclose for competitive reasons. But we are hopeful that this is not going to be a 1 year-and-out type of 505(b)(2) whereby we spend the requisite PDUFA fees, build up a product and then invite competition. So we do have strategies outside of intellectual property that, hopefully, will gain us longevity. But we're not talking compound patent IP, where you're typically seeing multiple years. That's not what we're talking about here."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of David Risinger from Morgan Stanley.",13,"Your next question comes from the line of David Risinger from Morgan Stanley."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is in -- is from the Qualitest business? And how much is hitting the Par business?",160,"A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is in -- is from the Qualitest business? And how much is hitting the Par business? So I'll make up a number. Let's say the hit was $10. Of the $10 hit, was it 2/3 to Qualitest and 1/3 to Par? Or was it half and half to each? Just trying to understand that. And then second, with respect to XIAFLEX, how should we think about that product sales sequentially in coming quarters? And then finally, actually, and this one is, I guess for Suky, you had mentioned moving parts in 2017. Could you just talk about the big moving parts that are uncertain? I mean, obviously, there are some certainty with Zetia and Seroquel. But what are the moving parts for revenue that are uncertain for '17 at this point?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","David, let me hit you with XIAFLEX question, then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% when you're looking at the U.S. And as we've -",159,"David, let me hit you with XIAFLEX question, then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% when you're looking at the U.S. And as we've -- as we laid out in our presentation in my comments, our expectation for the full year is product growth should be somewhere in the mid- to high-teens range, right? Now clearly, we are working to accelerate the product, but that is a -- if you are aware, our best current thinking is, right? So if you take a look at the 21% and the full year at mid- to high teens, there will be a slight moderation as we head into the new -- next few quarters. But this is still going to be well within the strong double-digit growth profile that we predicted for the product."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And David, your question on the price and the pressure, when we look at the Qualitest portfolio, which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in",91,"And David, your question on the price and the pressure, when we look at the Qualitest portfolio, which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in pain. A big portion of our portfolio is directed towards pain. It's not quite the barrier that it once was, and as a result, the pricing pressure that we saw was about 80% tied to legacy Qualitest, and about 20% tied to legacy Par."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following [indiscernible] to 2017. So let's talk about what's changed when -- since we last put our expectations for 2017, right? So the 3 main changes have been",354,"And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following [indiscernible] to 2017. So let's talk about what's changed when -- since we last put our expectations for 2017, right? So the 3 main changes have been a resetting of expectations for our Qualitest base business; the delay in the 505(b)(2) program, as we talked about, which is going out of 2016 but will be impacting positively 2017 and 2018 for that matter; and then we talked about V Gel, which we fully expect it to be genericized as we headed into 2017. It just happened much earlier than we expected. And we do have the authorized generic as an option for us to use going into 2017, right? So the real major downward revision there is the impact of the Qualitest base business. Now there are other moving parts that will impact what our final guidance for 2017 is, though, right? We will have to take a view on exactly how BELBUCA is going to do. It all depends on kind of where the inflection point is going to be. Obviously, tailwinds behind XIAFLEX will continue to grow. We will know more by the middle of this year in terms of what's happening at OPANA. We have a July 29 PDUFA date for our ADF relabeling request with the FDA. And we will also know more in terms of some of the other pipeline launches and other programs that Paul is pursuing in the Par business and exactly where they will fall in 2017, right? So those are the -- some of the real moving parts we have. We also signaled that we expect to increase our R&D spend, particularly behind the XIAFLEX pipeline. And to the extent that Paul has any new ideas from an R&D standpoint, we will try very hard to meet any additional funding requirements in that -- in the Par pipeline as well. So those are some of the moving parts. I don't know, Suky, whether you have -- there's anything else that you would point to?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. And so just understanding where our exit is in '16 before we make that final call.",42,"I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. And so just understanding where our exit is in '16 before we make that final call."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Elliot Wilbur from Raymond James.",13,"Your next question comes from the line of Elliot Wilbur from Raymond James."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","This is Daniel Sanchez on for Elliott Wilbur. I just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities as you work to put the mesh settlement issue behind you and if you think the wors",55,"This is Daniel Sanchez on for Elliott Wilbur. I just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities as you work to put the mesh settlement issue behind you and if you think the worst parts and claims with the highest value are over."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So let me just comment on the overall status of mesh and let Suky talk about the financial aspect. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail, which is that we took the steps to resolv",216,"Sure. So let me just comment on the overall status of mesh and let Suky talk about the financial aspect. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail, which is that we took the steps to resolve the higher quality claims, which is what led to an increase in our accrual that we announced in the fourth quarter call. Since then, the situation has not changed. There is a alleged potential for another 8,000 cases in the tail that we disclosed, but we were also very quick to point out that expectation is that a large proportion of those cases could be of lower quality. We don't have all the facts around them. We were also pointing to the fact that there is a potential fraudulent scheme that is running through many of these cases, which we are investigating currently. And as we pointed out before, these are typically the types of things you see at the very tail end of a mesh situation. We can't give you a precise projection of what the end date is, but we have confidence that we are seeing the real tail here. And maybe, Suky, you can you talk about the cash expectations in '16."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet, and you'll see that on our 10-Q, which will be issued in the very near future. Of that $1.9 billion, the amount of restricted c",167,"Sure. At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet, and you'll see that on our 10-Q, which will be issued in the very near future. Of that $1.9 billion, the amount of restricted cash or our cash authority that have been put into qualified settlement funds was about $0.5 billion, which leaves a residual $1.4 billion on a gross basis to be paid. We'd expect of that remaining $1.4 billion, about $750 million on a gross basis to be paid between -- for the rest of 2016 and then about $600 million to $650 million into 2017 or the residual of that $1.3 billion balance. So that's where we stand from a cash call basis. As we talked about earlier, we did receive the federal tax refund that we pointed to earlier this year. That came in early April, and we continue to look at ways to provide a shield around future liabilities."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","And any line of sight as to the magnitude of potential fraud cases? Or is it still too early to tell?",21,"And any line of sight as to the magnitude of potential fraud cases? Or is it still too early to tell?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's a active investigation. We have issued subpoenas in the case and also working with the judge in the MDL case as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it.",41,"It's a active investigation. We have issued subpoenas in the case and also working with the judge in the MDL case as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Rohit Vanjani from Oppenheimer.",12,"Your next question comes from the line of Rohit Vanjani from Oppenheimer."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","And sorry, I maybe missed some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate new competitor taking? And then same thing with FROVA, are you seeing a new compet",139,"And sorry, I maybe missed some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate new competitor taking? And then same thing with FROVA, are you seeing a new competitor there? And if so, how much did you reduce estimates by? And then secondly, for the generics unit, could you help me understand the business a little bit there? Do you have contracts primarily at the beginning of the year and that's where you get the renegotiations happening? Or do you -- or the majority of the contracts staggered throughout the year? Or are you seeing rofers [ph], where you're choosing not to engage? Or are most of the product sold ad hoc or at will? Or your customer can move pretty freely?"
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So let me just talk about -- briefly about V Gel and FROVA, and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to in the materials for today's call the relative impact on the rebasing of our 2016 guidance. We are not going to dis",122,"So let me just talk about -- briefly about V Gel and FROVA, and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to in the materials for today's call the relative impact on the rebasing of our 2016 guidance. We are not going to discuss our markets expectations anymore other than to say there is a single competitor on the market and we are effectively defending the branded product at the level that we would expect to do. With respect to FROVA, yes, we do have a new competitor. That is Glenmark. And currently, Par has also launched our authorized generic, so that is also in the market. Maybe you can address the other question."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. In terms of the consortiums this cycle, and I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against, so it's not like you come in, in Q1 and have to deal with 3 of the consort",208,"Yes, sure. In terms of the consortiums this cycle, and I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against, so it's not like you come in, in Q1 and have to deal with 3 of the consortiums. Red Oak does not actually put out bids. Their expectation is, is that they're going to be guaranteed best pricing. So their style is a little bit different as opposed to the OneStop program or the WBAD program or even the Econdisc program. Regarding rofers [ph], that is exactly what it is. So after you go through the consortium bid cycle, that does not mean that you are still not exposed for rofers [ph]. That being said, we defend against rofers [ph], and we have our fair share of wins. You have our fair share of losses. And at the end of the day, I think on a go-forward basis, this in an area that we're fairly strong and in terms of, at least, to protect ourselves from the legacy Par standpoint. And we are, in essence, rightsizing the Qualitest business legacy site in order to be able to defend against rofers [ph] on a go-forward basis."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","We have time for one final question, Kevin Kedra from Gabelli.",11,"We have time for one final question, Kevin Kedra from Gabelli."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just wondering when you think about strategically, how much sense does it still make to keep the generic and the brand of business together? Any thoughts about maybe separate those businesses? And then actually, I think that'll be good.",39,"Just wondering when you think about strategically, how much sense does it still make to keep the generic and the brand of business together? Any thoughts about maybe separate those businesses? And then actually, I think that'll be good."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Okay. Thanks. And the -- Kevin, the -- look, the -- it's a strategic question. I think one of the things that our company has benefited from over the course of the last 3 years since my arrival when we really set every accounts around the business is, in",231,"Okay. Thanks. And the -- Kevin, the -- look, the -- it's a strategic question. I think one of the things that our company has benefited from over the course of the last 3 years since my arrival when we really set every accounts around the business is, in fact, the diversity of the business, right? So the generics business, especially with the addition of Par, I know despite the rebasing that we are taking, it's a highly diversified business with multiple growth drivers. And we've also taken the steps to build critical mass in our branded business, right? But I have been also open that from a forward-looking standpoint, at a certain point in time, when we have critical mass in both our branded business as well as our Generics business, this can be both 2 very viable standalone businesses, right? So from a strategic standpoint, we remain open to thinking about creative ways of creating shareholder value. But as I pointed to earlier in my comments, our primary focus right now is operational execution. We have a full plate in Par in terms of restructuring that needs to be done, focus on the pipeline as well as in the branded business, growing XIAFLEX and growing the BELBUCA and investing in the pipeline. But certainly, we will keep all strategic options open to us as we think about the future."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","I would now like to turn the conference back over to Rajiv De Silva, CEO and President.",17,"I would now like to turn the conference back over to Rajiv De Silva, CEO and President."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, and I want to thank all of you for your attention today. There have been a lot of very good questions, and we've talked a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. But what I hope",259,"Thank you, and I want to thank all of you for your attention today. There have been a lot of very good questions, and we've talked a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. 
But what I hope that you will take away from this call today is that despite the rebasing of our 2016 guidance, Endo is a fundamentally different and stronger business than it was in 2013, and it is also a more compelling investment and growth story. 
In 2013, we had 2 primary and declining assets at that time and a very fragmented base of business across health care solutions divided in pharmaceuticals. You fast forward to today, we've rebuilt our branded portfolio and pipeline, with the acquisition of Auxilium, in particular XIAFLEX. We've divested noncore businesses. We've achieved scale and differentiation in our generics portfolio with the addition of Par [indiscernible]. That is what the future is going to be about, particularly as we think to see they are rebasing of our legacy Qualitest business. 
We're establishing international structure and footprint for growth and expansion. We narrowed the mesh tail, and we have built a business generating significant EBITDA even after this rebasing and free cash flow that we expect to grow going forward. 
So no one likes to rebase guidance more than I, but we have now reset our business so that we can move forward and effectively drive growth and value, and we thank you for your continued support. 
Thank you very much."
28071,331734375,975015,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may now all disconnect.",22,"Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may now all disconnect."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Ker",56,"Good afternoon, ladies and gentlemen, and welcome to the Q1 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin your conference."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmace",226,"Good afternoon, and thank you for joining us to discuss our first quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceuticals. We have prepared a slide presentation to accompany today's webcast and that presentation is posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements made by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings",706,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our first quarter 2016 earnings presentation. 
On the next 2 slides, you will see a brief agenda and an outline of key themes for today's call. To begin, I will provide a snapshot of our first quarter financial results which, despite some headwinds, were largely in line with our expectations. However, these headwinds have created substantial challenges to overcome in the remainder of the year. We are providing revised full year 2016 guidance today to reflect these challenges. We will spend some additional time discussing the state of our business, key drivers for this rebasing and our action plans moving forward. 
Specifically, there are 3 factors to call out that we will discuss in more detail on today's call: deeper-than-expected erosion in the legacy Qualitest business; delays in FDA actions related to our 505(b)(2) products; and an earlier-than-expected generic entrant for Voltaren Gel. Importantly, we will also talk about why we believe that our core growth drivers will continue to provide opportunities to execute against our strategic plan and allow us to return to organic growth, improve margins and delever in the medium term. 
Before we begin, I would like to take this opportunity to welcome our 2 new board members on behalf of our board and the company. We are delighted that Doug and Todd have accepted our invitation to join. We look forward to their contributions. 
Moving to Slide 6, you will see the Q1 snapshot of reported segment revenues. In our branded business, we saw solid continued growth for XIAFLEX, which performed well despite the expected historical trend of Q1 seasonality. This growth was offset in part by a decline in Voltaren Gel due to that product's loss of exclusivity in March and continued pressure on the pain market. In our generic segment, the base business erosion continued into the first quarter and was significantly deeper than we expected at approximately 30%. This was driven by continued pricing and competitive pressures on our commoditized and pain products. The erosion was partially offset by strong performance from our sterile injectables portfolio, including Vasostrict, and the overall performance of the legacy Par portfolio. We will return to these themes when we discuss full year guidance. 
The international business performed as expected with a modest decline in reported revenues. However, our emerging markets businesses continued to show both constant exchange rate revenue growth and underlying growth as well as margin expansion. 
On Slide 7, you will see our first quarter segment revenues as well as reported and underlying growth. 
Next, on Slide 8, we provided our first quarter financial results. 
Moving on to Slide 10. Let's talk about the state of our business and the context in which we are viewing the remainder of 2016. To best understand where Endo is now, it's important to also understand where we've been and what we've built. When I joined the company in 2013, we charted a new strategic course and outlined some very clear goals, as seen here in the left column. Over the next 3 years, we set out to achieve these goals and position Endo for growth. That strategy is still core to Endo and to how we run our business. However, what has become clear is that the 2016 specialty pharmaceutical landscape and market forces require an evolution of that strategy. 
So let's talk about our path forward. Our goal has not changed. We continue to aspire to build a leading global specialty pharmaceutical company. What has changed rapidly is the landscape and market environment within which we are operating, particularly in generics. What does this mean going forward? It means we're reshaping the path forward for Endo. We are rebasing expectations for the business and are evolving our current strategy to meet challenges and capitalize on opportunities. Ultimately, we are positioning the company for long-term organic and diversified growth, margin improvement and delevering. 
So let me now turn the call over to Paul to discuss key factors and drivers related to generics. Paul?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying and actual sales. The",1678,"Thank you, Rajiv, and thanks to all of you for joining us today. Let's start with a snapshot of our Q1 2016 generics revenue on Slide 13. Here we present a bridge between our pro forma generic sales for Q1 2015 and Q1 2016 underlying and actual sales. The variances between the sales totals resulted from a greater-than-anticipated erosion in base business of approximately 30%, driven particularly by the legacy Qualitest portfolio. While we expected base erosion to be higher in the first quarter than the full year, the actual erosion was much deeper across our pain portfolio and other commoditized products than originally anticipated. By contrast, the legacy Par portfolio is performing on track with internal expectations. Our sterile injectables product portfolio continued its strong performance with 86% growth over Q1 2015. Our new launches and alternative dosage product portfolio performance was stable and largely unchanged year-over-year. 
So let's discuss the factors that impacted these Q1 results and that we believe will shape our full year generics performance. Moving to Slide 14. There are rapidly changing market conditions that have affected both the broader generic sector and Par. First, we've seen a steep and rapid price erosion caused by payer consolidation that has been more even [ph] profound than anticipated. Its effect has exceeded what might have been expected from an ordinary downturn in the industry's traditional pricing cycle. The impact has been particularly acute in the more commodity-like product categories, such as our pain and controlled substances portfolio and our immediate-release solid oral dosage forms. 
Second, coupled with this consolidation and new payer environment, competitors are taking aggressive pricing actions to gain market share. Examples include both the 300- and 325-milligram strength of hydrocodone APAP, butalbital, morphine sulfate and oxycodone. 
Third, there's been a rapid erosion of the pain segment, driven by 3 things: one, continued market contraction; two, increased competitive capacity and pressure; and three, while still too early to judge the full impact, we believe the recently issued CDC guidelines will continue to put pressure on an already soft pain market. As you may know, approximately 40% of the legacy Qualitest portfolio was comprised of pain products, so this sector's specific weakness has had a disproportionate effect on our generics business. Fourth, there's been a recent and marked acceleration of FDA approval for generic products. While we'll ultimately expect this to also benefit the Par portfolio and our own pending submissions over time, the approvals and launches seen in late Q1 and in April of this year have resulted in greater competitive pressure for our products. Fifth and finally, delays in expected FDA actions related to our 505(b)(2) products means that we have yet to see the anticipated removal of unapproved competitive products from the market. Correspondingly, we have yet to achieve the market exclusivity that we expected for these products. It's important to note that we still expect these FDA actions, but now on a delayed time line. The removal of relevant unapproved products may not occur before first half of 2017 versus our original expectation of early 2016. 
Now that we've talked about what's happened in the generics market, let's also take a few minutes to review when some of these events surfaced, thereby impacting our generic business. In 2016, it's important to note that the U.S. generic landscape has continued to shift, with significant events and updates as recently as late March and April. In fact, it was not until late March that we confirmed the delays on the regulatory actions related to our 505(b)(2) products that I just mentioned. Then in April alone, we see at least 5 competitive product approvals and additional market entrants. Finally, we've also just completed our consortium bid cycle with a more negative output and an increased pricing pressure than we anticipated. 
Moving to Slide 16. I do want to take a few moments to discuss our ongoing integration of the Qualitest and Par businesses. Last fall and Q1 of this year, we were conducting an integration of 2 complex generic businesses. What became very clear to those of us who have been in the generic industry for some time is that the legacy Par operating model is better positioned to address the challenges of today's evolving market. As a result, we set out to shift the legacy Qualitest portfolio strategy from a high-volume approach to the high-value operating model long practiced by legacy Par. As part of the integration activities, we're also transitioning the legacy Qualitest systems and processes to the Par business platform. The legacy Par systems offer more real-time and product level data, allowing for faster analysis and reaction within a challenging and changing market. While many of these improvements were already planned at Qualitest, the integration of our business will accelerate the benefits. 
Next on Slide 17. Let's talk about what we're doing to address these challenges and best position our generic business moving forward, our action plan. First, we are continuing to maximize our key growth drivers, such as our sterile injectables portfolio, led by Vasostrict, and approximately 30 new products that we expect to launch this year. Next, our platform for long-term organic growth is our R&D pipeline. We are continuing to advance these more than 250 projects post-reprioritization and anticipate filing 25 to 30 new submissions in 2016 alone. We are also accelerating the implementation of an optimization and restructuring of our product portfolio and manufacturing facility network. I'll talk more about this restructuring shortly. Additionally, we are accelerating the move of legacy Qualitest business onto the Par platform. This is already substantially complete, as our commercial insight and forecasting capabilities have been fully transitioned. Finally, critical to our action plan is our ability to execute. This is not the first turbulent market environment that the Par team has successfully navigated. Our team is seasoned, capable and proven. 
Moving to Slide 18. Now permit me to provide some additional detail on the restructuring I mentioned earlier. Most importantly, this restructuring is an acceleration of our ongoing integration and broader optimization efforts designed to prioritize and grow high-value durable assets. It is entirely consistent with all our integration activities to date. The restructuring will affect our manufacturing sites in Charlotte and in Huntsville and will result in more than 60 product discontinuations. In addition, we are pruning less value-driven R&D projects so that we can prioritize our investments on differentiated and high-value projects. We expect that the restructuring will be completed by the third quarter of 2017 and will result in a total of approximately $60 million in annualized net run rate savings by Q4 of 2017. We expect to see about $10 million of that gross margin improvement this year. As a result, shortly, we will begin the process of informing employees about these changes. As part of that effort, approximately 740 employees will be impacted under a phased transition. For Endo, the Par management team and for me personally, this is both an extremely [ph] and disappointing to our company. We value our people, and for those who will be affected, we thank you all for what you've contributed to Endo. We'll be providing resources to help manage through this difficult transition. 
And while change is never easy, it is necessary to better position our generics division to successfully compete in the U.S. generics market. So on Slide 19. Let's talk about our full year revenue outlook for the generic segment. We have previously expected a mid-teens underlying growth rate for the business. Given the erosion now forecasted across the sector, and particularly for our base business, and the delay in regulatory action related to our 505(b)(2) products, offset by the strong growth projected for our sterile injectables and new launches and alternative dosage portfolios, we now expect underlying growth for our generics business to be in the low single digit percentage range. We do expect that erosion on our base business to moderate back to rates typical for the generic industry beyond 2016. The erosion in 2016 is expected to be more acute than historical trends due to our relative pricing and share levels in the pain markets prior to the observed and expected erosion. 
Moving to Slide 20. You'll see a look at our Q1 2016 reported generic net sales annualized versus our full year 2016 guidance midpoint. You can see the projected decline due to non-base business competitive entries and base erosion, which we expect to be approximately 5 years (sic) [ 5% ] per quarter through the end of the year. Our new product launches are a significant driver of growth, as illustrated by the green block, and bring you to our projected generic net sales midpoint for the year. 
Now let's look at our 2016 launches on Slide 21. We are on track to launch nearly 30 new products this year. 4 of these are first-to-file products including our generic Seroquel and generic Zetia products that will launch in the fourth quarter of 2016. Another 2 launch products are alternate dosages and another 9 are sterile injectables. Importantly, and as an illustration of our value-focused strategy and platform, nearly 1/3 of our projected launches are products that will be exclusive or face only one generic competitor. Finally, let's close this generics discussion with a quick review of our robust R&D pipeline on Slide 22. 
As I mentioned earlier, we have more than 250 projects in our reprioritized R&D pipeline. We anticipate launching more than 100 of them between 2016 and 2019, representing a total current market value of nearly $30 billion. Our pipeline is robust, diversified and populated by higher barrier-to-entry and higher-margin generic products. We believe that positions us strongly for future growth. I am confident in our platform and I believe that our pipeline is truly differentiated. I know that our team has the experience and the ability to address these challenges and to deliver future generics growth and margin expansion. 
With that, let me turn the call back over to Rajiv for a discussion on our branded business. Rajiv?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportunitie",825,"Thank you, Paul. Let me now take a few minutes to discuss our U.S. Branded business. Before I start, I would like to acknowledge the contributions of Brian Lortie, President U.S. Branded Pharmaceuticals, who will be leaving us to pursue other opportunities. Brian has been a critical part of the efforts to reposition our company over the last 3 years. We will miss him at Endo and wish him well in his future endeavors. 
Moving to Slide 24. Let's talk about factors affecting our U.S. Branded business. First, there has been a recent generic entrant for our Voltaren Gel product. This generic came into the market earlier than we expected, and it has affected our 2016 outlook for V Gel. Second, we have seen increasing pressure on our branded pain segment. This includes additional competitive entries as well as a continually increasing number of public policy and regulatory actions, such as the recent CDC guidelines around opioid prescribing and use. Additionally, there are reimbursement restrictions now in place for LIDODERM, further limiting the use of that branded product. Against this backdrop, we do continue to see significant growth potential in our differentiated product, BELBUCA. However, it has progressed at a slower pace than we initially expected due to pain market pressures. That said, we continue to believe in the future of this product as a Schedule III alternative in the opioid category. 
On Slide 25, you will see the opportunity for BELBUCA, the first and only buprenorphine Buccal Film for chronic pain management, which we launched in late February of this year. There are about 90 million total prescriptions written for the treatment of chronic pain below 160 milligrams of morphine sulfate equivalents or MSEs. BELBUCA is well positioned to source patients both from short-acting opioids as well as other long-acting opioids. Given the size of both these segments, even with a relatively small share of the available prescription base, BELBUCA could become a very meaningful product in this category. 
It is also important to note that even in these early days, BELBUCA is not only capturing switches from LAOs but also from SAOs and new therapy starts. Further, we have seen an increasing number of repeat prescriptions week-over-week. Its differentiated profile is resonating well with physicians and patients across the spectrum, and our early feedback on access, ease of use, efficacy and side effect profile have all been positive. 
Along these lines, let's look at Slide 26, to talk more about early progress on the BELBUCA launch. There are 3 areas that we have focused on in terms of early launch, traction and feedback. While I won't talk through each bullet here, we did want to provide a comprehensive look at where we are making progress and where we see opportunities to further accelerate BELBUCA launch traction. 
Next, on Slide 27, let's talk about XIAFLEX. XIAFLEX continues its double-digit demand growth profile, and we are making good progress in growing that business. We see a significant opportunity to expand both our share of the current treatment market as well as the size of the overall markets for both Dupuytren's contracture and Peyronie's disease. Across both of the DC and PD indications, we have new initiatives focused on driving growth. We are working to broaden our active injector base and have improved targeting to reach the most appropriate physicians. Our DTC and print ad campaign efforts are also showing signs of real traction. For example, visitors to the ""Ask About the Curve"" website spend about 10x longer on the site than an average website visit, and about 1 in 10 visitors click through to find the Peyronie's disease specialist in their area. 
We have also worked to improve convenience for physicians through our reimbursement support initiatives and our product savings program. Overall, these efforts position XIAFLEX for strong continued growth. We expect mid- to high teens percentage growth in 2016.
Moving to Slide 28. Let's talk about the other driver for XIAFLEX growth over the long term, our robust R&D pipeline. We see significant opportunity and substantial value for XIAFLEX across both therapeutic and aesthetic indications and have talked about how the product could be a $1 billion franchise for Endo by the mid-2020s. That opportunity is driven by the more than 12 potential indications currently in the R&D pipeline and the multiple additional programs in even earlier stages of development. As part of our evolved corporate strategy and initiatives to return to organic growth, we are accelerating our R&D programs for XIAFLEX and plan to move 5 programs into the clinic even earlier than previously expected in 2016. It is a time of significant opportunity for these growth drivers in our branded business. We have taken steps to best seize those opportunities and accelerate their growth while also managing the legacy products within our portfolio. 
With that, let me turn the call over to Suky to discuss our full year 2016 financial guidance. Suky?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo through the rest of 2016. On Slide 3",1034,"Thank you, Rajiv, and good afternoon, everyone. In an effort to provide you with more clarity, we are providing additional details on how the factors and market conditions that Paul and Rajiv discussed will impact Endo through the rest of 2016. On Slide 30, we have provided an outline of the key components of change to our rebased revenue guidance that lead to an 11% reduction. As you can see, the largest driver of the change is the greater-than-expected erosion in our generics base business. As a reminder, we define base generics as extended release, immediate release and pain and controlled-substance products. As with the branded business, our rest of the year projections are based on business and commercial assessment and recent trend analysis at a product-by-product level that also takes into account the outcomes of recent bid cycles and competitive actions. 
Approximately 55% of the decline is related to price erosion and 45% relates to volume declines. This is an important variable, as price declines fall to margin at 100%. I should also note, we expect to realize the value of delayed 505(b)(2) actions later in 2017. 
Next, on Slide 31, let's look at the drivers for the changes in our projected gross margin for 2016. Our previous guidance was 63% to 65% for the full year. Given the impacts of key events and market factors, we now expect full year gross margin to be in the range of 59% to 60%. Using the midpoint of the previous and revised guidance range, we expect gross margins to decline about 17% versus prior expectations. We are projecting a disproportionately higher erosion on gross margin versus revenue due to a number of factors that you will see detailed here in the blue call-out box. Importantly, we do expect to realize gross margin for our 505(b)(2) products in 2017, and we expect to offset the 2016 underabsorption through rationalization efforts into 2017.
Moving to Slide 32. We have provided a bridge from our previous EPS expectations for the full year to our revised guidance. The reduction in EPS reflect the revenue and gross margin drivers that I've just discussed. We've taken actions to help offset the declines we are projecting. In 2016, we are reducing OpEx across SG&A while remaining focused on prioritized investments against growth drivers and accelerating our branded R&D programs, and we project improvement in our tax rate. Lastly, we are taking actions to improve our gross margin profile through the plant rationalization that Paul covered earlier. 
On Slide 33, you will see our 2016 financial outlook by business segment, including expected, reported and underlying growth rates and gross margins across the portfolio. The branded business growth rate reflects the loss of exclusivity of V Gel. The generics outlook reflects the declines in the base business and the delayed regulatory actions that were discussed earlier. And international is broadly in line with previous expectations. 
Next, on Slide 34, we have outlined our full revised 2016 financial guidance. From a cadence perspective, we continue to see revenues and EPS weighted to the second half of the year, driven by the launches from the Par portfolio and continued growth from XIAFLEX and BELBUCA. We now expect approximately 46% of revenues and 39% of full year EPS in the first half of 2016. This implies a sequential step-down in Q2 due to a number of drivers, including the full quarter impact of recently launched generic competitors that we talked about earlier on the call. In addition, we expect a ramp-up in spending in the second quarter, primarily related to our acceleration of R&D programs and commercial efforts in U.S. Branded. We have talked through the moving parts around revenues and gross margin. We expect interest expense to continue to be about $455 million. Our tax rate will be lower due to continued progress around planning strategies and due to a lower mix of U.S.-sourced income while maintaining static debt benefits and acquired attributes. Depending on the nature and timing of potential discrete items, the cadence of tax rate through the year can be lumpy. Consistent with prior commentary, we do expect a step-up in our tax rate in outer years. We now project that rate to be in the high single digits. 
Next on Slide 35. While our first quarter cash flow from operations was negative, it was impacted by a number of items that we consider to be noncore. After considering these items, underlying cash flow from operations continues to be well correlated to adjusted net income. I will also note that our working capital metrics are in line with our expectations. Consistent with prior quarter, we have provided more details around working capital in the appendix of this presentation. 
Moving to Slide 36. It is important to note that we continue to project robust cash from operations prior to legal-related cash calls. I will note that in early Q2, we received the full tax refund that we pointed to earlier in the year. Ultimately, we expect to use remaining cash to pay down approximately $250 million to $300 million in debt in 2016. 
Finally, on Slide 37, let me provide you with a snapshot of our liquidity profile. This is important because our cash position and liquidity ratios remain strong and well within our covenants as defined under our debt agreements. We do not foresee any challenge in remaining well within those limits in 2016 and beyond. We expect our net debt leverage ratio to remain in the high 4x in 2016, with some fluctuations based on quarterly cadence. We continue to remain committed to delevering into 3 to 4x range over time. 
In summary, as we rebased our outlook for our business, which is driven by the factors that Rajiv and Paul spoke to earlier, we remain committed to driving financial discipline, including taking actions to improve gross margins, investing in growth drivers, becoming more efficient around G&A, continuing to improve our underlying tax rate, optimizing our cost of capital, driving improvements in working capital and improving after-tax cash flows from operations to service our liabilities and for investments in future growth. 
With that, let me turn the call back over to Rajiv."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. On Slide 39, you will see the c",545,"Thank you, Suky. Now that we have discussed the market factors, what we are doing to address them and the anticipated impact on our 2016 financial expectations, let's talk about how Endo is positioned for 2016 and beyond. 
On Slide 39, you will see the corporate strategy as we laid it out in 2013 and the actions we took to rebuild the business over the past 3 years. We have successfully changed the structure, the businesses and the growth profile of Endo. Now, given the evolving market conditions, it is time for us to continue to evolve our corporate strategy and transform the company for long-term durable growth. 
On Slide 40, let me talk about how we feel Endo is positioned for growth. Our aspiration to build a leading global specialty pharmaceutical company that improves lives and creates value has not changed. We are mindful, though, that we need to set appropriate medium-term goals reflecting current market conditions. This has meant rebasing of our financial guidance for 2016 and a reset of our previous expectations for 2017. However, our goals are clear: return to organic growth at levels above market averages; improve operating margins to be greater than 40%; and delever to between 3 to 4x. 3 core areas of focus will enable these goals: growth in our branded business and the XIAFLEX pipeline; growth in our generics business and pipeline; and the ongoing optimization of our existing business.
Moving to Slide 41. There are many key growth drivers that strongly position our U.S. Branded business for long-term growth. We know we have significant in-market growth opportunities in both XIAFLEX and BELBUCA. We are continuing to structure our team and our business to achieve that growth potential while also managing our diversified portfolio of legacy products. We are also accelerating our derisked innovative R&D pipeline to advance those programs and the time lines for their potential market entry. 
As we execute this year, we will be achieving key milestones across our U.S. Branded business and we will keep you updated regarding our progress. On Slide 42, let's talk about the durable portfolio and pipeline we have in our U.S. generics business. We are focused on driving growth through our differentiated higher barrier-to-entry products, like sterile injectables and our robust pipeline of more than 250 programs post-restructuring. We have a diversified and, importantly, reset base business and a robust highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they execute on these opportunities. 
Let's summarize on Slide 43. We have rebased our business and believe this is a time of significant opportunity for Endo. We have a clear plan to focus on strategic priorities: a return to organic growth, margin improvement and delevering. Our key growth -- our key future growth drivers continue to provide promise to deliver against these strategic priorities. And perhaps, most importantly, Endo is a resilient organization, and we are all committed to our future. Together, we will execute on our evolved corporate strategy and achieve our goal to deliver products that improve patients' lives while creating value for our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines to your questions. [Operator Instructions] Operator, may we have the first question, please?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your first question comes from the line of Randall Stanicky from RBC Capital Markets.",14,"Your first question comes from the line of Randall Stanicky from RBC Capital Markets."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to",69,"Rajiv or maybe for Paul, can you just talk about how much of this impact in generics is from new competitive entrants versus some of the consortiums coming back and pressing you on price? And then I guess part of that thinking is, as the FDA continues to approve more drugs, is there a risk that this continues? And is this just in pain or is it more broadly?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Randall, and I will have Paul answer the question.",10,"Thanks, Randall, and I will have Paul answer the question."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean, clearly, we're disappointed, right. We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say tha",262,"So I think it's really -- ultimately, it's a mix. When we look at the consortiums, I mean, clearly, we're disappointed, right. We did have some loss of business across the legacy Qualitest business. So from that standpoint, it was hurtful. I would say that it was tempered by some successes on the sterile side from the Par portfolio. So from that standpoint, it was a positive effect. When we look at those, they bounce in terms of specifically in the legacy Qualitest portfolio. We had challenges both in pain and, really, the solid oral dosage immediate-release portfolio. And what we were seeing was it was a combination of new competitors coming into the market that were established as well as just first-time players as well. So it was a combination of some smaller generic competitors entering the market that ultimately pushed the price down. And a lot of these occurrence were coming in the late March and April time frame. So in essence, it was several factors in terms of competition as well as loss of business. And clearly, on the FDA side, in terms of new competitors coming in and new approvals rather, I think with the GDUFA really starting to hit, we are going to see more players in some of these commodity-based products. But at the same time, we have 150 products at the FDA. So you should also assume that we will also get the positive impact of a quicker approval. So at the end of the day, we will get our fair share of wins."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Paul, on that, on Slide 20, you called out, I think, it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is date certain versus assumed or hoped approvals?",38,"Paul, on that, on Slide 20, you called out, I think, it's $415 million of new launch revenue that you're pointing to in the back half. How much of that is date certain versus assumed or hoped approvals?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. Right, right, right. So we've talked a little bit about this, around 75% is the new launches.",18,"Yes. Right, right, right. So we've talked a little bit about this, around 75% is the new launches."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Jason Gerberry from Leerink Partners.",13,"Your next question comes from the line of Jason Gerberry from Leerink Partners."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved, but",81,"I just wanted to follow up on this 505(b)(2) issue that you're facing. So I imagine that Vasostrict was a strong product for you in the quarter based on the IMS data. But how many products -- it sounds like you didn't get 505(b)(2) products approved, but that the FDA didn't remove certain unauthorized products from the market. So how many products are we talking about? If you could provide a little bit more detail there, that would be great."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we",159,"Sure. So Jason, we have 2 505(b)(2)s. They're both approved. So when we say the delay, we're talking about, to your point, working with the FDA to have the unapproved sources come off the market. Now what we were seeing was, in the case of Vasostrict, we were successful in a timely fashion. It's getting harder because the FDA is looking towards drug shortages and really having a high confidence that we're going to be able to supply the entire market. So in these 2 particular products that we are talking about, that's what we faced. We are partnering with the FDA to show that we have the ability and give confidence that we can supply the entire market. We're hoping that was going to happen in early 2016. I think the benefit of having these unapproved sources exit the market will be realized in 2017. It's not that it won't happen. It's just really pushing into next year."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage target to mid-3s now beyond, I guess, late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit",68,"If I could squeeze a follow-up. Just for Suky, you're pushing out the leverage target to mid-3s now beyond, I guess, late '16. Can you just talk about some of the 2017 variables on cash generation that'll help you delever? I know you have the FTC lawsuit now. You've got mesh. But could you just kind of walk us through some of the puts and takes there?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So we're not going to give guidance on 2017 at this time. There are a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to",302,"Yes, sure. So we're not going to give guidance on 2017 at this time. There are a number of moving parts that have to play out throughout 2016 before we're in a position to provide that type of guidance. But going into 2017, we would expect to continue to delever. We do see ourselves pushing that target from 3 to 4x from 2016 into 2017 or beyond. There are a number of moving parts that will help with that. Without giving specific guidance, some of the things I've pointed to earlier is, late in this year, we will build about $200 million of working capital. As far as the Seroquel and Zetia launch, that will be recovered in the first half of 2017 as we actually collect the cash on that revenue booked in 2016. As we move into next year, we expect mesh gross payments to moderate down slightly. This year, we would see those mesh payments as being somewhere between $800 million to $900 million. Next year, we would predict that, that would be somewhere around $600 million. So we should see a step-down in gross mesh payments into next year. And then the other big drivers are on capital expenditures. We do see a step-up this year as part of the integration of Par and Qualitest, primarily around the implementation of ERP systems. That should moderate down in 2017. And then we could see a slight step-up in the contingent consideration line that I've outlined here for '16, primarily due to the 505(b)(2) products that Paul has spoken to as well as V Gel. So there's a couple of moving parts that can kind of help you shape where '17 cash might be. But again, we do expect, over time, to delever back into that 3 to 4x range."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of David Amsellem from Piper Jaffray.",13,"Your next question comes from the line of David Amsellem from Piper Jaffray."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","You might have mentioned this, I apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that p",47,"You might have mentioned this, I apologize if I did miss it. But on Vasostrict, does the rebased guidance reflect any competition this year on the products? And can you just remind us your latest thoughts on when you do expect to see competitors on that product?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Dave, this is Paul. Regarding Vasostrict, right now, we are well protected with our API source. From that standpoint, we feel as though that we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO",95,"So Dave, this is Paul. Regarding Vasostrict, right now, we are well protected with our API source. From that standpoint, we feel as though that we are well positioned at least through 2017 on an exclusive basis. We are working very diligently with the PTO in order to get patent status, which would then have our legal team immediately list the patent to the Orange Book. That has not happened yet. It's in progress, but at this point in time, our defense is really our API source that should get us through at least 2017."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So no competition in the guidance this year.",8,"So no competition in the guidance this year."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","No. No competition in the guidance.",6,"No. No competition in the guidance."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Chris Schott from JPMorgan.",12,"Your next question comes from the line of Chris Schott from JPMorgan."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I guess the first one is just -- it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence, I guess, this round of cuts captures an accurate view",164,"I guess the first one is just -- it just seems like things have gone very bad very quickly in a number of line items of your business over the last 1.5 months or so. I guess what gives you confidence, I guess, this round of cuts captures an accurate view of the business going forward? I guess, has there been any change in approach to how conservative or not you're being with the guidance this time around? Or I guess just addressing investors' concerns that things continue to just deteriorate in the business. Can you just, I mean, at a high level just address that question? The second one was just talking about the generic outlook in '17. Just from our perspective, what do you think it's going to take to stabilize the legacy Qualitest business? And just how are you thinking about growth in the portfolio overall, once we get through this difficult 2016 and start to think about the longer-term portfolio?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Chris, let me just start, and I'm going to have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We've had several things that have not gone our way, and many of those things -- actually all of those thi",474,"So Chris, let me just start, and I'm going to have Paul continue. Now in terms of the things that have gone wrong this year, right, so you're right. We've had several things that have not gone our way, and many of those things -- actually all of those things have played out over the course of the last 4 to 6 weeks, right, in the second half of March and in early April. But I'll point to the 3 things that have happened, right, so the 3 material things that have happened. First one is the earlier-than-expected launch of the Voltaren Gel generic. So we clearly didn't see it coming as early as it did. We had forecasted it towards the very, very back end of this year at worst, and best case into 2017. Now that being said, we knew that there was going to be a generic for Voltaren Gel at some point, right, so -- and in fact, the newly revised agreement with GSK and Novartis give us the right to an authorized generic, so we will have a tail of that product going through 2017 and beyond. So yes, that was bad news. It was earlier than expected, but not something that fundamentally impacts our longer-term growth trajectory. The second event that Paul referred to was this delay in the 505(b)(2) programs. And again, our expectation, while it is bad news for 2016, is that it does, in fact, manifest itself from 2017 and will in fact benefit '17 as well as '18, depending on when the FDA actually acts. So then it comes down to the Qualitest base business, right, and I'm going to let Paul pick it up. But basically what we've seen is a real reset in Q1, and Paul talked about the impact of the consortiums, the confluence of competitors that came in for some of our bigger products, like the 325-milligram Hydro-APAP product, which is Qualitest's largest product that happened post -- mid-March. All of those things have happened in a way that has reset that business. And the way we have thought about the guidance is that we've clearly taken a view of saying, how do we predict this erosion continuing through this year, right? So we do see continued erosion through this year. But by the same token, and Paul will elaborate on this, our view is that as we go into 2017, the continued erosion in this base business will moderate to what you would typically see in a commoditized generic business, and the future really is about the pipeline and segments like the sterile injectable segment, right? So with that, let me just turn it over to Paul. Maybe you can talk a bit about our confidence about the remainder of the year and the moving parts going into '17."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So thanks, Rajiv. So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is, is that, historically, we've had successes with the Qualitest portfolio, but w",366,"So thanks, Rajiv. So Chris, your question is really on stabilization and really why do we think it's going to get better. I think the first thing that we want to talk about is, is that, historically, we've had successes with the Qualitest portfolio, but we've got a call it what it is. It is a mature portfolio that is susceptible to competition. With that, we are transferring the strategy from that high-volume throughput that, historically, had successes on economies of scale, to the more Par legacy success model of high-value products, where we're having more technically-challenging products, things that are more difficult to make. Now the first thing we have to do, we talked about the restructuring, right? So we need to take the portfolio. We've got to rightsize it. We've got to be real smart about product selection and what we're going to continue to sell in the market. We're making some very, very difficult decisions impacting some very talented people in our Charlotte and in our Huntsville facility. That's been very difficult for all of us. So that's the starting point: to focus on the restructuring plan. And it gets back down to our core values of operational execution, something that we are really driving home at Par. Rajiv talked about it already. The pipeline is where we're going to be able to reset ourselves. Ultimately, 75% of our value coming is from 2 products, fourth quarter. We've talked quite a bit about quetiapine and Zetia. I'm not going to spend a lot of time there. But we have to execute on the entire portfolio, and at the same time, we've got to continue to repopulate the products as we launch them. So that, coupled with -- again, got to get the 505(b)(2)s, and we have other 505(b)(2)s across the portfolio. It's not just the 2 that we're referring to, but we need to execute. We have a path forward. We have a good strategy. I think these are areas that are going to help us ultimately stabilize our base, and at the same time, we can't lose focus on our service levels and our quality and continue with diversification of our portfolio."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Greg Fraser from Deutsche Bank.",13,"Your next question comes from the line of Greg Fraser from Deutsche Bank."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Gregg Gilbert. On the product rationalization efforts, do you expect those to start to help gross margins during 2016? Or would those benefits -- or the benefits from those efforts be realized more in 2017 and beyond? And then I ju",88,"It's Greg Fraser on for Gregg Gilbert. On the product rationalization efforts, do you expect those to start to help gross margins during 2016? Or would those benefits -- or the benefits from those efforts be realized more in 2017 and beyond? And then I just had a quick one on the amendment to the standstill agreement with TPG that's mentioned in the press release. Can you just give us more color on that change and what you know about TPG's intentions with respect to the stock?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So I'll take the first one, Rajiv, on the gross margin and on the restructuring. So the question on gross margin for 2016 will be about $10 million.",29,"So I'll take the first one, Rajiv, on the gross margin and on the restructuring. So the question on gross margin for 2016 will be about $10 million."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, we've outlined that in the gross margin waterfall that you see in the presentation, Greg. In addition then, we'd expect that benefit -- net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realizat",50,"Yes, we've outlined that in the gross margin waterfall that you see in the presentation, Greg. In addition then, we'd expect that benefit -- net benefit to step up to somewhere about $40 million to $45 million in 2017, and we'll capture that full realization of $60 million by 2018."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And that's on a cumulative basis.",7,"And that's on a cumulative basis."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And Greg, just to answer your question on the TPG standstill, so when TPG first took shares when we acquired Par, there was a standstill agreement that prevented TPG from increasing their stake in the company. So in this instance, with the -- concurrent t",108,"And Greg, just to answer your question on the TPG standstill, so when TPG first took shares when we acquired Par, there was a standstill agreement that prevented TPG from increasing their stake in the company. So in this instance, with the -- concurrent to Todd Sisitsky coming on our board, our board put the decision to release TPG from that -- from the standstill agreement, subject to certain limits. And that was outlined in the 8-K that we filed with the amended standstill agreement. But effectively, it allows TPG to purchase up to another $250 million worth of shares, subject to a cap at 10% of ownership."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Liav Abraham from Citi.",9,"Your next question comes from Liav Abraham from Citi."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics, specifically in the legacy Par business? That's my first question. And then secondly, just a quick question on",73,"The pricing pressure that you talked about seemed to pertain primarily to the Qualitest business. Paul, can you talk about the pricing dynamics, specifically in the legacy Par business? That's my first question. And then secondly, just a quick question on the tax rate. Can you just remind us the accounting of your tax rate? Is this a GAAP tax rate or a cash tax rate? And what is your cash tax rate?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, we have -- this is Paul. In terms of legacy Par, in terms of the pricing pressure, for the most part, it's flat. Maybe low single digits in terms of price. But for the most part, it's flat. And again, it's -- we're able to defend it because for the m",76,"Yes, we have -- this is Paul. In terms of legacy Par, in terms of the pricing pressure, for the most part, it's flat. Maybe low single digits in terms of price. But for the most part, it's flat. And again, it's -- we're able to defend it because for the most part, that base business comprises quite a bit of modified release, sustained release. We've got the injectables as well, so a little less competition."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. Liav, moving to the tax question. So our tax rate -- adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt, for any IP and transfer price planning as well",99,"Yes. Liav, moving to the tax question. So our tax rate -- adjusted tax rate is based on adjusted net income at a statutory rate. And then from there, we deduct the benefits that we have for intercompany debt, for any IP and transfer price planning as well as for acquired attributes. That ultimately results in our adjusted effective tax rate, which is and has been significantly higher than our cash tax rate. Our cash tax rate has been negative for a number of years and is expected to be in the low single digits in our foreseeable future."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Marc Goodman from UBS.",12,"Your next question comes from the line of Marc Goodman from UBS."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year's guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be in",155,"Yes, I'm trying to understand these 505(b)(2)s and how significant they can be. I understand the amount of revenue that you're taking out of this year's guidance because those 2 were delayed, but I'm trying to understand how big can those 2 products be in the first place. I mean, are these going to be products like Vasostrict, which seems to be -- obviously, going to break $200 million this year, at least, that's what it seems? So just give us a sense of that as well as the other 505(b)(2)s that you have, as you say, in the pipeline. Will we see others launching in '17? Are they coming in '18, '19? When do they come? And how big can they be? And then just one quick one, which is you mentioned 60 product discontinuations. What are the sales on those products on an annual basis? And how much is that impacting this year?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict, and it's a little bit larger than you had indicated. It's in excess of around $300 million. Now the 505(b)(2)s that we've -- that we are working with",187,"So Marc, I'll take the 505(b)(2). Now starting with Vasostrict, we've disclosed the value of Vasostrict, and it's a little bit larger than you had indicated. It's in excess of around $300 million. Now the 505(b)(2)s that we've -- that we are working with the FDA, we have not, for competitive reasons, disclosed specifically the value. I would say they're not on the magnitude of Vasostrict. They're material, but nowhere near the magnitude of Vasostrict. I think, for competitive reasons. I think at this point, that's about as far as we can really go on the 2 products that we're working with, with the agency. Additionally, we have -- we do have a 505(b)(2) strategy to take unapproved drugs, run the requisite clinical trials and bring them to market. And we do have a handful of additional products that are at various stages across the entire portfolio of either injectables or solid oral dosage forms. But at this point, we're just not advanced enough to go into any more detail. And hopefully, in another quarter or 2, we'll be able to provide a little bit more visibility."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. I think, Marc, just to add to that, and this is certainly one of the core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. We're certainly very encouraged by the s",80,"Yes. I think, Marc, just to add to that, and this is certainly one of the core capabilities of the Par team. And as we look further into the future, we do expect this to be one of the core drivers for the business. We're certainly very encouraged by the success that the Par team has had with Vasostrict, so far. In terms of the impact of the product rationalization, Suky, do you want to talk about the revenue impact?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. So this year, we would see that revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million, so it steps up by about $70 million in '17. And again, our benefits that we talked about for the",80,"Yes. So this year, we would see that revenue impact is about $20 million. And then on a cumulative basis into '17, we'd see that about just under $90 million, so it steps up by about $70 million in '17. And again, our benefits that we talked about for the plant rationalization are net of that revenue reduction, so we do still expect to see $60 million margin improvement on a full run rate basis, net of the sales reduction."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Annabel Samimy from Stifel.",9,"Your next question comes from Annabel Samimy from Stifel."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 forward. But are we ever going to see the levels that we saw before you've taken this cut down? And what",86,"I wanted to understand the gross margins a little bit better. It sounds that on the rationalization, gross margins could possibly come back up in 2017 forward. But are we ever going to see the levels that we saw before you've taken this cut down? And what component of the Qualitest business is commoditized? How much of that 60 -- how much of the product rationalization is part of that commoditized business? And once that gets out, how do you see gross margins recovering after this?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So for -- Annabel, if I miss something there, just please weigh back in. But overall, we would see the gross margins, all else being equal, improve into 2017, given the rationalization of our products -- sorry, our plants that we talked about as wel",159,"Sure. So for -- Annabel, if I miss something there, just please weigh back in. But overall, we would see the gross margins, all else being equal, improve into 2017, given the rationalization of our products -- sorry, our plants that we talked about as well as because of the reduction in the lower-margin SKUs or products that we're rationalizing. I think other drivers to think about into 2017 as we continue to grow the Par portfolio, which we see as one with products with a margin profile above the existing gross margin average, we could see improvement from that driver. And then in addition, as we see growth from branded within XIAFLEX as well as BELBUCA, we would also see those as potentially expanding margins into 2017. So again, we're not in a position to provide full 2017 or beyond guidance, but we do see a path to recovering gross margins above where 2016 are going to land."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So are they recovering to the level that they had been at?",12,"So are they recovering to the level that they had been at?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's too early to tell at this time, Annabel.",10,"It's too early to tell at this time, Annabel."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Louise Chen from Guggenheim.",12,"Your next question comes from the line of Louise Chen from Guggenheim."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","So just to follow-up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is",79,"So just to follow-up on an earlier question on your '16 guidance. Just curious where you think there is further possibility for downside risk here in '16 guidance. Or do you think that this now incorporates the bear case scenario as well? And then this is not meant to be an antagonistic question, but people have been asking us. At what point you would consider strategic options for Endo if you can't create shareholder value on your own?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Louise. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly, right? It is disappointing for the company, and personally, disappointing for myself as well. So we have done an exhausti",502,"Thanks, Louise. So let me touch on both questions. So look, in terms of guidance, we do not take a reduction in our guidance lightly, right? It is disappointing for the company, and personally, disappointing for myself as well. So we have done an exhaustive assessment over the course of the last few weeks to ensure that we put as much thought as possible into how we assess the remainder of the year. And I would say, our guidance range for the full year is a realistic range, right? So no business is without its risks, and I think you know that. But we have taken a substantial downward revision in the base business in generics. We have -- and I commented on how we are treating Voltaren Gel. We've also taken the opportunity to address some other parts of our branded business because of the continued pressure in the pain market, that we rebase some of those products as well. So we've really taken the opportunity to take a hard look at the forecast in this rebasing, right? So we don't take this lightly. I mean, it's not something that we want to do more than once, right? So that's the course that we have taken. We are confident in this guidance range, and we have a team that is going to work extremely hard at executing against this range. But as always, as I already point [ph], that there is always risk. And then -- yes, one second. So Louise, I was also just going to answer the second question you asked. So for us and our Board of Directors, our goal is longer-term shareholder value creation, right? So certainly, that is -- the last -- the -- what's happened with the business over the course of the last few weeks and months is a disappointment and a setback. But I would point out that our future growth drivers remain unscathed in terms of these particular events that we talked about, right? So we point to XIAFLEX, the XIAFLEX pipeline. We talked to BELBUCA, which, even though, there is, potentially, a delay in terms of the launch trajectory of that product, we continue to believe in the future of that product. And the Par pipeline, which is the primary driver of that acquisition, is robust as ever, right? It continues to grow. The sterile injectables business is robust and growing, and I have every confidence in Paul and the team in terms of getting the generics business back on track. So from that standpoint, we believe that in the hands of our management team, with the appropriate rebasing that we've done in 2016, that there is a path to returning to organic growth, improving our margins and delevering, and therefore, to creating shareholder value going forward. So having said, we are also being very clear that our board is a shareholder-friendly board. And if there is ever any strategic alternative that presents itself, our board will, of course, evaluate it."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Andrew Finkelstein from Susquehanna.",12,"Your next question comes from the line of Andrew Finkelstein from Susquehanna."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Could you talk -- I'll give you a couple of things you can focus on. But at a high level as you talk about the new strategy and even reassessed the environment, I think you highlighted where are the growth drivers you currently have. But as you look longe",159,"Could you talk -- I'll give you a couple of things you can focus on. But at a high level as you talk about the new strategy and even reassessed the environment, I think you highlighted where are the growth drivers you currently have. But as you look longer term at trying to incubate additional drivers, where are the opportunities in this environment and the types of products that are going to have the right risk/reward to pursue? And then as you go about managing that, could you talk a little bit about how you're thinking about balancing cash generation in the near term, and particularly with regard to leverage ratios, versus investments you may want to make in longer-term opportunities? And just specifically on that, as you talk about rationalizing some of the legacy products, were these loss-making? Or is some cash flow being given up? And if so, what's the benefit in doing so at this point?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So thank you, Andrew. Let me just take your 3 questions, and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline",507,"So thank you, Andrew. Let me just take your 3 questions, and I will let Paul talk about the product rationalization question at the end. So from a long-term standpoint, I think what we continue to be very optimistic about is following the XIAFLEX pipeline, right? So we've pursued the cellulite indication. Our Phase IIb trial is in the clinic and currently recruiting patients. We feel positive about that. And you've also seen that we have increased confidence in being able to move forward, at least, 4 other indications into the clinic, right? And they fall generally into the areas of aesthetics as well as other therapeutic indications around the non-collagenists. So the one core priority for us is continued and increased investment in that R&D pipeline. In the -- the pain market, clearly, in terms of public policy and regulatory pressures, is increasing their market. As we said before, BELBUCA has a real profile that could really benefit in terms of some of the current concerns around Schedule II opioids, so we do think there's a future there. But as we look further out into the future, building on our portfolio across our branded business, we could see ourselves in multiple areas that have similar characteristics to other specialty areas, where with a smaller focused sales and marketing footprint that we can be successful. And following some of the therapeutic areas where XIAFLEX is going to get us to, it's going to be the best way for us to pursue that. Now leading to your next question, in terms of cash and our priorities for using the cash, as Suky explained when we talked about delevering, we do expect to continue to prioritize delevering. And delevering back to the 3 to 4x is an important goal for us. Now that is delayed from 2016 into 2017 but continues to be an important goal for us. At the same time, investing in our R&D pipeline, both in XIAFLEX as well as Par, are going to be very important priorities for us, which we will balance as we go, right? So those are going to be the most important uses of cash. And beyond that, and obviously, once we get into a position where we have excess cash and have the opportunity to look at, perhaps, bolt-on acquisitions, either for the generics business or the branded business, we will certainly look at those as they come up. Our preference would be to do so in the branded space, but that is a ways out. We want to make sure that we execute against our growth plan and delever as our primary priorities, and we always keep the option of returning cash holder -- cash to shareholders as an alternative as well. Now let me just turn this over to Paul because I want him to talk to you about some of the new areas that we might expand the pipeline into as well as the question that you had on product rationalization and the profitability impact of that."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Okay, thanks. So it's, obviously, a very important question, and I want to start by saying, this -- the decision in terms of the -- culling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of the normal cour",303,"Okay, thanks. So it's, obviously, a very important question, and I want to start by saying, this -- the decision in terms of the -- culling the portfolio, as I said, very, very difficult for us. But as you look at legacy Par and as part of the normal course, it really is an evolution where you need to consistently look at your portfolio. You have to make some tough decisions. You have to take your unprofitable products or products that are -- you're feeling pain and pressure on. That being said, we're the fourth-largest generic company. We are incredibly relevant. We will continue to be relevant in the industry, and I want to make that statement. And when you -- if you want to be able to compete with the 4 large consortiums, add Walmart in, those 5 companies representing in excess of 90% share, you really need a well-balanced portfolio. And what I mean by that is you need your fair share of Paragraph IVs. You need hard-to-make, technically challenging, solid oral dosage products. You need injectable products, and you do need commodities that are profitable. So that's going to be very important to us in terms of the Qualitest portfolio on a go-forward basis. Now on discontinuation of products, hard decisions. But by culling the portfolio in areas that is going to help us, parts that are ultimately being sold at losses, and we make the tough decisions, it's going to help us on the cash side. It's -- we're going to have a reduction in our operating costs. We'll have a reduction in working capital, and we'll also not need to invest as much in certain facilities from a CapEx standpoint. So from that standpoint, generally speaking, high level, those would be areas that we would have savings in."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. And I want to just come back to Annabel's question, playing off of what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have",155,"Yes. And I want to just come back to Annabel's question, playing off of what Paul just said there around gross margin outlook, I think I was answering maybe a little bit too narrowly and just thinking about 2017. But given the growth drivers that we have that Rajiv outlined earlier and given the focus on execution and efficiency that Paul and his team have around our manufacturing network, I think we do see a path to get back into the mid-60s over time. We're not going to time-bound that at this point yet. We're going to let more '16 play out. And as we move into 2017, we'll have a better view into that, but I do think the growth drivers are at a gross margin level that are higher than our overall corporate average. And again, through efficiency that Paul and his team will drive, there could be a pathway there over time."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Douglas Tsao farm Barclays.",12,"Your next question comes from the line of Douglas Tsao farm Barclays."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just first, in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA.",24,"Just first, in terms of Voltaren Gel, when do you anticipate launching an authorized generic? And then I have a quick question on BELBUCA."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will -- let me just address that on Paul's behalf. We're not going to talk about when we might launch an authorized generic for competitive reasons, and a lot of it is going to depend on how the competitive environment evolves with one competitor in the",68,"I will -- let me just address that on Paul's behalf. We're not going to talk about when we might launch an authorized generic for competitive reasons, and a lot of it is going to depend on how the competitive environment evolves with one competitor in the market. So far, we are very happy with the strategies that we have put around mitigating erosion of our branded product."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Okay. And then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective. I mean, when do you think we should start to see an inflection point",114,"Okay. And then just in terms of BELBUCA, I mean obviously, the initial launch, the first few weeks has gone a little more slowly, as you acknowledged. Just curious from your perspective. I mean, when do you think we should start to see an inflection point in the scripts? And then just also, obviously, you noted that very good coverage -- default coverage exists right now. When do you anticipate sort of finalizing that? And how are those talks going? And the pricing that you expect to get, is that sort of in line with your expectations, better, or perhaps, a little bit more challenged given the dynamics in the pain market right now?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Great. Thanks, Doug. So look, as I said, it's still early days on BELBUCA, right? And the last week for which we have data, I think, is the week of April 21, and we had roughly 650 prescriptions. And we continue to see momentum, right? And it's difficult",517,"Great. Thanks, Doug. So look, as I said, it's still early days on BELBUCA, right? And the last week for which we have data, I think, is the week of April 21, and we had roughly 650 prescriptions. And we continue to see momentum, right? And it's difficult to predict exactly when the inflection point is going to be, but what I can say is that the anecdotal feedback and the qualitative feedback from physicians has been very positive. And I, myself, have spent time in the field. And the fact that this is a Schedule III product, despite all the new pressure that is on physicians with the new CDC guidelines and everything else, the message resonates, right? But that being said, from the very beginning, we pointed to something that would likely lead to requiring more time to educate physicians, and that is the tapering and titration required with this product, right? So to the extent that you are trying to move a patient from other therapy onto BELBUCA, you have to taper that patient down per our label and then titrate the patient back up. And for most physicians, what they are trying to do is to figure out their own gut feel for how this works. Clearly, from a promotional standpoint, we have to stand behind what's on the label, but every physician will figure out what he or she is comfortable with. I would also say another encouraging sign is that the repeat prescription from those who prescribed is progressing very well, so we have as many repeat prescriptions now as we have new Rxs. So these are all good indicators. I'm going to hesitate to give you an exact time frame of when there's going to be an inflection point, but I would point to the second half of this year in terms of when we would expect to see a continued improvement in it. And I am afraid I've forgotten the second part of your question. Oh, yes, it was on the managed care. So it is progressing very well. As we have said before, we have roughly about 2/3 of commercial lives covered, at least with default coverage. We made very good progress in terms of converting the default coverage into actual coverage. Many of the plans require -- have confidentiality agreements that prevent us from talking about these things in a public way. But one that we can point to, where we have permission to talk about, is Express Scripts. That has been a very good win for us. We are continuing our discussions with other plans. And so far, there has -- it's going exactly as we had expected. Now the one piece that we would expect to not get to until 2017 is the Medicare Part D coverage, but that is on par with the -- all of the situations where a product launches midyear. We've also implemented a copay program that basically puts a product on par with competitive products. So in -- from all aspects, from an access standpoint, we are making good progress."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Ken Cacciatore from Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore from Cowen and Company."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just kind of reiterating what you all said, that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a",113,"Just kind of reiterating what you all said, that you're going through some really painful and difficult restructuring. So I'm still a little bit confused why there isn't a lot of contemplation about letting your business merge with another to allow for a total restructuring, kind of maximize all aspects of the business. And I guess the question, again, is why stay stand-alone? You could take equity in a pro forma company, realize the benefits of a larger entity while the value is extracted. And I guess, just for your shareholders wanting to know, are there indeed options on the table? And why isn't this very, very high in the list of options?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thanks, Ken. So let me refer back to my previous answer to a similar question, and I'll answer your question. End of the day, what is most important for our team and for our board is to ensure that we right the ship operationally, address the challenges t",195,"Thanks, Ken. So let me refer back to my previous answer to a similar question, and I'll answer your question. End of the day, what is most important for our team and for our board is to ensure that we right the ship operationally, address the challenges that we've seen and make the progress that we know we can make as a team, right? That being said, we've also always been clear that we're a shareholder-friendly management team, we're a shareholder-friendly board, and we will always look at strategic options that present themselves. Now one of the things that I have said in the past is, although from a debt market perspective as well as where our own equity is trading, we are not in a position to do substantial acquisitions. But I have pointed out that mergers are certainly options that we would consider if they present themselves, particularly where either on a relative value basis, it's something that makes sense, or we conclude that it's the best interest of our shareholders. So certainly, we will remain open to those options, but our primary focus and priority is on operationally executing against our plan."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from Irina Koffler from Mizuho.",9,"Your next question comes from Irina Koffler from Mizuho."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going-forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback",90,"I wanted to go through the 505(b)(2) again. It sounds like it's a big part of your going-forward strategy, and I just wanted to understand how competitive is this space. Are you guys going to get any additional players in the market based on your setback and delay into 2017? And then going forward, we have to rely on your execution of these programs, and yet we had a delay this year already. So what can you say to give us more conviction in your execution of these products?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I will let Paul answer it. I think I would just point to Vasostrict as an example of why you should have confidence in Par's ability to execute. It's been an extraordinarily successful product strategy and one where I don't think we've seen the final chap",64,"I will let Paul answer it. I think I would just point to Vasostrict as an example of why you should have confidence in Par's ability to execute. It's been an extraordinarily successful product strategy and one where I don't think we've seen the final chapter yet. Paul continues to work on it. But Paul, why don't you answer the rest of the question?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes. So again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA, through the 505(b)(2) process. Historically, these are typically older drugs, which we have to run requisite clinical trials in order to g",214,"Yes. So again, at the end of the day, we have a broad strategy in terms of getting unapproved drugs through the FDA, through the 505(b)(2) process. Historically, these are typically older drugs, which we have to run requisite clinical trials in order to get NDA status. When we can change a product and when we can get intellectual property, obviously, we're going to do that aggressively. On certain products, we're able to do that. In certain products, we are unable to do that. In the case of the products that we are referring to at this point in time, I would tell you that I don't believe that intellectual property is as strategic as we would like it to be. However, there are other things that we would be working towards that, at this point in time, I would not want to disclose for competitive reasons. But we are hopeful that this is not going to be a 1 year-and-out type of 505(b)(2) whereby we spend the requisite PDUFA fees, build up a product and then invite competition. So we do have strategies outside of intellectual property that, hopefully, will gain us longevity. But we're not talking compound patent IP, where you're typically seeing multiple years. That's not what we're talking about here."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of David Risinger from Morgan Stanley.",13,"Your next question comes from the line of David Risinger from Morgan Stanley."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is in -- is from the Qualitest business? And how much is hitting the Par business?",160,"A couple of questions. So with respect to the generic pricing and competitive pressures that hit your generics guidance, could you just help us understand how much of that is in -- is from the Qualitest business? And how much is hitting the Par business? So I'll make up a number. Let's say the hit was $10. Of the $10 hit, was it 2/3 to Qualitest and 1/3 to Par? Or was it half and half to each? Just trying to understand that. And then second, with respect to XIAFLEX, how should we think about that product sales sequentially in coming quarters? And then finally, actually, and this one is, I guess for Suky, you had mentioned moving parts in 2017. Could you just talk about the big moving parts that are uncertain? I mean, obviously, there is some certainty with Zetia and Seroquel. But what are the moving parts for revenue that are uncertain for '17 at this point?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","David, let me hit you with XIAFLEX question, then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% when you're looking at the U.S. And as we've -",157,"David, let me hit you with XIAFLEX question, then I will go to Paul on the pricing question and the moving parts in 2017. Look, I think on XIAFLEX, we had a very good first quarter. We had growth of about 21% when you're looking at the U.S. And as we've -- as we laid out in our presentation and my comments, our expectation for the full year is product growth should be somewhere in the mid- to high-teens range, right? Now clearly, we are working to accelerate the product, but that is a view of where our best current thinking is, right? So if you take a look at the 21% and the full year at mid- to high teens, there will be a slight moderation as we head into the new -- next few quarters. But this is still going to be well within the strong double-digit growth profile that we predicted for the product."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And David, your question on the price and the pressure, when we look at the Qualitest portfolio, which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in",91,"And David, your question on the price and the pressure, when we look at the Qualitest portfolio, which had served us well for so many years, as I said before, it is a mature portfolio which is subject to more than normal competition. We're very strong in pain. A big portion of our portfolio is directed towards pain. It's not quite the barrier that it once was, and as a result, the pricing pressure that we saw was about 80% tied to legacy Qualitest, and about 20% tied to legacy Par."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following view on 2017. So let's talk about what's changed when -- since we last put in our expectations for 2017, right? So the 3 main changes have been a resett",354,"And then let me start on your 2017 question, and I'll ask Suky to jump in. So let's take the following view on 2017. So let's talk about what's changed when -- since we last put in our expectations for 2017, right? So the 3 main changes have been a resetting of expectations for our Qualitest base business; the delay in the 505(b)(2) program, as we talked about, which is going out of 2016 but will be impacting positively 2017 and 2018, for that matter; and then we talked about V Gel, which we fully expected to be genericized as we headed into 2017. It just happened much earlier than we expected. And we do have the authorized generic as an option for us to use going into 2017, right? So the real major downward revision there is the impact of the Qualitest base business. Now there are other moving parts that will impact what our final guidance for 2017 is, though, right? We will have to take a view on exactly how BELBUCA is going to do. It all depends on kind of where the inflection point is going to be. Obviously, tailwinds behind XIAFLEX will continue to grow. We will know more by the middle of this year in terms of what's happening with OPANA. We have a July 29 PDUFA date for our ADF relabeling request with the FDA. And we will also know more in terms of some of the other pipeline launches and other programs that Paul is pursuing in the Par business and exactly where they will fall in 2017, right? So those are the -- some of the real moving parts we have. We also signaled that we expect to increase our R&D spend, particularly behind the XIAFLEX pipeline. And to the extent that Paul has any new ideas from an R&D standpoint, we will try very hard to meet any additional funding requirements in that -- in the Par pipeline as well. So those are some of the moving parts. I don't know, Suky, whether you have -- there's anything else that you would point to?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. And so just understanding where our exit is in '16 before we make that final call.",42,"I think the only other thing is the strong growth we've been seeing in the injectables portfolio. We continue to see that momentum into 2017. And so just understanding where our exit is in '16 before we make that final call."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Elliot Wilbur from Raymond James.",13,"Your next question comes from the line of Elliot Wilbur from Raymond James."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","This is Daniel Sanchez on for Elliott Wilbur. I just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities as you work to put the mesh settlement issue behind you and if you think the wors",55,"This is Daniel Sanchez on for Elliott Wilbur. I just wanted to get your latest thinking in regards to the eventual resolution time line and expected 2016 payment liabilities as you work to put the mesh settlement issue behind you and if you think the worst parts and claims with the highest value are over."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. So let me just comment on the overall status of mesh, and let Suky talk about the financial aspect. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail, which is that we took the steps to resol",216,"Sure. So let me just comment on the overall status of mesh, and let Suky talk about the financial aspect. So as we talked about in our fourth quarter call, we took a new approach to how we're dealing with the tail, which is that we took the steps to resolve the higher-quality claims, which is what led to an increase in our accrual that we announced in the fourth quarter call. Since then, the situation has not changed. There is an alleged potential for another 8,000 cases in the tail that we disclosed, but we were also very quick to point out that expectation is that a large proportion of those cases could be of lower quality. We don't have all the facts around them. We were also pointing to the fact that there is a potential fraudulent scheme that is running through many of these cases, which we are investigating currently. And as we pointed out before, these are typically the types of things you see at the very tail end of a mass tort situation. We can't give you a precise projection of what the end date is, but we have confidence that we are seeing the real tail here. And maybe, Suky, you can you talk about the cash expectations in '16."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Sure. At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet, and you'll see that on our 10-Q, which will be issued in the very near future. Of that $1.9 billion, the amount of restricted c",166,"Sure. At the end of the first quarter, we'll have a total product liability accrual of about $1.9 billion on the balance sheet, and you'll see that on our 10-Q, which will be issued in the very near future. Of that $1.9 billion, the amount of restricted cash or our cash that's already been put into qualified settlement funds was about $0.5 billion, which leaves a residual $1.4 billion on a gross basis to be paid. We'd expect of that remaining $1.4 billion, about $750 million on a gross basis to be paid between -- for the rest of 2016 and then about $600 million to $650 million into 2017 or the residual of that $1.3 billion balance. So that's where we stand from a cash call basis. As we talked about earlier, we did receive the federal tax refund that we pointed to earlier this year. That came in early April, and we continue to look at ways to provide a shield around future liabilities."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","And any line of sight as to the magnitude of potential fraud cases? Or is it still too early to tell?",21,"And any line of sight as to the magnitude of potential fraud cases? Or is it still too early to tell?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","It's an active investigation. We have issued subpoenas in the case and also working with the judge in the MDL case as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it.",41,"It's an active investigation. We have issued subpoenas in the case and also working with the judge in the MDL case as well other parts of the law enforcement infrastructure in the country, so we really can't comment on it."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Your next question comes from the line of Rohit Vanjani from Oppenheimer.",12,"Your next question comes from the line of Rohit Vanjani from Oppenheimer."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","And sorry, I maybe missed some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate the new competitor taking? And then same thing with FROVA, are you seeing a new co",139,"And sorry, I maybe missed some of the commentary on Voltaren to Doug's question, but how much did you reduce your Voltaren estimates by? Or how much share do you anticipate the new competitor taking? And then same thing with FROVA, are you seeing a new competitor there? And if so, how much did you reduce estimates by? And then secondly, for the generics unit, could you help me understand the business a little bit there? Do you have contracts primarily at the beginning of the year and that's where you get the renegotiations happening? Or do you -- are the majority of the contracts staggered throughout the year? Or are you seeing ROFRs, where you're choosing not to engage? Or are most of the products sold ad hoc or at will, where your customer can move pretty freely?"
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","So let me just talk about -- briefly about V Gel and FROVA, and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to, in the materials for today's call, the relative impact on the rebasing of our 2016 guidance. We are not going to d",122,"So let me just talk about -- briefly about V Gel and FROVA, and I will pass it on to Paul. With respect to Voltaren Gel, we have pointed to, in the materials for today's call, the relative impact on the rebasing of our 2016 guidance. We are not going to discuss our markets expectations anymore other than to say there is a single competitor on the market and we are effectively defending the branded product at the level that we would expect to do. With respect to FROVA, yes, we do have a new competitor. That is Glenmark. And currently, Par has also launched our authorized generic, so that is also in the market. Maybe you can address the other question."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Yes, sure. In terms of the consortiums this cycle, and I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against, so it's not like you come in, in Q1 and have to deal with 3 of the consort",204,"Yes, sure. In terms of the consortiums this cycle, and I think you had that exactly right. So they are staggered. So each consortium has a different time frame that we bid against, so it's not like you come in, in Q1 and have to deal with 3 of the consortiums. Red Oak does not actually put out bids. Their expectation is, is that they're going to be guaranteed best pricing. So their style is a little bit different as opposed to the OneStop program or the WBAD program or even the Econdisc program. Regarding ROFRs, that is exactly what it is. So after you go through the consortium bid cycle, that does not mean that you are still not exposed for ROFRs. That being said, we defend against ROFRs, and we have our fair share of wins. You have our fair share of losses. And at the end of the day, I think on a go-forward basis, this in an area that we're fairly strong in, in terms of, at least, to protect ourselves from the legacy Par standpoint. And we are, in essence, rightsizing the Qualitest business legacy side in order to be able to defend against ROFRs on a go-forward basis."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","We have time for one final question, Kevin Kedra from Gabelli.",11,"We have time for one final question, Kevin Kedra from Gabelli."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Analysts","Just wondering when you think about strategically, how much sense does it still make to keep the generic and the branded business together? Any thoughts about maybe separate those businesses? And then -- actually, I think that'll be good.",39,"Just wondering when you think about strategically, how much sense does it still make to keep the generic and the branded business together? Any thoughts about maybe separate those businesses? And then -- actually, I think that'll be good."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Okay. Thanks. And the -- Kevin, the -- look, the -- it's a strategic question. I think one of the things that our company has benefited from over the course of the last 3 years since my arrival, when we really settled [ph] accounts around the business is,",231,"Okay. Thanks. And the -- Kevin, the -- look, the -- it's a strategic question. I think one of the things that our company has benefited from over the course of the last 3 years since my arrival, when we really settled [ph] accounts around the business is, in fact, the diversity of the business, right? So the generics business, especially with the addition of Par, I know despite the rebasing that we are taking, it's a highly diversified business with multiple growth drivers. And we've also taken the steps to build critical mass in our branded business, right? But I have been also open that from a forward-looking standpoint, at a certain point in time, when we have critical mass in both our branded business as well as our generics business, these can be both 2 very viable stand-alone businesses, right? So from a strategic standpoint, we remain open to thinking about creative ways of creating shareholder value. But as I pointed to earlier in my comments, our primary focus right now is operational execution. We have a full plate in Par in terms of restructuring that needs to be done, focus on the pipeline, as well as in the branded business, growing XIAFLEX and growing the BELBUCA and investing in the pipeline. But certainly, we will keep all strategic options open to us as we think about the future."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","I would now like to turn the conference back over to Rajiv De Silva, CEO and President.",17,"I would now like to turn the conference back over to Rajiv De Silva, CEO and President."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Executives","Thank you, and I want to thank all of you for your attention today. There have been a lot of very good questions, and we've talked a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. But what I hope",259,"Thank you, and I want to thank all of you for your attention today. There have been a lot of very good questions, and we've talked a lot about the different factors that have impacted our 2016 guidance as well as other financial updates. 
But what I hope that you will take away from this call today is that despite the rebasing of our 2016 guidance, Endo is a fundamentally different and stronger business than it was in 2013, and it is also a more compelling investment and growth story. 
In 2013, we had 2 primary and declining assets at that time and a very fragmented base of business across health care solutions, divided in pharmaceuticals. You fast-forward to today, we've rebuilt our branded portfolio and pipeline, with the acquisition of Auxilium, in particular XIAFLEX. We've divested noncore businesses. We've achieved scale and differentiation in our generics portfolio with the addition of Par. In fact, that is what the future is going to be about, particularly as we think [ph] to see the rebasing of our legacy Qualitest business. 
We're establishing international structure and footprint for growth and expansion. We narrowed the mesh tail, and we have built a business generating significant EBITDA even after this rebasing, and free cash flow that we expect to grow going forward. 
So no one likes to rebase guidance more than I, but we have now reset our business so that we can move forward and effectively drive growth and value, and we thank you for your continued support. 
Thank you very much."
28071,331734375,975066,"Endo International plc, Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may now all disconnect.",22,"Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may now all disconnect."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome 'to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to to introduce your host for today's conference, Ms.",54,"Good day, ladies and gentlemen, and welcome 'to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] 
As a reminder, this conference is being recorded. I would now like to to introduce your host for today's conference, Ms. Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",241,"Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceuticals. 
We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials, including our Frequently Asked Questions document, are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements made by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Legation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K we are furnishing with the SEC today for Endo's reasons for, including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our second quarter 2016 earni",765,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our second quarter 2016 earnings presentation. To start, here is a brief agenda for today's call. 
Moving to Slide 3. The second quarter was a busy and productive one for us at Endo. I am pleased that we delivered solid revenue and adjusted earnings per share results in the second quarter, with revenue performance across all business units broadly in line or ahead of company expectations. We also made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. We have made an important addition to the management team, made good progress on key growth drivers and progressed our ongoing legal reorganization, which provides us with operational flexibility and benefits. Suky will talk about this reorganization in more detail later in the call.
Against the backdrop of this progress, we are taking steps to increase investments in our future organic growth drivers, branded and generics R&D as well as BELBUCA and XIAFLEX promotional efforts. Importantly, we are pleased to affirm our full year 2016 revenue and adjusted EPS guidance despite these additional investments. 
On Slide 4, you will see a snapshot of our solid segment results for the second quarter. 
Moving to Slide 5. Let me discuss in further detail how we remain focused on operational execution and achieving our key milestones. We announced the appointment of Joe Ciaffoni as our new President of the U.S. Branded business. We are delighted that Joe has joined Endo, bringing his proven expertise in launching and growing branded products and look forward to his contributions when he assumes his new post later this month. 
We continue to drive growth in our generic sterile injectables products, and our generics base business is performing right in line with expectations we communicated to you in May of this year. We secured a patent for our largest product, Vasostrict, and continued to launch differentiated generics products and filed new ANDAs with the FDA. 
In our international business, we filed our BELBUCA submission and secured rights to XIAFLEX in Canada. And we have also advanced our branded R&D pipeline and have recently opted into another new potential indication for XIAFLEX Human Lipoma.
So on Slide 6, let's discuss our branded business. Our branded performance in the second quarter was broadly in line with our expectations, which underlie our segment revenue and margin guidance provided in May. We drove continued XIAFLEX demand while abroad, particularly in Peyronie's disease. We are advancing our BELBUCA launch efforts, increasing the total prescriptions to date and growing the number of repeat prescriptions.
In the quarter, we also saw better-than-expected results, driven by contracting for the branded Voltaren Gel and performance across some of our other products such as LIDODERM, NASCOBAL and SUPPRELIN L.A. 
Moving to Slide 7. Let's take a closer look at XIAFLEX's performance. We are making good progress with this key growth asset, and that is transferring into continued growth. In Peyronie's disease, a market that we think has considerable growth and expansion potential, we delivered nearly 20% demand growth in the second quarter versus the same period last year. We continue to expand our physician injector base, and our disease awareness campaign, Ask About the Curve, has shown early signs of successfully engaging PD patients. In Dupuytren's contracture, a more mature market and one where XIAFLEX launched more than 5 years ago, we still drove 5% demand growth in the quarter over the second quarter last year. Revenues for the quarter were impacted by greater-than-expected destocking. For the full year 2016, we now expect low double-digit pro forma revenue growth for XIAFLEX. 
On Slide 8, let's move next to International Pharmaceuticals. We continue to drive performance in line with expectations that underlie our revenue and margin guidance provided in May for Paladin, [indiscernible] and SOMAR. At Paladin, we filed our BELBUCA submission and acquired the Canadian rights to XIAFLEX last quarter. Both products have potential long-term growth drivers for the business. And the additions could provide longer-term growth as we manage the expected loss of exclusivity on select products in the Canadian market this year. 
In our [indiscernible] and SOMAR businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume. And we continue to improve our operating margins. 
Now to talk about our U.S. Generics performance, let me turn the call over to Paul. Paul?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thank you all for joining us on the call. Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all while",534,"Thank you, Rajiv, and thank you all for joining us on the call. 
Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all while delivering performance in line with our expectations. Our sterile injectables business continues to grow, led by Vasostrict. Importantly, we also secured a patent for that product that does not expire until 2035 and which we believe further strengthens our market position. 
And our new launches in alternative segment, we've launched 11 products since the beginning of the year and continue to file new ANDs with the FDA while replenishing our R&D pipeline. As we expected, and in line with the trends consistent across the broader generic industry, our base business declined by approximately 5% sequentially from first quarter 2016, driven by consortium pricing pressures in competitive generic entrants. 
Finally, our adjusted gross margin for the generics business remained in line with expectations. I would like to note that second quarter revenues benefited modestly from some favorable timing between Q2 and Q3, driven by customers advancing some of their orders ahead of the Fourth of July holiday. 
Moving on to Slide 10. I'd like to provide you with an update on the action plan that we outlined last quarter to drive long-term growth across our generics portfolio. While I won't go into the detail on each of these items, I do think it's important to note that we are in progress, on track or have already completed all the core components of our action plan. For example, we continue to make progress on key growth drivers like our 505(b)(2) in sterile injectables programs as well as launching a steady stream of new, differentiated products this year. We're also reprioritizing and accelerating our R&D pipeline. We've already rationalized numerous lower-value projects as part of our restructuring and are on track to find approximately 25 to 30 new ANDA submissions in 2016. We made progress on our accelerated restructuring plan for the generics manufacturing network and continue to project approximately $60 million in annual net run rate savings to be fully realized by fourth quarter 2017. We've largely completed the transition of the legacy Qualitest business onto the Par platform, including commercial insight, forecasting, wholesaler data management and other capabilities. And finally, we are executing on our operational plan. 
We have delivered a second quarter that is in line with the expectations that underline our guidance for revenue and adjusted margins grievously communicated in May.
So let me talk briefly about our product launches to date and those anticipated for the remainder of the year. 
On Slide 11, you'll see a familiar chart. We have updated it to show all the price we have successfully launched so far in 2016. You can also see those projects that we expect to launch into the marketplace in the second half of the year. Importantly, we are on track for our November and December 2016 launches of generic Seroquel XR and generic Zetia. 
With that, let me turn the call over to Suky to discuss the financial performance of the company in the quarter and our projected outlook. Suky?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good afternoon, everyone. Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP compliance",1076,"Thank you, Paul, and good afternoon, everyone. 
Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP compliance and disclosure interpretations, or CNDI guidance, in May. Endo has adopted these guidelines and, as a result, is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. This policy has no impact on Endo's historic or forward-looking GAAP tax or cash tax profile. Also, the initiation of a legal entity reorganization in the first quarter has limited the impact of this change on our adjusted effective tax rate for the year and moving forward. 
Moving to Slide 14. We provided more detail about the legal entity reorganization that I just mentioned. As part of the continued integration of our Qualitest and Par businesses, we initiated a legal entity reorganization that moves the generics business to a new U.S. holding company structure that is separate from the legacy branded business structure. The reorganization provides operating Flexibility and benefits while also reducing the potential impact related to future limits on the use of tax attributes by utilizing most of our attributes to offset an intercompany gain. As a result of this reorganization, the tax bases of U.S. Generics business assets have been stepped up to their fair value, which will provide ongoing cash tax benefit and flexibility in moving assets with limited tax leakage.
The utilization of acquired attributes that I mentioned earlier would have had an unfavorable impact of approximately $160 million on our full year adjusted tax expense under Endo's non-GAAP policy prior to the adoption of the SEC's C&DI. The elimination of this acquired attribute benefit was offset by an improved mix of jurisdictional adjusted pretax income resulting primarily from the reorganization. 
This reorg also gave rise to a discrete net GAAP tax benefit of approximately $450 million in the second quarter from outside bases differences. This benefit has been excluded from our adjusted effective tax rate in accordance with our policy. 
As I talked about earlier, as a result of the SEC's C&DI, Endo is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. However, since we utilized almost all of our tax attributes through the legal entity reorganization,  the implementation of the updated C&DI guidance is not expected to have a material impact on our 2016 and forward-looking adjusted tax rate. Endo continues to project an adjusted effective tax rate of 0 to 2%, as guided, in our first quarter 2016 earnings announcement. We expect to have a GAAP tax benefit and a negative cash tax rate for 2016.
Importantly, for our outlook for 2017 and future years, we expect our adjusted effective tax rate to be in the high single digits to low double digits and our average cash tax rate to be below 5% over the next 5 years. 
Next, on Slide 15, you will see a snapshot of the second quarter GAAP and non-GAAP financial results. Rajiv covered company and segment revenues earlier, so I will not review that here. 
On a GAAP basis, we delivered earnings per share of $1.75 in the quarter versus a loss of $0.49 in the second quarter of 2015. 2016 second quarter GAAP results were driven by an operating loss of $48 million, offset by the tax benefit that I discussed earlier. Tax benefit also offset the impact of a higher share count in 2016. 
Our GAAP operating loss was largely impacted by a decrease in gross margins due to higher mix of generics revenue in the second quarter compared to 2015 and due to incremental amortization expense associated with the stepped up value of intangible assets from Par. On an adjusted basis, overall Q2 results are slightly better than previously guided. 
To summarize the points Rajiv and Paul made, revenue was better than expected due to sterile injectables, stronger-than-expected performance from a number of branded products and a modest timing benefit related to quarter-end buying patterns. Adjusted net income and EPS are better than guided as a result of higher revenues discussed earlier. 
On Slide 16, while the second quarter was ahead of our guided expectations, we are maintaining our guidance ranges, as some of the upside in the second quarter was driven by favorable timing. As Rajiv much, we are also going to invest at a higher level than originally planned in our key growth drivers in the second half of the year through reallocation of operating expenses and a modest step-up in spending. 
Regarding the cadence of revenues and adjusted earnings in the second half of the year, we continue to project the fourth quarter to be disproportionately larger than the rest of the year's quarters due to the launch of the generics Seroquel and Zetia. For third quarter 2016, we expect revenues in the range of $830 million to $870 million and adjusted earnings per share of $0.77 to $0.82. This implies a sequential step-down in third quarter 2016. The anticipated decline is driven by the product order timing benefits in second quarter that we expect to reverse in third quarter, lower U.S. branded sales related to generic competition for Voltaren Gel, continued slowing in the testosterone market, continued decline in legacy pain products, and an increased investment in R&D as well as XIAFLEX and BELBUCA promotional efforts. 
Moving to cash and liquidity on Slide 17. On a year-to-date basis, GAAP cash flow from operations totaled approximately $555 million. We have also highlighted some of the material moving parts that have impacted our reported or GAAP cash flows for the year. 
On Slide 18, we are reiterating our view on cash available to pay down debt in 2016. We continue to project debt pay-down of approximately $250 million in 2016 and to exit the year at a mid- to high 4x net debt to pro forma adjusted EBITDA leverage ratio. As noted in our press release, we ended the quarter with approximately $670 million in unrestricted cash and approximately $390 million in restricted cash and a net debt-to-leverage ratio of approximately 4.6x. 
To summarize, we are encouraged by our second quarter financial results and pleased to affirm our full year outlook while increasing investment in key growth drivers. 
Now to close out the call, let me turn it back over to Rajiv. Rajiv?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 20. In summary, there are a number of 3 [ph] growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA",312,"Thank you, Suky. 
Moving to Slide 20. In summary, there are a number of 3 [ph] growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. We are continuing to optimize our team and our business to achieve their growth potential while also managing our diversified portfolio of other products. We are also accelerating our R&D pipeline to advance those programs and the time lines for their potential market entry. 
We continue to execute on these growth drivers in the second quarter and expect to achieve additional key milestones through the end of this year and beyond. 
On Slide 21, let's recap the key achievements in our U.S. Generics business. We are focused on driving growth through our differentiated, higher barrier to entry products like sterile injectables and our robust pipeline of more than 250 programs for restructuring. We have a diversified reset base business and a robust, highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they continue to execute on these opportunities. 
Let's briefly summarize our call today on Slide 22. In Q2, we delivered solid top and adjusted bottom line results beating our Q2 adjusted results guidance. We made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. And we are affirming our full year 2016 revenue and adjusted EPS guidance while increasing our investment in branded and generic R&D and BELBUCA and XIAFLEX promotion. 
Endo is executing on our strategic priorities, and we continue to believe that this is a time of significant opportunity for the company, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer. Keri?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator,",16,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] 
Operator,"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","[Operator Instructions] And our first question comes from the line of Louise Chen from Guggenheim.",15,"[Operator Instructions] 
And our first question comes from the line of Louise Chen from Guggenheim."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Quite a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also what was going on with the customer destocking this quarter? Second thing is, I wonder if you have at a",76,"Quite a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also what was going on with the customer destocking this quarter? Second thing is, I wonder if you have at any update on the divesting the noncore assets to pay down debt. And the last thing is, are you seeing any stabilization in your Qualitest business?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations. So as you might rec",357,"Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations. So as you might recall, we had a very robust growth in the first quarter. We have seen a little bit of a slowdown in Dupuytren's contracture in the second quarter. But as we look out over the remainder of the year, we do feel confident in the double-digit growth trajectory that we have talked about. Now in terms of the revenue profile, as you know, customer stocking is largely out of our control, though, typically, XIAFLEX stocking in the specialty pharmacy, in general, is around 14 days, about 2 weeks. But from time to time, we do see some unusual changes, which is what happened in the second quarter. Our stocking is around 1 week, so approximately half of what it typically is. Now we have seen this behavior in the past, and typically, over the course of the year, it tends to normalize. But by and large, it is out of our control. So what we look to is demand while growth. And that's where when we look at the 19% growth in Peyronie's, we do feel very good about the indication, given that from a longer-term perspective, for our on-market indications, the biggest opportunity is in Peyronie's. In terms of divestment of noncore assets, I just wanted to be clear that from a company perspective, we don't feel compelled to divest any assets. We are confident in our business and the natural delevering nature of the business, given the -- our substantial cash flows, particularly as we look beyond the [indiscernible] payments in '16 and '17. Now that being said, I think we've also been clear that as a company and as a board, we're always -- we are shareholder-friendly, and when there are opportunities that come our way that are value-creating, we will certainly evaluate them on a standard basis. Paul, maybe you can comment on the Qualitest business."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When you",141,"Yes, sure. So Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When you look at our base business play, we define that as the pain control substances as well as the oral extended-release and immediate-release products. That also includes some of the Par portfolio. When you look at that on a quarter-over-quarter basis, we communicated this at our last earnings call, that we were anticipating about 5% erosion quarter-over-quarter, and that's exactly where we landed. So it's in line with our expectations and how we communicated. So generally, our base business is falling in line, and we're not seeing the heavy erosion that we realized in Q1."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being consider",89,"I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being considered at this point. And Paul, can you confirm that there have been no T4 [ph] certifications on base [indiscernible]? You got that patent issued. Can you quantify the stocking benefit for your business? And can you comment on whether you have an [indiscernible] filing and/or a program in the works?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Greg. So as you know, the company doesn't comment on any ongoing business, although I will continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery around that",106,"Thank you, Greg. So as you know, the company doesn't comment on any ongoing business, although I will continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery around that. And again, what -- as I've said in the past, our board is always open to shareholder-friendly, strategic opportunities and we will remain open to such opportunities as they come our way. But really, our focus now is on the operations of the business. So let me just turn to Paul, 3 [ph] parts of that question. Paul knows destocking and ephedrine."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So I'll be brief. I think, in case of Vasostrict, the answer is we've not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are, basically, our run rate is  we have converted all the",115,"So I'll be brief. I think, in case of Vasostrict, the answer is we've not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are, basically, our run rate is  we have converted all the and approved product to approved products. So we're really normalized in that regard. And then Greg, I think, your last question was on ephedrine. And I think what we can say right now is in case of any product that we are essentially not our policy to discuss any product that we don't already disclosed to our corporate presentations at this point in time, Greg."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And sorry, on the stocking, I meant for you to quantify that stock, wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry.",25,"And sorry, on the stocking, I meant for you to quantify that stock, wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Greg, this is Suky. That's always an exact time when you're trying to measure exactly what and order comes in from one period to the next, especially around holiday weekend. But where we are now we would estimate that to be around $15 million to $",51,"Yes. So Greg, this is Suky. That's always an exact time when you're trying to measure exactly what and order comes in from one period to the next, especially around holiday weekend. But where we are now we would estimate that to be around $15 million to $20 million in revenue."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Annable Samimy with Stifel.",13,"And our next question comes from the line of Annable Samimy with Stifel."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just curious to know, last quarter you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's",79,"I was just curious to know, last quarter you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's shaping up for 2017 in terms of reaching your delevering goals of being under 4x in 2017? And can you still satisfy with some of the mesh payments that you're still seeing?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile [indiscernible]",22,"Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile [indiscernible]"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So regarding the, really, what we refer to as restructuring the operations, there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run rat",114,"Sure. So regarding the, really, what we refer to as restructuring the operations, there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run rate that we anticipate for fourth quarter 2017. We've made some difficult decisions that we've talked about regarding the Charlotte and the Huntsville facilities with respect to -- in terms of employees and synergies. Those decisions have had essentially 3 ways to them. We've executed on wave number one, and we are on track to meet the expectations that we've communicated. So, so far, we are executing on the plan."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I'm sorry, are they having revenue and EBITDA impact right now?",12,"I'm sorry, are they having revenue and EBITDA impact right now?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Think about what we've already talked about on the first quarter call, was part of the restructuring, Annabel. [indiscernible]",20,"Think about what we've already talked about on the first quarter call, was part of the restructuring, Annabel. [indiscernible]"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay, sorry. And then if you can just talk about the leverage. Sorry.",13,"Okay, sorry. And then if you can just talk about the leverage. Sorry."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So as I said, we are about 4 6 [ph] now. We expect to exit the year somewhere between mid to high 4s. A key component of that going into 2017 is we remain committed to deleveraging the low 4x over the midterm is how we characterized the fact on the",168,"Sure. So as I said, we are about 4 6 [ph] now. We expect to exit the year somewhere between mid to high 4s. A key component of that going into 2017 is we remain committed to deleveraging the low 4x over the midterm is how we characterized the fact on the first quarter call. So we're not putting specific timing around that. And then I think the option to your question is something around mesh. What I would say there is as of the second quarter, we had just below $1.6 billion accrued on the balance sheet with just below $400 million in restricted cash. So that's essentially money that's already out the door for funding of mesh, which leaves an incremental or remaining $1.2 billion on a pretax basis. We expect that $1.2 billion to be serviced as another $300 million to $400 million in the second half of this year and then somewhere around $600 million to $700 million on a pretax basis in '17."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Steven Stewart with Goldman Sachs.",14,"And our next question comes from the line of Steven Stewart with Goldman Sachs."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns.",34,"Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Suky, you want to...",4,"Suky, you want to..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'd say, first of all, overall on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, wi",48,"Sure. So I'd say, first of all, overall on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, will be primarily volume-driven."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts",",Great. And just one quick follow-up on the CDC guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?",38,",
Great. And just one quick follow-up on the CDC guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The trends continue, Steven. So we have continued pressure in terms of prescription volumes in the opioid space. I mean, look at the branded space alone, new prescriptions on the branded for down double digits since the announcement of the CDC guidelines.",88,"The trends continue, Steven. So we have continued pressure in terms of prescription volumes in the opioid space. I mean, look at the branded space alone, new prescriptions on the branded for down double digits since the announcement of the CDC guidelines. But that is all incorporated. It was incorporated into our forward-looking guidance in May, and we don't have a different view in terms of the full year. And we, of course, the stock when we think about '17 later on this year or early in 2017."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Gary Nachman with BMO Capital Markets.",15,"And our next question comes from the line of Gary Nachman with BMO Capital Markets."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Rajiv, you mentioned improved contracting for some other branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA",46,"Rajiv, you mentioned improved contracting for some other branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA going forward?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But suddenly, in terms of defense of the branded products, we've had better-than-expected success with con",118,"Sure. So Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But suddenly, in terms of defense of the branded products, we've had better-than-expected success with contracting that we've done with commercial plans, and that's, largely speaking, what's helped us in the first part of the year. As you know, we have authorized the launch of Voltaren Gel AG through half, and that is taking place as we speak. I know the course of the year, we do expect the Authorized Generic to take more share of the overall molecule. And then Gary your second question, I just -- if you can [indiscernible]"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","BELBUCA, you said you're increasing promotions. Interested what your plans are.",11,"BELBUCA, you said you're increasing promotions. Interested what your plans are."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product",302,"Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product beyond just the overall environment in opioid, one is the process of getting physician comfortable with the tapering and titrating requirements in terms of switching patients between different opioids and onto BELBUCA. And secondly, it's around the payer environment and how they see the [indiscernible] products. So on the latter, we made good progress at this point. We have contracted roughly around 85% of commercial lives, and about 70% of that without any restrictions beyond the label. We expect to continue to improve that over the course of the year. But of course, at this point in the launch of the product like this, we don't yet have government reimbursement. But what we see as being the real opportunity is the pharmacoeconomic and public health argument for why [indiscernible] product like BELBUCA is preferable to other opioids such as the scheduled 2 products in terms of where it is introduced in the treatment algorithm. And a lot of the investment that we're now making is around improving our fact base in terms of making those market access arguments. And clearly, we still continue to have a large investment from a field force standpoint, and that continues. And we also increasing our investment around physician education, particularly around the treatment and [indiscernible] of the product. But really, the upside benefit of the longer-term growth of the product is really predicated on us being able to really anchor buprenorphine as an effective and safe alternative in the opioid space, both on a peer standpoint as well as from a physician standpoint."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Liav Abraham with Citi.",13,"And our next question comes from the line of Liav Abraham with Citi."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just a broader question on the generics environment. I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be interested in your thought on how",77,"Just a broader question on the generics environment. I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be interested in your thought on how you see the growth strategy evolving post 2016, if possible, and perhaps you can touch on any updates on reimbursement and physician training and how you feel about ongoing double-digit file growth post 2016."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Paul, you want to talk about the generics environment question?",10,"Paul, you want to talk about the generics environment question?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. I think we've stated before in terms of competition in how we feel about the consortium. At the end of the day, we've got ourselves 4 large cons",153,"Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. I think we've stated before in terms of competition in how we feel about the consortium. At the end of the day, we've got ourselves 4 large consortiums. They're representing around 90%. And we're going to have to still compete with Teva head-on as we would in any case. And typically, you wanted to just be very careful about trying to go after too much share. Just take a balanced approach. So I envision that we're strong competitors. Teva's strong competitor even with the portfolio getting larger, we need to execute on our plan of bringing new products into the marketplace. And I don't think the fact that they've got the active portfolio as a negative impact to Endo Par if that, in fact, is your question that you're trying to allude do."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Liav, going to your XIAFLEX question. We continue to believe that there's a real long-term opportunity with XIAFLEX as an oral platform for the company, given the fact there's a biologic, given the multitude of potential indications that we have as well a",433,"Liav, going to your XIAFLEX question. We continue to believe that there's a real long-term opportunity with XIAFLEX as an oral platform for the company, given the fact there's a biologic, given the multitude of potential indications that we have as well as potential in the on-market indications. That being said, we have been making predictions about '17 and beyond, but I would say that we are very optimistic when we look at the current results that we are seeing in Peyronie's disease, which we think is the great opportunity for the 2 -- of the 2 on-market indications. And there are 3 areas in which we have made promotion investments and we expect to step up for the remainder of the year as well as going to '17, and they will be following. One is an area which we already talked about, which is that we continue to need to make the lives of patients [indiscernible] prescribe the product easy. And that's mostly around reimbursement support, and we've substantially increased the level of internal resourcing around that as well as targeted third parties to support that. The second is a longer-term opportunity around disease awareness building. And we have begun to do piloting and early investments, particularly in Peyronie's, through our online campaign, Ask About the Curve. And it's, of course, too early to fully realize the benefit from it or fully conclude what the benefits will look like, but the early signs of web click-throughs and patient interest in going on to our site of physicians selected, for example, substantial uptick in that, right? Now clearly, for a product like this, the cycle from the time you get patient interest in the product or interest going to physician to the time that he would have her first injection could be 6 to 9 months, which is why we always point out to the back half of this year, '17 before we really begin to see the benefit from it. The third thing I would say is, this is probably more so true for Dupuytren's contracture than Peyronie's, is the need to make a compelling argument around the pharmacoeconomic benefits of an intervention like XIAFLEX versus surgery. And that's more of a opportunity for us in Dupuytren's contracture, where the hand surgeons who treat the conditions often see surgical option as the first option. And we, of course, had very good success with the product with these physicians, but getting to the next level is going to require making the human strong argument on why this is the best interest of patients."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellem with Piper Jaffray.",14,"And our next question comes from the line of David Amsellem with Piper Jaffray."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you'd said the competition could be a couple of years away and that still all the latest",95,"So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you'd said the competition could be a couple of years away and that still all the latest thinking more if the patent give you some more wiggle room. And then secondly, on the generics pipeline, and it may be premature to ask this, but beyond the bigger launches for later this year, maybe talk about some potentially significant launches that you think could happen in 2017."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from 2 diffe",446,"Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from 2 different views. There was always a possibility that there could be a file that was issue with the FDA, pre-Orange Book file listing, and that's something where maybe we feel a little bit better about. And typically, what happened is if an application was in at the FDA for several months, prior to the Orange Book listing, what you would expect is for a generic competitor to find a Paragraph IV very quickly and then we would have been noticed. That didn't happen from that standpoint. We feel a little bit better. If an application went on file a month or 2, pre-June 28 or shortly thereafter, that's where we're not going to have that visibility. But if we were to get a Paragraph IV, say, today, it would take about 60 to 90 days for an application to be accepted for filing. So we would probably look to be in a 30-month stay, ticking somewhere late fourth quarter. That's the way I would start looking at it. So from that standpoint, we had originally said that we felt good through 2017. We probably will be in a position to stay that we feel a little bit good through 2018, but we'll have better visibility around fourth quarter. In terms of the generic pipeline, from a standpoint of where we feel real good about, I think we'd like to focus a little bit on the 505(b)(2) side. And that's an area of strength of the company, right? So while we haven't disclosed specifics, we do have a series of 505(b)(2)s that are starting to come through to fruition. And frankly, maybe we can talk a little bit more in terms of products that we feel a little bit better about. We had previously talked about 2 505(b)(2)s that we did not shed a light on. We feel little bit better about them now. They are 2 forms of potassium. One is a liquid and one is a powder form. We have started to receive positive feedback from the FDA in terms of removing unapproved sources. That's going to come to an end, whereby these unapproved sources will have the remainder of 2016 or so to have product into the market. These types of products will show benefit to Par and Endo in 2017. So that's an area that we'd like to focus in on. Thank you."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from David Risinger with Morgan Stanley.",11,"And our next question comes from David Risinger with Morgan Stanley."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair val",171,"I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair value. I haven't had a chance to look at the numbers there. Could you just talk about that, how it was valued and what it was determined to be worth? And then third, in terms of Vasostrict, we saw that you took a recent price increase at the end of July of 20%. Just wanted to get a sense for how much upward potential you have for pricing. It seems like you have a lot of flexibility to raise price, but then again, there may be pushback. I don't really know. And maybe you could also comment on how much of that will be able to flow through. Should we just assume that, that 20% largely flows through to pretax income or not?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So let me answer the BELBUCA question and touch on Vaso, and I will -- on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we are using a pull-thro",359,"So let me answer the BELBUCA question and touch on Vaso, and I will -- on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we are using a pull-through method to recognize revenue. So it has been minimal revenue recognition in the first half of the year, so single-digit millions. And the -- we've also been clear that given our launch ramp expectations that we expect the contributions in 2016, in total, to be relatively modest. So we would look to 2017 really as the first year of revenue contributions for BELBUCA, and I would be clear about expectations at the appropriate time. In terms of pricing, and I'll let Paul answer this specific question, I'll point out the following, which is from an oral perspective, the Endo business benefits from volumes, not price. And in particular, generics business has predominantly more price pressure than upward price potential. And if any prices -- any price increase that we might be able to take on the true generics part of it is all owned by the presentation that we've seen on the base business. Now products like Vasostrict are a little different and that they are sold basis of the NDA, although this is within Par. But even in those cases, we take a responsible approach to pricing increase. And just because we have flexibility does not mean that we will take a price increase. In the case of Vasostrict, the Par has been very thoughtful about how to price the product as NDA. [indiscernible] to the product, it is still in the low hundreds in terms of -- sorry, 125 or so, plus or minus, in terms of unit costs. And a substantial I might've investment also gone into our Rochester Michigan facility to support this product and CapEx in excess of $100 million. And from a forward-looking standpoint, our philosophy in price increases will not change, which is that we'll be responsible about how we think about it. But Paul, maybe have a specific commentary on Vasostrict."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think Rajiv captured it very well. At the end of the day, we look at the life-saving drug. And when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and that will go",202,"I think Rajiv captured it very well. At the end of the day, we look at the life-saving drug. And when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and that will going to be able to continue to supply the market. And to Rajiv's point, we had to make investments in raw materials, in components and specific equipment for this particular product. We had the CapEx that Rajiv is referring to. And in essence, 20% of our overall CapEx goes into the Rochester facility to keep it compliant. It's a big commitment specifically on this injectable that product of the live-saving product. And then in terms of like general price increases and whatnot, I think, again, when you look at the total generics business, in essence, we are a volume-driven company, to Rajiv's point. When you look at it as an one of our product specific in the case of this one product, it's true that we have taken some price increases they have been responsible. So with that, I'll turn it over to Suky to talk about the pretax question."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on generics fair value, you're correct. Ulti",166,"Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on generics fair value, you're correct. Ultimately, the restructuring or reorganization that we implemented ultimately steps up the fair value of many of the assets within our generics business. That is the tax basis of those assets, which provides ongoing dribble cash tax benefit and also provides flexibility in our ability to move those assets throughout our legal entities without residual tax leakage. It is our policy. We don't to specific asset values, but directionally, the way to think about how we value them is on future value based on discounted cash flows of our outlook for each of the products. And that goes into all of our intangible testing as well as our goodwill testing, et cetera, same analysis that underpins the valuation and, ultimately, the step-up."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just 2 here. First, Paul, broadening out on Larry's question earlier. And as you move past this rest of your generics base business, do you inherently see a more competitive generic industry that we've seen in the past when we factor in a higher level of",149,"Just 2 here. First, Paul, broadening out on Larry's question earlier. And as you move past this rest of your generics base business, do you inherently see a more competitive generic industry that we've seen in the past when we factor in a higher level of new product approvals from FDA, the behavior you're seeing from some of your larger and sent of competitors, et cetera? Or is this kind of similar competitive dynamics than we've previously experienced in the space? And the second question was on the comment on [indiscernible] products. Can just give us a sense of the size of those opportunities as we think out to 2017? How attractive are these? How large of an end market can we think about? And finally, are there any other 505(b)(2)s, not sure of the names, but should we think about additional approvals in 2017 that could help revenue?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So the first part in terms of the market and competitive nature, I mean, clearly, with the consortiums getting larger, and we're seeing it now with Walmart now being part of the McKesson OneStop, I mean, the consolidation have put more pressure back on us",234,"So the first part in terms of the market and competitive nature, I mean, clearly, with the consortiums getting larger, and we're seeing it now with Walmart now being part of the McKesson OneStop, I mean, the consolidation have put more pressure back on us. But I think from where we stand, we feel good about how we reset the base business. We talk a lot about that in terms of I hate referring to Qualitest versus [indiscernible]. When you look at our total business, we have -- we've made our decisions. Right now, it gets down to operational execution. And the way that we compete is to execute flawlessly on our R&D pipeline. That's where we're focused right now, R&D execution and quality. These are things that going to set us apart, clearly [indiscernible], and that is going to create some more pressure on all the generic manufacturers. About, these are going to outperform our going to be the companies that are strong and compliance, strong and service levels and how the pipeline, and those are 3 components that we feel that we are very well positioned on a go-forward basis. Regarding the question on potassium, if I recall, and help me out here, I think we have shown a waterfall bridge about some maybe the last quarter or so that we were referring to some of the unapproved products that were delayed."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think what I would say, Paul, is that we have referred to it. And of course, if you were to our Q1 presentation, we had identified, although we did not identify it as potassium, but now we had, the demand of revenues associated with this product th",136,"Yes. I think what I would say, Paul, is that we have referred to it. And of course, if you were to our Q1 presentation, we had identified, although we did not identify it as potassium, but now we had, the demand of revenues associated with this product that is pushed out of '16. I would hasten to add, though, that as the removal of the FDA -- sorry, of the products guests pushed out, the possibility of a new generic competition for the product is that some point, right? So it's probably a finite life for full production chloride. We don't quite know what it is. So I would not ultimately assume that the same upside that we moved out of '16 to '17. But clearly, a substantial component of that will materialize in '17."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And one last question. 505(b)(2) other other what we should think about in '17 or just think about potential at this point?",22,"And one last question. 505(b)(2) other other what we should think about in '17 or just think about potential at this point?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Nothing right now we're as prepared to talk about the 2 potassium products.",14,"Nothing right now we're as prepared to talk about the 2 potassium products."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Douglas Tsao with Barclays.",13,"And our next question comes from the line of Douglas Tsao with Barclays."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just first maybe, Paul, if you could help us understand in terms of your comment about 505(b)(2)s in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program throu",159,"Just first maybe, Paul, if you could help us understand in terms of your comment about 505(b)(2)s in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program through 2017? And is that lasting to '18? And the just also will be could provide some additional color in terms of the comments in the slides that sort of generics business is going through some of the same dynamics they were in 2008, 2009. If you could provide a little color in terms of what exactly those dynamics were. And then just in terms of the controlled substances generics business. One of your competitors sort of had a better quarter, similar to you, in terms of the near term, but they did suggest that maybe some of the headwinds would persist in '17. Are you expecting to see that same dynamic play out?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there's a lot there. Let's see if we can tackle one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally, high",237,"Okay, so there's a lot there. Let's see if we can tackle one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally, high level, we are launching somewhere between 25 to 30 ANDAs in 2016. I would say that, that is probably a normal run rate for just the ANDA standpoint. On top of that, you're going to see the potassium products start to gain some traction. But I would tell you that the stock like a blockbuster Zetia [indiscernible] I'm pointing to right now for 2017, but we have 25 to 30 launches that are going to be makeup of a good part of 2017. They're all important, and that's the way that we are building out ourselves. So you got to look at the ANDAs. You got to look at the 505(b)(2)s. And then on top of that, we have a very successful and growing injectables business that is still a big part of our future and will start to see more benefit of that particular segment. And our alternative dosage forms all coming into place. So new launches are important, but we're also still driving value through some of our launches that we've seen in 2015 and '16 on the injectables side. So that was the first question. And..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think I would just add one thing. Obviously, what you see from us is that the 505(b)(2) strategy is an important one and there's obviously multiple ideas that Paul and the team will progress in a given time. But we are not going to specifically talk abo",81,"I think I would just add one thing. Obviously, what you see from us is that the 505(b)(2) strategy is an important one and there's obviously multiple ideas that Paul and the team will progress in a given time. But we are not going to specifically talk about anything beyond the ones that we have simply from a competitive standpoint. Paul, I think, the remaining questions from the dynamics in the market in the 2008 [ph] timeframe and the controlled substance."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So 2008, some the challenges that we all had was we all went through the economic crisis when we have to make some difficult decisions back in 2008, 2009. I think Par was fairly hard because the type of portfolio that we had, which was, for the most",377,"Yes. So 2008, some the challenges that we all had was we all went through the economic crisis when we have to make some difficult decisions back in 2008, 2009. I think Par was fairly hard because the type of portfolio that we had, which was, for the most part, a commoditized business. And we had to make certain and tough decisions based upon how we started looking at products on a go-forward basis. And we were also a little bit on the volume side versus a value side. We made a conscious decision to start to look towards more difficult-to-make products. Now that's something that we've executed very, very well on, and that's where we're looking at our total portfolio. Now immediate-release products are always going to be important to Par, right? And that's going to help build volume [indiscernible] for wholesalers. But we're looking for longevity and that's why you're going to see us move more towards the alternative dosage forms in the injectable forms and continue with the Paragraph IV side. That is a key difference from today versus where we were back in 2008. The challenge that we have today is the consortium. The consortiums have gotten bigger and stronger, and that goes right back to having the execute on the earlier statement that I made is the competitive going to survive and do well are the companies that going to have compliance across-the-board, something that we've done very, very well. We spend more some economic amount of capital to compliance, service levels and execution on the R&D side. And there was a question on control some stuff [indiscernible]. So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think with the consortiums getting larger, they have allowed some new players to come into markets and get quota. We talked about this in the past. Still an important part of our business, but it is more of a base business the as I see it, right? So its' important, but it's not the growth driver that it had been previously for number of years. But again, for Arma, every product is important. Just doesn't have the barrier that it once had."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Do you expect some of the headwinds to persist into next year?",12,"Do you expect some of the headwinds to persist into next year?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And specifically in pain?",4,"And specifically in pain?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Controlled substances.",3,"Yes. Controlled substances."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, we're starting to see the challenges that we're just seeing on the opioid. So from the sheer nature of these types of products being Somewhat out of favor right now. You're seeing erosion that natural erosion across-the-board, right? Now what you'r",126,"Again, we're starting to see the challenges that we're just seeing on the opioid. So from the sheer nature of these types of products being Somewhat out of favor right now. You're seeing erosion that natural erosion across-the-board, right? Now what you're going to see is an uptake in other pain medications, right? Those are things that we also have to take into consideration. So I'm not going to say it's an even trade-off, but the scripts have to go someplace so maybe they're going to be moving away from opioids, but you have to look at our entire portfolio. And we have other products in our portfolio in pain that are outside of opioid. So that's pretty much the way we're looking at it today."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The other thing we would say is we don't expect this he major reason as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us.",34,"The other thing we would say is we don't expect this he major reason as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now the guidance is, hey, with all these products were going to la",144,"Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now the guidance is, hey, with all these products were going to launch next year, but now we have a lot of certainty and we will be launching these products next year. So I just want to make sure that, that's what I'm hearing. Second, when you talked about the $15 million to $20 million of buying patterns in generics that 2Q pulled out of 3Q, can just tell us which area it was in you break out the business in base, injectables or the new launch alternatives? And which one was it in? And then third, can you just tell us what the gross margin was for generics for the quarter?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Regarding the potassium products, I think the safest way to address the question is what the FDA is telling us is we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communication to",163,"Regarding the potassium products, I think the safest way to address the question is what the FDA is telling us is we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communication to the unapproved sources of liquid and powder that there is a specific timeline that they have to finish up certain amounts of manufacturing and the ability to sell through at a certain point in time. That's going to come to an end in 2016. Now there's going to be a product that will be in the market. What we don't know is exactly the number of units that these unapproved sources will be making up both forms of potassium. That will carry into some period of time. What we're saying now, though, is that we have reasonable confidence that we are going to get the benefit in 2017. Likely, we'll see the benefit in Q1 or Q2."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?",22,"And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","That's our understanding.",4,"That's our understanding."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","It just went out like in the past month or this is new news?",14,"It just went out like in the past month or this is new news?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","This has gone out over the last several weeks.",9,"This has gone out over the last several weeks."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Your question on the buying...",6,"Your question on the buying..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Marc, it's Suky on the customer stocking and the advancement of orders where we characterize about $15 million, $20 million. It's really across the entire portfolio start a specific customer nor a specific product or segment. So I kind of allocate",144,"Yes. So Marc, it's Suky on the customer stocking and the advancement of orders where we characterize about $15 million, $20 million. It's really across the entire portfolio start a specific customer nor a specific product or segment. So I kind of allocated proportionately to our different business unit within generics. So base businesses are roughly around 50% of the total revenues, so I would account for maybe 50% of that $15 million to $20 million in base and the rest of it across the other portions of our business. And then I think there was another question on the gross margin, sorry. Yes, so gross margin held up right in line with expectations. So we set guidance for full year about generics gross margins in low 50s, and that's where we ended in Q2. And our outlook remains consistent for the full year."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our next question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I just have another generics question and then a mesh question. But Paul, just approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as the reset and move forward w",72,"I just have another generics question and then a mesh question. But Paul, just approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as the reset and move forward with an improving? Or do you still view this as a cyclical uncertainty that will linger as FDA continues to ramp approval or a combination of the both?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is th",172,"So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is that the portfolio has been reset, resized, and we had 5% erosion sequentially between Q2 to Q1. And while the major consortium hit us behind us, we still have the right of first refusal, those are normal course. That's still going to come out was from the base business play. So I think there going to stay with that 5% sequential base erosion quarter-over-quarter throughout 2016. After that happens, and we still feel good, we communicated as we get to 2017 that base erosion should normalize. Normalize was defined as historical Par base erosion. And that's where we were getting to that 10% number, maybe even a point or 2 higher. But about 10% is what we're looking at on a go forward basis as we enter 22017."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","But stable beyond?",3,"But stable beyond?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters in",87,"If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters into OneStop. That's also something that we need to think about. But at this point in time, taking that into consideration, we still feel that, that 10% will be the right erosion factor on a go-forward basis."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay, great. And then Suky, just a quick question for you on mesh. On the after-tax mesh liability for next year, has that changed from the number you gave was in early March? And then the lingering 8,000 cases, I mean, any change in how you guys are thin",51,"Okay, great. And then Suky, just a quick question for you on mesh. On the after-tax mesh liability for next year, has that changed from the number you gave was in early March? And then the lingering 8,000 cases, I mean, any change in how you guys are thinking about those?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'll talk to the numbers, and then maybe Rajiv will talk to the sort of where we are in the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax yield on that, which is ultim",108,"Sure. So I'll talk to the numbers, and then maybe Rajiv will talk to the sort of where we are in the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax yield on that, which is ultimately embodied in a low single-digit tax rate for 2017. So we do expect to see a cash tax rate for 2017. So we do still expect to see a post-tax mesh cash call, which is significantly lower than $600 million to $700 million. So nothing has changed on that front. And then on the remaining 8,000..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think you're referring to the commentary that we made earlier this year when we entered into a set of a settlement around some high-value cases. At that time, we said that there were another reported 8,000 or so cases out there, which, largely spea",205,"Yes. I think you're referring to the commentary that we made earlier this year when we entered into a set of a settlement around some high-value cases. At that time, we said that there were another reported 8,000 or so cases out there, which, largely speaking, which is where we have much information about this cases. And that has not changed. And the incidents of new claims coming in has also been  has trickled down to the low single digits on a weekly basis, and it's been fairly consistent for the last several months. The other thing we pointed out with those 8,000 cases was that there was a potential fraudulent scheme that is running through some components of that, and our priority was driving that to ground and figuring out whether in fact that there was fraud perpetrators. So we have a series of subpoenas that have been issued. We are able -- we are in litigation mode around those subpoenas. But as we pointed out back in the beginning of the year, this process would take months, if not several quarters, to resolve. And we continue to defend ourselves through this process. So in other words, no new news in terms of mesh."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna.",13,"And our next question comes from the line of Andrew Finkelstein with Susquehanna."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for Vaso [indiscernible]. And then as we look at",104,"I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for Vaso [indiscernible]. And then as we look at the run rates for some of the branded products in the quarter, is there anything else to point out? You talked about the destocking on XIAFLEX. But some products like LIDODERM and OPANA, how do you characterize the sales for those in the quarter relative to what you might consider a run rate based on where the scripts are?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Paul?",2,"Sure. Paul?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some of the other earnings call. It is true that we do have an exclusive",99,"So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some of the other earnings call. It is true that we do have an exclusive arrangement with a single API source, and it is understood that there are multiple API sources available. And ultimately, we are prepared to vigorously defend our intellectual property and also our proposition in respect to this particular case. That's probably as far as we can do at this point in time."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that to say that you do not have exclusive arrangements with the others?",14,"Is that to say that you do not have exclusive arrangements with the others?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think what we said is that we do have a single exclusive arrangement with an API source.",18,"I think what we said is that we do have a single exclusive arrangement with an API source."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though, obviously, we pointed those as our future growth drivers. And from quarter-to-quarter, we're able the perfor",267,"And on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though, obviously, we pointed those as our future growth drivers. And from quarter-to-quarter, we're able the performance in those brands. So there are brands like LIDODERM, which, as a branded product, has now really been reduced to a small component because the product is, as far as we're concerned, fully genericized with 3 generic competitors in the market, including our own Authorized Generic. But from a contracting standpoint, we still hold some proportion of the market in our branded products, but clearly subject to generic pressures. OPANA, we pointed to OPANA as one of the products that was impacted by the CDC guidelines and the general slowdown in the opioid market, and I think that trend is continuing along the lines that we expected. But we also have a series of smaller products that we don't talk much about that are also doing quite well, that are promoted. SUPPRELIN L.A. has been a very sticky and very good performance for us for a long period of time. NASCOBAL, which is a product that came over with the [indiscernible] transaction and is a branded product that's promoted by our field force resource doing quite well, right? As we look across the portfolio, in the branded business beyond that we have to talk about, we do see points of good performance, which we will just help us in Q2 and we expect to help us for the course of the remainder of the year as well."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most have been asked, but maybe, Paul, I didn't hear you mentioned adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in UNIMS sales. Just curious if that's there's a potential opportunity there, how you think about the market. Where i",63,"Most have been asked, but maybe, Paul, I didn't hear you mentioned adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in UNIMS sales. Just curious if that's there's a potential opportunity there, how you think about the market. Where is the market competition mainly in compounding pharmacies? Just kind of curious if you have any thoughts that'd be great."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room with respect to cardiac resuscitation or [indiscernible] shock, followed by Vasostrict. So they are basic",118,"Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room with respect to cardiac resuscitation or [indiscernible] shock, followed by Vasostrict. So they are basically sold and promoted exactly the same way. They just wanted first-line or the second line. With respect to the uptick, right now, we did -- we took an appropriate price increase. It is an NDA. We follow the same practice in terms of it being an unapproved product. It is now an approved 505(b)(2). So it's similar in nature into what we've done with Vasostrict, but for the fact that there are unapproved sources of adrenaline on the market today."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and subtle price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that you're ex",115,"One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and subtle price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that you're expecting and then something more easy and volume and [indiscernible] recent price increase? And for Suky, can you talk a little bit about what you see as some of the key detractors sequentially with the guide of the third quarter revenues? Looks like it's fairly strong downtick. I know that the wholesale volume is not going to recur, but what other items you expecting to go the other way, to go negative?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So David, I think you understand the Vasostrict's situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market. So maybe the las",141,"So David, I think you understand the Vasostrict's situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market. So maybe the last quarter or 2, you're seeing standard run rate for Vasostrict. So I think we've met our max on the volume side of Vasostrict. So that's where we are now. As Rajiv indicated, we took a modest price increase. That's the way this product is going to behave on a go-forward basis. So I think we've maxed out on the volume side. And it's just being able to navigate with the market and if we are to take the appropriate price increases on a go-forward basis. But we haven't made any determination see it."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, David. And Suky, on your question on your third quarter sequential reduction, the first thing I would say is generally, as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter, specif",287,"Yes, David. And Suky, on your question on your third quarter sequential reduction, the first thing I would say is generally, as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter, specifically around timing, that could be material to the quarter. But on a whole year basis, they are not meaningful. But having said that, given our recent in Q1 and given the launches that we've got in fourth quarter, we are providing quarterly guidance at least for this year. For the third quarter, the way to think about the step-down is, one, you talked about already, which is the stocking that we saw in the second quarter. Our assumption is that, that reverses in the third quarter. Also what underpin our assumption of the step-down is continued erosion in retail as that continues to face competition from a generic standpoint. We would expect LIDODERM to step down modestly. Our testosterone products continue to decline quarter-over-quarter, particularly because of the market. And then, again, we also expect to see some modest decline in our pain products. All of those declines are partially offset by growth in XIAFLEX and BELBUCA as well as Par launches. But net-net, our assumptions lead us to a decline on revenue into the third quarter. From an investment standpoint, that's all coming in the backdrop as we increase our investments against generics R&D as well as branded R&D and BELBUCA and XIAFLEX as Rajiv started earlier. So those are the moving parts that lead us to the third quarter. Again, what we're doing is taking a very prudent approach of applying quarterly guidance, given the lumpiness of the year."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","That's helpful. And is there any change in assumptions for branded gross-to-net that's negative sequentially?",16,"That's helpful. And is there any change in assumptions for branded gross-to-net that's negative sequentially?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","At this point, we wouldn't see anything material sequentially. Again, there can also be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains.",30,"At this point, we wouldn't see anything material sequentially. Again, there can also be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Donald Ellis with JMP Securities.",14,"And our next question comes from the line of Donald Ellis with JMP Securities."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most of my questions have been answered. But since you guys traffic in the open-market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions of",44,"Most of my questions have been answered. But since you guys traffic in the open-market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions of narcotics?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The -- as you pointed out, we have had another experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work in OPANA reformulation, in fact, to make abuse of the product more difficult. That being said, I thin",138,"The -- as you pointed out, we have had another experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work in OPANA reformulation, in fact, to make abuse of the product more difficult. That being said, I think the public health environment debate around this, [indiscernible] dialogue around this, while encouraging abuse transformation, it's still unclear at what point the entire market will shift to products that [indiscernible], right? So in terms of FDA's own determination of what constitutes a  lot of debate. We don't have a crystal ball, and we'll be speculating. But certainly, as we look at foreword, on a longer-term perspective, one would think that the long-acting products would transition to more abusive formulations what is event happened in the short term. That is anyone's guess."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","If they're going to deal with the pushback from the PBMC reimbursing for likely more expensive abuse-deterrent versions.",19,"If they're going to deal with the pushback from the PBMC reimbursing for likely more expensive abuse-deterrent versions."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, look, I'm speculating, but I would also say that while there's a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet needs in the country. Ther",124,"Again, look, I'm speculating, but I would also say that while there's a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet needs in the country. There are 100 million patients with chronic pain, and there are certain categories obtain such as cancer pain, that you are going to need and opioid in order to survive and manage that kind of pain, right? So I think, in the end, from a full patient need standpoint, we do believe that the opioid will have a place in the market for that. Now from a price standpoint and how PBMs versus regulators, that I really [indiscernible]."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about the 2017 returning to more of a normalized erosion environment for the generics business, you mentioned essentially a 10% erosion rate, maybe a couple of perc",262,"Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about the 2017 returning to more of a normalized erosion environment for the generics business, you mentioned essentially a 10% erosion rate, maybe a couple of percentage points more. But I just wanted to make sure that applies to the entire generic book of business or just my assumption would be that the injectable piece, of course, would be much more stable, and that rate would sort of apply to the solid dose business. But I wanted to confirm that. And then for Suky, question earlier was asked about sort of the ability to realize price increases on Vasostrict. And just trying to get a better sense of how we should be thinking about the company's ability to sort of realize those price increases, whether or not there's been a change in at the relative realization rate in terms of what's actually dropping to the pretax line. And then last question for Rajiv. You talked several times now about accelerating investments and the continuing to invest both the additional resources on the R&D, so that the market drive some of your future high-growth assets. And obviously, the message is heard loud and clear with respect to '16. But I guess, and sort of thinking about external expectations in '17, '18 and kind of beyond, it seems like the anticipation at this point is that spend levels remain relatively flat. I'm just kind of wondering how you're thinking about maybe that just in general terms at least directionally."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Elliott, this is Paul. And the first question, I apologize if I wasn't clear. In terms of that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And that include",115,"Okay. So Elliott, this is Paul. And the first question, I apologize if I wasn't clear. In terms of that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And that includes our extended-release solid oral dose, our immediate-release solid oral doses and our pain and controlled substances group. So it excludes injectables. It excludes the alternative dosage forms and, of course, new products. So that's the way we're defining it. And maybe you can just help me out on your Vasostrict question. I want to make sure I understand it. Maybe you could just repeat that for us."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Longer shortage list price goes up 20%. Has there been any dramatic change in terms of sort of what the company can actually realize of that increase [indiscernible] pretax line?",31,"Longer shortage list price goes up 20%. Has there been any dramatic change in terms of sort of what the company can actually realize of that increase [indiscernible] pretax line?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","[indiscernible] we don't see any major change in the complexion of gross to net on Vasostrict and where we are now.",21,"[indiscernible] we don't see any major change in the complexion of gross to net on Vasostrict and where we are now."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Elliott, in terms of your question on investment. If I step back for a second here, over the course of the last 3 years, we made some major steps, major projects in reshaping the company. And I think we find ourselves now in a very good position where we",190,"Elliott, in terms of your question on investment. If I step back for a second here, over the course of the last 3 years, we made some major steps, major projects in reshaping the company. And I think we find ourselves now in a very good position where we have some great assets across all of our businesses. And as we transition our business to really being an organic growth story, it is a very important imperative for us that we begin to really invest for future sustainable organic growth. And so hence, the investment step-up that we're talking about in R&D, hence, the investment behind XIAFLEX and BELBUCA that we think are going to be real growth drivers over the course of the next 5 years. At this point, we can't make any comment on investment levels and so in '18. But I would point to the fact that we're talking about is investing in long-term growth assets. So long-term growth assets require long-term investments, and that's our philosophy. And obviously, we'll take a more specific view on what that means for '17 and beyond when we have that."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One, did you notice any favorable any share shift in OPANA after the district court ruling in May? Two, and then he took price increases at the beginning of 3Q series of products LIDODERM, SUPPRELIN and you mentioned Vasostrict. Are your wholesale contrac",151,"One, did you notice any favorable any share shift in OPANA after the district court ruling in May? Two, and then he took price increases at the beginning of 3Q series of products LIDODERM, SUPPRELIN and you mentioned Vasostrict. Are your wholesale contract structured pretty typically where they have a 30-day buy-in so you'll see 2/3 of the pricing increase, 33 Ken and the full amount in 4Q? And then could you actually give the XIAFLEX shift and the breakdown in Perrone's end Dupuytren's for 1Q and 2Q? And then lastly, the strength in also for the that is where humans and the guidance that you have this added expense in BELBUCA and XIAFLEX. So what's making the but confused about how you're maintaining from the strength in the quarter. And the surprise in another product that allow you to maintain the guides or where is that offsetting strength coming from?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay. So there were a lot of questions and I'll see if I can I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question. What was it? You're talking with the patent cases, the rulings and our path forward there. Is that correct?",50,"Okay. So there were a lot of questions and I'll see if I can I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question. What was it? You're talking with the patent cases, the rulings and our path forward there. Is that correct?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Asking you saw sure shift because of the ...",9,"Asking you saw sure shift because of the ..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure shift. I'm sorry. We've seen a modest share shift. But as we have always indicated, the majority of the prescriptions we expected to go to the impact of generic, which is debt.",33,"Sure shift. I'm sorry. We've seen a modest share shift. But as we have always indicated, the majority of the prescriptions we expected to go to the impact of generic, which is debt."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Wondering if there was any upside from where you thought kind of ...",13,"Wondering if there was any upside from where you thought kind of ..."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","There are puts and takes in OPANA, right? There's it'll bit of modest uptick in share and possibly continue uptick because of our increased promotion because the product is in PDUFA position behind BELBUCA and field force. On the other hand, you have the",93,"There are puts and takes in OPANA, right? There's it'll bit of modest uptick in share and possibly continue uptick because of our increased promotion because the product is in PDUFA position behind BELBUCA and field force. On the other hand, you have the declining of the market affect. So net-net is not a product where we expect to see any substantial uptick. The -- you had a question on XIAFLEX. So in terms of XIAFLEX, I'm happy to go through them, but FAQ for the first quarter as well as second quarter."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","[indiscernible] offline.",2,"[indiscernible] offline."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","[indiscernible] we have to do it. It's already in the FAQs if you want to take advanced to it. It's identified between the 2 indications. In terms of your question about investments being increased investment in the R&D and sales and marketing, so some of",87,"[indiscernible] we have to do it. It's already in the FAQs if you want to take advanced to it. It's identified between the 2 indications. In terms of your question about investments being increased investment in the R&D and sales and marketing, so some of it, as Suky mentioned in his script, is simply reallocation, and some of it is a modest uptick in our investment level, particularly in the third quarter, which is one of the other contributing factors to how we guided the third quarter."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was asking what offset. What's new is you have the added expenses in BELBUCA and XIAFLEX any are still maintaining your EPS guidance, right? I was wondering what changed for you that was positive to make you keep that. Was it the strong quarter where yo",59,"I was asking what offset. What's new is you have the added expenses in BELBUCA and XIAFLEX any are still maintaining your EPS guidance, right? I was wondering what changed for you that was positive to make you keep that. Was it the strong quarter where you got strong products or in some products allowance and maintain your guidance?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So part of it is the upside coming from the second quarter. Part of it is we do feel good about how gross margins profile is trending in the second half as well.",34,"Yes. So part of it is the upside coming from the second quarter. Part of it is we do feel good about how gross margins profile is trending in the second half as well."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And the last one I had was a bid about your price increases where you take to price increases on LIDODERM [indiscernible]. Do you have typical wholesaler contracts where it's they get a 30-day buy-in so you see maybe 2/3 of the price increase in the",59,"Okay. And the last one I had was a bid about your price increases where you take to price increases on LIDODERM [indiscernible]. Do you have typical wholesaler contracts where it's they get a 30-day buy-in so you see maybe 2/3 of the price increase in the quarter you take the price and then the full amount in 4Q?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointe",60,"No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointed to the overall price increase benefit generally in the mid-single digits for our branded portfolio on a full year basis."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our last question comes from Irina Koffler with Mizuho.",10,"And our last question comes from Irina Koffler with Mizuho."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","It seems like your flattest dealing with the balance of very durable assets. And same thing with L.A. you guys are doing a great job with those 2 products.  but are your really the best owners of these assets. Do you have the right synergies? And would so",54,"It seems like your flattest dealing with the balance of very durable assets. And same thing with L.A. you guys are doing a great job with those 2 products.  but are your really the best owners of these assets. Do you have the right synergies? And would someone else potentially value these assets more?"
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Irina, I can't speak to help someone else would value assets. But what I would say is that these assets [indiscernible] up of assets that make sense for a company like us. They require relatively small sales and marketing footprint. the Type of support",111,"So Irina, I can't speak to help someone else would value assets. But what I would say is that these assets [indiscernible] up of assets that make sense for a company like us. They require relatively small sales and marketing footprint. the Type of support in terms of advertising and promotion that's required around the brand, even with the step-up, as well within the means of the company like us. And also when you look at the R&D pipeline and the investments that are required to develop XIAFLEX, which is already a well-characterized molecule from a safety and effective standpoint, we do think we have the right owner of these assets."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think that wraps up the call. we'd like to thank everyone for joining us this afternoon.",17,"I think that wraps up the call. we'd like to thank everyone for joining us this afternoon."
28071,375875901,1030245,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ms. Ker",53,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to introduce your host for today's conference, Ms. Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",240,"Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceutical. 
We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials, including our Frequently Asked Questions document, are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K we are furnishing with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our second quarter 2016 earni",765,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our second quarter 2016 earnings presentation. To start, here is a brief agenda for today's call. 
Moving to Slide 3. The second quarter was a busy and productive one for us at Endo. I am pleased that we delivered solid revenue and adjusted earnings per share results in the second quarter, with revenue performance across all business units broadly in line or ahead of company expectations. We also made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. We have made an important addition to the management team, made good progress on key growth drivers and progressed our ongoing legal entity reorganization, which provides us with operational flexibility and benefits. Suky will talk about this reorganization in more detail later in the call. Against the backdrop of this progress, we are taking steps to increase investments in our future organic growth drivers, branded and generics R&D as well as BELBUCA and XIAFLEX promotional efforts. Importantly, we are pleased to affirm our full year 2016 revenue and adjusted EPS guidance despite these additional investments. 
On Slide 4, you will see a snapshot of our solid segment results for the second quarter. 
Moving to Slide 5. Let me discuss in further detail how we remain focused on operational execution and achieving our key milestones. We announced the appointment of Joe Ciaffoni as our new President of the U.S. Branded business. We are delighted that Joe has joined Endo, bringing his proven expertise in launching and growing branded products and look forward to his contributions when he assumes his new post later this month. 
We continue to drive growth in our generic sterile injectables products, and our Generics Base business is performing right in line with expectations we communicated to you in May of this year. We secured a patent for our largest product, Vasostrict, and continued to launch differentiated generics products and filed new ANDAs with the FDA. 
In our international business, we filed our BELBUCA submission and secured rights to XIAFLEX in Canada. And we have also advanced our branded R&D pipeline and have recently opted into another new potential indication for XIAFLEX Human Lipoma.
So on Slide 6, let's discuss our branded business. Our branded performance in the second quarter was broadly in line with our expectations, which underlie our segment revenue and margin guidance provided in May. We drove continued XIAFLEX demand while abroad, particularly in Peyronie's disease. We are advancing our BELBUCA launch efforts, increasing the total prescriptions to date and growing the number of repeat prescriptions. In the quarter, we also saw better-than-expected results, driven by contracting for the branded Voltaren Gel and performance across some of our other products such as LIDODERM, NASCOBAL and SUPPRELIN LA. 
Moving to Slide 7. Let's take a closer look at XIAFLEX's performance. We are making good progress with this key growth asset, and that is transferring into continued growth. In Peyronie's disease, a market that we think has considerable growth and expansion potential, we delivered nearly 20% demand growth in the second quarter versus the same period last year. We continue to expand our physician/injector base, and our disease awareness campaign, Ask About the Curve, has shown early signs of successfully engaging PD patients. In Dupuytren's contracture, a more mature market and one where XIAFLEX launched more than 5 years ago, we still drove 5% demand growth in the quarter over the second quarter last year. Revenues for the quarter were impacted by greater-than-expected destocking. For the full year 2016, we now expect low double-digit pro forma revenue growth for XIAFLEX. 
On Slide 8, let's move next to International Pharmaceuticals. We continue to drive performance in line with expectations that underlie our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we filed our BELBUCA submission and acquired the Canadian rights to XIAFLEX last quarter. Both products are potential long-term growth drivers for the business, and the additions could provide longer-term growth as we manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our operating margins. 
Now to talk about our U.S. Generics performance, let me turn the call over to Paul. Paul?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thank you, all, for joining us on the call. Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all whi",534,"Thank you, Rajiv, and thank you, all, for joining us on the call. 
Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all while delivering performance in line with our expectations. Our sterile injectables business continues to grow, led by Vasostrict. Importantly, we also secured a patent for that product that does not expire until 2035 and which we believe further strengthens our market position. And our new launches in alternative dose segment, we've launched 11 products since the beginning of the year and continue to file new ANDAs with the FDA while replenishing our R&D pipeline. As we expected and in line with trends consistent across the broader generic industry, our base business declined by approximately 5% sequentially from first quarter 2016, driven by consortium pricing pressures in competitive generic entrants. Finally, our adjusted gross margin for the generics business remained in line with expectations. I would like to note that second quarter revenues benefited modestly from some favorable timing between Q2 and Q3, driven by customers advancing some of their orders ahead of the 4th of July holiday. 
Moving on to Slide 10. I'd like to provide you with an update on the action plan that we outlined last quarter to drive long-term growth across our generics portfolio. While I won't go into the detail on each of these items, I do think it's important to note that we are in progress, on track or have already completed all the core components of our action plan. For example, we continue to make progress on key growth drivers like our 505(b)(2) in sterile injectable programs as well as launching a steady stream of new, differentiated products this year. We're also reprioritizing and accelerating our R&D pipeline. We've already rationalized numerous lower-value projects as part of our restructuring and are on track to file approximately 25 to 30 new ANDA submissions in 2016. We made progress on our accelerated restructuring plan for the generics manufacturing network and continue to project approximately $60 million in annual net run rate savings to be fully realized by fourth quarter 2017. We've largely completed the transition of the legacy Qualitest business onto the Par platform, including commercial insight, forecasting, wholesaler data management and other capabilities. And finally, we are executing on our operational plan. We have delivered a second quarter that is in line with the expectations that underline our guidance for revenue and adjusted margins previously communicated in May.
So let me talk briefly about our product launches to date and those anticipated for the remainder of the year. 
On Slide 11, you'll see a familiar chart. We have updated it to show all the price we have successfully launched so far in 2016. You can also see those projects that we expect to launch into the marketplace in the second half of the year. Importantly, we are on track for our November and December 2016 launches of generic Seroquel XR and generic Zetia. 
With that, let me turn the call over to Suky to discuss the financial performance of the company in the quarter and our projected outlook. Suky?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good afternoon, everyone. Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance",1076,"Thank you, Paul, and good afternoon, everyone. 
Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance and Disclosure Interpretations or C&DI guidance in May. Endo has adopted these guidelines and, as a result, is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. This policy has no impact on Endo's historic or forward-looking GAAP tax or cash tax profile. Also, the initiation of a legal entity reorganization in the first quarter has limited the impact of this change on our adjusted effective tax rate for the year and moving forward. 
Moving to Slide 14, we provided more detail about the legal entity reorganization that I just mentioned. As part of the continued integration of our Qualitest and Par businesses, we initiated a legal entity reorganization that moves the generics business to a new U.S. holding company structure that is separate from the legacy branded business structure. The reorganization provides operating flexibility and benefits while also reducing the potential impact related to future limits on the use of tax attributes by utilizing most of our attributes to offset an intercompany gain. As a result of this reorganization, the tax bases of U.S. Generics business assets have been stepped up to their fair value, which will provide ongoing cash tax benefit and flexibility in moving assets with limited tax leakage. The utilization of acquired attributes that I mentioned earlier would have had an unfavorable impact of approximately $160 million on our full year adjusted tax expense under Endo's non-GAAP policy prior to the adoption of the SEC's C&DI. The elimination of this acquired attribute benefit was offset by an improved mix of jurisdictional adjusted pretax income resulting primarily from the reorganization. This reorg also gave rise to a discrete net GAAP tax benefit of approximately $450 million in the second quarter from outside basis differences. This benefit has been excluded from our adjusted effective tax rate in accordance with our policy. 
As I talked about earlier, as a result of the SEC's C&DI, Endo is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. However, since we utilized almost all of our tax attributes through the legal entity reorganization,  the implementation of the updated C&DI guidance is not expected to have a material impact on our 2016 and forward-looking adjusted tax rate. Endo continues to project an adjusted effective tax rate of 0 to 2%, as guided, in our first quarter 2016 earnings announcement. We expect to have a GAAP tax benefit and a negative cash tax rate for 2016. Importantly, for our outlook for 2017 and future years, we expect our adjusted effective tax rate to be in the high single digits to low double digits and our average cash tax rate to be below 5% over the next 5 years. 
Next, on Slide 15, you will see a snapshot of the second quarter GAAP and non-GAAP financial results. Rajiv covered company and segment revenues earlier, so I will not review that here. 
On a GAAP basis, we delivered earnings per share of $1.75 in the quarter versus a loss of $0.49 in the second quarter of 2015. 2016 second quarter GAAP results were driven by an operating loss of $48 million, offset by the tax benefit that I discussed earlier. Tax benefit also offset the impact of a higher share count in 2016. 
Our GAAP operating loss was largely impacted by a decrease in gross margins due to a higher mix of generic revenue in the second quarter compared to 2015 and due to incremental amortization expense associated with the stepped-up value of intangible assets from Par. On an adjusted basis, overall Q2 results are slightly better than previously guided. 
To summarize the points Rajiv and Paul made, revenue was better than expected due to sterile injectables, stronger-than-expected performance from a number of branded products and a modest timing benefit related to quarter-end buying patterns. Adjusted net income and EPS are better than guided as a result of higher revenues discussed earlier. 
On Slide 16, while the second quarter was ahead of our guided expectations, we are maintaining our guidance ranges, as some of the upside in the second quarter was driven by favorable timing. As Rajiv mentioned, we are also going to invest at a higher level than originally planned in our key growth drivers in the second half of the year through reallocation of operating expenses and a modest step-up in spending. 
Regarding the cadence of revenues and adjusted earnings in the second half of the year, we continue to project the fourth quarter to be disproportionately larger than the rest of the year's quarters due to the launch of the generics Seroquel and Zetia. For third quarter 2016, we expect revenues in the range of $830 million to $870 million and adjusted earnings per share of $0.77 to $0.82. This implies a sequential step-down in third quarter 2016. The anticipated decline is driven by the product order timing benefits in second quarter that we expect to reverse in third quarter, lower U.S. branded sales related to generic competition for Voltaren Gel, continued slowing in the testosterone market, continued declines in legacy pain products and an increased investment in R&D as well as XIAFLEX and BELBUCA promotional efforts. 
Moving to cash and liquidity on Slide 17. On a year-to-date basis, GAAP cash flow from operations totaled approximately $555 million. We have also highlighted some of the material moving parts that have impacted our reported or GAAP cash flows for the year. 
On Slide 18, we are reiterating our view on cash available to pay down debt in 2016. We continue to project debt pay-down of approximately $250 million in 2016 and to exit the year at a mid- to high 4x net debt to pro forma adjusted EBITDA leverage ratio. As noted in our press release, we ended the quarter with approximately $670 million in unrestricted cash and approximately $390 million in restricted cash and a net debt-to-leverage ratio of approximately 4.6x. 
To summarize, we are encouraged by our second quarter financial results and pleased to affirm our full year outlook while increasing investment in key growth drivers. 
Now to close out the call, let me turn it back over to Rajiv. Rajiv?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. W",310,"Thank you, Suky. 
Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. We are continuing to optimize our team and our business to achieve their growth potential while also managing our diversified portfolio of other products. We are also accelerating our R&D pipeline to advance those programs and the time lines for their potential market entry. We continue to execute on these growth drivers in the second quarter and expect to achieve additional key milestones through the end of this year and beyond. 
On Slide 21, let's recap the key achievements in our U.S. Generics business. We are focused on driving growth through our differentiated, higher barrier-to-entry products like sterile injectables and our robust pipeline of more than 250 programs for restructuring. We have a diversified reset base business and a robust, highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they continue to execute on these opportunities. 
Let's briefly summarize our call today on Slide 22. In Q2, we delivered solid top and adjusted bottom line results, beating our Q2 adjusted results guidance. We made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. And we are affirming our full year 2016 revenue and adjusted EPS guidance while increasing our investment in branded and generic R&D and BELBUCA and XIAFLEX promotion. Endo is executing on our strategic priorities, and we continue to believe that this is a time of significant opportunity for the company, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] 
Operator, may we have the first question, please?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Louise Chen with Guggenheim.",13,"And our first question comes from the line of Louise Chen with Guggenheim."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have",78,"So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have any update on the divesting of the non-core assets to pay down debt. And the last thing is, are you seeing any stabilization in your Qualitest business?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you mig",367,"Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you might recall, we had a very robust growth in the first quarter. We have seen a little bit of a slowdown in Dupuytren's contracture in the second quarter. But as we look out over the remainder of the year, we do feel confident in the double-digit growth trajectory that we have talked about. Now in terms of the revenue profile, as you know, customer stocking is largely out of our control, though, typically, XIAFLEX stocking in the specialty distributors and the specialty pharmacies, in general, is around 14 days, about 2 weeks. But from time to time, we do see some unusual changes to it, which is what happened in the second quarter. Our stocking is around 1 week, so approximately half of what it typically is. Now we have seen this behavior in the past, and typically, over the course of the year, it tends to normalize. But by and large, it is out of our control. So what we look to is demand while growth. And that's where when we look at the 19% growth in Peyronie's, we do feel very good about this indication, given that from a longer-term perspective, for our on-market indications, the biggest opportunity is in Peyronie's. In terms of divestments of non-core assets, I just wanted to be clear that from a company perspective, we don't feel compelled to divest any assets. We are confident in our business and the natural delevering nature of the business, given the -- our substantial cash flows, particularly as we look beyond the known mesh payments in '16 and '17. That being said, I think we've also been clear that as a company and as a board, we are always -- we are shareholder-friendly. And when there are any opportunities that come our way that are value-creating, we will certainly evaluate them on a standard basis. Paul, maybe you can comment on the Qualitest business."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When yo",142,"Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When you look at our base business play, we define that as the pain and control substances as well as the oral extended-release and immediate-release products. That also includes some of the Par portfolio. When you look at that on a quarter-over-quarter basis, we communicated this at our last earnings call, that we were anticipating about 5% erosion quarter-over-quarter, and that's exactly where we landed. So it's in line with our expectations and how we communicated. So generally, our base business is falling in line, and we're not seeing the heavy erosion that we realized in Q1."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being consider",91,"I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being considered at this point. And, Paul, can you confirm that there have been no P4 certifications on Vasostrict and see why you [ph] got that patent issued? Can you quantify the stocking benefit for your business? And can you comment on whether you have an ephedrine filing and/or a program in the works?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to open, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery arou",111,"Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to open, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery around that. And again, what -- as I've said in the past, our board is always open to shareholder-friendly, strategic opportunities, and we will remain open to such opportunities as they come our way. But really, our focus now is on the operations of the business. So let me just turn to Paul. I think there were 3 parts of that question, Paul, with stocking and ephedrine."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted al",118,"So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted all the unapproved product to approved product. So we're really normalized in that regard. And then, Greg, I think your last question was on ephedrine. And I think what we can say right now is in case of any product, that we are -- essentially not our policy to discuss any product that we don't already disclosed into our corporate presentations at this point in time, Greg."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry.",27,"And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million",51,"Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million to $20 million in revenue."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Annabel Samimy with Stifel.",13,"And our next question comes from the line of Annabel Samimy with Stifel."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's",82,"I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's shaping up for 2017 in terms of reaching your delevering goals of being under 4x in 2017? And can you still satisfy with -- that with some of the mesh payments that you're still seeing?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile [indiscernible].",22,"Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile [indiscernible]."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So regarding the -- really, what we refer to as restructuring the operations, there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run r",115,"Sure. So regarding the -- really, what we refer to as restructuring the operations, there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run rate that we anticipate for fourth quarter 2017. We've made some difficult decisions that we've talked about regarding the Charlotte and the Huntsville facilities with respect to -- in terms of employees and synergies. Those decisions have had essentially 3 ways to them, and we've executed on wave #1. And we are on track to meet the expectations that we've communicated. So, so far, we are executing on the plan."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I'm sorry, are they having revenue and EBITDA impact right now?",12,"I'm sorry, are they having revenue and EBITDA impact right now?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Nothing about what we've already talked about on our first quarter call was part of the restructuring, Annabel. [indiscernible]",20,"Nothing about what we've already talked about on our first quarter call was part of the restructuring, Annabel. [indiscernible]"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. Sorry. And then if you can just talk about the leverage. Sorry.",13,"Okay. Sorry. And then if you can just talk about the leverage. Sorry."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the f",167,"Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the first quarter call. So we're not putting specific timing around that. And then I think the offshoot to your question was something around mesh. And what I would say there is, as of the second quarter, we had just below $1.6 billion accrued on the balance sheet, with just below $400 million in restricted cash. So that's essentially money that's already out the door for funding of mesh, which leaves an incremental or remaining $1.2 billion on a pretax basis. We expect that $1.2 billion to be serviced as another $300 million to $400 million in the second half of this year and then somewhere around $600 million to $700 million on a pretax basis in '17."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Stephan Stewart with Goldman Sachs.",14,"And our next question comes from the line of Stephan Stewart with Goldman Sachs."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns.",34,"Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Suky, do you want to...",5,"Suky, do you want to..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, w",48,"Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, will be primarily volume-driven."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts",",Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?",40,",
Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The trends continue, Stephan . So they have continued pressure in terms of prescription volumes in the opioid space. I mean, look at the branded space alone, new prescriptions in the branded vol are down double digits since the announcement of the CDC gui",91,"The trends continue, Stephan . So they have continued pressure in terms of prescription volumes in the opioid space. I mean, look at the branded space alone, new prescriptions in the branded vol are down double digits since the announcement of the CDC guidelines, but that is all incorporated -- it was incorporated into our forward-looking guidance in May. And we don't have a different view in terms of the full year. We will, of course, take stock when we think about '17 later on this year or early in 2017."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Gary Nachman with BMO Capital Markets.",15,"And our next question comes from the line of Gary Nachman with BMO Capital Markets."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA",47,"Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA going forward?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But suddenly, in terms of defense of the branded products, we've had better-than-expected success with co",118,"Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But suddenly, in terms of defense of the branded products, we've had better-than-expected success with contracting that we've done with commercial plans, and that's, largely speaking, what's helped us in the first part of the year. Now as you know, we have authorized the launch of Voltaren Gel AG through Par, and that is taking place as we speak. And over the course of the year, we do expect the Authorized Generic to take more share of the overall molecule. And then, Gary, your second question, I just -- if we can..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","BELBUCA.",1,"BELBUCA."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are.",15,"BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product",305,"Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product beyond just the overall environment in opioid, one is the process of getting physician community comfortable with the tapering and titrating requirements in terms of switching patients between different opioids and onto BELBUCA. And secondly, it's around the payer environment and how they see the Schedule III products. So on the latter, we made good progress. At this point, we have contracted roughly around 85% of commercial lives, and about 70% of that at -- without any restrictions beyond the label, we expect to continue to improve that over the course of the year. But, of course, at this point, in launch of a product like this, we don't yet have [indiscernible] reimbursement. But what we see as being the real opportunity is the pharmacoeconomic and public health argument for why Schedule III product like BELBUCA is preferable to other opioids such as the Schedule II products in terms of where it is introduced in the treatment algorithm. And a lot of the investment that we are now making is around improving our fact base in terms of making those market access arguments. Clearly, we still continue to have a large investment from a field force standpoint, and that continues. We're also increasing our investment around physician education, particularly around the treatment and titrating of the product. But really, the upside benefit and the longer-term growth of the product is really predicated on us being able to really anchor buprenorphine as a effective and safe alternative in the opioid space, both on a peer standpoint as well as from a physician standpoint."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Liav Abraham with Citi.",13,"And our next question comes from the line of Liav Abraham with Citi."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be intereste",81,"First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be interested in your thoughts on how you see the growth trajectory evolving post 2016, if possible, and perhaps you can touch on any updates on reimbursement and physician training and how you feel about ongoing double-digit file growth post 2016."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Paul, do you want to talk about the generics environment question?",11,"Paul, do you want to talk about the generics environment question?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition in how we feel about the consortium. At the end of the day, we've got our",161,"Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition in how we feel about the consortium. At the end of the day, we've got ourselves 4 large consortiums. They're representing around 90%. And we're going to have to still compete with Teva head-on as we would in any case. And typically, you want to just be very careful about trying to go after too much share. Just got to take a balanced approach. So I envision that we're strong competitors. Teva's a strong competitor. Even with the portfolio getting larger, we need to execute on our plan of bringing new products into the marketplace. And I don't think of the fact that they've got the Actavis portfolio as a negative impact to Endo Par, if that, in fact, is your question that you're trying to allude to."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as",449,"Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as potential in the on-market indications. That being said, we have -- we will not be making any particular prediction around '17 and beyond. But I would say that we are very optimistic when we look at the current results that we are seeing in Peyronie's disease, which we think is the great opportunity for the 2 -- of the 2 on-market indications. And there are 3 areas in which we have made promotion investments and we expect to step up for the remainder of the year as well as going into '17, and they will be following. One is an area which we already talked about, which is that we continue to need to make the lives of patients who currently prescribe the product easy. And then that's mostly around reimbursement support. And we've substantially increased the level of internal resourcing around that as well as targeted third parties to support that. The second is a longer-term opportunity around disease awareness building. And we have begun to do piloting and early investments, particularly in Peyronie's, through our online campaign, Ask About the Curve. And it's, of course, too early to fully realize the benefit from it or fully conclude what the benefits will look like. But the early signs of web click-throughs and patient interest in going on to our site of physicians selected, for example, substantial uptick in that, right? Now, clearly, for a product like this, the cycle from the time you get a patient interest in the product or interest in going to physician, to the time that he would have a first injection could be 6 to 9 months, right, which is why we always pointed to the back half of this year '17 before we really begin to see the benefit from it. And the third thing I would say is, and this is probably more so true for Dupuytren's contracture than Peyronie's, is the need to make a compelling argument around the pharmacoeconomic benefits of a intervention like XIAFLEX versus surgery. And that's more of a opportunity for us in Dupuytren's contracture, where the hand surgeons who treat the condition often see surgical option as a -- as the first option. And we've, of course, had very good success with the product with these physicians. But getting to the next level is going to require making an even strong argument around why this is the best interest of patients."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellem with Piper Jaffray.",14,"And our next question comes from the line of David Amsellem with Piper Jaffray."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the lat",96,"So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the latest thinking? Or does the patent give you some more wiggle room? And then secondly, on the generics pipeline, and it may be premature to ask this, but beyond the bigger launches for later this year, maybe talk about some potentially significant launches that you think could happen in 2017."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from",450,"Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from 2 different views. There was always a possibility that there could be a file that was issued with the FDA pre-Orange Book patent listing, and that's something where maybe we feel a little bit better about. And typically, what happened is if an application was in at the FDA for several months prior to the Orange Book listing, what you would expect is for a generic competitor to file a Paragraph IV very quickly and then we would have been noticed. That didn't happen from that standpoint. We feel a little bit better. If an application went on file a month or 2, pre-June 28 or shortly thereafter, that's where we're not going to have that visibility. But if we were to get a Paragraph IV, say, today, it would take about 60 to 90 days for an application to be accepted for filing. So we would probably look to be in a 30-month stay, ticking somewhere late fourth quarter. That's the way I would start looking at it. So from that standpoint, we had originally said that we felt good through 2017. We probably will be in a position to say that we feel a little bit good through 2018, but we'll have better visibility around fourth quarter. In terms of the generic pipeline, from a standpoint of where we feel real good about, I think we'd like to focus a little bit on the 505(b)(2) side. I think that's an area of strength of the company, right? So while we haven't disclosed specifics, we do have a series of 505(b)(2)s that are starting to come through to fruition. And frankly, maybe we can talk a little bit more in terms of products that we feel a little bit better about. We had previously talked about 2 505(b)(2)s that we did not shed a lot of light on. We feel little bit better about them now. They are 2 forms of potassium. One is a liquid, and one is a powder form. We have started to receive positive feedback from the FDA in terms of removing unapproved sources. That's going to come to an end, whereby these unapproved sources will have the remainder of 2016 or so to have product into the market. These types of products will show benefit to Par and Endo in 2017. So that's an area that we'd like to focus in on. Thank you."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from David Risinger with Morgan Stanley.",11,"And our next question comes from David Risinger with Morgan Stanley."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair va",171,"I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair value. I haven't had a chance to look at the numbers there. Could you just talk about that, how it was valued and what it was determined to be worth? And then third, in terms of Vasostrict, we saw that you took a recent price increase at the end of July of 20%. Just wanted to get a sense for how much upward potential you have for pricing. It seems like you have a lot of flexibility to raise price, but then again, there may be pushback. I don't really know. And maybe you could also comment on how much of that will be able to flow through. Should we just assume that, that 20% largely flows through to pretax income or not?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we",379,"David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we are using a pull-through method to recognize revenue. So it has been minimal revenue recognition in the first half of the year, so single-digit millions. And the -- we've also been clear that given our launch ramp expectations that we expect the contributions in 2016, in total, to be relatively modest. So we would look to 2017, really as the first year of revenue contributions for BELBUCA, and I would be clear about what those expectations are at the appropriate time. In terms of pricing, and I'll let Paul answer the specific question in retrospect, but I will point out the following, which is, from an overall perspective, the Endo business benefits from volume, not price. And in particular, generics business has predominantly more price pressure than upward price potential. And if any prices -- any price increase that we might be able to take on the true generics part of it as, this is all owned by the price erosion that we see on the base business. Now products like Vasostrict are a little different, in that they are sold on the basis of NDA, although they are sold within Par. But even in those cases, we take a responsible approach to price increases. And just because we have flexibility, does not mean that we will take a price increase. In the case of Vasostrict, the Par has been very thoughtful about how to price the product as the NDA. If we're a life-saving product, it is still in the low hundreds in terms -- sorry, about 125 or so, plus or minus, in terms of what unit costs. And a substantial amount of investment also gone into our Rochester, Michigan facility to support this product and CapEx in excess of $100 million. And from a forward-looking standpoint, our philosophy on price increases will not change, which is that we will be responsible about how we think about it. But Paul, maybe you have a specific commentary on Vasostrict."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and",208,"Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and that we're going to be able to continue to supply the market. And to Rajiv's point, we had to make investments in raw materials, in components and specific equipment for this particular product. We had the CapEx that Rajiv is referring to. And in essence, 20% of our overall CapEx goes into the Rochester facility to keep it compliant. It's a big commitment specifically on this injectable, that product that's a live-saving product. And then in terms of like general price increases and whatnot, I think, again, when you look at the total generics business, in essence, we are a volume-driven company, to Rajiv's point. When you want to look at it as then, as one-off on a product-specific, in the case of this one product, it's true that we have taken some price increases, but they had been responsible. So with that, I'll turn it over to Suky, to talk about the pretax question."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct.",170,"Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct. Ultimately, the restructuring or reorganization that we implemented, ultimately steps up the fair value of many of the assets within our generics business. That is the tax basis of those assets, which provides ongoing and durable cash tax benefit, and also provides flexibility in our ability to move those assets throughout our legal entities without residual tax leakage, which is our policy. We don't talk to specific asset values, but directionally, the way to think about how we value them is on future value based on discounted cash flows of our outlook for each of the products. And that goes into all of our intangible testing as well as our goodwill testing, et cetera. It's same analysis that underpins the valuation and, ultimately, the step-up."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just 2 here. First, Paul, broadening out on [indiscernible] question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry that we've seen in the past, when we factor in a higher",150,"Just 2 here. First, Paul, broadening out on [indiscernible] question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry that we've seen in the past, when we factor in a higher level of new product approvals from FDA, the behavior you're seeing from some of your larger and smaller competitors, et cetera? Or is this kind of similar competitive dynamics than we've previously experienced in the space? And the second question was on the comments on those potassium products. Can you maybe just give us a sense of the size of those opportunities as we think out to 2017? How attractive are these? How large of an end market can we think about? And finally, are there any other 505(b)(2)s, not necessarily the names, but should we think about additional approvals in 2017 that could help revenue?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger, and we're seeing it now with Walmart now being part of the McKesson OneStop, I mean, the consolidation helps put more pressure back on us. B",240,"So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger, and we're seeing it now with Walmart now being part of the McKesson OneStop, I mean, the consolidation helps put more pressure back on us. But, I think from where we stand, we feel good about where -- how we reset the base business. We talked a lot about that in terms of, and I hate referring back to Qualitest versus Barba [ph]. When you looked at our total business, we have -- we've made our decisions. Right now, it gets down to operational execution. And the way that we compete is to execute flawlessly on our R&D pipeline. That's where we're focused right now, R&D execution and quality. These are things that going to set us apart, because clearly, consortiums are getting bigger, and that is going to create some more pressure on all the generic manufacturers. The companies that are going to outperform are going to be the companies that are strong in compliance, strong in service levels and have a pipeline, and those are 3 components that we feel that we're very well positioned on a go-forward basis. Regarding the question on potassium, if I recall, and help me out here, I think we had shown a waterfall bridge about some, maybe the last quarter or so, that we were referring to some unapproved products that were delayed."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified, although we did not identify it as potassium, but now we can, the demand of revenues associated with this",144,"Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified, although we did not identify it as potassium, but now we can, the demand of revenues associated with this product that is pushed out of '16. I would hasten to add, though, that as the removal of the FDA -- sorry, of the products gets pushed out, the possibility of a new generic competition for the product is there at some point, right? So there's a -- it's probably a finite life for potassium chloride. We don't quite know what that is. So I would not automatically assume that the same upside that we moved out of '16 will be there for '17. But clearly, a substantial component of that will materialize in '17."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?",26,"One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think right now we're just prepared to talk about the 2 potassium products.",15,"I think right now we're just prepared to talk about the 2 potassium products."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Douglas Tsao with Barclays.",13,"And our next question comes from the line of Douglas Tsao with Barclays."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program thro",163,"Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program through 2017? And is that lasting to '18? And the just also, I was hoping you could provide some additional color in terms of the comments in the slides that the sort of generics business is going through some of the same dynamics that they were in 2008, 2009. If you could provide a little color in terms of what exactly those dynamics were. And then just in terms of the controlled substances generics business. One of your competitors sort of had a better quarter, similar to you, in terms of the near term, but they did suggest that maybe some of the headwinds would persist into '17. Are you expecting to see that same dynamic play out?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally,",242,"Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally, high level, we are launching somewhere between 25 to 30 ANDAs in 2016. I would say that, that is probably a normal run rate for just the -- for an ANDA standpoint. On top of that, you're going to see the potassium products start to gain some traction. But I would tell you that there's not like a blockbuster Zetia [indiscernible] that I'm pointing to right now for 2017, but we have 25 to 30 launches that are going to make up a good part of 2017. They're all important, and that's the way that we are building out ourselves. So you got to look at the ANDAs. You got to look at the 505(b)(2)s. And then on top of that, we have a very successful and growing injectables business that is still a big part of our future and we'll start to see more benefit of, of that particular segment. And our alternative dosage forms, all coming into play, so. New launches are important, but we're also still driving value through some of our launches that we've seen in 2015 and '16 on the injectables side. So that was the first question. And..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to pump [ph] and there's obviously multiple ideas that Paul and the team will progress in a giv",96,"I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to pump [ph] and there's obviously multiple ideas that Paul and the team will progress in a given time. But we are not going to specifically talk about anything beyond the ones that we have, simply from a competitive standpoint. Paul, I think, the remaining questions are on the dynamics in the market in the 2008 timeframe and in the controlled substance outlook."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was fairly hard because the type of portfolio that we had, which was a, for t",383,"Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was fairly hard because the type of portfolio that we had, which was a, for the most part, a commoditized business. And we had to make certain and tough decisions based upon how we started looking at products on a go-forward basis. And we were also a little bit on the volume side versus a value side. And we made a conscious decision to start to look towards more difficult-to-make products. Now that's something that we've executed very, very well on, and that's where we're looking at our total portfolio. Now immediate-release products are always going to be important to Par, right? And that's going to help build volume incentives for wholesalers. But we're looking for longevity, and that's why you're going to see us move more towards the alternative dosage forms, the injectable forms and continue with the Paragraph IV side. That is a key difference from today versus where we were back in 2008. The challenge that we have today is the consortiums. The consortiums have gotten bigger and stronger, and that goes right back to having the execute on, on the earlier statement that I made, is the companies that are going to survive and do well are the companies that going to have compliance across-the-board, something that we've done very, very well. We spend an enormous amount of resources in CapEx and to compliance, service levels and execution on the R&D side. And there was a question on controlled substances. So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think, with the consortiums getting larger, they have allowed some new players to come into market and get quota. We talked about this in the past. Still an important part of our business, but it is more of a base business play as I see it, right? So it's important, but it's not the growth driver that it had been previously for a number of years. But again, for Par, every product's important. Just doesn't have the barrier that it once had."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Do you expect some of the headwinds to persist into next year?",12,"Do you expect some of the headwinds to persist into next year?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","In -- specifically in pain?",5,"In -- specifically in pain?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Controlled substances.",3,"Yes. Controlled substances."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion, that natural erosion across-the-board, right? Now what",127,"Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion, that natural erosion across-the-board, right? Now what you're going to see is an uptake in other pain medications, right? Those are things that we also have to take into consideration. So I'm not going to say it's an even trade-off, but the scripts have to go someplace, so maybe they're going to be moving away from opioids, but you have to look at our entire portfolio. And we have other products in our portfolio in pain that are outside of opioid. So that's pretty much the way we're looking at it today."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us.",34,"The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is, hey, we thought these products were going to",145,"Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is, hey, we thought these products were going to launch next year, but now we have a lot of certainty and we will be launching these products next year. So I just want to make sure that, that's what I'm hearing. Second, when you talked about the $15 million to $20 million of buying patterns in generics that 2Q pulled out of 3Q, can just tell us which area it was in you break out the business in base, the injectables or the new launch alternatives? So which one was it in? And then third, can you just tell us what the gross margin was for generics for the quarter?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is, there's been a communicat",165,"Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is, there's been a communication to the unapproved sources of liquid and powder that there is a specific timeline that they have to finish up certain amounts of manufacturing and the ability to sell through at a certain point in time. That's going to come to an end in 2016. Now there's going to be a product that will be in the market, but we don't know is exactly the number of units that these unapproved sources will be making up both forms of potassium. That will carry into some period of time. What we're saying now though is, that we have with reasonable confidence that we are going to get the benefit in 2017. Likely, we'll see the benefit in Q1 or Q2."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?",22,"And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","That's our understanding.",4,"That's our understanding."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And that just went out, like in the past month, or this is new news?",15,"And that just went out, like in the past month, or this is new news?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","This has gone out over the last several weeks.",9,"This has gone out over the last several weeks."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Your question on the buying...",6,"Your question on the buying..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of a",148,"Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of allocate it proportionately to our different business units within generics. So base business is roughly around 50% of the total revenues, so I would account for maybe 50% of that $15 million to $20 million in base, and the rest of it across the other portions of our business. And then I think there was another question, on the gross margin, sorry. Yes, so gross margin held up right, right in line with expectations. So we set guidance for full year of generics gross margin in the low 50s, and that's where we ended in Q2. And our outlook remains consistent for the full year."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our next question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward",73,"I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward with things improving? Or do you still view this as, I'll call it cyclical uncertainty that linger as FDA continues to ramp approvals, or a combination of those?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, i",173,"So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, is that the portfolio has been reset, resized, and we had 5% erosion sequentially between Q2 to Q1. And while the major consortium hit is behind us, we still have the right of first refusals, those are normal course. That's still going to come out was from the base business play. So I think we're going to stay with that 5% sequential base erosion quarter-over-quarter throughout 2016. After that happens, and we still feel good, we communicated as we get to 2017 that base erosion should normalize. Normalize was defined as historical Par base erosion. And that's where we were getting to that 10% number, maybe even a point or 2 higher. But about 10% is what we're looking at on a go forward basis as we entered 2017."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","But stable beyond?",3,"But stable beyond?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson and OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enter",88,"If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson and OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters into OneStop. That's also something that we need to think about. But at this point in time, taking that into consideration, we still feel that, that 10% will be the right erosion factor on a go-forward basis."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay, great. And then, Suky, just a quick question for you, on mesh. For, on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys a",52,"Okay, great. And then, Suky, just a quick question for you, on mesh. For, on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys are thinking about those?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is",109,"Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is ultimately embodied in a low single-digit tax rate for 2017. So we do expect to see a cash tax rate for 2017. So we do still expect to see a post-tax mesh cash call, which is significantly lower than $600 million to $700 million. So nothing has changed on that front. And then on the remaining 8,000 cases..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which, largely spea",212,"Yes. I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which, largely speaking, is not, where we're largely speaking, does not have much information about these cases. And that has not changed. And the incidents of new claims coming in has also been -- has trickled down to a, to the low single digits on a weekly basis, and it's been fairly consistent for the last several months. The other thing we pointed out, with those 8,000 cases was that there was a potential fraudulent scheme that was running through some components of that, and our priority was driving that to ground and figuring out whether in fact that there was fraud perpetrators. So we have a series of subpoenas that have been issued. We are able -- we are in litigation mode around those subpoenas. But as we pointed out, back in the beginning of the year, this process, it would take months, if not several quarters, to resolve. And we continue to defend ourselves through this process. So in other words, no new news, in terms of mesh."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna.",13,"And our next question comes from the line of Andrew Finkelstein with Susquehanna."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run",103,"I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run rates for some of the branded products in the quarter, is there anything else to point out? You talked about the destocking on XIAFLEX. But some products like LIDODERM and OPANA, how do you characterize the sales for those in the quarter relative to what you might consider a run rate, based on where the scripts are?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Paul, you want to...",5,"Sure. Paul, you want to..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some of the other earnings call. It is true that we do have an exclusive",100,"So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some of the other earnings call. It is true that we do have an exclusive arrangement with a single API source, and it is understood that there are multiple API sources available. And ultimately, we are prepared to vigorously defend our intellectual property and also our position in respect to this particular case. So that's probably as far as we can go at this point in time."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that to say that you do not have exclusive arrangements with the others?",14,"Is that to say that you do not have exclusive arrangements with the others?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think what we said is that we do have a single, exclusive arrangement with an API source.",18,"I think what we said is that we do have a single, exclusive arrangement with an API source."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are a",278,"And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are able to benefit from the performance in those brands. So there are brands like LIDODERM, which, as a branded product, has now really been reduced to a small component, because the product is, as far as we are concerned, fully genericized with 3 generic competitors in the market, including our own Authorized Generic. But from a contracting standpoint, we still hold some proportion of the market on our branded product. But clearly subject to generic pressures. OPANA, we pointed to OPANA as one of the products that was impacted by the CDC guidelines and the general slowdown in the opioid market, and I think that trend is continuing along the lines that we expected. But we also have a series of smaller products that we don't talk much about, that are also doing quite well, that are promoted. SUPPRELIN L.A. has been a very sticky and very good performance for us for a long period of time. NASCOBAL, which is a product that came over with the Par transaction and is a branded product that's promoted by our field force, is also doing quite well, right? So as we look across the portfolio, in the branded business, beyond the ones that we actually talk about, we do see points of good performance, which we would -- just helped us in Q2 and we expect to help us over the course and remainder of the year as well."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how you think about the market?",67,"Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how you think about the market? Where is the market competition mainly in compounding pharmacies? Just kind of curious if you have any thoughts there, that'd be great."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basical",122,"Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basically sold and promoted exactly the same way. They just want it as a first-line or on a second line. With respect to the uptick, right now, we did -- we took an appropriate price increase. It is an NDA. We follow the same practice in terms of it being an unapproved product. It is now an approved 505(b)(2). So it's similar in nature into what we've done with Vasostrict, but for the fact that there are unapproved sources of adrenaline on the market today."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that",120,"One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that you're expecting, and then something more easier to volume and you're just benefitting from that recent price increase? And for Suky, can you talk a little bit about what you see as some of the key detractors sequentially, with regards to the third quarter revenues? Looks like a fairly strong downtick. I know that the wholesale volume is not going to recur, but what other items you're expecting to go the other way, to go negative?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last",139,"So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last quarter or 2, you're seeing standard run rate for Vasostrict. So I think we've met our max on the volume side of Vasostrict. So that's where we are now. As Rajiv indicated, we took a modest price increase. That's the way this product is going to behave on a go-forward basis. So I think we've maxed out on the volume side. And it's just being able to navigate with the market, and if we are to take appropriate price increases on a go-forward basis. But we haven't made any determinations yet."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter",288,"Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter, specifically around timing that could be material to the quarter. But on a whole year basis, they're not meaningful. But having said that, given our reset in Q1 and given the launches that we've got in fourth quarter, we are providing quarterly guidance at least for this year. For the third quarter, the way to think about the step-down is, one, you talked about already, which is the stocking that we saw in the second quarter. Our assumption is that reverses in the third quarter. Also, what underpins our assumption of the step-down is continued erosion in retail as that continues to face competition from a generic standpoint. We would expect LIDODERM to step down modestly. Our testosterone products continue to decline quarter-over-quarter, particularly because of the market. And then, again, we also expect to see some modest decline in our pain products. All of those declines are partially offset by growth in XIAFLEX and BELBUCA as well as Par launches. But net-net, our assumptions lead us to a decline on revenue into the third quarter. From an investment standpoint, that's all coming in the backdrop as we increase our investments against generics R&D as well as branded R&D and BELBUCA and XIAFLEX, as Rajiv has talked about earlier. So those are the moving parts that lead us to the third quarter. Again, what we're doing is taking a very prudent approach of applying quarterly guidance, given the lumpiness of the year."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?",16,"That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains.",30,"At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Donald Ellis with JMP Securities.",14,"And our next question comes from the line of Donald Ellis with JMP Securities."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions o",45,"Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions of narcotics?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The -- as you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being sai",155,"The -- as you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being said, I think the -- to the public health environment debate around this, FDA dialog around this, while encouraging abuse deterrent formulation, it's still unclear at what point the entire market will shift to products that are ""abuse deterrent"" right? So the, in terms of the FDA's own determination of what constitutes it does in a lot of debate. We don't have a crystal ball, and we'll be speculating. But, with certainly, as we look forward, on a longer-term perspective, one would think that the long-acting products would transition to more abuse deterrent formulations, but is that going to happen in the short term, that is anyone's guess."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","How do you think if they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?",25,"How do you think if they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this, and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet",137,"Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this, and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet needs in the country. There are 100 million patients who suffer from chronic pain, and there are certain categories of pain, such as cancer pain, that you are going to need an opioid in order to survive and manage that kind of pain, right? So I think, in the end, from a pure patient need standpoint, we do believe that the opioid, schedule 2 opioids will have a place in the market for that. Now from a pricing standpoint, and how PBMs [indiscernible] versus regulators, that I really can't answer."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage p",264,"Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage points more. But I just wanted to make sure that applies to the entire generic book of business or just my assumption would be that the injectable piece, of course, would be much more stable, and that rate would sort of apply to the solid dose business, but I wanted to confirm that. And then for Suky, question earlier was asked about sort of the ability to realize price increases on Vasostrict. And just trying to get a better sense of how we should be thinking about the company's ability to sort of realize those price increases, whether or not there's been any change in that the relative realization rate, in terms of what's actually dropping to the pretax line. And then, last question for Rajiv. You talked several times now about accelerating investments and continuing to invest both the additional resources on the R&D, and then selling the marketing side, to drive some of your future high-growth assets. And obviously, the message has been heard loud and clear with respect to '16. But I guess, in sort of thinking about external expectations in '17, '18 and kind of beyond, it seems like the anticipation at this point is that spend levels remain relatively flat. I'm just kind of wondering, how you're thinking about maybe that, maybe just in general terms, at least directionally."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that, that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And tha",122,"Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that, that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And that includes our extended-release solid oral dosage, our immediate-release solid oral doseage, in our pain controlled substances group. So it excludes injectables. It excludes the alternative dosage forms and, of course, new products. So that's the way we're defining it. And maybe you can just help me out on your Vasostrict question. I want to make sure I understand it. I know when to, to Suky, maybe you could just repeat that for us."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize, on that [indiscernible] increase, let me get a sense of how much involves the pretax line?",47,"The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize, on that [indiscernible] increase, let me get a sense of how much involves the pretax line?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now.",37,"Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now the, in a very good",198,"And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now the, in a very good position where we have some great assets across all of our businesses. And as we transition our business to really being an organic growth story, it is a very important imperative for us that we begin to really invest for future sustainable organic growth. And so hence, the investment step-up that we're talking about in R&D, hence the investment behind, as like XIAFLEX and BELBUCA that we think are going to be real growth drivers over the course of the next 5 years. At this point, we can't make any comment on investment levels in '17 or '18. But I would point to the fact that what we're talking about is investing in long-term growth assets, right? So long-term growth assets require long-term investment, and that's our philosophy. And obviously, we'll take a more specific view on what that means for '17 and beyond when we said that."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict.",168,"One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict. Are your wholesaler contracts structured pretty typically, where they have a 30-day buy-in, so you'll see 2/3 of the price increase in 3Q, and then the full amount in 4Q? And then, could you actually give the XIAFLEX file shift and the breakdown in Perrone's and Dupuytren's for 1Q and 2Q? And then lastly, the strength in, well also for the guidance where you maintain the guidance that you have this added expense in BELBUCA and XIAFLEX. So what's making -- I was a little bit confused about how you're maintaining this. Is it from the strength in the quarter, and the surprise in V Gel, and other products that's allowing you to maintain the guidance or where is that offsetting strength coming from?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the, about the patent cases, the rulings",60,"Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the, about the patent cases, the rulings and our path forward there, is that accurate?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just asking yes, if you saw a share shift because of the ...",15,"I was just asking yes, if you saw a share shift because of the ..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Share shift. I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt.",37,"Share shift. I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes, and I was just wondering if there was any upside from where you thought kind of ...",18,"Yes, and I was just wondering if there was any upside from where you thought kind of ..."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Look if there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the oth",107,"Look if there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the other hand, you have the declining opioid market effect, right. So net-net. It is not a product where we expect to see any substantial uptick. The -- you had a question on XIAFLEX. So in terms of XIAFLEX vials. And I'm happy to go through them, but they are, in our FAQs for the first quarter as well as second quarter."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","We can do it offline, if -- sorry, go ahead.",10,"We can do it offline, if -- sorry, go ahead."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being increased investment in R&D and sales and marketing, so some of it",89,"Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being increased investment in R&D and sales and marketing, so some of it, as Suky mentioned in his script, is simply reallocation, and some of it is a modest uptick in our investment level, particularly in the third quarter, which is one of the other contributing factors to how we guided the third quarter."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was i",74,"I was just asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was it the strong quarter, where you got strong V Gel and other products, or is there something else going on where you're allowed to maintain your guidance?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well.",39,"Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And the last one I had was the bid about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the pric",62,"Okay. And the last one I had was the bid about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the price increase in the quarter, you take the price and then the full amount in 4Q?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointe",61,"No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointed to the overall price increase benefit generally is in the mid-single digits for our branded portfolio, on a full year basis."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our last question comes the line from Irina Koffler with Mizuho.",12,"And our last question comes the line from Irina Koffler with Mizuho."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","It seems like your flags is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. you guys are doing a great job with those 2 products.  But are you really the best owners of these assets? Do you have the right synergie",58,"It seems like your flags is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. you guys are doing a great job with those 2 products.  But are you really the best owners of these assets? Do you have the right synergies? And would someone else potentially value these assets more?"
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets, both [indiscernible] is a type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The",115,"So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets, both [indiscernible] is a type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The type of support, in terms of advertising and promotion that's required around the brand, even with the step-up, is well within the means of a company like us. And also, when you look at the R&D pipeline and the investments that are required to develop XIAFLEX, which is already a well-characterized molecule from a safety and effectiveness standpoint, we do think we are the right owner of these assets."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon.",18,"Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon."
28071,375875901,1030437,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ms. Ker",53,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to introduce your host for today's conference, Ms. Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",240,"Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceutical. 
We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials, including our Frequently Asked Questions document, are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K we are furnishing with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our second quarter 2016 earni",767,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our second quarter 2016 earnings presentation. To start, here is a brief agenda for today's call. 
Moving to Slide 3. The second quarter was a busy and productive one for us at Endo. I am pleased that we delivered solid revenue and adjusted earnings per share results in the second quarter, with revenue performance across all business units broadly in line or ahead of company expectations. We also made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. We have made an important addition to the management team, made good progress on key growth drivers and progressed our ongoing legal entity reorganization, which provides us with operational flexibility and benefits. Suky will talk about this reorganization in more detail later in the call. Against the backdrop of this progress, we are taking steps to increase investments in our future organic growth drivers, branded and generics R&D as well as BELBUCA and XIAFLEX promotional efforts. Importantly, we are pleased to affirm our full year 2016 revenue and adjusted EPS guidance despite these additional investments. 
On Slide 4, you will see a snapshot of our solid segment results for the second quarter. 
Moving to Slide 5. Let me discuss in further detail how we remain focused on operational execution and achieving our key milestones. We announced the appointment of Joe Ciaffoni as our new President of the U.S. Branded business. We are delighted that Joe has joined Endo, bringing his proven expertise in launching and growing branded products and look forward to his contributions when he assumes his new post later this month. 
We continue to drive growth in our generic sterile injectables products, and our Generics Base business is performing right in line with expectations we communicated to you in May of this year. We secured a patent for our largest product, Vasostrict, and continue to launch differentiated generics products and file new ANDAs with the FDA. 
In our international business, we filed our BELBUCA submission and secured rights to XIAFLEX in Canada. And we have also advanced our branded R&D pipeline and have recently opted into another new potential indication for XIAFLEX, human lipoma.
So on Slide 6, let's discuss our branded business. Our branded performance in the second quarter was broadly in line with our expectations, which underlie our segment revenue and margin guidance provided in May. We drove continued XIAFLEX demand by a broad -- particularly in Peyronie's disease. We are advancing our BELBUCA launch efforts, increasing the total prescriptions to date and growing the number of repeat prescriptions. In the quarter, we also saw better-than-expected results, driven by contracting for the branded Voltaren Gel and performance across some of our other products such as LIDODERM, NASCOBAL and SUPPRELIN LA. 
Moving to Slide 7. Let's take a closer look at XIAFLEX's performance. We are making good progress with this key growth asset, and that is transferring into continued growth. In Peyronie's disease, a market that we think has considerable growth and expansion potential, we delivered nearly 20% demand growth in the second quarter versus the same period last year. We continue to expand our physician/injector base, and our disease awareness campaign, Ask About the Curve, has shown early signs of successfully engaging PD patients. In Dupuytren's contracture, a more mature market and one where XIAFLEX launched more than 5 years ago, we still drove 5% demand growth in the quarter over the second quarter last year. Revenues for the quarter were impacted by greater-than-expected destocking. For the full year 2016, we now expect low double-digit pro forma revenue growth for XIAFLEX. 
On Slide 8, let's move next to International Pharmaceuticals. We continue to drive performance in line with expectations that underlie our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we filed our BELBUCA submission and acquired the Canadian rights to XIAFLEX last quarter. Both products are potential long-term growth drivers for the business, and the additions could provide longer-term growth as we manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our operating margins. 
Now to talk about our U.S. Generics performance, let me turn the call over to Paul. Paul?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thank you, all, for joining us on the call. Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all whi",534,"Thank you, Rajiv, and thank you, all, for joining us on the call. 
Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all while delivering performance in line with our expectations. Our sterile injectables business continues to grow, led by Vasostrict. Importantly, we also secured a patent for that product that does not expire until 2035 and which we believe further strengthens our market position. In our new launches in alternative dosage segment, we've launched 11 products since the beginning of the year and continue to file new ANDAs with the FDA while replenishing our R&D pipeline. As we expected and in line with trends consistent across the broader generic industry, our base business declined by approximately 5% sequentially from first quarter 2016, driven by consortium pricing pressures in competitive generic entrants. Finally, our adjusted gross margin for the generics business remained in line with expectations. I would like to note that second quarter revenues benefited modestly from some favorable timing between Q2 and Q3, driven by customers advancing some of their orders ahead of the 4th of July holiday. 
Moving on to Slide 10. I'd like to provide you with an update on the action plan that we outlined last quarter to drive long-term growth across our generics portfolio. While I won't go into the detail on each of these items, I do think it's important to note that we are in progress, on track or have already completed all the core components of our action plan. For example, we continue to make progress on key growth drivers like our 505(b)(2) in sterile injectable programs as well as launching a steady stream of new, differentiated products this year. We're also reprioritizing and accelerating our R&D pipeline. We've already rationalized numerous lower-value projects as part of our restructuring and are on track to file approximately 25 to 30 new ANDA submissions in 2016. We made progress on our accelerated restructuring plan for the generics manufacturing network and continue to project approximately $60 million in annual net run rate savings to be fully realized by fourth quarter 2017. We've largely completed the transition of the legacy Qualitest business onto the Par platform, including commercial insight, forecasting, wholesaler data management and other capabilities. And finally, we are executing on our operational plan. We have delivered a second quarter that is in line with the expectations that underlie our guidance for revenue and adjusted margins previously communicated in May.
So let me talk briefly about our product launches to date and those anticipated for the remainder of the year. 
On Slide 11, you'll see a familiar chart. We have updated it to show all the products we have successfully launched so far in 2016. You can also see those products that we expect to launch into the marketplace in the second half of the year. Importantly, we are on track for our November and December 2016 launches of generic Seroquel XR and generic Zetia. 
With that, let me turn the call over to Suky to discuss the financial performance of the company in the quarter and our projected outlook. Suky?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good afternoon, everyone. Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance",1080,"Thank you, Paul, and good afternoon, everyone. 
Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance and Disclosure Interpretations or C&DI guidance in May. Endo has adopted these guidelines and, as a result, is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. This policy has no impact on Endo's historic or forward-looking GAAP tax or cash tax profile. Also, the initiation of a legal entity reorganization in the first quarter has limited the impact of this change on our adjusted effective tax rate for the year and moving forward. 
Moving to Slide 14, we provided more detail about the legal entity reorganization that I just mentioned. As part of the continued integration of our Qualitest and Par businesses, we initiated a legal entity reorganization that moves the generics business to a new U.S. holding company structure that is separate from the legacy branded business structure. The reorganization provides operating flexibility and benefits while also reducing the potential impact related to future limits on the use of tax attributes by utilizing most of our attributes to offset an intercompany gain. As a result of this reorganization, the tax bases of U.S. Generics business assets have been stepped up to their fair value, which will provide ongoing cash tax benefit and flexibility in moving assets with limited tax leakage. The utilization of acquired attributes that I mentioned earlier would have had an unfavorable impact of approximately $160 million on our full year adjusted tax expense under Endo's non-GAAP policy prior to the adoption of the SEC's C&DI. The elimination of this acquired attribute benefit was offset by an improved mix of jurisdictional adjusted pretax income resulting primarily from the reorganization. This reorg also gave rise to a discrete net GAAP tax benefit of approximately $450 million in the second quarter from outside basis differences. This benefit has been excluded from our adjusted effective tax rate in accordance with our policy. 
As I talked about earlier, as a result of the SEC's C&DI, Endo is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. However, since we utilized almost all of our tax attributes through the legal entity reorganization,  the implementation of the updated C&DI guidance is not expected to have a material impact on our 2016 and forward-looking adjusted tax rate. Endo continues to project an adjusted effective tax rate of 0 to 2%, as guided in our first quarter 2016 earnings announcement. We expect to have a GAAP tax benefit and a negative cash tax rate for 2016. Importantly, for our outlook for 2017 and future years, we expect our adjusted effective tax rate to be in the high single digits to low double digits and our average cash tax rate to be below 5% over the next 5 years. 
Next, on Slide 15, you will see a snapshot of the second quarter GAAP and non-GAAP financial results. Rajiv covered company and segment revenues earlier, so I will not review that here. 
On a GAAP basis, we delivered earnings per share of $1.75 in the quarter versus a loss of $0.49 in the second quarter of 2015. 2016 second quarter GAAP results were driven by an operating loss of $48 million, offset by the tax benefit that I discussed earlier. Tax benefit also offset the impact of a higher share count in 2016. 
Our GAAP operating loss was largely impacted by a decrease in gross margins due to a higher mix of generic revenue in the second quarter compared to 2015 and due to incremental amortization expense associated with the stepped-up value of intangible assets from Par. On an adjusted basis, overall Q2 results are slightly better than previously guided. 
To summarize the points Rajiv and Paul made, revenue was better than expected due to sterile injectables, stronger-than-expected performance from a number of branded products and a modest timing benefit related to quarter-end buying patterns. Adjusted net income and EPS are better than guided as a result of higher revenues discussed earlier. 
On Slide 16, while the second quarter was ahead of our guided expectations, we are maintaining our guidance ranges, as some of the upside in the second quarter was driven by favorable timing. As Rajiv mentioned, we are also going to invest at a higher level than originally planned in our key growth drivers in the second half of the year through a reallocation of operating expenses and a modest step-up in spending. 
Regarding the cadence of revenues and adjusted earnings in the second half of the year, we continue to project the fourth quarter to be disproportionately larger than the rest of the year's quarters due to the launch of the generics Seroquel and Zetia. For third quarter 2016, we expect revenues in the range of $830 million to $870 million and adjusted earnings per share of $0.77 to $0.82. This implies a sequential step-down in third quarter of 2016. The anticipated decline is driven by the product order timing benefits in the second quarter that we expect to reverse in the third quarter, lower U.S. branded sales related to generic competition for Voltaren Gel, continued slowing in the testosterone market, continued declines in legacy pain products and an increased investment in R&D as well as XIAFLEX and BELBUCA promotional efforts. 
Moving to cash and liquidity on Slide 17. On a year-to-date basis, GAAP cash flow from operations totaled approximately $555 million. We have also highlighted some of the material moving parts that have impacted our reported or GAAP cash flows for the year. 
On Slide 18, we are reiterating our view on cash available to pay down debt in 2016. We continue to project debt pay-down of approximately $250 million in 2016 and to exit the year at a mid- to high 4x net debt to pro forma adjusted EBITDA leverage ratio. As noted in our press release, we ended the quarter with approximately $670 million in unrestricted cash and approximately $390 million in restricted cash and a net debt-to-leverage ratio of approximately 4.6x. 
To summarize, we are encouraged by our second quarter financial results and pleased to affirm our full year outlook while increasing investment in key growth drivers. 
Now to close out the call, let me turn it back over to Rajiv. Rajiv?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. W",310,"Thank you, Suky. 
Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. We are continuing to optimize our team and our business to achieve their growth potential while also managing our diversified portfolio of other products. We are also accelerating our R&D pipeline to advance those programs and the time lines for their potential market entry. We continue to execute on these growth drivers in the second quarter and expect to achieve additional key milestones through the end of this year and beyond. 
On Slide 21, let's recap the key achievements in our U.S. Generics business. We are focused on driving growth through our differentiated, higher barrier-to-entry products like sterile injectables and our robust pipeline of more than 250 programs for restructuring. We have a diversified reset base business and a robust, highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they continue to execute on these opportunities. 
Let's briefly summarize our call today on Slide 22. In Q2, we delivered solid top and adjusted bottom line results, beating our Q2 adjusted results guidance. We made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. And we are affirming our full year 2016 revenue and adjusted EPS guidance while increasing our investment in branded and generic R&D and BELBUCA and XIAFLEX promotion. Endo is executing on our strategic priorities, and we continue to believe that this is a time of significant opportunity for the company, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] 
Operator, may we have the first question, please?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Louise Chen with Guggenheim.",13,"And our first question comes from the line of Louise Chen with Guggenheim."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have",78,"So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have any update on the divesting of the non-core assets to pay down debt. And the last thing is, are you seeing any stabilization in your Qualitest business?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you mig",369,"Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you might recall, we had a very robust growth in the first quarter. We have seen a little bit of a slowdown in Dupuytren's contracture in the second quarter. But as we look out over the remainder of the year, we do feel confident in the double-digit growth trajectory that we have talked about. Now in terms of the revenue profile, as you know, customer stocking is largely out of our control, though, typically, XIAFLEX stocking in the specialty distributors and the specialty pharmacies, in general, is around 14 days, about 2 weeks. But from time to time, we do see some unusual changes to it, which is what happened in the second quarter. Our stocking is around 1 week, so approximately half of what it typically is. Now we have seen this behavior in the past, and typically, over the course of the year, it tends to normalize. But by and large, it is out of our control. So what we look to is demand while growth. And that's where when we look at the 19% growth in Peyronie's, we do feel very good about this indication, given that from a longer-term perspective, for our on-market indications, the biggest opportunity is in Peyronie's. In terms of divestments of non-core assets, I just wanted to be clear that from a company perspective, we don't feel compelled to divest any assets. We are confident in our business and the natural delevering nature of the business, given the -- our substantial cash flows, particularly as we look beyond the known mesh payments in '16 and '17. That being said, I think we've also been clear that as a company and as a board, we are always -- we are shareholder-friendly. And when there are any opportunities that come our way that are value-creating, we will certainly evaluate them on a -- our standard basis. Paul, maybe you can comment on the Qualitest business."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But maybe high level, when you look at the Qualitest business for the most part, it's really known as a base business play. W",141,"Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But maybe high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When you look at our base business play, we define that as the pain-control substances as well as the oral extended-release and immediate-release products. That also includes some of the Par portfolio. When you look at that on a quarter-over-quarter basis, we communicated this at our last earnings call, that we were anticipating about 5% erosion quarter-over-quarter, and that's exactly where we landed. So it's in line with our expectations and how we communicated. So generally, our base business is falling in line, and we're not seeing the heavy erosion that we realized in Q1."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being consider",88,"I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being considered at this point. And, Paul, can you confirm that there have been no P4 certifications on Vasostrict since you got that patent issued? Can you quantify the stocking benefit for your business? And can you comment on whether you have an ephedrine filing and/or a program in the works?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to be opened, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery",112,"Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to be opened, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery around that. And again, what -- as I've said in the past, our board is always open to shareholder-friendly, strategic opportunities, and we will remain open to such opportunities as they come our way. But really, our focus now is on the operations of the business. So let me just turn to Paul. I think there were 3 parts of that question, Paul, with stocking and ephedrine."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted al",118,"So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted all the unapproved product to approved product. So we're really normalized in that regard. And then, Greg, I think your last question was on ephedrine. And I think what we can say right now is in case of any product, that we are -- essentially not our policy to discuss any product that we don't already disclose into our corporate presentations at this point in time, Greg."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry.",27,"And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million",51,"Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million to $20 million in revenue."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Annabel Samimy with Stifel.",13,"And our next question comes from the line of Annabel Samimy with Stifel."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's",82,"I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's shaping up for 2017 in terms of reaching your delevering goals of being under 4x in 2017? And can you still satisfy with -- that with some of the mesh payments that you're still seeing?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile and our expectations.",24,"Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile and our expectations."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So regarding the -- really, what we refer to as the restructuring of the operations -- there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual",118,"Sure. So regarding the -- really, what we refer to as the restructuring of the operations -- there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run rate that we anticipate for fourth quarter 2017. We've made some difficult decisions that we've talked about regarding the Charlotte and the Huntsville facilities with respect to -- in terms of employees and synergies. Those decisions have had essentially 3 waves to them, and we've executed on wave #1. And we are on track to meet the expectations that we've communicated. So, so far, we are executing on the plan."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that having -- I'm sorry, is that having any revenue and EBITDA impact right now?",16,"Is that having -- I'm sorry, is that having any revenue and EBITDA impact right now?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Nothing above what we've already talked about on our first quarter call, with part of the restructuring, Annabel. It's already baked into our guidance.",25,"Nothing above what we've already talked about on our first quarter call, with part of the restructuring, Annabel. It's already baked into our guidance."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. Sorry. And then if you can just talk about the leverage. Sorry.",13,"Okay. Sorry. And then if you can just talk about the leverage. Sorry."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the f",167,"Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the first quarter call. So we're not putting specific timing around that. And then I think the offshoot to your question was something around mesh. And what I would say there is, as of the second quarter, we had just below $1.6 billion accrued on the balance sheet, with just below $400 million in restricted cash. So that's essentially money that's already out the door for funding of mesh, which leaves an incremental or remaining $1.2 billion on a pretax basis. We expect that $1.2 billion to be serviced as another $300 million to $400 million in the second half of this year and then somewhere around $600 million to $700 million on a pretax basis in '17."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Stephan Stewart with Goldman Sachs.",14,"And our next question comes from the line of Stephan Stewart with Goldman Sachs."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns.",34,"Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Suky, do you want to...",5,"Suky, do you want to..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, w",48,"Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, will be primarily volume-driven."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts",",Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?",40,",
Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The trends continue, Stephan, so they have -- we have seen continued pressure in terms of prescription volumes in the opioid space. I mean, if you look at the branded space alone, new prescriptions in the branded vol are down double digits since the annou",96,"The trends continue, Stephan, so they have -- we have seen continued pressure in terms of prescription volumes in the opioid space. I mean, if you look at the branded space alone, new prescriptions in the branded vol are down double digits since the announcement of the CDC guidelines, but that is all incorporated -- it was incorporated into our forward-looking guidance in May. And we don't have a different view in terms of the full year. We will, of course, take stock when we think about '17 later on this year or early in 2017."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Gary Nachman with BMO Capital Markets.",15,"And our next question comes from the line of Gary Nachman with BMO Capital Markets."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA",47,"Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA going forward?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But certainly, in terms of defense of the branded products, we've had better-than-expected success with c",119,"Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But certainly, in terms of defense of the branded products, we've had better-than-expected success with contracting that we've done with the commercial plans, and that's largely speaking what's helped us in the first part of the year. Now as you know, we have authorized the launch of Voltaren Gel AG through Par, and that is taking place as we speak. And over the course of the year, we do expect the Authorized Generic to take more share of the overall molecule. And then, Gary, your second question, I just -- if we can..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","BELBUCA.",1,"BELBUCA."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are.",15,"BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product",308,"Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product beyond just the overall environment in opioid, one is the process of getting the physician community comfortable with the tapering and titrating requirements in terms of switching patients between different opioids and onto BELBUCA. And secondly, it's around the payer environment and how they see the Schedule III products. So on the latter, we made good progress. At this point, we have contracted roughly around 85% of commercial lives, and about 70% of that at -- without any restrictions beyond the label, we expect to continue to improve that over the course of the year. But, of course, at this point, in a launch of a product like this, we don't yet have government reimbursement. But what we see as being the real opportunity is the pharmacoeconomic and public health argument for why a Schedule III product like BELBUCA is preferable to other opioids such as the Schedule II products in terms of where it is introduced in the treatment algorithm. And a lot of the investment that we are now making is around improving our fact base in terms of making those market access arguments. Clearly, we still continue to have a large investment from a field force standpoint, and that continues. We're also increasing our investment around physician education, particularly around the treatment and titrating of the product. But really, the upside benefit and the longer-term growth of the product is really predicated on us being able to really anchor buprenorphine as a effective and safe alternative in the opioid space, both on a peer standpoint as well as from a physician standpoint."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Liav Abraham with Citi.",13,"And our next question comes from the line of Liav Abraham with Citi."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be intereste",81,"First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be interested in your thoughts on how you see the growth trajectory evolving post 2016, if possible, and perhaps you can touch on any updates on reimbursement and physician training and how you feel about ongoing double-digit file growth post 2016."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Paul, do you want to talk about the generics environment question?",11,"Paul, do you want to talk about the generics environment question?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition on how we feel about the consortium. At the end of the day, we've got our",163,"Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition on how we feel about the consortium. At the end of the day, we've got ourselves 4 large consortiums. They're representing around 90%. And we're going to have to still compete with Teva head-on as we would in any case. And typically, you want to just be very careful about trying to go after too much share. Just got to take a balanced approach. So I envision that we're strong competitors. Teva's a strong competitor. Even with the portfolio getting larger, we need to execute on our plan of bringing new products into the marketplace. And I don't think the fact that they've got the Actavis portfolio has a negative impact to Endo Par if that -- If that, in fact, is your question that you're trying to allude to."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as",455,"Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as potential in the on-market indications. That being said, we have -- we will not be making any particular prediction around '17 and beyond. But I would say that we are very optimistic when we look at the current results that we are seeing in Peyronie's disease, which we think is the great opportunity for the 2 -- of the 2 on-market indications. And there are 3 areas in which we have made promotion investments and we expect to step up for the remainder of the year as well as going into '17, and they will be the following. One is an area which we already talked about, which is that we continue to need to make the lives of patients who currently are prescribed the product easy. And then that's mostly around reimbursement support. And we've substantially increased the level of internal resourcing around that as well as targeted third parties to support that. The second is a longer-term opportunity around disease awareness building. And we have begun to do piloting and early investments, particularly in Peyronie's, through our online campaign, Ask About the Curve. And it's, of course, too early to fully realize the benefit from it or fully conclude what the benefits will look like. But the early signs of web click-throughs and patient interest in going onto our site to a physician selector, for example, there's been substantial uptick in that, right? Now, clearly, for a product like this, the cycle from the time you get a patient interested in the product or interest in going to physician, to the time that he would have a first injection could be 6 to 9 months, right, which is why we always pointed to the back half of this year '17 before we really begin to see the benefit from it. And the third thing I would say is -- and this is probably more so true for Dupuytren's contracture than Peyronie's, is the need to make a compelling argument around the pharmacoeconomic benefits of a intervention like XIAFLEX versus surgery. And that's more of an opportunity for us in Dupuytren's contracture, where the hand surgeons who treat the condition often see the surgical option as a -- as the first option. And we've, of course, had very good success with the product with these physicians. But getting to the next level is going to require making an even strong argument around why this is the best interest of patients."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellem with Piper Jaffray.",14,"And our next question comes from the line of David Amsellem with Piper Jaffray."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the lat",96,"So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the latest thinking? Or does the patent give you some more wiggle room? And then secondly, on the generics pipeline, and it may be premature to ask this, but beyond the bigger launches for later this year, maybe talk about some potentially significant launches that you think could happen in 2017."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is",451,"Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from 2 different views. There was always a possibility that there could be a file that was issued with the FDA pre-Orange Book patent listing, and that's something where maybe we feel a little bit better about. And typically, what happened is if an application was in at the FDA for several months prior to the Orange Book listing, what you would expect is for a generic competitor to file a Paragraph IV very quickly and then we would have been noticed. That didn't happen; from that standpoint. We feel a little bit better. If an application went on file a month or 2, pre-June 28 or shortly thereafter, that's where we're not going to have that visibility. But if we were to get a Paragraph IV, say, today, it would take about 60 to 90 days for an application to be accepted for filing. So we would probably look to be in a 30-month stay, ticking somewhere late fourth quarter. That's the way I would start looking at it. So from that standpoint, we had originally said that we felt good through 2017. We probably will be in a position to say that we feel a little bit good through 2018, but we'll have better visibility around fourth quarter. In terms of the generic pipeline, from a standpoint of where we feel real good about, I think we'd like to focus a little bit on the 505(b)(2) side. I think that's an area of strength of the company, right? So while we haven't disclosed specifics, we do have a series of 505(b)(2)s that are starting to come through to fruition. And frankly, maybe we can talk a little bit more in terms of products that we feel a little bit better about. We had previously talked about 2 505(b)(2)s that we did not shed a lot of light on. We feel little bit better about them now. They are 2 forms of potassium. One is a liquid, and one is a powder form. We have started to receive positive feedback from the FDA in terms of removing unapproved sources. That's going to come to an end, whereby these unapproved sources will have the remainder of 2016 or so to have product into the market. These types of products will show benefit to Par and Endo in 2017. So that's an area that we'd like to focus in on. Thank you."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from David Risinger with Morgan Stanley.",11,"And our next question comes from David Risinger with Morgan Stanley."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair va",171,"I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair value. I haven't had a chance to look at the numbers there. Could you just talk about that, how it was valued and what it was determined to be worth? And then third, in terms of Vasostrict, we saw that you took a recent price increase at the end of July of 20%. Just wanted to get a sense for how much upward potential you have for pricing. It seems like you have a lot of flexibility to raise price, but then again, there may be pushback. I don't really know. And maybe you could also comment on how much of that will be able to flow through. Should we just assume that, that 20% largely flows through to pretax income or not?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we",379,"David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we are using a pull-through method to recognize revenue. So it has been minimal revenue recognition in the first half of the year, so single-digit millions. And the -- we've also been clear that given our launch ramp expectations that we expect the contributions in 2016, in total, to be relatively modest. So we would look to 2017, really as the first year of revenue contributions for BELBUCA, and I would be clear about what those expectations are at the appropriate time. In terms of pricing, and I'll let Paul answer the specific question in retrospect, but I will point out the following, which is, from an overall perspective, the Endo business benefits from volume, not price. And in particular, generics business has predominantly more price pressure than upward price potential. And any prices -- any price increase that we might be able to take on the true generics part of it as -- is overwhelmed by the price erosion that we see on the base business. Now products like Vasostrict are a little different, in that they are sold on the basis of NDA, although they are sold within Par. But even in those cases, we take a responsible approach to price increases. And just because we have flexibility does not mean that we will take a price increase. In the case of Vasostrict, the Par has been very thoughtful about how to price the product as an NDA. And, for a life-saving product, it is still in the low hundreds in terms -- sorry, about 125 or so, plus or minus, in terms of what a unit costs. And a substantial amount of investment has also gone into our Rochester, Michigan facility to support this product, and CapEx in excess of $100 million. And from a forward-looking standpoint, our philosophy on price increases will not change, which is that we will be responsible about how we think about it. But Paul, maybe you have a specific commentary on Vasostrict."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and",208,"Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and that we're going to be able to continue to supply the market. And to Rajiv's point, we had to make investments in raw materials, in components and specific equipment for this particular product. We had the CapEx that Rajiv is referring to. And in essence, 20% of our overall CapEx goes into the Rochester facility to keep it compliant. So it's a big commitment specifically on this injectable, that product that's a life-saving product. And then in terms of like general price increases and whatnot, I think, again, when you look at the total generics business, in essence, we are a volume-driven company, to Rajiv's point. When you want to look at it as a one-off on a product-specific, in the case of this one product, it's true that we have taken some price increases, but they had been responsible. So with that, I'll turn it over to Suky, to talk about the pretax question."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct.",170,"Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct. Ultimately, the restructuring or reorganization that we implemented ultimately steps up the fair value of many of the assets within our generics business. That is the tax basis of those assets, which provides ongoing and durable cash tax benefit, and also provides flexibility in our ability to move those assets throughout our legal entities without residual tax leakage, which is our policy. We don't talk to specific asset values, but directionally, the way to think about how we value them is on future value based on discounted cash flows of our outlook for each of the products. And that goes into all of our intangible testing as well as our goodwill testing, et cetera. It's same analysis that underpins the valuation and, ultimately, the step-up."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just 2 here. First, Paul, broadening out on I think Liav's question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry than we've seen in the past, when we factor in a higher l",152,"Just 2 here. First, Paul, broadening out on I think Liav's question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry than we've seen in the past, when we factor in a higher level of new product approvals from FDA, the behavior you're seeing from some of your larger and smaller competitors, et cetera? Or is this kind of similar competitive dynamics than we've previously experienced in the space? And the second question was on the comment on those potassium products. Can you maybe just give us a sense of the size of those opportunities as we think out to 2017? How attractive are these? How large of an end market can we think about? And finally, are there any other 505(b)(2)s, not necessarily the names, but should we think about additional approvals in 2017 that could help revenue?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger -- and we're seeing it now with Walmart now being part of the McKesson OneStop -- I mean, the consolidation does put more pressure back on us",243,"So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger -- and we're seeing it now with Walmart now being part of the McKesson OneStop -- I mean, the consolidation does put more pressure back on us. But, I think from where we stand, we feel good about where -- how we reset the base business. We talked a lot about that in terms of -- and I hate referring back to Qualitest versus Barba [ph]. When you look at our total business, we have -- we've made our decisions. Right now, it gets down to operational execution. And the way that we compete is to execute flawlessly on our R&D pipeline. That's where we're focused right now, R&D execution and quality. These are things that going to set us apart, because clearly, consortiums are getting bigger, and that is going to create some more pressure on all the generic manufacturers. The companies that are going to outperform are going to be the companies that are strong in compliance, strong in service levels and have a pipeline, and those are 3 components that we feel that we're very well positioned on a go-forward basis. Regarding the question on potassium, if I recall, and help me out here, I think we had shown a waterfall bridge about some, maybe the last quarter or so, that we were referring to some unapproved products that were delayed."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified -- although we did not identify it as potassium, but now we can -- the demand of revenues associated with t",145,"Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified -- although we did not identify it as potassium, but now we can -- the demand of revenues associated with this product is pushed out of '16. I would hasten to add, though, that as the removal of the FDA -- sorry, of the products gets pushed out, the possibility of a new generic competition for the product is there at some point, right? So there's a -- it's probably a finite life for potassium chloride. We don't quite know what that is. So I would not automatically assume that the same upside that we moved out of '16 will be there for '17. But clearly, a substantial component of that will materialize in '17."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?",26,"One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think right now we're just prepared to talk about the 2 potassium products.",15,"I think right now we're just prepared to talk about the 2 potassium products."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Douglas Tsao with Barclays.",13,"And our next question comes from the line of Douglas Tsao with Barclays."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program thro",163,"Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program through 2017? And is that lasting to '18? And the just also, I was hoping you could provide some additional color in terms of the comments in the slides that the sort of generics business is going through some of the same dynamics that they were in 2008, 2009. If you could provide a little color in terms of what exactly those dynamics were. And then just in terms of the controlled substances generics business. One of your competitors sort of had a better quarter, similar to you, in terms of the near term, but they did suggest that maybe some of the headwinds would persist into '17. Are you expecting to see that same dynamic play out?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally,",243,"Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally, high level, we are launching somewhere between 25 to 30 ANDAs in 2016. I would say that, that is probably a normal run rate for just the -- for an ANDA standpoint. On top of that, you're going to see the potassium products start to gain some traction. But I would tell you that there's not like a blockbuster Zetia [indiscernible] that I'm pointing to right now for 2017, but we have 25 to 30 launches that are going to make up a good part of 2017. They're all important, and that's the way that we are building out ourselves. So you got to look at the ANDAs. You got to look at the 505(b)(2)s. And then on top of that, we have a very successful and growing injectables business that is still a big part of our future and we'll start to see more benefit of -- of that particular segment and our alternative dosage forms, all coming into play. So new launches are important, but we're also still driving value through some of our launches that we've seen in 2015 and '16 on the injectables side. So that was the first question. And..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to us, and there's obviously multiple ideas that Paul and the team will progress in a given tim",95,"I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to us, and there's obviously multiple ideas that Paul and the team will progress in a given time. But we are not going to specifically talk about anything beyond the ones that we have, simply from a competitive standpoint. Paul, I think, the remaining questions are on the dynamics in the market in the 2008 timeframe and in the controlled substances outlook."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was hit fairly hard because the type of portfolio that we had, which was a, f",280,"Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was hit fairly hard because the type of portfolio that we had, which was a, for the most part, a commoditized business. And we had to make certain and tough decisions based upon how we started looking at products on a go-forward basis. And we were also a little bit on the volume side versus a value side. And we made a conscious decision to start to look towards more difficult-to-make products. Now that's something that we've executed very, very well on, and that's where we're looking at our total portfolio. Now immediate-release products are always going to be important to Par, right? And that's going to help build volume incentives for wholesalers. But we're looking for longevity, and that's why you're going to see us move more towards the alternative dosage forms, the injectable forms and continue with the Paragraph IV side. That is a key difference from today versus where we were back in 2008. The challenge that we have today is the consortiums. The consortiums have gotten bigger and stronger, and that goes right back to having to execute on -- on the earlier statement that I made, is the companies that are going to survive and do well are the companies that going to have compliance across-the-board, something that we've done very, very well. We spend an enormous amount of resources and CapEx into compliance, service levels and execution on the R&D side. And there was a question on controlled substances?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Controlled substances outlook.",3,"Controlled substances outlook."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think, with the consortiums getting larger, they have allowed some new players to come into market and get quota. We talked about",104,"So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think, with the consortiums getting larger, they have allowed some new players to come into market and get quota. We talked about this in the past. Still an important part of our business, but it is more of a base business play as I see it, right? So it's important, but it's not the growth driver that it had been previously for a number of years. But again, for Par, every product's important. Just doesn't have the barrier that it once had."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Do you expect some of the headwinds to persist into next year?",12,"Do you expect some of the headwinds to persist into next year?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","In -- specifically in pain?",5,"In -- specifically in pain?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Controlled substances.",3,"Yes. Controlled substances."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion -- that natural erosion across-the-board, right? Now wha",128,"Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion -- that natural erosion across-the-board, right? Now what you're going to see is an uptake in other pain medications, right? Those are things that we also have to take into consideration. So I'm not going to say it's an even trade-off, but the scripts have to go someplace, so maybe they're going to be moving away from opioids, but you have to look at our entire portfolio. And we have other products in our portfolio in pain that are outside of opioid. So that's pretty much the way we're looking at it today."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us.",34,"The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is ""Hey, we thought these products were going to",145,"Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is ""Hey, we thought these products were going to launch next year, but now we have a lot of certainty and we will be launching these products next year."" So I just want to make sure that, that's what I'm hearing. Second, when you talked about the $15 million to $20 million of buying patterns in generics that 2Q pulled out of 3Q, can just tell us which area it was in? You break out the business in base, the injectables or the new launch alternatives, so which one was it in? And then third, can you just tell us what the gross margin was for generics for the quarter?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communicati",165,"Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communication to the unapproved sources of liquid and powder that there is a specific timeline that they have to finish up certain amounts of manufacturing and the ability to sell through at a certain point in time. That's going to come to an end in 2016. Now there's going to be a product that will be in the market, but we don't know is exactly the number of units that these unapproved sources will be making up both forms of potassium. That will carry into some period of time. What we're saying now though is, that we have with reasonable confidence that we are going to get the benefit in 2017. Likely, we'll see the benefit in Q1 or Q2."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?",22,"And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","That's our understanding.",4,"That's our understanding."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And that just went out, like in the past month, or this is new news?",15,"And that just went out, like in the past month, or this is new news?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","This has gone out over the last several weeks.",9,"This has gone out over the last several weeks."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Your question on the buying...",6,"Your question on the buying..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of a",148,"Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of allocate it proportionately to our different business units within generics. So base business is roughly around 50% of the total revenues, so I would account for maybe 50% of that $15 million to $20 million in base, and the rest of it across the other portions of our business. And then I think there was another question, on the gross margin, sorry. Yes, so gross margin held up right, right in line with expectations. So we set guidance for full year of generics gross margin in the low 50s, and that's where we ended in Q2. And our outlook remains consistent for the full year."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our next question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward",75,"I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward with things improving? Or do you still view this as, I'll call it cyclical uncertainty that's going to linger as FDA continues to ramp approvals, or a combination of those?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, i",176,"So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, is that the portfolio has been reset, resized, and we had 5% erosion sequentially between Q2 to Q1. And while the major consortium hit is behind us, we still have the right of first refusals, those are normal course. That's still going to come at us from the base business play. So I think we're going to stay with that 5% sequential base erosion quarter-over-quarter throughout 2016. After that happens, and we still feel good, we communicated as we get to 2017 that base erosion should normalize --  and ""normalize"" was defined as historical Par base erosion. And that's where we were getting to that 10% number, maybe even a point or 2 higher. But about 10% is what we're looking at on a go forward basis as we enter into 2017."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","But stable beyond?",3,"But stable beyond?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters in",87,"If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters into OneStop. That's also something that we need to think about. But at this point in time, taking that into consideration, we still feel that, that 10% will be the right erosion factor on a go-forward basis."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay, great. And then, Suky, just a quick question for you, on mesh. For -- on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys",53,"Okay, great. And then, Suky, just a quick question for you, on mesh. For -- on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys are thinking about those?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is",109,"Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is ultimately embodied in a low single-digit tax rate for 2017. So we do expect to see a cash tax rate for 2017. So we do still expect to see a post-tax mesh cash call, which is significantly lower than $600 million to $700 million. So nothing has changed on that front. And then on the remaining 8,000 cases..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which,",215,"Yes. So Randall, I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which, largely speaking, is not, where we largely speaking do not have much information about these cases. And that has not changed. And the incidence of new claims coming in has also been -- has trickled down to a, to the low single digits on a weekly basis, and it's been fairly consistent for the last several months. The other thing we pointed out with those 8,000 cases was that there was a potential fraudulent scheme that was running through some components of that, and our priority was driving that to the ground and figuring out whether in fact that there was fraud perpetrators. So we have a series of subpoenas that have been issued. We are able -- we are in litigation mode around those subpoenas. But as we pointed out, back in the beginning of the year, this process, it would take months, if not several quarters, to resolve. And we continue to defend ourselves through this process. So in other words, no new news in terms of mesh."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna.",13,"And our next question comes from the line of Andrew Finkelstein with Susquehanna."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run",103,"I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run rates for some of the branded products in the quarter, is there anything else to point out? You talked about the destocking on XIAFLEX. But some products like LIDODERM and OPANA, how do you characterize the sales for those in the quarter relative to what you might consider a run rate, based on where the scripts are?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Paul, you want to...",5,"Sure. Paul, you want to..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some -- the other earnings call. It is true that we do have an exclusive",100,"So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some -- the other earnings call. It is true that we do have an exclusive arrangement with a single API source, and it is understood that there are multiple API sources available. And ultimately, we are prepared to vigorously defend our intellectual property and also our position in respect to this particular case. So that's probably as far as we can go at this point in time."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that to say that you do not have exclusive arrangements with the others?",14,"Is that to say that you do not have exclusive arrangements with the others?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think what we said is that we do have a single, exclusive arrangement with an API source.",18,"I think what we said is that we do have a single, exclusive arrangement with an API source."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are a",277,"And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are able to benefit from the performance in those brands. So there are brands like LIDODERM, which, as a branded product, has now really been reduced to a small component, because the product is, as far as we are concerned, fully genericized with 3 generic competitors in the market, including our own authorized generic. But from a contracting standpoint, we still hold some proportion of the market on our branded product. But clearly subject to generic pressures. OPANA, we pointed to OPANA as one of the products that was impacted by the CDC guidelines and the general slowdown in the opioid market, and I think that trend is continuing along the lines that we expected. But we also have a series of smaller products that we don't talk much about, that are also doing quite well, that are promoted. SUPPRELIN L.A. has been a very sticky and very good performance for us for a long period of time. NASCOBAL, which is a product that came over with the Par transaction and is a branded product that's promoted by our field force, is also doing quite well, right? So as we look across the portfolio, in the branded business, beyond the ones that we actually talk about, we do see points of good performance, which -- which just helped us in Q2 and we expect to help us over the course and remainder of the year as well."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how do you think about the mark",68,"Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how do you think about the market? Where is the market competition mainly in compounding pharmacies? Just kind of curious if you have any thoughts there; that'd be great."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basical",121,"Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basically sold and promoted exactly the same way. They just -- one is first-line and one is second line. With respect to the uptick, right now, we did -- we took an appropriate price increase. It is an NDA. We follow the same practice in terms of it being an unapproved product. It is now an approved 505(b)(2). So it's similar in nature into what we've done with Vasostrict, but for the fact that there are unapproved sources of adrenaline on the market today."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that",120,"One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that you're expecting, and that there'll be more easing volume and you're just benefiting from that recent price increase? And for Suky, can you talk a little bit about what you see as some of the key detractors sequentially, with regards to the third quarter revenues? Looks like a fairly strong downtick. I know that the wholesale volume is not going to recur, but what other items you're expecting to go the other way, to go negative?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last",139,"So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last quarter or 2, you're seeing standard run rate for Vasostrict. So I think we've met our max on the volume side of Vasostrict. So that's where we are now. As Rajiv indicated, we took a modest price increase. That's the way this product is going to behave on a go-forward basis. So I think we've maxed out on the volume side. And it's just being able to navigate with the market, and if we are to take appropriate price increases on a go-forward basis. But we haven't made any determinations yet."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter",288,"Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter, specifically around timing that could be material to the quarter. But on a whole year basis, they're not meaningful. But having said that, given our reset in Q1 and given the launches that we've got in fourth quarter, we are providing quarterly guidance at least for this year. For the third quarter, the way to think about the step-down is, one, you talked about already, which is the stocking that we saw in the second quarter. Our assumption is that reverses in the third quarter. Also, what underpins our assumption of the step-down is continued erosion in retail as that continues to face competition from a generic standpoint. We would expect LIDODERM to step down modestly. Our testosterone products continue to decline quarter-over-quarter, particularly because of the market. And then, again, we also expect to see some modest decline in our pain products. All of those declines are partially offset by growth in XIAFLEX and BELBUCA as well as Par launches. But net-net, our assumptions lead us to a decline on revenue into the third quarter. From an investment standpoint, that's all coming in the backdrop as we increase our investments against generics R&D as well as branded R&D and BELBUCA and XIAFLEX, as Rajiv has talked about earlier. So those are the moving parts that lead us to the third quarter. Again, what we're doing is taking a very prudent approach of applying quarterly guidance, given the lumpiness of the year."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?",16,"That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains.",30,"At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Donald Ellis with JMP Securities.",14,"And our next question comes from the line of Donald Ellis with JMP Securities."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions o",45,"Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions of narcotics?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The -- As you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being sai",156,"The -- As you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being said, I think the -- to the public health environment debate around this, FDA dialogue around this, while encouraging abuse deterrent formulation, it's still unclear at what point the entire market will shift to products that are ""abuse deterrent"" right? So the -- in terms of the FDA's own determination of what constitutes it, that's a lot of debate. We don't have a crystal ball, and we'll be speculating. But, with -- Certainly, as we look forward, on a longer-term perspective, one would think that the long-acting products would transition to more abuse deterrent formulations. But is that going to happen in the short term? That is anyone's guess."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","How do you think that they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?",25,"How do you think that they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet",137,"Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet needs in the country. There are 100 million patients who suffer from chronic pain, and there are certain categories of pain, such as cancer pain, that you are going to need an opioid in order to survive and manage that kind of pain, right? So I think, in the end, from a pure patient need standpoint, we do believe that the opioid, schedule 2 opioids will have a place in the market for that. Now from a pricing standpoint, and how PBMs reimburse versus regulated, that I really can't answer."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage p",265,"Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage points more. But I just wanted to make sure that applies to the entire generic book of business or just my assumption would be that the injectable piece, of course, would be much more stable, and that rate would sort of apply to the solid dose business, but I wanted to confirm that. And then for Suky, question earlier was asked about sort of the ability to realize price increases on Vasostrict. And just trying to get a better sense of how we should be thinking about the company's ability to sort of realize those price increases, whether or not there's been any change in that -- the relative realization rate, in terms of what's actually dropping to the pretax line. And then, last question for Rajiv. You talked several times now about accelerating investments and continuing to invest both the additional resources on the R&D, and the selling and marketing side to drive some of your future high-growth assets. And obviously, the message has been heard loud and clear with respect to '16. But I guess, in sort of thinking about external expectations in '17, '18 and kind of beyond, it seems like the anticipation at this point is that spend levels remain relatively flat. I'm just kind of wondering, how you're thinking about maybe that, maybe just in general terms, at least directionally."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that -- that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And t",123,"Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that -- that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And that includes our extended-release solid oral dosage, our immediate-release solid oral dosage, in our pain controlled substances group. So it excludes injectables. It excludes the alternative dosage forms and, of course, new products. So that's the way we're defining it. And maybe you can just help me out on your Vasostrict question. I want to make sure I understand it. I know it went to Suky, maybe you could just repeat that for us."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize on that level of increase? I'm trying to get a sense of how much of it falls to the pretax line.",52,"The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize on that level of increase? I'm trying to get a sense of how much of it falls to the pretax line."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now.",37,"Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now in the, in a very g",200,"And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now in the, in a very good position where we have some great assets across all of our businesses. And as we transition our business to really being an organic growth story, it is a very important imperative for us that we begin to really invest for future sustainable organic growth. And so hence, the investment step-up that we're talking about in R&D and hence the investment behind, as like XIAFLEX and BELBUCA that we think are going to be real growth drivers over the course of the next 5 years. At this point, we can't make any comment on investment levels in '17 or '18. But I would point to the fact that what we're talking about is investing in long-term growth assets, right? So long-term growth assets require long-term investment, and that's our philosophy. And obviously, we'll take a more specific view on what that means for '17 and beyond when we get there."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict.",169,"One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict. Are your wholesaler contracts structured pretty typically, where they have a 30-day buy-in, so you'll see 2/3 of the price increase in 3Q, and then the full amount in 4Q? And then, could you actually give the XIAFLEX vial shift and the breakdown in Perrone's and Dupuytren's for 1Q and 2Q? And then lastly, the strength in -- well also for the guidance where you maintain the guidance that you have this added expense in BELBUCA and XIAFLEX. So what's making -- I was a little bit confused about how you're maintaining it. Is it from the strength in the quarter, and the surprise in V Gel, and other products that's allowing you to maintain the guidance or where is that offsetting strength coming from?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the -- about the patent cases, the ruling",61,"Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the -- about the patent cases, the rulings and our path forward there, is that accurate?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just asking yes, if you saw a share shift because of the ...",15,"I was just asking yes, if you saw a share shift because of the ..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Share shift. I'm sorry.",4,"Share shift. I'm sorry."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yeah, right [indiscernible]",3,"Yeah, right [indiscernible]"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt.",36,"I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes, and I was just wondering if there was any upside from whatever you thought kind of ...",18,"Yes, and I was just wondering if there was any upside from whatever you thought kind of ..."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Look if -- there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the",108,"Look if -- there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the other hand, you have the declining opioid market effect, right? So net-net. It is not a product where we expect to see any substantial uptick. The -- you had a question on XIAFLEX. So in terms of XIAFLEX vials. And I'm happy to go through them, but they are, in our FAQs for the first quarter as well as second quarter."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","We can do it offline, if -- sorry, go ahead.",10,"We can do it offline, if -- sorry, go ahead."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being -- increased investment in R&D and sales and marketing, so some of",90,"Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being -- increased investment in R&D and sales and marketing, so some of it, as Suky mentioned in his script, is simply reallocation, and some of it is a modest uptick in our investment level, particularly in the third quarter, which is one of the other contributing factors to how we guided the third quarter."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","No, I was asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was it",74,"No, I was asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was it the strong quarter, where you got strong V Gel and other products, or is there something else going on where you're allowed to maintain your guidance?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well.",39,"Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And the last one I had was the bit about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the pric",62,"Okay. And the last one I had was the bit about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the price increase in the quarter, you take the price and then the full amount in 4Q?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointe",61,"No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointed to the overall price increase benefit generally is in the mid-single digits for our branded portfolio, on a full year basis."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our last question comes the line from Irina Koffler with Mizuho.",12,"And our last question comes the line from Irina Koffler with Mizuho."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","It seems like your XIAFLEX is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. You guys are doing a great job with those 2 products. But are you really the best owners of these assets? Do you have the right synergi",58,"It seems like your XIAFLEX is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. You guys are doing a great job with those 2 products. But are you really the best owners of these assets? Do you have the right synergies? And would someone else potentially value these assets more?"
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets fall squarely into the type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The type",115,"So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets fall squarely into the type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The type of support, in terms of advertising and promotion that's required around the brand, even with the step-up, is well within the means of a company like us. And also, when you look at the R&D pipeline and the investments that are required to develop XIAFLEX, which is already a well-characterized molecule from a safety and effectiveness standpoint, we do think we are the right owner of these assets."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon.",18,"Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon."
28071,375875901,1030532,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ms. Ker",53,"Good day, ladies and gentlemen, and welcome to the Q2 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to introduce your host for today's conference, Ms. Keri Mattox, Senior Vice President of Investor Relations and Corporate Affairs. You may begin."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of",240,"Thank you. Good afternoon, and thank you for joining us to discuss our second quarter 2016 financial results. With me on today's call are Rajiv De Silva, President and CEO of Endo; Suky Upadhyay, Chief Financial Officer; and Paul Campanelli, President of Par Pharmaceutical. 
We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials, including our Frequently Asked Questions document, are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K we are furnishing with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Rajiv."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our second quarter 2016 earni",767,"Thank you, Keri. Good afternoon, everyone, and thank you for joining us for today's call. I hope that you have all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our second quarter 2016 earnings presentation. To start, here is a brief agenda for today's call. 
Moving to Slide 3. The second quarter was a busy and productive one for us at Endo. I am pleased that we delivered solid revenue and adjusted earnings per share results in the second quarter, with revenue performance across all business units broadly in line or ahead of company expectations. We also made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. We have made an important addition to the management team, made good progress on key growth drivers and progressed our ongoing legal entity reorganization, which provides us with operational flexibility and benefits. Suky will talk about this reorganization in more detail later in the call. Against the backdrop of this progress, we are taking steps to increase investments in our future organic growth drivers, branded and generics R&D as well as BELBUCA and XIAFLEX promotional efforts. Importantly, we are pleased to affirm our full year 2016 revenue and adjusted EPS guidance despite these additional investments. 
On Slide 4, you will see a snapshot of our solid segment results for the second quarter. 
Moving to Slide 5. Let me discuss in further detail how we remain focused on operational execution and achieving our key milestones. We announced the appointment of Joe Ciaffoni as our new President of the U.S. Branded business. We are delighted that Joe has joined Endo, bringing his proven expertise in launching and growing branded products and look forward to his contributions when he assumes his new post later this month. 
We continue to drive growth in our generic sterile injectables products, and our Generics Base business is performing right in line with expectations we communicated to you in May of this year. We secured a patent for our largest product, Vasostrict, and continue to launch differentiated generics products and file new ANDAs with the FDA. 
In our international business, we filed our BELBUCA submission and secured rights to XIAFLEX in Canada. And we have also advanced our branded R&D pipeline and have recently opted into another new potential indication for XIAFLEX, human lipoma.
So on Slide 6, let's discuss our branded business. Our branded performance in the second quarter was broadly in line with our expectations, which underlie our segment revenue and margin guidance provided in May. We drove continued XIAFLEX demand by a broad -- particularly in Peyronie's disease. We are advancing our BELBUCA launch efforts, increasing the total prescriptions to date and growing the number of repeat prescriptions. In the quarter, we also saw better-than-expected results, driven by contracting for the branded Voltaren Gel and performance across some of our other products such as LIDODERM, NASCOBAL and SUPPRELIN LA. 
Moving to Slide 7. Let's take a closer look at XIAFLEX's performance. We are making good progress with this key growth asset, and that is transferring into continued growth. In Peyronie's disease, a market that we think has considerable growth and expansion potential, we delivered nearly 20% demand growth in the second quarter versus the same period last year. We continue to expand our physician/injector base, and our disease awareness campaign, Ask About the Curve, has shown early signs of successfully engaging PD patients. In Dupuytren's contracture, a more mature market and one where XIAFLEX launched more than 5 years ago, we still drove 5% demand growth in the quarter over the second quarter last year. Revenues for the quarter were impacted by greater-than-expected destocking. For the full year 2016, we now expect low double-digit pro forma revenue growth for XIAFLEX. 
On Slide 8, let's move next to International Pharmaceuticals. We continue to drive performance in line with expectations that underlie our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we filed our BELBUCA submission and acquired the Canadian rights to XIAFLEX last quarter. Both products are potential long-term growth drivers for the business, and the additions could provide longer-term growth as we manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our operating margins. 
Now to talk about our U.S. Generics performance, let me turn the call over to Paul. Paul?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv, and thank you, all, for joining us on the call. Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all whi",534,"Thank you, Rajiv, and thank you, all, for joining us on the call. 
Turning to Slide 9. We remain focused on the continued integration of Par and Qualitest, advancing our pipeline and restructuring our manufacturing footprint for improved margins, all while delivering performance in line with our expectations. Our sterile injectables business continues to grow, led by Vasostrict. Importantly, we also secured a patent for that product that does not expire until 2035 and which we believe further strengthens our market position. In our new launches in alternative dosage segment, we've launched 11 products since the beginning of the year and continue to file new ANDAs with the FDA while replenishing our R&D pipeline. As we expected and in line with trends consistent across the broader generic industry, our base business declined by approximately 5% sequentially from first quarter 2016, driven by consortium pricing pressures in competitive generic entrants. Finally, our adjusted gross margin for the generics business remained in line with expectations. I would like to note that second quarter revenues benefited modestly from some favorable timing between Q2 and Q3, driven by customers advancing some of their orders ahead of the 4th of July holiday. 
Moving on to Slide 10. I'd like to provide you with an update on the action plan that we outlined last quarter to drive long-term growth across our generics portfolio. While I won't go into the detail on each of these items, I do think it's important to note that we are in progress, on track or have already completed all the core components of our action plan. For example, we continue to make progress on key growth drivers like our 505(b)(2) in sterile injectable programs as well as launching a steady stream of new, differentiated products this year. We're also reprioritizing and accelerating our R&D pipeline. We've already rationalized numerous lower-value projects as part of our restructuring and are on track to file approximately 25 to 30 new ANDA submissions in 2016. We made progress on our accelerated restructuring plan for the generics manufacturing network and continue to project approximately $60 million in annual net run rate savings to be fully realized by fourth quarter 2017. We've largely completed the transition of the legacy Qualitest business onto the Par platform, including commercial insight, forecasting, wholesaler data management and other capabilities. And finally, we are executing on our operational plan. We have delivered a second quarter that is in line with the expectations that underlie our guidance for revenue and adjusted margins previously communicated in May.
So let me talk briefly about our product launches to date and those anticipated for the remainder of the year. 
On Slide 11, you'll see a familiar chart. We have updated it to show all the products we have successfully launched so far in 2016. You can also see those products that we expect to launch into the marketplace in the second half of the year. Importantly, we are on track for our November and December 2016 launches of generic Seroquel XR and generic Zetia. 
With that, let me turn the call over to Suky to discuss the financial performance of the company in the quarter and our projected outlook. Suky?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good afternoon, everyone. Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance",1080,"Thank you, Paul, and good afternoon, everyone. 
Let's start on Slide 13, where we've outlined finance updates around the recent SEC guidelines and our adjusted effective tax rate policy moving forward. As you're aware, the FCC issued non-GAAP Compliance and Disclosure Interpretations or C&DI guidance in May. Endo has adopted these guidelines and, as a result, is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. This policy has no impact on Endo's historic or forward-looking GAAP tax or cash tax profile. Also, the initiation of a legal entity reorganization in the first quarter has limited the impact of this change on our adjusted effective tax rate for the year and moving forward. 
Moving to Slide 14, we provided more detail about the legal entity reorganization that I just mentioned. As part of the continued integration of our Qualitest and Par businesses, we initiated a legal entity reorganization that moves the generics business to a new U.S. holding company structure that is separate from the legacy branded business structure. The reorganization provides operating flexibility and benefits while also reducing the potential impact related to future limits on the use of tax attributes by utilizing most of our attributes to offset an intercompany gain. As a result of this reorganization, the tax bases of U.S. Generics business assets have been stepped up to their fair value, which will provide ongoing cash tax benefit and flexibility in moving assets with limited tax leakage. The utilization of acquired attributes that I mentioned earlier would have had an unfavorable impact of approximately $160 million on our full year adjusted tax expense under Endo's non-GAAP policy prior to the adoption of the SEC's C&DI. The elimination of this acquired attribute benefit was offset by an improved mix of jurisdictional adjusted pretax income resulting primarily from the reorganization. This reorg also gave rise to a discrete net GAAP tax benefit of approximately $450 million in the second quarter from outside basis differences. This benefit has been excluded from our adjusted effective tax rate in accordance with our policy. 
As I talked about earlier, as a result of the SEC's C&DI, Endo is no longer excluding the noncash deferred tax expense associated with acquired attributes in our adjusted effective tax rate. However, since we utilized almost all of our tax attributes through the legal entity reorganization,  the implementation of the updated C&DI guidance is not expected to have a material impact on our 2016 and forward-looking adjusted tax rate. Endo continues to project an adjusted effective tax rate of 0 to 2%, as guided in our first quarter 2016 earnings announcement. We expect to have a GAAP tax benefit and a negative cash tax rate for 2016. Importantly, for our outlook for 2017 and future years, we expect our adjusted effective tax rate to be in the high single digits to low double digits and our average cash tax rate to be below 5% over the next 5 years. 
Next, on Slide 15, you will see a snapshot of the second quarter GAAP and non-GAAP financial results. Rajiv covered company and segment revenues earlier, so I will not review that here. 
On a GAAP basis, we delivered earnings per share of $1.75 in the quarter versus a loss of $0.49 in the second quarter of 2015. 2016 second quarter GAAP results were driven by an operating loss of $48 million, offset by the tax benefit that I discussed earlier. Tax benefit also offset the impact of a higher share count in 2016. 
Our GAAP operating loss was largely impacted by a decrease in gross margins due to a higher mix of generic revenue in the second quarter compared to 2015 and due to incremental amortization expense associated with the stepped-up value of intangible assets from Par. On an adjusted basis, overall Q2 results are slightly better than previously guided. 
To summarize the points Rajiv and Paul made, revenue was better than expected due to sterile injectables, stronger-than-expected performance from a number of branded products and a modest timing benefit related to quarter-end buying patterns. Adjusted net income and EPS are better than guided as a result of higher revenues discussed earlier. 
On Slide 16, while the second quarter was ahead of our guided expectations, we are maintaining our guidance ranges, as some of the upside in the second quarter was driven by favorable timing. As Rajiv mentioned, we are also going to invest at a higher level than originally planned in our key growth drivers in the second half of the year through a reallocation of operating expenses and a modest step-up in spending. 
Regarding the cadence of revenues and adjusted earnings in the second half of the year, we continue to project the fourth quarter to be disproportionately larger than the rest of the year's quarters due to the launch of the generics Seroquel and Zetia. For third quarter 2016, we expect revenues in the range of $830 million to $870 million and adjusted earnings per share of $0.77 to $0.82. This implies a sequential step-down in third quarter of 2016. The anticipated decline is driven by the product order timing benefits in the second quarter that we expect to reverse in the third quarter, lower U.S. branded sales related to generic competition for Voltaren Gel, continued slowing in the testosterone market, continued declines in legacy pain products and an increased investment in R&D as well as XIAFLEX and BELBUCA promotional efforts. 
Moving to cash and liquidity on Slide 17. On a year-to-date basis, GAAP cash flow from operations totaled approximately $555 million. We have also highlighted some of the material moving parts that have impacted our reported or GAAP cash flows for the year. 
On Slide 18, we are reiterating our view on cash available to pay down debt in 2016. We continue to project debt pay-down of approximately $250 million in 2016 and to exit the year at a mid- to high 4x net debt to pro forma adjusted EBITDA leverage ratio. As noted in our press release, we ended the quarter with approximately $670 million in unrestricted cash and approximately $390 million in restricted cash and a net debt-to-leverage ratio of approximately 4.6x. 
To summarize, we are encouraged by our second quarter financial results and pleased to affirm our full year outlook while increasing investment in key growth drivers. 
Now to close out the call, let me turn it back over to Rajiv. Rajiv?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Suky. Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. W",310,"Thank you, Suky. 
Moving to Slide 20. In summary, there are a number of key growth drivers that position our U.S. Branded business for long-term growth. We believe strongly in the significant in-market growth opportunities for both XIAFLEX and BELBUCA. We are continuing to optimize our team and our business to achieve their growth potential while also managing our diversified portfolio of other products. We are also accelerating our R&D pipeline to advance those programs and the time lines for their potential market entry. We continue to execute on these growth drivers in the second quarter and expect to achieve additional key milestones through the end of this year and beyond. 
On Slide 21, let's recap the key achievements in our U.S. Generics business. We are focused on driving growth through our differentiated, higher barrier-to-entry products like sterile injectables and our robust pipeline of more than 250 programs for restructuring. We have a diversified reset base business and a robust, highly compliant manufacturing network. In 2016 and beyond, our success will be driven by Paul and his proven team as they continue to execute on these opportunities. 
Let's briefly summarize our call today on Slide 22. In Q2, we delivered solid top and adjusted bottom line results, beating our Q2 adjusted results guidance. We made substantial progress on our continued focus on operational execution and enhancing flexibility for our business. And we are affirming our full year 2016 revenue and adjusted EPS guidance while increasing our investment in branded and generic R&D and BELBUCA and XIAFLEX promotion. Endo is executing on our strategic priorities, and we continue to believe that this is a time of significant opportunity for the company, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Let me now turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] Operator, may we have the first question, please?",23,"Thank you, Rajiv. We'd like now to open the lines for your questions. [Operator Instructions] 
Operator, may we have the first question, please?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our first question comes from the line of Louise Chen with Guggenheim.",13,"And our first question comes from the line of Louise Chen with Guggenheim."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have",78,"So I had a few here. First question I had was on XIAFLEX. If you could give us more color on how you get to the double-digit growth for the year. And also, what was going on with the customer destocking this quarter? Second thing is, I wonder if you have any update on the divesting of the non-core assets to pay down debt. And the last thing is, are you seeing any stabilization in your Qualitest business?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you mig",369,"Sure. Louise, let me address the first 2 questions, and I will have Paul address the third one. So in XIAFLEX, as we have commented in the past, the growth profile does tend to be a little bit lumpy and have some seasonal fluctuations to it. So as you might recall, we had a very robust growth in the first quarter. We have seen a little bit of a slowdown in Dupuytren's contracture in the second quarter. But as we look out over the remainder of the year, we do feel confident in the double-digit growth trajectory that we have talked about. Now in terms of the revenue profile, as you know, customer stocking is largely out of our control, though, typically, XIAFLEX stocking in the specialty distributors and the specialty pharmacies, in general, is around 14 days, about 2 weeks. But from time to time, we do see some unusual changes to it, which is what happened in the second quarter. Our stocking is around 1 week, so approximately half of what it typically is. Now we have seen this behavior in the past, and typically, over the course of the year, it tends to normalize. But by and large, it is out of our control. So what we look to is demand while growth. And that's where when we look at the 19% growth in Peyronie's, we do feel very good about this indication, given that from a longer-term perspective, for our on-market indications, the biggest opportunity is in Peyronie's. In terms of divestments of non-core assets, I just wanted to be clear that from a company perspective, we don't feel compelled to divest any assets. We are confident in our business and the natural delevering nature of the business, given the -- our substantial cash flows, particularly as we look beyond the known mesh payments in '16 and '17. That being said, I think we've also been clear that as a company and as a board, we are always -- we are shareholder-friendly. And when there are any opportunities that come our way that are value-creating, we will certainly evaluate them on a -- our standard basis. Paul, maybe you can comment on the Qualitest business."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But maybe high level, when you look at the Qualitest business for the most part, it's really known as a base business play. W",141,"Yes, sure. So, Louise, I would say that we're really not separating out the Qualitest and the Par businesses too much any longer. But maybe high level, when you look at the Qualitest business for the most part, it's really known as a base business play. When you look at our base business play, we define that as the pain-control substances as well as the oral extended-release and immediate-release products. That also includes some of the Par portfolio. When you look at that on a quarter-over-quarter basis, we communicated this at our last earnings call, that we were anticipating about 5% erosion quarter-over-quarter, and that's exactly where we landed. So it's in line with our expectations and how we communicated. So generally, our base business is falling in line, and we're not seeing the heavy erosion that we realized in Q1."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Greg Gilbert with Deutsche Bank.",14,"And our next question comes from the line of Greg Gilbert with Deutsche Bank."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being consider",88,"I have a few. First, Rajiv, can you comment on whether the company is considering any business combinations right now? I know you're open and shareholder-friendly in general, but maybe you could comment specifically whether there's anything being considered at this point. And, Paul, can you confirm that there have been no P4 certifications on Vasostrict since you got that patent issued? Can you quantify the stocking benefit for your business? And can you comment on whether you have an ephedrine filing and/or a program in the works?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to be opened, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery",112,"Thank you, Greg. So as you know, the company doesn't comment on any ongoing business to be opened, though I would continue to stress that our priority for this year is operational execution. And hopefully, what you've seen from us is a quarter of delivery around that. And again, what -- as I've said in the past, our board is always open to shareholder-friendly, strategic opportunities, and we will remain open to such opportunities as they come our way. But really, our focus now is on the operations of the business. So let me just turn to Paul. I think there were 3 parts of that question, Paul, with stocking and ephedrine."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted al",118,"So I'll be brief. I think in case of Vasostrict, the answer is we have not been noticed of any Paragraph IV filing in terms of stocking. I think we're at normal course right now. We believe that we are -- basically, our run rate is -- we have converted all the unapproved product to approved product. So we're really normalized in that regard. And then, Greg, I think your last question was on ephedrine. And I think what we can say right now is in case of any product, that we are -- essentially not our policy to discuss any product that we don't already disclose into our corporate presentations at this point in time, Greg."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry.",27,"And sorry, on the stocking, I meant for you to quantify that stock -- the wholesaler buying pattern benefit in the quarter for the overall portfolio. Sorry."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million",51,"Yes. So, Greg, this is Suky. That's always an exact science when you're trying to measure exactly when an order comes in from one period to the next, especially around holiday weekend. But where we are now, we would estimate that to be around $15 million to $20 million in revenue."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Annabel Samimy with Stifel.",13,"And our next question comes from the line of Annabel Samimy with Stifel."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's",82,"I was just curious to know, last quarter, you talked about some, I guess, paring down of the commoditized portion of the base business. And so I was just wondering, from that perspective, on top of your balance sheet, how can we think about the way that's shaping up for 2017 in terms of reaching your delevering goals of being under 4x in 2017? And can you still satisfy with -- that with some of the mesh payments that you're still seeing?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile and our expectations.",24,"Let me just have Paul address the portfolio rationalization question you had, and then Suky will talk about the delevering profile and our expectations."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So regarding the -- really, what we refer to as the restructuring of the operations -- there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual",118,"Sure. So regarding the -- really, what we refer to as the restructuring of the operations -- there is about 7 years of products that we've discontinued or in progress of discontinuing. So we're right on track, and that goes back to the $60 million annual net run rate that we anticipate for fourth quarter 2017. We've made some difficult decisions that we've talked about regarding the Charlotte and the Huntsville facilities with respect to -- in terms of employees and synergies. Those decisions have had essentially 3 waves to them, and we've executed on wave #1. And we are on track to meet the expectations that we've communicated. So, so far, we are executing on the plan."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that having -- I'm sorry, is that having any revenue and EBITDA impact right now?",16,"Is that having -- I'm sorry, is that having any revenue and EBITDA impact right now?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Nothing above what we've already talked about on our first quarter call, with part of the restructuring, Annabel. It's already baked into our guidance.",25,"Nothing above what we've already talked about on our first quarter call, with part of the restructuring, Annabel. It's already baked into our guidance."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. Sorry. And then if you can just talk about the leverage. Sorry.",13,"Okay. Sorry. And then if you can just talk about the leverage. Sorry."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the f",167,"Sure. Yes. So as I said, we're about 4.6 now. We expect to exit the year somewhere between mid- to high 4s. A key component of that going into 2017 is we remain committed to delevering the low 4x over the midterm, is how we characterized the fact on the first quarter call. So we're not putting specific timing around that. And then I think the offshoot to your question was something around mesh. And what I would say there is, as of the second quarter, we had just below $1.6 billion accrued on the balance sheet, with just below $400 million in restricted cash. So that's essentially money that's already out the door for funding of mesh, which leaves an incremental or remaining $1.2 billion on a pretax basis. We expect that $1.2 billion to be serviced as another $300 million to $400 million in the second half of this year and then somewhere around $600 million to $700 million on a pretax basis in '17."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Stephan Stewart with Goldman Sachs.",14,"And our next question comes from the line of Stephan Stewart with Goldman Sachs."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns.",34,"Just a follow-up on the generic business. Wondering how much of the performance this quarter was volume versus price if you exclude the base business and the benefit from the wholesaler buying patterns."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Suky, do you want to...",5,"Suky, do you want to..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, w",48,"Sure. So I'd say, first of all, overall, on a total generics portfolio basis, we're seeing more pricing pressure than pricing opportunity. And overall, our growth for this year on a pro forma and underlying basis, which we said in the low single digits, will be primarily volume-driven."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts",",Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?",40,",
Great. And just 1 quick follow-up on the CDC opioid prescribing guidelines. I know you guys did include something in full year guidance last quarter. Has there been any meaningful change to how you guys were thinking about it then?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The trends continue, Stephan, so they have -- we have seen continued pressure in terms of prescription volumes in the opioid space. I mean, if you look at the branded space alone, new prescriptions in the branded vol are down double digits since the annou",96,"The trends continue, Stephan, so they have -- we have seen continued pressure in terms of prescription volumes in the opioid space. I mean, if you look at the branded space alone, new prescriptions in the branded vol are down double digits since the announcement of the CDC guidelines, but that is all incorporated -- it was incorporated into our forward-looking guidance in May. And we don't have a different view in terms of the full year. We will, of course, take stock when we think about '17 later on this year or early in 2017."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Gary Nachman with BMO Capital Markets.",15,"And our next question comes from the line of Gary Nachman with BMO Capital Markets."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA",47,"Rajiv, you mentioned improved contracting for some of the branded products on Slide 6. Could you explain this a little bit more? How did this help you in 2Q? And is that sustainable? And also specifically, what are you planning to do to accelerate BELBUCA going forward?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But certainly, in terms of defense of the branded products, we've had better-than-expected success with c",119,"Sure. So, Gary, in terms of the improved contracting, I think you're referring to the statement that we made about Voltaren Gel, if I'm not mistaken. But certainly, in terms of defense of the branded products, we've had better-than-expected success with contracting that we've done with the commercial plans, and that's largely speaking what's helped us in the first part of the year. Now as you know, we have authorized the launch of Voltaren Gel AG through Par, and that is taking place as we speak. And over the course of the year, we do expect the Authorized Generic to take more share of the overall molecule. And then, Gary, your second question, I just -- if we can..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","BELBUCA.",1,"BELBUCA."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are.",15,"BELBUCA, you said you're increasing promotions behind it. I'm just curious what your plans are."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product",308,"Sure. So in BELBUCA, the feedback continues to be similar to what we talked about in the first quarter, which is positive feedback from physicians, positive feedback into the patient experience. The 2 areas which are leading to slow uptake of the product beyond just the overall environment in opioid, one is the process of getting the physician community comfortable with the tapering and titrating requirements in terms of switching patients between different opioids and onto BELBUCA. And secondly, it's around the payer environment and how they see the Schedule III products. So on the latter, we made good progress. At this point, we have contracted roughly around 85% of commercial lives, and about 70% of that at -- without any restrictions beyond the label, we expect to continue to improve that over the course of the year. But, of course, at this point, in a launch of a product like this, we don't yet have government reimbursement. But what we see as being the real opportunity is the pharmacoeconomic and public health argument for why a Schedule III product like BELBUCA is preferable to other opioids such as the Schedule II products in terms of where it is introduced in the treatment algorithm. And a lot of the investment that we are now making is around improving our fact base in terms of making those market access arguments. Clearly, we still continue to have a large investment from a field force standpoint, and that continues. We're also increasing our investment around physician education, particularly around the treatment and titrating of the product. But really, the upside benefit and the longer-term growth of the product is really predicated on us being able to really anchor buprenorphine as an effective and safe alternative in the opioid space, both on a peer standpoint as well as from a physician standpoint."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Liav Abraham with Citi.",13,"And our next question comes from the line of Liav Abraham with Citi."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be intereste",81,"First question is just a broader question on the generics environment. Well, I'd be curious if you anticipate any change in the environment, given that the Allergan generics deal closed last week. And then secondly, a question on XIAFLEX. I'd be interested in your thoughts on how you see the growth trajectory evolving post 2016, if possible, and perhaps you can touch on any updates on reimbursement and physician training and how you feel about ongoing double-digit file growth post 2016."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Paul, do you want to talk about the generics environment question?",11,"Paul, do you want to talk about the generics environment question?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition on how we feel about the consortium. At the end of the day, we've got our",160,"Yes, sure. So, Liav, it's Paul here. I don't anticipate any major changes for Par Endo with respect to the Teva deal closing. And I think we've stated before in terms of competition on how we feel about the consortium. At the end of the day, we've got ourselves 4 large consortiums. They're representing around 90%. And we're going to have to still compete with Teva head-on as we would in any case. And typically, you want to just be very careful about trying to go after too much share. Just got to take a balanced approach. So I envision that we're strong competitors. Teva's a strong competitor. Even with the portfolio getting larger, we need to execute on our plan of bringing new products into the marketplace. And I don't think the fact that they've got the Actavis portfolio has a negative impact to Endo Par if that in fact is your question that you're trying to allude to."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as",455,"Liav, going to your XIAFLEX question, we continue to believe that there's a real long-term opportunity with XIAFLEX as a oral platform for the company, given the fact this is a biologic, given the multitude of potential indications that we have as well as potential in the on-market indications. That being said, we have -- we will not be making any particular prediction around '17 and beyond. But I would say that we are very optimistic when we look at the current results that we are seeing in Peyronie's disease, which we think is the great opportunity for the 2 -- of the 2 on-market indications. And there are 3 areas in which we have made promotion investments and we expect to step up for the remainder of the year as well as going into '17, and they will be the following. One is an area which we already talked about, which is that we continue to need to make the lives of patients who currently are prescribed the product easy. And then that's mostly around reimbursement support. And we've substantially increased the level of internal resourcing around that as well as targeted third parties to support that. The second is a longer-term opportunity around disease awareness building. And we have begun to do piloting and early investments, particularly in Peyronie's, through our online campaign, Ask About the Curve. And it's, of course, too early to fully realize the benefit from it or fully conclude what the benefits will look like. But the early signs of web click-throughs and patient interest in going onto our site to a physician selector, for example, there's been substantial uptick in that, right? Now, clearly, for a product like this, the cycle from the time you get a patient interested in the product or interest in going to physician, to the time that he would have a first injection could be 6 to 9 months, right, which is why we always pointed to the back half of this year '17 before we really begin to see the benefit from it. And the third thing I would say is -- and this is probably more so true for Dupuytren's contracture than Peyronie's, is the need to make a compelling argument around the pharmacoeconomic benefits of a intervention like XIAFLEX versus surgery. And that's more of an opportunity for us in Dupuytren's contracture, where the hand surgeons who treat the condition often see the surgical option as a -- as the first option. And we've, of course, had very good success with the product with these physicians. But getting to the next level is going to require making an even strong argument around why this is the best interest of patients."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Amsellem with Piper Jaffray.",14,"And our next question comes from the line of David Amsellem with Piper Jaffray."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the lat",96,"So on Vasostrict, now with the patent in place, it's a question for Paul, maybe talk about how you're thinking about the longer-term durability of the product. I know you had said that competition could be a couple of years away. And is that still the latest thinking? Or does the patent give you some more wiggle room? And then secondly, on the generics pipeline, and it may be premature to ask this, but beyond the bigger launches for later this year, maybe talk about some potentially significant launches that you think could happen in 2017."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is",451,"Yes, sure. So regarding Vasostrict, I would tell you, it's still a little bit early. We do, in fact, feel better. Obviously, we got the Orange Book patent listed in June. I think it was June 28. The way we kind of look at this product right now simply is from 2 different views. There was always a possibility that there could be a file that was issued with the FDA pre-Orange Book patent listing, and that's something where maybe we feel a little bit better about. And typically, what happened is if an application was in at the FDA for several months prior to the Orange Book listing, what you would expect is for a generic competitor to file a Paragraph IV very quickly and then we would have been noticed. That didn't happen; from that standpoint. We feel a little bit better. If an application went on file a month or 2, pre-June 28 or shortly thereafter, that's where we're not going to have that visibility. But if we were to get a Paragraph IV, say, today, it would take about 60 to 90 days for an application to be accepted for filing. So we would probably look to be in a 30-month stay, ticking somewhere late fourth quarter. That's the way I would start looking at it. So from that standpoint, we had originally said that we felt good through 2017. We probably will be in a position to say that we feel a little bit good through 2018, but we'll have better visibility around fourth quarter. In terms of the generic pipeline, from a standpoint of where we feel real good about, I think we'd like to focus a little bit on the 505(b)(2) side. I think that's an area of strength of the company, right? So while we haven't disclosed specifics, we do have a series of 505(b)(2)s that are starting to come through to fruition. And frankly, maybe we can talk a little bit more in terms of products that we feel a little bit better about. We had previously talked about 2 505(b)(2)s that we did not shed a lot of light on. We feel little bit better about them now. They are 2 forms of potassium. One is a liquid, and one is a powder form. We have started to receive positive feedback from the FDA in terms of removing unapproved sources. That's going to come to an end, whereby these unapproved sources will have the remainder of 2016 or so to have product into the market. These types of products will show benefit to Par and Endo in 2017. So that's an area that we'd like to focus in on. Thank you."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from David Risinger with Morgan Stanley.",11,"And our next question comes from David Risinger with Morgan Stanley."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair va",171,"I may have missed it, but could you just remind us what the BELBUCA sales were in the first and second quarter of this year, and how much you think it can ramp over the next couple of quarters? Second, you mentioned that generics was reassessed to fair value. I haven't had a chance to look at the numbers there. Could you just talk about that, how it was valued and what it was determined to be worth? And then third, in terms of Vasostrict, we saw that you took a recent price increase at the end of July of 20%. Just wanted to get a sense for how much upward potential you have for pricing. It seems like you have a lot of flexibility to raise price, but then again, there may be pushback. I don't really know. And maybe you could also comment on how much of that will be able to flow through. Should we just assume that, that 20% largely flows through to pretax income or not?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we",379,"David, let me answer the BELBUCA question and touch on Vaso, and I will -- then, I'm sorry, on the pricing philosophy, and then I'll have Suky and Paul build on the answer. So for BELBUCA in the first couple of quarters, we've been clear that we think we are using a pull-through method to recognize revenue. So it has been minimal revenue recognition in the first half of the year, so single-digit millions. And the -- we've also been clear that given our launch ramp expectations that we expect the contributions in 2016, in total, to be relatively modest. So we would look to 2017, really as the first year of revenue contributions for BELBUCA, and I would be clear about what those expectations are at the appropriate time. In terms of pricing, and I'll let Paul answer the specific question in retrospect, but I will point out the following, which is, from an overall perspective, the Endo business benefits from volume, not price. And in particular, generics business has predominantly more price pressure than upward price potential. And any prices -- any price increase that we might be able to take on the true generics part of it as -- is overwhelmed by the price erosion that we see on the base business. Now products like Vasostrict are a little different, in that they are sold on the basis of NDA, although they are sold within Par. But even in those cases, we take a responsible approach to price increases. And just because we have flexibility does not mean that we will take a price increase. In the case of Vasostrict, the Par has been very thoughtful about how to price the product as an NDA. And for a life-saving product, it is still in the low hundreds in terms -- sorry, about 125 or so, plus or minus, in terms of what a unit costs. And a substantial amount of investment has also gone into our Rochester, Michigan facility to support this product, and CapEx in excess of $100 million. And from a forward-looking standpoint, our philosophy on price increases will not change, which is that we will be responsible about how we think about it. But Paul, maybe you have a specific commentary on Vasostrict."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and",208,"Well I think Rajiv captured it very well. I mean at the end of the day, we look at this life-saving drug, and when we got the NDA approved, we do have to make commitments to the FDA and we have to ensure that there's not going to be any drug shortages and that we're going to be able to continue to supply the market. And to Rajiv's point, we had to make investments in raw materials, in components and specific equipment for this particular product. We had the CapEx that Rajiv is referring to. And in essence, 20% of our overall CapEx goes into the Rochester facility to keep it compliant. So it's a big commitment specifically on this injectable, that product that's a life-saving product. And then in terms of like general price increases and whatnot, I think, again, when you look at the total generics business, in essence, we are a volume-driven company, to Rajiv's point. When you want to look at it as a one-off on a product-specific, in the case of this one product, it's true that we have taken some price increases, but they had been responsible. So with that, I'll turn it over to Suky, to talk about the pretax question."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct.",170,"Sure. So we would expect that price increase to fall to pretax operating income as any other price movement, either up or down, would fall to the bottom line and through margin. And then David, to your question on the generics fair value, you're correct. Ultimately, the restructuring or reorganization that we implemented ultimately steps up the fair value of many of the assets within our generics business. That is the tax basis of those assets, which provides ongoing and durable cash tax benefit, and also provides flexibility in our ability to move those assets throughout our legal entities without residual tax leakage, which is our policy. We don't talk to specific asset values, but directionally, the way to think about how we value them is on future value based on discounted cash flows of our outlook for each of the products. And that goes into all of our intangible testing as well as our goodwill testing, et cetera. It's same analysis that underpins the valuation and, ultimately, the step-up."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Chris Schott with JPMorgan.",13,"And our next question comes from the line of Chris Schott with JPMorgan."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just 2 here. First, Paul, broadening out on I think Liav's question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry than we've seen in the past, when we factor in a higher l",152,"Just 2 here. First, Paul, broadening out on I think Liav's question earlier. And as you move past this reset of your generic base business, do you inherently see a more competitive generic industry than we've seen in the past, when we factor in a higher level of new product approvals from FDA, the behavior you're seeing from some of your larger and smaller competitors, et cetera? Or is this kind of similar competitive dynamics than we've previously experienced in the space? And the second question was on the comment on those potassium products. Can you maybe just give us a sense of the size of those opportunities as we think out to 2017? How attractive are these? How large of an end market can we think about? And finally, are there any other 505(b)(2)s, not necessarily the names, but should we think about additional approvals in 2017 that could help revenue?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger -- and we're seeing it now with Walmart now being part of the McKesson OneStop -- I mean, the consolidation does put more pressure back on us",243,"So the first part, in terms of the market competitive nature, I mean clearly, with the consortiums getting larger -- and we're seeing it now with Walmart now being part of the McKesson OneStop -- I mean, the consolidation does put more pressure back on us. But, I think from where we stand, we feel good about where -- how we reset the base business. We talked a lot about that in terms of -- and I hate referring back to Qualitest versus Barba [ph]. When you look at our total business, we have -- we've made our decisions. Right now, it gets down to operational execution. And the way that we compete is to execute flawlessly on our R&D pipeline. That's where we're focused right now, R&D execution and quality. These are things that going to set us apart, because clearly, consortiums are getting bigger, and that is going to create some more pressure on all the generic manufacturers. The companies that are going to outperform are going to be the companies that are strong in compliance, strong in service levels and have a pipeline, and those are 3 components that we feel that we're very well positioned on a go-forward basis. Regarding the question on potassium, if I recall, and help me out here, I think we had shown a waterfall bridge about some, maybe the last quarter or so, that we were referring to some unapproved products that were delayed."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified -- although we did not identify it as potassium, but now we can -- the demand of revenues associated with t",145,"Yes. I think what I would say, Paul, is that we had referred to it, and of course, if you were to go through our Q1 presentation, we had identified -- although we did not identify it as potassium, but now we can -- the demand of revenues associated with this product is pushed out of '16. I would hasten to add, though, that as the removal of the FDA -- sorry, of the products gets pushed out, the possibility of a new generic competition for the product is there at some point, right? So there's a -- it's probably a finite life for potassium chloride. We don't quite know what that is. So I would not automatically assume that the same upside that we moved out of '16 will be there for '17. But clearly, a substantial component of that will materialize in '17."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?",26,"One last question. Just on the 505(b)(2)s are there other ones we should think about in '17, or should just think about potassium at this point?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think right now we're just prepared to talk about the 2 potassium products.",15,"I think right now we're just prepared to talk about the 2 potassium products."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Douglas Tsao with Barclays.",13,"And our next question comes from the line of Douglas Tsao with Barclays."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program thro",163,"Just first, maybe Paul, if you could help us understand in terms of your comment about 505(b)(2)s, in terms of the pipeline. I mean, are you suggesting that the bulk of the growth we see from the generics business will come from the 505(b)(2) program through 2017? And is that lasting to '18? And the just also, I was hoping you could provide some additional color in terms of the comments in the slides that the sort of generics business is going through some of the same dynamics that they were in 2008, 2009. If you could provide a little color in terms of what exactly those dynamics were. And then just in terms of the controlled substances generics business. One of your competitors sort of had a better quarter, similar to you, in terms of the near term, but they did suggest that maybe some of the headwinds would persist into '17. Are you expecting to see that same dynamic play out?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally,",243,"Okay, so there's a lot there. Let's see if we can tackle them one by one. Okay. So in terms of how we're looking at 2000 -- now we're not going into great detail about 2017. I think that's something we have avoided providing guidance. But maybe generally, high level, we are launching somewhere between 25 to 30 ANDAs in 2016. I would say that, that is probably a normal run rate for just the -- for an ANDA standpoint. On top of that, you're going to see the potassium products start to gain some traction. But I would tell you that there's not like a blockbuster Zetia [indiscernible] that I'm pointing to right now for 2017, but we have 25 to 30 launches that are going to make up a good part of 2017. They're all important, and that's the way that we are building out ourselves. So you got to look at the ANDAs. You got to look at the 505(b)(2)s. And then on top of that, we have a very successful and growing injectables business that is still a big part of our future and we'll start to see more benefit of -- of that particular segment and our alternative dosage forms, all coming into play. So new launches are important, but we're also still driving value through some of our launches that we've seen in 2015 and '16 on the injectables side. So that was the first question. And..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to us, and there's obviously multiple ideas that Paul and the team will progress in a given tim",95,"I think I would just add one thing to that Doug, and obviously, I think what you are -- what you see from us is that the 505(b)(2) strategy is an important one to us, and there's obviously multiple ideas that Paul and the team will progress in a given time. But we are not going to specifically talk about anything beyond the ones that we have, simply from a competitive standpoint. Paul, I think, the remaining questions are on the dynamics in the market in the 2008 timeframe and in the controlled substances outlook."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was hit fairly hard because the type of portfolio that we had, which was a, f",280,"Yes. So 2008, some the challenges that we all had is that we all went through the economic crisis, and we had to make some difficult decisions back in 2008 and 2009. I think Par was hit fairly hard because the type of portfolio that we had, which was a, for the most part, a commoditized business. And we had to make certain and tough decisions based upon how we started looking at products on a go-forward basis. And we were also a little bit on the volume side versus a value side. And we made a conscious decision to start to look towards more difficult-to-make products. Now that's something that we've executed very, very well on, and that's where we're looking at our total portfolio. Now immediate-release products are always going to be important to Par, right? And that's going to help build volume incentives for wholesalers. But we're looking for longevity, and that's why you're going to see us move more towards the alternative dosage forms, the injectable forms and continue with the Paragraph IV side. That is a key difference from today versus where we were back in 2008. The challenge that we have today is the consortiums. The consortiums have gotten bigger and stronger, and that goes right back to having to execute on -- on the earlier statement that I made, is the companies that are going to survive and do well are the companies that going to have compliance across-the-board, something that we've done very, very well. We spend an enormous amount of resources and CapEx into compliance, service levels and execution on the R&D side. And there was a question on controlled substances?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Controlled substances outlook.",3,"Controlled substances outlook."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think, with the consortiums getting larger, they have allowed some new players to come into market and get quota. We talked about",104,"So controlled substances, again, an important part of the overall portfolio, but it's not the barrier that it once was. And I think, with the consortiums getting larger, they have allowed some new players to come into market and get quota. We talked about this in the past. Still an important part of our business, but it is more of a base business play as I see it, right? So it's important, but it's not the growth driver that it had been previously for a number of years. But again, for Par, every product's important. Just doesn't have the barrier that it once had."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Do you expect some of the headwinds to persist into next year?",12,"Do you expect some of the headwinds to persist into next year?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","In -- specifically in pain?",5,"In -- specifically in pain?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Controlled substances.",3,"Yes. Controlled substances."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion -- that natural erosion across-the-board, right? Now wha",128,"Again, so we're starting to see the challenges that we're just seeing on the opioids. So from the sheer nature of these types of products being somewhat out of favor right now, you're seeing erosion -- that natural erosion across-the-board, right? Now what you're going to see is an uptake in other pain medications, right? Those are things that we also have to take into consideration. So I'm not going to say it's an even trade-off, but the scripts have to go someplace, so maybe they're going to be moving away from opioids, but you have to look at our entire portfolio. And we have other products in our portfolio in pain that are outside of opioid. So that's pretty much the way we're looking at it today."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us.",34,"The other thing we would say is we don't expect to a major reset as we saw in Q1 against our pain portfolio, as most of that impact was already felt behind us."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Marc Goodman with UBS.",13,"And our next question comes from the line of Marc Goodman with UBS."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is ""Hey, we thought these products were going to",145,"Paul, just to confirm. So on these 505(b)(2)s, you have had the conversations with the FDA. You're comfortable that the FDA is actually comfortable with you with all the supply issues. And now, the guidance is ""Hey, we thought these products were going to launch next year, but now we have a lot of certainty and we will be launching these products next year."" So I just want to make sure that, that's what I'm hearing. Second, when you talked about the $15 million to $20 million of buying patterns in generics that 2Q pulled out of 3Q, can just tell us which area it was in? You break out the business in base, the injectables or the new launch alternatives, so which one was it in? And then third, can you just tell us what the gross margin was for generics for the quarter?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communicati",165,"Regarding the potassium products, I think the safest way to address the question is, what the FDA is telling us is that we need to be prepared to produce product. And that is what we're doing. So in essence, our understanding is there's been a communication to the unapproved sources of liquid and powder that there is a specific timeline that they have to finish up certain amounts of manufacturing and the ability to sell through at a certain point in time. That's going to come to an end in 2016. Now there's going to be a product that will be in the market, but we don't know is exactly the number of units that these unapproved sources will be making up both forms of potassium. That will carry into some period of time. What we're saying now though is, that we have with reasonable confidence that we are going to get the benefit in 2017. Likely, we'll see the benefit in Q1 or Q2."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?",22,"And just to be clear, so what's new here is that actual communication from FDA to the generics has already gone out?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","That's our understanding.",4,"That's our understanding."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","And that just went out, like in the past month, or this is new news?",15,"And that just went out, like in the past month, or this is new news?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","This has gone out over the last several weeks.",9,"This has gone out over the last several weeks."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Your question on the buying...",6,"Your question on the buying..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of a",148,"Yes. So Marc, it's Suky on the customer stocking and the advancement of orders, where we characterize about $15 million, $20 million. It's really across the entire portfolio, it's not a specific customer nor a specific product or segment. So I'd kind of allocate it proportionately to our different business units within generics. So base business is roughly around 50% of the total revenues, so I would account for maybe 50% of that $15 million to $20 million in base, and the rest of it across the other portions of our business. And then I think there was another question, on the gross margin, sorry. Yes, so gross margin held up right, right in line with expectations. So we set guidance for full year of generics gross margin in the low 50s, and that's where we ended in Q2. And our outlook remains consistent for the full year."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Randall Stanicky with RBC Capital Markets.",15,"And our next question comes from the line of Randall Stanicky with RBC Capital Markets."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward",75,"I just have another generics question, and then a mesh question. But Paul, just to approach the same topic from maybe another angle. As you think about the generics base environmentally, 2Q versus 1Q, should we think about this as a reset and move forward with things improving? Or do you still view this as, I'll call it cyclical uncertainty that's going to linger as FDA continues to ramp approvals, or a combination of those?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, i",176,"So Randall, I don't think anything's really changed in terms of what we've communicated on the sequential erosion, right? So the important thing is that we dealt with the consortium bid cycle, and we all know what the impact was. The important thing is, is that the portfolio has been reset, resized, and we had 5% erosion sequentially between Q2 to Q1. And while the major consortium hit is behind us, we still have the right of first refusals, those are normal course. That's still going to come at us from the base business play. So I think we're going to stay with that 5% sequential base erosion quarter-over-quarter throughout 2016. After that happens, and we still feel good, we communicated as we get to 2017 that base erosion should normalize --  and ""normalize"" was defined as historical Par base erosion. And that's where we were getting to that 10% number, maybe even a point or 2 higher. But about 10% is what we're looking at on a go forward basis as we enter into 2017."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","But stable beyond?",3,"But stable beyond?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters in",87,"If -- I feel that, that is -- it will be stable. I don't see a large consortium hit that we experienced with the McKesson OneStop. So from that standpoint, yes, it will be -- it will normalize. Now I'd like to see what happens with Walmart as it enters into OneStop. That's also something that we need to think about. But at this point in time, taking that into consideration, we still feel that, that 10% will be the right erosion factor on a go-forward basis."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay, great. And then, Suky, just a quick question for you, on mesh. For -- on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys",53,"Okay, great. And then, Suky, just a quick question for you, on mesh. For -- on the after-tax mesh liability for next year, has that changed from the number you gave us in early March? And then, the lingering 8,000 cases, I mean, any change in how you guys are thinking about those?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is",109,"Sure. So I'll talk to the numbers, and then maybe Rajiv, you'll talk to the, sort of where we are on the rest of the cases. So on a pretax basis, consistently around $600 million to $700 million next year. And then there is a tax shield on that, which is ultimately embodied in a low single-digit tax rate for 2017. So we do expect to see a cash tax rate for 2017. So we do still expect to see a post-tax mesh cash call, which is significantly lower than $600 million to $700 million. So nothing has changed on that front. And then on the remaining 8,000 cases..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which,",215,"Yes. So Randall, I think you're referring to the commentary that we made earlier this year when we entered into a set of settlements around some high-value cases. At that time, we said that there were another purported 8,000 or so cases out there, which, largely speaking, is not, where we largely speaking do not have much information about these cases. And that has not changed. And the incidence of new claims coming in has also been -- has trickled down to a, to the low single digits on a weekly basis, and it's been fairly consistent for the last several months. The other thing we pointed out with those 8,000 cases was that there was a potential fraudulent scheme that was running through some components of that, and our priority was driving that to the ground and figuring out whether in fact that there was fraud perpetrators. So we have a series of subpoenas that have been issued. We are able -- we are in litigation mode around those subpoenas. But as we pointed out, back in the beginning of the year, this process, it would take months, if not several quarters, to resolve. And we continue to defend ourselves through this process. So in other words, no new news in terms of mesh."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Andrew Finkelstein with Susquehanna.",13,"And our next question comes from the line of Andrew Finkelstein with Susquehanna."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run",103,"I was hoping to go back to Vasostrict. There was a suit filed by a potential competitor, and I was wondering if there are any statements you can make about your contractual relationships with API suppliers for vasopressin. And then, as we look at the run rates for some of the branded products in the quarter, is there anything else to point out? You talked about the destocking on XIAFLEX. But some products like LIDODERM and OPANA, how do you characterize the sales for those in the quarter relative to what you might consider a run rate, based on where the scripts are?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Sure. Paul, you want to...",5,"Sure. Paul, you want to..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some -- the other earnings call. It is true that we do have an exclusive",100,"So on Vasostrict, obviously, we're not going to be speculating on any ongoing litigation. And I think what we can do is just really reaffirm some of the facts that we've discussed on some -- the other earnings call. It is true that we do have an exclusive arrangement with a single API source, and it is understood that there are multiple API sources available. And ultimately, we are prepared to vigorously defend our intellectual property and also our position in respect to this particular case. So that's probably as far as we can go at this point in time."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Is that to say that you do not have exclusive arrangements with the others?",14,"Is that to say that you do not have exclusive arrangements with the others?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","I think what we said is that we do have a single, exclusive arrangement with an API source.",18,"I think what we said is that we do have a single, exclusive arrangement with an API source."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are a",275,"And Andrew, just on your question about the branded products, we have the benefit of a pretty diverse portfolio of products beyond BELBUCA and XIAFLEX, though obviously, we point to those as our future growth drivers. And from quarter-to-quarter, we are able to benefit from the performance in those brands. So there are brands like LIDODERM, which, as a branded product, has now really been reduced to a small component, because the product is, as far as we are concerned, fully genericized with 3 generic competitors in the market, including our own authorized generic. But from a contracting standpoint, we still hold some proportion of the market on our branded product. But clearly subject to generic pressures. OPANA, we pointed to OPANA as one of the products that was impacted by the CDC guidelines and the general slowdown in the opioid market, and I think that trend is continuing along the lines that we expected. But we also have a series of smaller products that we don't talk much about, that are also doing quite well, that are promoted. SUPPRELIN L.A. has been a very sticky and very good performance for us for a long period of time. NASCOBAL, which is a product that came over with the Par transaction and is a branded product that's promoted by our field force, is also doing quite well, right? So as we look across the portfolio, in the branded business, beyond the ones that we actually talk about, we do see points of good performance, which just helped us in Q2 and we expect to help us over the course and remainder of the year as well."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Jason Gerberry with Leerink Partners.",14,"And our next question comes from the line of Jason Gerberry with Leerink Partners."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how do you think about the mark",68,"Most have been asked, but maybe, Paul, I didn't hear you mention adrenaline as a 505(b)(2) opportunity. There was a big pickup in price in June IMS sales, and just curious if that's -- there's a potential opportunity there, how do you think about the market? Where is the market competition mainly in compounding pharmacies? Just kind of curious if you have any thoughts there; that'd be great."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basical",121,"Well, adrenaline is very similar to Vasostrict, with the exception that adrenaline is typically first-line therapy when you go into an emergency room, with respect to cardiac resuscitation or anaphylactic shock, followed by Vasostrict. So they are basically sold and promoted exactly the same way. They just -- one is first-line and one is second line. With respect to the uptick, right now, we did -- we took an appropriate price increase. It is an NDA. We follow the same practice in terms of it being an unapproved product. It is now an approved 505(b)(2). So it's similar in nature into what we've done with Vasostrict, but for the fact that there are unapproved sources of adrenaline on the market today."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of David Buck with Northland Capital Markets.",15,"And our next question comes from the line of David Buck with Northland Capital Markets."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that",120,"One for Paul and one for Suky. Paul, in your commentary on Vasostrict, you talked about converting the unapproved products and coupled to that price increase that you recently took. Is it fair to say that you've gotten most of the volume opportunity that you're expecting, and that there'll be more easing volume and you're just benefiting from that recent price increase? And for Suky, can you talk a little bit about what you see as some of the key detractors sequentially, with regards to the third quarter revenues? Looks like a fairly strong downtick. I know that the wholesale volume is not going to recur, but what other items you're expecting to go the other way, to go negative?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last",139,"So David, I think you understand the Vasostrict situation pretty well. We launched the product probably about 1.5 years ago. And the way we see it right now is that we do not believe that there is any more unapproved drug in the market, so maybe the last quarter or 2, you're seeing standard run rate for Vasostrict. So I think we've met our max on the volume side of Vasostrict. So that's where we are now. As Rajiv indicated, we took a modest price increase. That's the way this product is going to behave on a go-forward basis. So I think we've maxed out on the volume side. And it's just being able to navigate with the market, and if we are to take appropriate price increases on a go-forward basis. But we haven't made any determinations yet."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter",288,"Yes, David. And it's Suky, on your question around the third quarter sequential reduction, the first thing I would say is, generally as a default, we tend to prefer not to give quarterly guidance because there are a lot of things that can affect a quarter, specifically around timing that could be material to the quarter. But on a whole year basis, they're not meaningful. But having said that, given our reset in Q1 and given the launches that we've got in fourth quarter, we are providing quarterly guidance at least for this year. For the third quarter, the way to think about the step-down is, one, you talked about already, which is the stocking that we saw in the second quarter. Our assumption is that reverses in the third quarter. Also, what underpins our assumption of the step-down is continued erosion in retail as that continues to face competition from a generic standpoint. We would expect LIDODERM to step down modestly. Our testosterone products continue to decline quarter-over-quarter, particularly because of the market. And then, again, we also expect to see some modest decline in our pain products. All of those declines are partially offset by growth in XIAFLEX and BELBUCA as well as Par launches. But net-net, our assumptions lead us to a decline on revenue into the third quarter. From an investment standpoint, that's all coming in the backdrop as we increase our investments against generics R&D as well as branded R&D and BELBUCA and XIAFLEX, as Rajiv has talked about earlier. So those are the moving parts that lead us to the third quarter. Again, what we're doing is taking a very prudent approach of applying quarterly guidance, given the lumpiness of the year."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?",16,"That's helpful. And is there any change in assumptions for branded gross-to-net that's negative, sequentially?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains.",30,"At this point, we wouldn't see anything material sequentially. Again, there can always be lumpiness from quarter-to-quarter, but for the full year, our gross margin profile for the brand remains."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Donald Ellis with JMP Securities.",14,"And our next question comes from the line of Donald Ellis with JMP Securities."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions o",45,"Most of my questions have been answered. But since you guys traffic in the opioid market pretty significantly, what can you tell us about your current thoughts about when, how and if there will be a meaningful transition to the opioid deterrent versions of narcotics?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","The -- As you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being sai",156,"The -- As you point out, we have had a lot of experience and heritage in the pain market, including in opioids. And we ourselves have done a lot of work around OPANA's reformulation, in fact, to make the abuse of the product more difficult. That being said, I think the -- to the public health environment debate around this, FDA dialogue around this, while encouraging abuse deterrent formulation, it's still unclear at what point the entire market will shift to products that are ""abuse deterrent"" right? So the -- in terms of the FDA's own determination of what constitutes it, that's a lot of debate. We don't have a crystal ball, and we'll be speculating. But, with -- Certainly, as we look forward, on a longer-term perspective, one would think that the long-acting products would transition to more abuse deterrent formulations. But is that going to happen in the short term? That is anyone's guess."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","How do you think that they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?",25,"How do you think that they're going to deal with the pushback from the PBMs in the reimbursing for, likely more expensive, abuse-deterrent versions?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet",137,"Again, look, I'm just speculating, but I would also say the following, which is, while there is a lot of debate in the public health environment about this and certainly from the pain environment as well, in the end, chronic pain is one of the most unmet needs in the country. There are 100 million patients who suffer from chronic pain, and there are certain categories of pain, such as cancer pain, that you are going to need an opioid in order to survive and manage that kind of pain, right? So I think, in the end, from a pure patient need standpoint, we do believe that the opioid, schedule 2 opioids will have a place in the market for that. Now from a pricing standpoint, and how PBMs reimburse versus regulated, that I really can't answer."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Elliot Wilbur with Raymond James.",14,"And our next question comes from the line of Elliot Wilbur with Raymond James."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage p",265,"Real quickly, maybe just a point of clarification for Paul. Paul, earlier, when you talked about 2017 returning to more of a normalized erosion environment for the generics business, mentioned essentially a 10% erosion rate, maybe a couple of percentage points more. But I just wanted to make sure that applies to the entire generic book of business or just my assumption would be that the injectable piece, of course, would be much more stable, and that rate would sort of apply to the solid dose business, but I wanted to confirm that. And then for Suky, question earlier was asked about sort of the ability to realize price increases on Vasostrict. And just trying to get a better sense of how we should be thinking about the company's ability to sort of realize those price increases, whether or not there's been any change in that -- the relative realization rate, in terms of what's actually dropping to the pretax line. And then, last question for Rajiv. You talked several times now about accelerating investments and continuing to invest both the additional resources on the R&D, and the selling and marketing side to drive some of your future high-growth assets. And obviously, the message has been heard loud and clear with respect to '16. But I guess, in sort of thinking about external expectations in '17, '18 and kind of beyond, it seems like the anticipation at this point is that spend levels remain relatively flat. I'm just kind of wondering, how you're thinking about maybe that, maybe just in general terms, at least directionally."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that -- that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And t",123,"Okay. So Elliott, this is Paul. And to the first question, I apologize if I wasn't clear. In terms of that -- that 10% range on base erosion, that is, as we define, the collective Par and Qualitest business as we look at how we define base business. And that includes our extended-release solid oral dosage, our immediate-release solid oral dosage, in our pain controlled substances group. So it excludes injectables. It excludes the alternative dosage forms and, of course, new products. So that's the way we're defining it. And maybe you can just help me out on your Vasostrict question. I want to make sure I understand it. I know it went to Suky, maybe you could just repeat that for us."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize on that level of increase? I'm trying to get a sense of how much of it falls to the pretax line.",52,"The long and short of it is, as the list price goes up 20%, has there been any dramatic change in terms of sort of what the company could actually realize on that level of increase? I'm trying to get a sense of how much of it falls to the pretax line."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now.",37,"Yes, sorry, Elliot and I guess this goes back to the question that David asked as well. We don't see any major change in the complexion of gross to net on Vasostrict and where we are now."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now in the, in a very g",200,"And then Elliott, in terms of your question on investment. If I just step back for a second here, over the course of the last 3 years, we made some major steps, major progress in reshaping the company. And I think we find ourselves now in the, in a very good position where we have some great assets across all of our businesses. And as we transition our business to really being an organic growth story, it is a very important imperative for us that we begin to really invest for future sustainable organic growth. And so hence, the investment step-up that we're talking about in R&D and hence the investment behind, as like XIAFLEX and BELBUCA that we think are going to be real growth drivers over the course of the next 5 years. At this point, we can't make any comment on investment levels in '17 or '18. But I would point to the fact that what we're talking about is investing in long-term growth assets, right? So long-term growth assets require long-term investment, and that's our philosophy. And obviously, we'll take a more specific view on what that means for '17 and beyond when we get there."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our next question comes from the line of Rohit Vanjani with Oppenheimer.",13,"And our next question comes from the line of Rohit Vanjani with Oppenheimer."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict.",169,"One, did you notice any favorable share shift in OPANA after the district court ruling in May? Two, and then, I think you took price increases at the beginning of 3Q on a series of products, LIDODERM, PERCOCET, SUPPRELIN and then you mentioned Vasostrict. Are your wholesaler contracts structured pretty typically, where they have a 30-day buy-in, so you'll see 2/3 of the price increase in 3Q, and then the full amount in 4Q? And then, could you actually give the XIAFLEX vial shift and the breakdown in Perrone's and Dupuytren's for 1Q and 2Q? And then lastly, the strength in -- well also for the guidance where you maintain the guidance that you have this added expense in BELBUCA and XIAFLEX. So what's making -- I was a little bit confused about how you're maintaining it. Is it from the strength in the quarter, and the surprise in V Gel, and other products that's allowing you to maintain the guidance or where is that offsetting strength coming from?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the -- about the patent cases, the ruling",61,"Okay, so there were a lot of questions there, and I'll see if I can get all of them and then I'll ask Suky to help me with that. In terms of OPANA, just to clarify your question, what was it? You were talking with the -- about the patent cases, the rulings and our path forward there, is that accurate?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","I was just asking yes, if you saw a share shift because of the ...",15,"I was just asking yes, if you saw a share shift because of the ..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Share shift. I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt.",37,"Share shift. I'm sorry. So yes, look, we've seen a modest share shift. But as we had always indicated, the majority of these prescriptions we expect it to go to the impact of generic, which is debt."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Yes, and I was just wondering if there was any upside from whatever you thought kind of ...",18,"Yes, and I was just wondering if there was any upside from whatever you thought kind of ..."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Look if -- there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the",108,"Look if -- there are puts and takes in OPANA, right? So there's a little bit of modest uptick in share, and possibly continued uptick because of our increased promotion because the product is in a P2 position behind BELBUCA in our pain pill force. On the other hand, you have the declining opioid market effect, right? So net-net. It is not a product where we expect to see any substantial uptick. The -- you had a question on XIAFLEX. So in terms of XIAFLEX vials. And I'm happy to go through them, but they are, in our FAQs for the first quarter as well as second quarter."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","We can do it offline, if -- sorry, go ahead.",10,"We can do it offline, if -- sorry, go ahead."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being -- increased investment in R&D and sales and marketing, so some of",90,"Yes, we can -- I will do it. It's already in the FAQs, if you want to take a glance through it. It's identified between the 2 indications. In terms of your question about investments being -- increased investment in R&D and sales and marketing, so some of it, as Suky mentioned in his script, is simply reallocation, and some of it is a modest uptick in our investment level, particularly in the third quarter, which is one of the other contributing factors to how we guided the third quarter."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","No, I was asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was it",74,"No, I was asking for the offset. So you have, what's new is you have the added expenses in BELBUCA and XIAFLEX, and you're still maintaining your EPS guidance, right? So I was wondering what changed for you, that was positive to make you keep that. Was it the strong quarter, where you got strong V Gel and other products, or is there something else going on where you're allowed to maintain your guidance?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well.",39,"Yes. So part of it is the upside coming from the second quarter. Part of it is that we do feel good about how gross margin, how the gross margin profile is trending in the second half as well."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And the last one I had was the bit about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the pric",62,"Okay. And the last one I had was the bit about your price increases, where you took some price increases on LIDODERM PERCOCET, and SUPPRELIN. Do you have typical wholesaler contracts where it's -- they get a 30-day buy-in, so you see maybe 2/3 of the price increase in the quarter, you take the price and then the full amount in 4Q?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointe",61,"No. We don't have that phenomenon in our wholesale agreements. What I would also say is that much of our branded portfolio is contracted. So these price increases don't automatically translate into gross margin improvements. We've kind of generally pointed to the overall price increase benefit generally is in the mid-single digits for our branded portfolio, on a full year basis."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","And our last question comes the line from Irina Koffler with Mizuho.",12,"And our last question comes the line from Irina Koffler with Mizuho."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Analysts","It seems like your XIAFLEX is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. You guys are doing a great job with those 2 products. But are you really the best owners of these assets? Do you have the right synergi",58,"It seems like your XIAFLEX is doing really well, and it's a very durable asset, and the same thing with SUPPRELLIN L.A. You guys are doing a great job with those 2 products. But are you really the best owners of these assets? Do you have the right synergies? And would someone else potentially value these assets more?"
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets fall squarely into the type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The type",115,"So Irina, I can't speak to how someone else would value the assets. But what I would say that these assets fall squarely into the type of assets that make sense for a company like us. They require a relatively small sales and marketing footprint. The type of support, in terms of advertising and promotion that's required around the brand, even with the step-up, is well within the means of a company like us. And also, when you look at the R&D pipeline and the investments that are required to develop XIAFLEX, which is already a well-characterized molecule from a safety and effectiveness standpoint, we do think we are the right owner of these assets."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Executives","Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon.",18,"Operator, I think that wraps up the call. We'd like to thank everyone for joining us this afternoon."
28071,375875901,1031900,"Endo International plc, Q2 2016 Earnings Call, Aug 08, 2016",2016-08-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri M",53,"Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri Mattox, Senior Vice President in Investor Relations and Corporate Affairs. Please go ahead."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appoi",246,"Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appointed interim Chief Financial Officer; and Joe Ciaffoni, President of Endo Pharmaceuticals, our U.S. Branded business. We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Paul. Paul?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our third quarter 2016 earnings p",870,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our third quarter 2016 earnings presentation. To start, here's a brief agenda for today's call. Moving to Slide 3. As you know, the third quarter brought some changes and I believe, a sharpened focus on operational execution at Endo. Despite some headwinds for our Generics Base business, the overall diversity of our portfolio did enable us to deliver solid revenue and adjusted earnings per share results in the third quarter with revenue performance across all business units broadly in line or ahead of company expectations. 
I recently took on the role of CEO, and I am working to realize the potential for Endo moving forward. Our product-by-product assessment of the business and our portfolios is in progress, and we are working on the development of a strategic plan. Importantly, we are once again pleased to reaffirm our 2016 revenues and adjusted EPS guidance. 
On Slide 4. You will see a snapshot of our segment revenues for the third quarter. 
Moving to Slide 5. Let's discuss our branded business. Our branded performance in the third quarter was stronger than our expectations, which underlies our segment revenue and margin guidance provided earlier this year. We delivered solid XIAFLEX demand, particularly in Peyronie's disease, and our revenue growth expectation for XIAFLEX continues to be in the low double digits for the year. The BELBUCA launch is progressing, and we are evaluating how to maximize the value of this differentiated product within a challenging opioid market. We did see outperformance by select U.S. Branded products, including Voltaren Gel, LIDODERM and some products in our other branded portfolio. 
Moving to Slide 6. Let's talk about our international pharmaceuticals. Our results were in line with the expectations that underlie our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we drove solid performance across our base business, launched Nucynta and secured the Canadian rights for XIAFLEX. The additions of these products can provide longer-term growth as we continue to manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our adjusted operating margins. 
Turning to Slide 7 and our generics business. We continued to deliver overall segment performance in line with our expectations. Our sterile injectables business continues to grow led by Vasostrict. In new launches and alternative dosages, we saw better-than-expected performance from alternative dosages, especially the LIDODERM authorized generic, and we have launched 15 products since the beginning of the year. We continue to file new ANDAs with the FDA while replenishing our R&D pipeline. 
Our base business declined approximately 20% sequentially from the second quarter 2016 driven by higher-than-expected consortium pricing pressures, a vast consortium structure and certain competitive generic entrants late in the quarter. Excluding stocking and onetime factors, this decline was approximately 15% from the second quarter 2016. We now expect full year base business decline to be in the low 30s percentage range. Given this deeper-than-expected erosion for our base business for the quarter and the year, our base business erosion rate in 2017 may be larger than our previous assumption of a return to historic part [ph] annual erosion rates of 10% to 12%. We will update our assumptions on 2017 base erosion as part of our full year 2017 guidance on our year-end earnings call. It is important to note that Par's strategy is focused not on this base segment but on prioritizing [ph] growing higher-quality, higher barrier-to-entry products and continuing to advance and replenish our differentiating R&D pipeline. 
Moving on to Slide 8. You will see a chart tracking our new product launches. We have updated to show the 15 products that we have successfully launched so far in 2016. We've had a number of smaller product launches shift into early 2017 and others that we have rationalized due to commercialization assessments and our ongoing portfolio of prioritization but still anticipate that we will launch approximately 20 new products this year, including our first-to-file exclusive products, generic SEROQUEL XR and generic Zetia. 
Let's turn to Slide 9 to talk about those 2 key fourth quarter launches. Importantly, we've now launched our generic SEROQUEL XR product. The initial launch has gone smoothly, and all manufacturing, launch activities and product shipments are on track. Our expected December 2016 launch of generic Zetia is also progressing on track. We have received final approval from the FDA and have an agreement in place with Merck through our partner, Glenmark. This product is manufactured through that partnership with Glenmark, and we have a product in our warehouse and we're ready to launch with marketing exclusivity. Together, we expect these 2 first-to-file launches to contribute in line with our previously communicated projections. 
With that, let me turn the call over to Blaise Coleman to discuss the financial performance of the company and the quarter and our projected outlook. Blaise?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have",483,"Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have loss per share of $0.86 in the quarter versus a loss of $3.84 in the third quarter of 2015. GAAP net loss for continuing operations in the third quarter of 2016 decreased to $191 million compared to a GAAP net loss from continuing operations of $804 million during the same period in 2015, primarily due to goodwill and intangible asset impairment charges recorded during third quarter 2015. On an adjusted basis, overall third quarter results are better than previously guided. 
To summarize the points that Paul made, revenue was strong due to continued performance from XIAFLEX and better than expected due to outperformance by sterile injectables, alternative dosages and select other branded products. Adjusted net income and EPS are better than guided as a result of higher revenues, better gross margin percentage due to product mix and lower operating expenses primarily due to timing. 
On Slide 12, we are again reaffirming our revenue and adjusted EPS full year guidance. We expect revenues to be approximately $3.87 billion to $4.03 billion and adjusted EPS to be between $4.50 and $4.80. Given our overperformance in Q3 versus our expectations, we have increased confidence in our overall full year guidance range, which takes into account several moving parts, including the range of our launch forecast for our first-to-file generic versions of SEROQUEL XR and Zetia, projections around year-end timing of product sales and shipments and continued pricing pressure for our U.S. Generics Base business. 
Moving to cash and liquidity on Slide 13. On a year-to-date basis, cash flow from operations totaled approximately $443 million. We've also highlighted some of the material moving parts that have impacted our cash flow from operations on a quarterly and September year-to-date basis. 
On Slide 14, we are updating our view on estimated free cash flow in 2016. We now project debt paydown of approximately $330 million in 2016 and to exit the year in the high 4x range for our net debt to adjusted EBITDA leverage ratio. While we've provided some color in the past on potential free cash flow headwinds and tailwinds in 2017, given our dynamic sector environment and our ongoing strategic assessment, both of which could impact cash flows in 2017 versus previous expectations, we will wait to provide any details or updates for next year until we provide our full year 2017 financial guidance in late February. 
As noted in our press release, we ended the quarter with approximately $562 million in unrestricted cash, approximately $276 million in restricted cash and a net debt to adjusted EBITDA leverage ratio of approximately 4.9x. 
Now let me turn it back over to Paul."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper",539,"Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper-than-expected base erosion trends that we see and saw in the third quarter indicate stronger headwinds on the front as we exit the year. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid cycles that we expect to wait [ph] on our generics business moving forward, could impact our adjusted gross margin profile. And our 505(b)(2) expectation and longer-term 505(b)(2) strategy has been impacted by the competitive landscape, regulatory actions and the pricing environment. We will provide more detailed insights into the expected impacts of these trends on our 2017 financial outlook when we provide full year guidance in late February 2017.  I would like to note that deeper-than-expected erosion and demand for our products and/or changes to our resource allocation resulting from our strategic assessment could result in changes in the carrying values of assets across our segments. 
Next, XIAFLEX. We've identified XIAFLEX as a core U.S. Branded product and growth driver for Endo moving forward. We continue to put resources and efforts behind accelerating traction and growth in our Dupuytren's contracture and Peyronie's disease indications. We're also analyzing our R&D pipeline. Cellulite remains the primary focus there, and we look forward to reporting out on our Phase IIb data upon the completion of that trial. Other potential indications are currently undergoing a full commercial assessment and analysis so that we can best prioritize our R&D efforts and determine clinical trial time lines moving forward. 
The launch of BELBUCA is also progressing. We continue to believe that BELBUCA offers a compelling and differentiated product profile, and we want to ensure that we are best positioned moving forward. 
Finally, as the new CEO, I am spending a lot of time evaluating and working with our legal team to further develop and execute on our strategy with respect to the ongoing mesh litigation. 
On Slide 17, let's talk about my CEO assessment process. As I mentioned, we are pleased to reaffirm our revenue and adjusted EPS full year 2016 financial guidance. Overall, business performance continues to be broadly in line with our expectations. We are in the process of conducting a bottoms-up product-by-product assessment of all 3 of our business units. We expect that we'll be ready to communicate our evolved corporate strategy in the February 2017 time frame of our fourth quarter 2016 earnings announcement. As we've done in the past, we expect that we'll also communicate our full year 2017 financial guidance and expectations for our business at that time. 
In closing, Endo is sharpening its focus on operational execution, and I am excited to be leading the company. I want to take a moment to thank all of our dedicated employees whose hard work and commitment to the company make what we do possible. We continue to believe that this is a time of significant opportunity for Endo, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Now let me turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?",23,"Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our first question is from the line of Greg Gilbert of Deutsche Bank. Our next question is from Elliot Wilbur of Raymond James.",23,"Our first question is from the line of Greg Gilbert of Deutsche Bank. 
Our next question is from Elliot Wilbur of Raymond James."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepa",116,"Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepared commentary? Just trying to figure out, is this a result of a renewed bid cycle or some structural change on the consortiums with some of the recent movement? Or is it simply just existing competitors be a lot more aggressive and current product markets or the impact of new competition or maybe all 3? But if you could just maybe give a little bit more clarity behind that, it would be helpful."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks, Elliot, and I think that's right. I think you kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real pru",280,"Yes. Thanks, Elliot, and I think that's right. I think you kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real prudent approach here. But when we look at what's happening, we did have anticipated -- especially higher-than-anticipated pressure from the consortiums, and we did, in essence, see a little more discounting for some of the more established generic competitors, so a little bit of that going on as well. When we see the 20% erosion factor that we talked about, in essence, if we exclude a couple of onetime events, we are more in the 15% erosion for the quarter. And specifically, when you look at the area in which we were -- effect [ph] that we had 2 products that were authorized generics, right? So these are products that you know that we -- that are revenue drivers. But in essence, they are large -- they're lower-margin contributors to the Par franchise. So metoprolol and budesonide were 2 products that -- we see additional competition from budesonide, and then we had a little heavier-than-expected competition at Red Oak from a competitor on the metoprolol  aging. And then structurally, we're seeing some changes at McKesson. As you know, they are moving away from their San Francisco operation, and you're going to start to see a shift in McKesson to their European operation now [ph] referred to Claris 1. So they're starting to kick in, and you'll see a change on a go-forward basis as they kind of unite with Walmart."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from the line of Louise Chen of Guggenheim.",12,"Our next question is from the line of Louise Chen of Guggenheim."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expecte",47,"It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expected to continue?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay, great. So I'm going to pass the first question over to Blaise.",13,"Okay, great. So I'm going to pass the first question over to Blaise."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter [ph] of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at o",176,"Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter [ph] of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our growth rate sequentially for XIAFLEX at a total molecule level, we grew about 12%, and the majority of that was due to a stocking movement. At the end of Q2, we had about 6 days on hand. And at the end of Q3, we have about 8 days on hand. In terms of gross margin, we had favorable mix during the quarter, again a little bit stronger than the sterile injectables and some of the areas that Paul talked about. If you look at our full year guidance, we did change our assumption to be at the upper end of our gross margin range. So we would expect to see the events [ph] that we've seen on a year-to-date basis playing through on a full year basis."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray. Our next question is from Jason Gerberry of Leerink Partners.",20,"Our next question is from David Amsellem of Piper Jaffray. 
Our next question is from Jason Gerberry of Leerink Partners."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that becaus",108,"I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that because fourth quarter is usually a little bit seasonally strong. And then the second question Paul, maybe -- can you provide a little bit of framework of this DOJ process? I mean, how do you think in general these processes play out from a time line perspective, how long before investors can get some visibility regarding how this process may evolve?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just",247,"Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just talk to the facts here. So this is a subpoena that we received over 2 years ago, and I think it's safe to say that we believe that we've cooperated with the DOJ and that there's -- in essence, there's no new information. And as it pertains specifically to Par, it was a focus around 2 products and one product of which we do not even sell. So from that standpoint, we're feeling reasonably confident in our position. At least that's what we believe. And to be specific, the issue deals with a product called doxycycline hyclate. It's a product we do not even sell. There may be some confusion at the DOJ, but we sell a product that was called doxycycline monohydrate. And then the second product is a product called digoxin. And in essence, what occurred there, Par came into an already established market with 2 generic competitors, plus the brand. We were the fourth entrant to an established market, and we never took our price -- there was never a price increase with respect to digoxin. So I think that's probably a statement of fact here by Par, and that's our position."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","[Yes. Jason, and on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales las",68,"[
Yes. Jason, and on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last year on a pro forma basis is [ph] on a pro forma basis were around $50 million."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Randall Stanicky of RBC Capital Markets.",11,"Our next question is from Randall Stanicky of RBC Capital Markets."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Paul, is this heightened generic erosion, is this just cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the",94,"Paul, is this heightened generic erosion, is this just cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the generic side could make sense if we're looking at a couple of years down the road. But I guess the question specifically, do you have visibility or comfort level that 2017 could be get a low watermark for some of these challenges and headwinds? And then I have one quick follow-up."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, branded, the erosion factor here was greater than what we had originally assumed. An",237,"Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, branded, the erosion factor here was greater than what we had originally assumed. And we have communicated earlier that we thought we're going to be in the 10% to 12% range for 2017. The reality is that it'll be likely a little more steeper than that and that we [ph] just want to be a little bit mindful and thoughtful on how we communicate this. But when you look at the Par portfolio, the base is really not our focus. When you look at the products in our pipeline, products that we're launching, we're looking at more differentiated products. So we are -- as you know, as we call the portfolio out in some of the historical Qualitest products, we're now really moving to more technically challenging products that should be able to withstand pushback on either the trade or competitors. So we're shifting away from a highly commoditized portfolio as we move forward. So I feel we're going to have more erosion to deal with because the portfolio is still quite large. But over time, as we launch more products, we should be in a better position to keep our margins at the historical 50 -- low-50 percentage [ph] on a go-forward basis."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So can we just narrow that [indiscernible] a bit? So you were talking about a 15% erosion factor net of one-timers [ph] in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual.",66,"So can we just narrow that [indiscernible] a bit? So you were talking about a 15% erosion factor net of one-timers [ph] in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think about the near term relative to what we're seeing currently versus what you previously guided?[ph]"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you k",135,"Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you know, on the authorized generics side, Par is holding a small percentage on gross margin, yet we booked the sale. So when we get hit on competition, it's not uncommon to see a higher erosion factoring as the portfolio swings away from AGs into more differentiated products, a likelihood is that we will be able to push back. But I just want to be a little mindful that there's still a fair number of commodities in the portfolio and we'll come back and provide more color in 2017."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Marc Goodman of UBS.",9,"Our next question is from Marc Goodman of UBS."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said there longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? O",83,"When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said there longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or is the FDA more against approving these 505(b)(2)s? Or basically the pricing is going to get worse for these things. So is it all 3 of them? Or is it one versus the other, just give us more color I think."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So sure. So Marc, when I look at 505(b)(2)s, I'd li to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo Par strategy, but I'd break them into 2 categories. When you",404,"So sure. So Marc, when I look at 505(b)(2)s, I'd li to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo Par strategy, but I'd break them into 2 categories. When you look at portfolios that are historically in either the injectable portfolio or even some of the legacy Par brands that have shifted over to Endo, those are pure 505(b)(2)s, and we have the resources and the R&D to continue to develop those products. But just to drill into specifically where I think you're headed is when Par undertakes a conversion of an unapproved drug to approved status, and those I break into 2 categories, operate those into a category whereby we will continue with our 505(b)(2) strategy of taking unapproved drugs and converting them, one into requisite clinical trials and putting a brand strategy behind that, where that may be detailed either through Joe's Endo team or Tony injectable team. That we will fight for intellectual property. That falls into one category. We have intellectual property, it should be normal course. The product will be priced appropriately for the work in which we've done to get approval for, and then hopefully, our intellectual property will stick and we have something that we can build upon. Where we're getting some challenges is in the third category where we developed a 505(b)(2) where we now have a brand we are working with the FDA to remove the unapproved sources yet we don't have intellectual property. So now we have a timing issue. That's an area that we just need to pause a little bit because the window is a shorter period of time for contribution. So now in today's environment, there are pricing pressures and we got to be a little bit mindful of that. So we will continue with the strategy, understanding that we can get intellectual property, that these 505(b)(2), in essence, will behave like a super generic, where we'll have the benefit and contribution driven by volume, but the pricing environment is going to be a little bit tighter and the likelihood is that you will see ANDAs coming in at a quicker rate, but that's fine. That's still a meaningful product for the Par portfolio and we will continue to do that, but that's where we will see a little pressure."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Chris Schott of JPMorgan.",9,"Our next question is from Chris Schott of JPMorgan."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Dana Flanders on for Chris. Just my first one. Can you maybe talk more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines just how wou",95,"This is Dana Flanders on for Chris. Just my first one. Can you maybe talk more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines just how would you characterize replenishing the pipeline and expanding the alternative dosage form business? And then my second quick one, just on Vasostrict, the competitive landscape, just any updates today. Or is this still status quo and you're feeling pretty confident on exclusivity for the next year or 2?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So the first one is on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. The product is run",289,"So the first one is on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. The product is running. It's converted nicely, and in essence, there is no update and I view that as a positive. Regarding the 2017 pipeline, we've kind of touched on this. Well, we're not going to disclose specifically our products because we don't place ourselves at a competitive disadvantage. What I will call out is we don't have the 2 blockbusters that you're seeing right now in Zetia. That we don't have but you need to remember that we are getting the benefit and the carryover of those 2 products from the fourth quarter of 2016 into the first quarter. So that's going to help us project into 2017. We've got a solid pipeline but they are smaller products. Some of them contain Paragraph IVs, some are first-to-market opportunities. At this point in time, we're not going to disclose them because we're not going to place ourselves at a competitive disadvantage. We're going to continue with our 505(b)(2) strategy. We're doing very nicely with our potassium liquid product. We're starting to build momentum with our potassium powder product. Vasostrict continues to perform. The injectable portfolio continuous to perform. And as I indicated before, our strategy, as we pick our R&D pipeline targets for the generic sector, we are going to continue to fund more opportunity into the injectable hard manufacturer category and we're going to continue with our modified release solid oral dosage approach whereby we are hoping that we will get less competition."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Donald Ellis of GMP Securities.",10,"Our next question is from Donald Ellis of GMP Securities."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us [indiscernible] is the reimbursement landscape improving for BELBUCA? And then it looked like th",61,"A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us [indiscernible] is the reimbursement landscape improving for BELBUCA? And then it looked like there was a drug product over our corporate inventory in the quarter. Would you be able to quantify that?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe Hughes who can talk a little bit about BELBUCA.",32,"So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe Hughes who can talk a little bit about BELBUCA."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, thanks for the question Donald. From a XIAFLEX perspective, the big breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective, we generally ha",63,"Yes, thanks for the question Donald. From a XIAFLEX perspective, the big breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective, we generally have broad availability in line to the label. And where we are working on improving the reimbursement is both in Medicare and Medicaid."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And terms of the inventory question, we already talked about XIAFLEX from a generic standpoint. We did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million.",44,"And terms of the inventory question, we already talked about XIAFLEX from a generic standpoint. We did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Liav Abraham of Citi.",9,"Our next question is from Liav Abraham of Citi."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Can you just remind us of the pushes and pulls in cash flows, in free cash outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?",34,"Can you just remind us of the pushes and pulls in cash flows, in free cash outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Liav, this is Paul. I'm going to pass on that question on the free cash flow over to Blaise.",19,"Liav, this is Paul. I'm going to pass on that question on the free cash flow over to Blaise."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to provide any forward-looking com",128,"Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to provide any forward-looking comments for '17 either from a P&L or cash flow standpoint. In terms of your question on covenants, right now just to remind you, we do have 2 maintenance covenants on our secured debt, which is our term loans A and B and our revolver. And so our secured leverage covenant is less than 3.85x adjusted EBITDA and we're currently at 2.1x, and we also have an interest coverage covenant which that is -- this the covenant is greater than 2.5x and we're currently at 3.8x."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Stephan Stewart of Goldman Sachs.",5,"Stephan Stewart of Goldman Sachs."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just wanted to follow up on the pipeline question. Without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics",46,"Just wanted to follow up on the pipeline question. Without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics business beyond first half of '17?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Again, I think right now, we're going to come back in February of 2017. We'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there has been some c",98,"Again, I think right now, we're going to come back in February of 2017. We'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there has been some challenges. But ultimately I'm going to go right back to the 505(b)(2)s and products like Vasostrict in adrenaline have served us well. But Steve, I think right now what we're going to do is come back in the February time frame and provide a little bit more color."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just one follow-up on the DOJ investigation. I guess how confident are you that it brings sense around the products mentioned versus just the start of something broader?",29,"Just one follow-up on the DOJ investigation. I guess how confident are you that it brings sense around the products mentioned versus just the start of something broader?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, again, Steve, I'm not going to comment on the DOJ. In my opinion on the DOJ investigation, I think right now we'll be -- what I communicated earlier are our statement of facts. We don't sell one product and we didn't take our price up on digoxin, and",54,"Yes, again, Steve, I'm not going to comment on the DOJ. In my opinion on the DOJ investigation, I think right now we'll be -- what I communicated earlier are our statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I think that's our position."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Andrew Finkelstein of Susquehanna.",9,"Our next question is from Andrew Finkelstein of Susquehanna."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I was just hoping specifically on the outlook for Vasostrict, how are you thinking about pricing going forward over the next year.",22,"I was just hoping specifically on the outlook for Vasostrict, how are you thinking about pricing going forward over the next year."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way that we will would be looking at this is that we have the product position where we needed to be. Anything that we consider",78,"Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way that we will would be looking at this is that we have the product position where we needed to be. Anything that we consider on a go-forward basis would be more mindful and thoughtful of the current environment. I think that's probably the best way I would characterize our pricing strategy on Vasostrict."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","And nothing to suggest pressure relative to the kind of net pricing or volume you're seeing now?",18,"And nothing to suggest pressure relative to the kind of net pricing or volume you're seeing now?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","I'm not sure I understand what you mean by on pressure.",12,"I'm not sure I understand what you mean by on pressure."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I mean absent a competitor, you're not -- you would expect the gross to net to be comparable to how they exist now.",23,"I mean absent a competitor, you're not -- you would expect the gross to net to be comparable to how they exist now."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Right, the status quo.",4,"Right, the status quo."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","This question is from Gary Nachman of BMO Capital Markets.",10,"This question is from Gary Nachman of BMO Capital Markets."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is actually Chris for Gary. I just wanted to maybe get a little bit more clarity on the other branded revenue that was a pretty good percentage of the U.S. brand, so if you could go into some of those pieces.",42,"This is actually Chris for Gary. I just wanted to maybe get a little bit more clarity on the other branded revenue that was a pretty good percentage of the U.S. brand, so if you could go into some of those pieces."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure, I'll pass it over to Blaise.",8,"Yes, sure, I'll pass it over to Blaise."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation or performed better than our expectations. A couple of products in there that performed well. [indiscernible] performed well in o",47,"Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation or performed better than our expectations. A couple of products in there that performed well. [indiscernible] performed well in our FORTESTA franchise performed well."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Annabel Samimy of Stifel.",9,"Our next question is from Annabel Samimy of Stifel."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Esther in for Annabel. I just wanted to get your thoughts on divestment and have you made any further decision on [indiscernible] you're going to go?",28,"This is Esther in for Annabel. I just wanted to get your thoughts on divestment and have you made any further decision on [indiscernible] you're going to go?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Right now we haven't made any clear decisions on monetizing any assets right now. I mean what we're doing here is my first 30 days or so, what we are, we're assessing our businesses and we're assessing much of our business that includes the bra",130,"Yes, sure. Right now we haven't made any clear decisions on monetizing any assets right now. I mean what we're doing here is my first 30 days or so, what we are, we're assessing our businesses and we're assessing much of our business that includes the brand and international and the generics business. We're looking at all components and all assets. And frankly, at this point in time, we're putting together a strategy plan and we will come back. But at this point in time, there's been no decision to divest any asset. And as we get closer to our February earnings call, we'll provide more color, whether this is something that we will be considering. But at this point in time, there's been no movement on divesting any assets."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Sumant Kulkarni of Bank of America.",11,"Our next question is from Sumant Kulkarni of Bank of America."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Both are fairly bigger strategic ones for Paul. You have base business and the erosion of the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile injectables and oth",87,"Both are fairly bigger strategic ones for Paul. You have base business and the erosion of the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile injectables and other alternative dosage forms? And secondly, given that Par does not have or Endo does not have a biosimilar strategy now, do you think your R&D spend is appropriately focused to get the best possible opportunities that are out there on small molecule generics?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So the first question in terms of the erosion, in terms of on the injectable side, so I think right now I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But I think",302,"Yes. So the first question in terms of the erosion, in terms of on the injectable side, so I think right now I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But I think one of our advantages, and I said this repeatedly, I think it's a good time for Endo to have a sterile injectables facilities on U.S. soil. I think that separates us from the competition. So I'm seeing a lot of quality compliance issues with our competitors. I'm seeing a lot of back order issues. I think this gives us an advantage. And also I think having a facility on U.S. soil with the R&D team and the manufacturing and quality teams that we have, I think that's an advantage for us. When I look at our product launches, we are always first-to-market in our categories in which we choose to play, and I think that provides a good set point for us as we move forward and, ultimately, execute on our GPO contract. So once we do that, we're holding the contract and it's ours to defend. I think that differentiates us. Regarding the question on biosimilars, I know we'll come back, I missed one, but the questions on biosimilars, maybe that is not a primary strategy of ours today. An area that we have focused in on it -- I'm not going to get too deep into it but, we are focusing on polypeptides. That is challenging chemistry. I think that's going to start to set us apart and that's going to leverage our capabilities both on the internal R&D side, partnerships that we've established and taking advantage of the Rochester facility. And I apologize I think I missed maybe your first question."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just on the R&D side on small molecules, do you think you're appropriately funded right now? Or will that require any kind of bolstering going forward?",27,"Just on the R&D side on small molecules, do you think you're appropriately funded right now? Or will that require any kind of bolstering going forward?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering and again we will communicate in the February time frame. What we are doing is focusing on those harder to make pro",110,"So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering and again we will communicate in the February time frame. What we are doing is focusing on those harder to make products, whether they're topicals, creams, ointments, ophthalmics and things that may take small clinical trials. So that, to us, is an area that we have the skill set with our teams in place and something that we're starting to do well. That, coupled with our Paragraph IV strategy, I think places of in a position to deliver a higher value generics on a going forward basis."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Greg Gilbert of Deutsche Bank.",10,"Our next question is from Greg Gilbert of Deutsche Bank."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Greg Gilbert. I think you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what pro forma sales for generics base in 2015 that, that eros",56,"It's Greg Fraser on for Greg Gilbert. I think you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what pro forma sales for generics base in 2015 that, that erosion would be off of?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So what we said was our full year base erosion down in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that.",31,"So what we said was our full year base erosion down in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, the pro forma base business in 2015 is 17 52",11,"Yes, the pro forma base business in 2015 is 17 52"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Great, that's helpful. Can you also give us a sense of how much contribution from generic launches is into the guidance for 4Q.",23,"Great, that's helpful. Can you also give us a sense of how much contribution from generic launches is into the guidance for 4Q."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","For this year?",3,"For this year?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I'm sorry. Can you repeat that question?",8,"I'm sorry. Can you repeat that question?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, just trying to get a sense of how much contribution from new generic launches in 4Q is expected into your full year guidance?",24,"Yes, just trying to get a sense of how much contribution from new generic launches in 4Q is expected into your full year guidance?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","We have Zetia and. So we gave that number.",9,"We have Zetia and. So we gave that number."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","[indiscernible] in the second half.",5,"[indiscernible] in the second half."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Sorry Paul, the second half launches, there's a number we communicated before, which includes and Zetia, and that's around $425 million. And there's a range around that sort of the midpoint. But the $425 million, that's the total.",38,"Sorry Paul, the second half launches, there's a number we communicated before, which includes and Zetia, and that's around $425 million. And there's a range around that sort of the midpoint. But the $425 million, that's the total."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","That's the total.",4,"That's the total."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just a couple of quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?",39,"Just a couple of quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Let me take the mesh question first. In terms of how we look at that for 2017, let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So i",146,"Let me take the mesh question first. In terms of how we look at that for 2017, let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So it's about $900 million of liability still to be serviced. We would expect about $300 million to be paid in Q4 and then the balance of that to be paid in the 2017 fairly evenly over the first 3 quarters of 2017. In terms of modeling any sort of cash benefit or shield around that, we recommend it and continue to that from a modeling standpoint to model our cash tax rate as a percentage of adjusted income at the enterprise level, and our guidance previously still stands, which is in the low single digits"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And with regards to BELBUCA, we booked low single-digit.",9,"And with regards to BELBUCA, we booked low single-digit."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray.",10,"Our next question is from David Amsellem of Piper Jaffray."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So just wanted to drill down on the potassium products and the opportunities there. And really specifically a couple of questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smal",92,"So just wanted to drill down on the potassium products and the opportunities there. And really specifically a couple of questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smaller. But what's the right way of thinking about it in terms of orders of magnitude, smaller? And then how should we think about the competitive dynamics of that product? Just trying to get a sense of how important that's going to be in terms of a 2017 contributor?"
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","All right. So first of all, it is an important contributor for 2017, and I think the easier ones for you to understand is right now there's 2 forms. There's a liquid form and there's a powder form. The liquid form, you can easily go to IMS data and calcul",372,"All right. So first of all, it is an important contributor for 2017, and I think the easier ones for you to understand is right now there's 2 forms. There's a liquid form and there's a powder form. The liquid form, you can easily go to IMS data and calculate the units there. We have, in essence, converted the entire market, maybe not entire market probably in the very high 90s. So what I'm politely saying is that we've executed in all the unapproved sources have been off the market for a couple of months. So that to me is a running nicely. But there's no barrier-to-entry, so you just have to be aware that a ANDA can be filed and that product has been approved since I believe around 2014. So you just got to make an assumption. At some point, a company that has liquid capabilities can enter the market. The powder is the one that probably has created the most question because there's so many different forms of powder. And I think in terms of sizing that and I think it's safe to say that it's probably easier for us to communicate the number of packets in the market and then you can go back and do the math. In essence, this is an $18 million pack market. They're broken into 30s and 100s. I would tell you that's probably irrelevant, but for your math, go back, you're using 80 [ph] million in packets and then you can look at standard single source type generic pricing relative to 505(b)(2). I want to make the assumption that is a single source, highly genericized type product. That's the way I would think that you should look at the powder. Now having said that, there are still pull-through of unapproved sources. So the unapproved sources were asked to exit the market back in the June time frame, and I believe that they had 2 months to produce product and 3 months to sell through product. So there's going to be a period of time where it's probably going to take us to Q1 before we see that conversion. So I think those are your levers in order to calculate the powder opportunity."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao of Barclays.",4,"Douglas Tsao of Barclays."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So Paul, just curious when you think about your expectations for Zetia and SEROQUEL, those launches, were very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands that have been retaining 60-plu",108,"So Paul, just curious when you think about your expectations for Zetia and SEROQUEL, those launches, were very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands that have been retaining 60-plus-percent in products that have been multisourced. So just curious in terms of your confidence that those will pick up traction as much as you want. And then also just if you could provide some comment -- if I look at the IMS data, didn't really get much traction with the Crestor product launch. Just curious if you have any sort of perspective on what might've happened there."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So Crestor is probably the easier one. I mean I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week headstart based upon a settlement agreement. And then about maybe 9 or 10 companies fol",290,"So Crestor is probably the easier one. I mean I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week headstart based upon a settlement agreement. And then about maybe 9 or 10 companies followed on. So the reality is while it was a large product, there was an awful lot of competition, and we have a short burst, and at the end of the day, pricing fell to probably somewhere around 98.5% to 99% off the brand wagon. And again, that's not an area that we don't want to compete. That was a decision that was made many, many years ago and the market dynamics changed in that regard. On the [indiscernible] launch is behaving as we expected. So I feel pretty confident about that product on a go-forward basis. The product launch came out on November 1 and we've already taken on around 96%, 97% of the market in terms of signing on accounts. So it's behaving as we expected. In the case of Zetia, the reference that you're making in terms of brand retention, we've taken our -- what we believe is an appropriate approach to the fact that perhaps the brand could retain some percentage based upon maybe some PBM contracts. So that's been taken into consideration. I think what's maybe important is in this particular product, about 88% of the product is handed to the retail chains. I think that's an important factors so we feel pretty good about how this product's going to behave and we've taken in generic conversion in terms of what I think is appropriate. So I feel good about where Zetia will head. No guarantees but feel good."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks.",24,"And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thanks, Christie, and thank you all for joining us. I'll turn it over to Paul to close out the call.",20,"Thanks, Christie, and thank you all for joining us. I'll turn it over to Paul to close out the call."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thanks, Keri. I mean As I said, this is really an important time for Endo, and we do appreciate your continued interest and support of the company and we look forward to provide you with update as we move forward. Thank you for joining us for today's call",62,"Thanks, Keri. I mean As I said, this is really an important time for Endo, and we do appreciate your continued interest and support of the company and we look forward to provide you with update as we move forward. Thank you for joining us for today's call and we will see you back in our February earnings call. Thank you all."
28071,405113130,1079275,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program and you may all disconnect. Everyone have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program and you may all disconnect. Everyone have a great day."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri M",53,"Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri Mattox, Senior Vice President in Investor Relations and Corporate Affairs. Please go ahead."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appoi",246,"Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appointed interim Chief Financial Officer; and Joe Ciaffoni, President of Endo Pharmaceuticals, our U.S. Branded business. We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Paul. Paul?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our third quarter 2016 earnings p",868,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our third quarter 2016 earnings presentation. To start, here's a brief agenda for today's call. Moving to Slide 3. As you know, the third quarter brought some changes and I believe, a sharpened focus on operational execution at Endo. Despite some headwinds for our Generics Base business, the overall diversity of our portfolio did enable us to deliver solid revenue and adjusted earnings per share results in the third quarter with revenue performance across all business units broadly in line or ahead of company expectations. 
I recently took on the role of CEO, and I am working to realize the potential for Endo moving forward. Our product-by-product assessment of the business and our portfolios is in progress, and we are working on the development of a strategic plan. Importantly, we are once again pleased to reaffirm our 2016 revenues and adjusted EPS guidance. 
On Slide 4. You will see a snapshot of our segment revenues for the third quarter. 
Moving to Slide 5. Let's discuss our branded business. Our branded performance in the third quarter was stronger than our expectations, which underlies our segment revenue and margin guidance provided earlier this year. We delivered solid XIAFLEX demand, particularly in Peyronie's disease, and our revenue growth expectation for XIAFLEX continues to be in the low double digits for the year. The BELBUCA launch is progressing, and we are evaluating how to maximize the value of this differentiated product within a challenging opioid market. We did see outperformance by select U.S. Branded products, including Voltaren Gel, LIDODERM and some products in our other branded portfolio. 
Moving to Slide 6. Let's talk about our international pharmaceuticals. Our results were in line with the expectations that underlie our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we drove solid performance across our base business, launched Nucynta and secured the Canadian rights for XIAFLEX. The additions of these products can provide longer-term growth as we continue to manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our adjusted operating margins. 
Turning to Slide 7 and our generics business. We continued to deliver overall segment performance in line with our expectations. Our sterile injectables business continues to grow led by Vasostrict. In new launches and alternative dosages, we saw better-than-expected performance from alternative dosages, especially the LIDODERM authorized generic, and we have launched 15 products since the beginning of the year. We continue to file new ANDAs with the FDA while replenishing our R&D pipeline. 
Our base business declined approximately 20% sequentially from the second quarter 2016 driven by higher-than-expected consortium pricing pressures, a vast consortium structure and certain competitive generic entrants late in the quarter. Excluding stocking and onetime factors, this decline was approximately 15% from the second quarter 2016. We now expect full year base business decline to be in the low 30s percentage range. Given this deeper-than-expected erosion for our base business for the quarter and the year, our base business erosion rate in 2017 may be larger than our previous assumption of a return to historic Par annual erosion rates of 10% to 12%. We will update our assumptions on 2017 base erosion as part of our full year 2017 guidance on our year-end earnings call. It is important to note that Par's strategy is focused not on this base segment but on prioritizing growing higher-quality, higher barrier-to-entry products and continuing to advance and replenish our differentiating R&D pipeline. 
Moving on to Slide 8. You will see a chart tracking our new product launches. We have updated to show the 15 products that we have successfully launched so far in 2016. We've had a number of smaller product launches shift into early 2017 and others that we have rationalized due to commercialization assessments and our ongoing portfolio of prioritization but still anticipate that we will launch approximately 20 new products this year, including our first-to-file exclusive products, generic SEROQUEL XR and generic Zetia. 
Let's turn to Slide 9 to talk about those 2 key fourth quarter launches. Importantly, we've now launched our generic SEROQUEL XR product. The initial launch has gone smoothly, and all manufacturing, launch activities and product shipments are on track. Our expected December 2016 launch of generic Zetia is also progressing on track. We have received final approval from the FDA and have an agreement in place with Merck through our partner, Glenmark. This product is manufactured through that partnership with Glenmark, and we have a product in our warehouse and we're ready to launch with marketing exclusivity. Together, we expect these 2 first-to-file launches to contribute in line with our previously communicated projections. 
With that, let me turn the call over to Blaise Coleman to discuss the financial performance of the company and the quarter and our projected outlook. Blaise?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have",483,"Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have loss per share of $0.86 in the quarter versus a loss of $3.84 in the third quarter of 2015. GAAP net loss for continuing operations in the third quarter of 2016 decreased to $191 million compared to a GAAP net loss from continuing operations of $804 million during the same period in 2015, primarily due to goodwill and intangible asset impairment charges recorded during third quarter 2015. On an adjusted basis, overall third quarter results are better than previously guided. 
To summarize the points that Paul made, revenue was strong due to continued performance from XIAFLEX and better than expected due to outperformance by sterile injectables, alternative dosages and select other branded products. Adjusted net income and EPS are better than guided as a result of higher revenues, better gross margin percentage due to product mix and lower operating expenses primarily due to timing. 
On Slide 12, we are again reaffirming our revenue and adjusted EPS full year guidance. We expect revenues to be approximately $3.87 billion to $4.03 billion and adjusted EPS to be between $4.50 and $4.80. Given our overperformance in Q3 versus our expectations, we have increased confidence in our overall full year guidance range, which takes into account several moving parts, including the range of our launch forecast for our first-to-file generic versions of SEROQUEL XR and Zetia, projections around year-end timing of product sales and shipments and continued pricing pressure for our U.S. Generics Base business. 
Moving to cash and liquidity on Slide 13. On a year-to-date basis, cash flow from operations totaled approximately $443 million. We've also highlighted some of the material moving parts that have impacted our cash flow from operations on a quarterly and September year-to-date basis. 
On Slide 14, we are updating our view on estimated free cash flow in 2016. We now project debt paydown of approximately $330 million in 2016 and to exit the year in the high 4x range for our net debt to adjusted EBITDA leverage ratio. While we've provided some color in the past on potential free cash flow headwinds and tailwinds in 2017, given our dynamic sector environment and our ongoing strategic assessment, both of which could impact cash flows in 2017 versus previous expectations, we will wait to provide any details or updates for next year until we provide our full year 2017 financial guidance in late February. 
As noted in our press release, we ended the quarter with approximately $562 million in unrestricted cash, approximately $276 million in restricted cash and a net debt to adjusted EBITDA leverage ratio of approximately 4.9x. 
Now let me turn it back over to Paul."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper",538,"Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper-than-expected base erosion trends that we see and saw in the third quarter indicate stronger headwinds on the front as we exit the year. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid cycles that we expect to weight on our generics business moving forward, could impact our adjusted gross margin profile. And our 505(b)(2) expectation and longer-term 505(b)(2) strategy has been impacted by the competitive landscape, regulatory actions and the pricing environment. We will provide more detailed insights into the expected impacts of these trends on our 2017 financial outlook when we provide full year guidance in late February 2017. I would like to note that deeper-than-expected erosion and demand for our products and/or changes to our resource allocation resulting from our strategic assessment could result in changes in the carrying values of assets across our segments. 
Next, XIAFLEX. We've identified XIAFLEX as a core U.S. Branded product and growth driver for Endo moving forward. We continue to put resources and efforts behind accelerating traction and growth in our Dupuytren's contracture and Peyronie's disease indications. We're also analyzing our R&D pipeline. Cellulite remains the primary focus there, and we look forward to reporting out on our Phase IIb data upon the completion of that trial. Other potential indications are currently undergoing a full commercial assessment and analysis so that we can best prioritize our R&D efforts and determine clinical trial time lines moving forward. 
The launch of BELBUCA is also progressing. We continue to believe that BELBUCA offers a compelling and differentiated product profile, and we want to ensure that we are best positioned moving forward. 
Finally, as the new CEO, I am spending a lot of time evaluating and working with our legal team to further develop and execute on our strategy with respect to the ongoing mesh litigation. 
On Slide 17, let's talk about my CEO assessment process. As I mentioned, we are pleased to reaffirm our revenue and adjusted EPS full year 2016 financial guidance. Overall, business performance continues to be broadly in line with our expectations. We are in the process of conducting a bottoms-up product-by-product assessment of all 3 of our business units. We expect that we'll be ready to communicate our evolved corporate strategy in the February 2017 time frame of our fourth quarter 2016 earnings announcement. As we've done in the past, we expect that we'll also communicate our full year 2017 financial guidance and expectations for our business at that time. 
In closing, Endo is sharpening its focus on operational execution, and I am excited to be leading the company. I want to take a moment to thank all of our dedicated employees whose hard work and commitment to the company make what we do possible. We continue to believe that this is a time of significant opportunity for Endo, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Now let me turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?",23,"Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our first question is from the line of Greg Gilbert of Deutsche Bank. Our next question is from Elliot Wilbur of Raymond James.",23,"Our first question is from the line of Greg Gilbert of Deutsche Bank. 
Our next question is from Elliot Wilbur of Raymond James."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepa",116,"Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepared commentary? Just trying to figure out, is this a result of a renewed bid cycle or some structural change on the consortiums with some of the recent movement? Or is it simply just existing competitors be a lot more aggressive and current product markets or the impact of new competition or maybe all 3? But if you could just maybe give a little bit more clarity behind that, it would be helpful."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks, Elliot, and I think that's right. I think you kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real pru",278,"Yes. Thanks, Elliot, and I think that's right. I think you kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real prudent approach here. But when we look at what's happening, we did have anticipated -- especially higher-than-anticipated pressure from the consortiums, and we did, in essence, see a little more discounting for some of the more established generic competitors, so a little bit of that going on as well. When we see the 20% erosion factor that we talked about, in essence, if we exclude a couple of onetime events, we are more in the 15% erosion for the quarter. And specifically, when you look at the area in which we were -- effect that we had 2 products that were authorized generics, right? So these are products that you know that we -- that are revenue drivers. But in essence, they are large -- they're lower-margin contributors to the Par franchise. So metoprolol and budesonide were 2 products that -- we see additional competition from budesonide, and then we had a little heavier-than-expected competition at Red Oak from a competitor on the metoprolol aging. And then structurally, we're seeing some changes at McKesson. As you know, they are moving away from their San Francisco operation, and you're going to start to see a shift in McKesson to their European operation now referred to Claris 1. So they're starting to kick in, and you'll see a change on a go-forward basis as they kind of unite with Walmart."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from the line of Louise Chen of Guggenheim.",12,"Our next question is from the line of Louise Chen of Guggenheim."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expecte",47,"It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expected to continue?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay, great. So I'm going to pass the first question over to Blaise.",13,"Okay, great. So I'm going to pass the first question over to Blaise."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our gr",173,"Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our growth rate sequentially for XIAFLEX at a total molecule level, we grew about 12%, and the majority of that was due to a stocking movement. At the end of Q2, we had about 6 days on hand. And at the end of Q3, we have about 8 days on hand. In terms of gross margin, we had favorable mix during the quarter, again a little bit stronger than the sterile injectables and some of the areas that Paul talked about. If you look at our full year guidance, we did change our assumption to be at the upper end of our gross margin range. So we would expect to see events that we've seen on a year-to-date basis playing through on a full year basis."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray. Our next question is from Jason Gerberry of Leerink Partners.",20,"Our next question is from David Amsellem of Piper Jaffray. 
Our next question is from Jason Gerberry of Leerink Partners."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that becaus",108,"I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that because fourth quarter is usually a little bit seasonally strong. And then the second question Paul, maybe -- can you provide a little bit of framework of this DOJ process? I mean, how do you think in general these processes play out from a time line perspective, how long before investors can get some visibility regarding how this process may evolve?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just",247,"Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just talk to the facts here. So this is a subpoena that we received over 2 years ago, and I think it's safe to say that we believe that we've cooperated with the DOJ and that there's -- in essence, there's no new information. And as it pertains specifically to Par, it was a focus around 2 products and one product of which we do not even sell. So from that standpoint, we're feeling reasonably confident in our position. At least that's what we believe. And to be specific, the issue deals with a product called doxycycline hyclate. It's a product we do not even sell. There may be some confusion at the DOJ, but we sell a product that was called doxycycline monohydrate. And then the second product is a product called digoxin. And in essence, what occurred there, Par came into an already established market with 2 generic competitors, plus the brand. We were the fourth entrant to an established market, and we never took our price -- there was never a price increase with respect to digoxin. So I think that's probably a statement of fact here by Par, and that's our position."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last y",68,"Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last year on a pro forma basis and saw on a pro forma basis were around $50 million."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Randall Stanicky of RBC Capital Markets.",11,"Our next question is from Randall Stanicky of RBC Capital Markets."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Paul, is this heightened generic erosion, is this just cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the",94,"Paul, is this heightened generic erosion, is this just cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the generic side could make sense if we're looking at a couple of years down the road. But I guess the question specifically, do you have visibility or comfort level that 2017 could be get a low watermark for some of these challenges and headwinds? And then I have one quick follow-up."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, branded, the erosion factor here was greater than what we had originally assumed. An",234,"Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, branded, the erosion factor here was greater than what we had originally assumed. And we have communicated earlier that we thought we're going to be in the 10% to 12% range for 2017. The reality is that it'll be likely a little more steeper than that. And we just want to be a little bit mindful and thoughtful on how we communicate this. But when you look at the Par portfolio, the base is really not our focus. When you look at the products in our pipeline, products that we're launching, we're looking at more differentiated products. So we are -- as you know, as we call the portfolio out in some of the historical Qualitest products, we're now really moving to more technically challenging products that should be able to withstand pushback on either the trade or competitors. So we're shifting away from a highly commoditized portfolio as we move forward. So I feel we're going to have more erosion to deal with because the portfolio is still quite large. But over time, as we launch more products, we should be in a better position to keep our margins at the historical 50 -- low-50 percentage on a go-forward basis."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think",68,"So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think about the near term relative to what we're seeing currently versus what you previously thought you would see?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you k",137,"Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you know, on the authorized generic side, Par is holding a small percentage on gross margin, yet we booked the sale. So when we get hit on competition, it's not all uncommon to see a higher erosion factor. Now as the portfolio swings away from AGs into more differentiated products, the likelihood is that we will be able to push back. But I just want to be a little mindful that there's still a fair number of commodities in the portfolio, and we'll come back and provide more color in 2017."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Marc Goodman of UBS.",9,"Our next question is from Marc Goodman of UBS."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or",83,"When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or is the FDA more against approving these 505(b)(2)s? Or basically, the pricing is going to get worse for these things? So is it all 3 of them? Or is it one versus the other? Just give us more color I think."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When yo",410,"So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When you look at portfolios that are historically in either the injectable portfolio or even some of the legacy Par brands that have shifted over to Endo, those are pure 505(b)(2)s, and we have the resources and the R&D to continue to develop those products. But just to drill into specifically where I think you're headed is when Par undertakes a conversion of an unapproved drug to approved status, and those I break into 2 categories, operate those into a category whereby we will continue with our 505(b)(2) strategy of taking unapproved drugs and converting them, running the requisite clinical trials and putting a brand strategy behind that, where that may be detailed either through Joe's Endo team or Tony Pera's injectable team. That we will fight for intellectual property. That falls into one category. When we have intellectual property, it should be normal course. We'll launch the product. It will be priced appropriately for the work in which we've done to gain approval for. And then hopefully, our intellectual property will stick and we have something that we can build upon. Where we're getting some challenges is in the third category, where we develop a 505(b)(2) where we now have a brand we are working with the FDA to remove the unapproved sources, yet we don't have intellectual property. So now we have a timing issue. That's an area that we just need to pause a little bit because the window is a shorter period of time for contribution. So now in today's environment, there are pricing pressures, and we've got to be a little bit mindful of that. So we will continue with the strategy, understanding that when we can get intellectual property, that these 505(b)(2)s, in essence, will behave like a super generic, where we'll have the benefit and contribution driven by volume, but the pricing environment is going to be a little bit tighter and the likelihood is that we will see ANDAs coming in at a quicker rate. But that's fine. That's still a meaningful product for the Par portfolio, and we will continue to do that. But that's where we will see a little pressure."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Chris Schott of JPMorgan.",9,"Our next question is from Chris Schott of JPMorgan."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just",96,"This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just how would you characterize replenishing the pipeline and expanding the alternative dosage form business? And then my second quick one, just on Vasostrict, the competitive landscape. Just any updates there. Is this still status quo and you're feeling pretty confident on exclusivity for the next year or 2?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. T",293,"Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. The product is running. It's converted nicely. And in essence, there's no update, and I'll view that as a positive. Regarding the 2017 pipeline, we've kind of touched on this. We're not going to disclose specifically our products because we don't want to place ourselves at a competitive disadvantage. What I will call out is we don't have the 2 blockbusters that you're seeing right now in Zetia and quetiapine. That we don't have, but you need to remember that we are getting the benefit and the carryover of those 2 products from the fourth quarter of 2016 into the first quarter. So that's going to help us project into 2017. We've got a solid pipeline, but they are smaller products. Some of them contain Paragraph IVs. Some are first-to-market opportunities. At this point in time, we're not going to disclose them because we're not going to place ourselves at a competitive disadvantage. We're going to continue with our 505(b)(2) strategy. We're doing very nicely with our potassium liquid product. We're starting to build momentum with our potassium powder product. Vasostrict continues to perform. The injectable portfolio continuous to perform. And as I indicated before, our strategy, as we pick our R&D pipeline targets for the generic sector, we are going to continue to fund more opportunity into the injectable hard-to-manufacture category. And we're going to continue with our modified release solid oral dosage approach, whereby we are hoping that we will get less competition."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Donald Ellis of JMP Securities.",10,"Our next question is from Donald Ellis of JMP Securities."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it",70,"A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it looked like there was a drug down in -- over our corporate wholesale inventory in the quarter. Would you be able to quantify that?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA.",33,"Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the big breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally h",63,"Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the big breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally have broad availability in line to the label. And where we are working on improving the reimbursement is both in Medicare and Medicaid."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million.",44,"In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Liav Abraham of Citi.",9,"Our next question is from Liav Abraham of Citi."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?",36,"Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise.",19,"Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-lookin",129,"Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-looking comments for '17 either from a P&L or cash flow standpoint. In terms of your question on covenants, right now just to remind you, we do have 2 maintenance covenants on our secured debt, which is our term loans A and B in our revolver. And so our secured leverage covenant is less than 3.85x adjusted EBITDA, and we're currently at 2.1x. And we also have an interest coverage covenant, which -- that is -- the covenant is greater than 2.5x, and we're currently at 3.8x."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Stephan Stewart of Goldman Sachs.",5,"Stephan Stewart of Goldman Sachs."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just wanted to follow up on the pipeline question. Without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics",47,"Just wanted to follow up on the pipeline question. Without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics business beyond the first half of '17?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Again, I think right now, we're going to come back in February of 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some",98,"Again, I think right now, we're going to come back in February of 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some challenges. But ultimately, I'm going to point right back to the 505(b)(2)s, and products like Vasostrict and Adrenalin have served us well. But Stephan, I think right now what we're going to do is come back in the February time frame and provide a little bit more color."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just one follow-up on the DOJ investigation. I guess, how confident are you that it ring-centered around the products mentioned versus just the start of something broader?",28,"Just one follow-up on the DOJ investigation. I guess, how confident are you that it ring-centered around the products mentioned versus just the start of something broader?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I th",53,"Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I think that's our position."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Andrew Finkelstein of Susquehanna.",9,"Our next question is from Andrew Finkelstein of Susquehanna."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year.",21,"I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way that we would be looking at this is that we have the product position where we needed to be, and anything that we consider",78,"Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way that we would be looking at this is that we have the product position where we needed to be, and anything that we consider on a go-forward basis would be more mindful and thoughtful of the current environment. I think that's probably the best way I would characterize our pricing strategy on Vasostrict."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?",18,"And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","I'm not sure I understand what you mean by unpressure.",11,"I'm not sure I understand what you mean by unpressure."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I mean, absent a competitor, you're not -- you would expect the gross to net to be comparable to how they exist now.",23,"I mean, absent a competitor, you're not -- you would expect the gross to net to be comparable to how they exist now."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, absolutely. Yes, right, the status quo.",7,"Yes, absolutely. Yes, right, the status quo."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Next question is from Gary Nachman of BMO Capital Markets.",10,"Next question is from Gary Nachman of BMO Capital Markets."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces.",43,"This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, okay, sure. So we'll pass it over to Blaise.",10,"Yes, okay, sure. So we'll pass it over to Blaise."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed w",53,"Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed well, and our FORTESTA franchise played -- performed well."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Annabel Samimy of Stifel.",9,"Our next question is from Annabel Samimy of Stifel."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?",28,"This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our bus",140,"Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our business, that includes the brand and international and the generics business. We're looking at all components and all our assets. And frankly, at this point in time, we're putting together a strategy plan, and we will come back. But at this point in time, there's been no decisions to divest any asset. And we're -- as we get closer to our February earnings call, we'll provide more color whether this is something that we will be considering. But at this point in time, there's been no movement on divesting any assets."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Sumant Kulkarni of Bank of America.",11,"Our next question is from Sumant Kulkarni of Bank of America."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile",94,"Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile injectables and alternate dosage forms? And secondly, given that Par does not have -- or Endo does not have a biosimilar strategy now, do you think your R&D spend is appropriately focused to get the best possible use of the opportunities that are out there on small molecule generics?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But",308,"Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But Sumant, I think one of our advantages, and I said this repeatedly, I think it is a good time for Endo to have a sterile injectables facilities on U.S. soil. I think that separates us from the competition. So I'm seeing a lot of quality compliance issues with our competitors. I'm seeing a lot of back order issues. I think this gives us an advantage. And also, I think having a facility on U.S. soil with the R&D team and the manufacturing and quality teams that we have, I think that's an advantage for us. When I look at our product launches, we are always first-to-market in our categories in which we choose to play, and I think that provides a good set point for us as we move forward and ultimately, execute on our GPO contract. So once we do that, we're holding the contract and it's ours to defend. I think that differentiates us. Regarding the question on biosimilars, I know -- will come back, I've missed one. But the questions on the biosimilars, while maybe that's not a primary strategy of Par's today, an area that we have focused in on -- and I'm not going to get too deep into it, but we are focusing on polypeptides. That is challenging chemistry. I think that's going to start to set us apart, and that's going to leverage our capabilities both on the internal R&D side, partnerships that we've established and taking advantage of the Rochester facility. And I apologize. I think I missed maybe your first question."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or will that require any kind of bolstering going forward?",29,"It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or will that require any kind of bolstering going forward?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make pro",105,"So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make products, whether they're topicals, creams, ointments, ophthalmics, and things that may take small clinical trials. So that, to us, is an area that we have the skill set with our teams in place, and it's something that we're starting to do well. That, coupled with our Paragraph IV strategy, I think places us in a position to deliver higher-value generics on a go-forward basis."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Greg Gilbert of Deutsche Bank.",10,"Our next question is from Greg Gilbert of Deutsche Bank."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics",61,"It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics Base in 2015 that, that erosion would be off of?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that.",32,"So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, the pro forma base business in 2015 is 17 52 [ph].",12,"Yes, the pro forma base business in 2015 is 17 52 [ph]."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?",24,"Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","For this year?",3,"For this year?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I'm sorry. Can you repeat that question?",8,"I'm sorry. Can you repeat that question?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance.",24,"Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Well, we have Zetia and quetiapine. So have we given that number?",12,"Well, we have Zetia and quetiapine. So have we given that number?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","We gave it for the second half.",7,"We gave it for the second half."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that at sort of the midpoint.",38,"Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that at sort of the midpoint."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. But the $425 million was the total.",8,"Okay. But the $425 million was the total."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","That's the total, all in, yes.",7,"That's the total, all in, yes."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?",40,"Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So r",146,"Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So really, it's about $900 million of liability still to be serviced. We would expect about $300 million to be paid in Q4, and then the balance of that to be paid in 2017 fairly evenly over the first 3 quarters of 2017. In terms of modeling any sort of cash benefit or shield around that, we recommended and continue to do that from a modeling standpoint to model our cash tax rate as a percentage of adjusted income at the enterprise level. And our guidance previously still stands, which is in the low single digits"
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And with regards to BELBUCA, we booked low single digit million.",11,"And with regards to BELBUCA, we booked low single digit million."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray.",10,"Our next question is from David Amsellem of Piper Jaffray."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smalle",91,"So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smaller. But what's the right way of thinking about it in terms of orders of magnitude, smaller? And then how should we think about the competitive dynamics of that product? Just trying to get a sense of how important that's going to be in terms of a 2017 contributor."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calc",375,"All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calculate the units there. We have, in essence, converted the entire market. Maybe you might say the entire market is probably in the very high 90s. So what I'm politely saying is that we've executed, and all the unapproved sources have been off the market for a couple of months. So that, to me, is running nicely. But there's no barrier to entry, so you just have to be aware that an ANDA can be filed. And that product has been approved since, I believe, around 2014. So you just got to make an assumption. At some point, a company that has liquid capabilities can enter the market. The powder is the one that probably has created the most questions because there's so many different forms of powder. And I think in terms of sizing that -- and I think it's safe to say that we -- it's probably easier for us to communicate the number of packets in the market, and then you can go back and do the math. In essence, this is an 18 million pack market, right? And they're broken into 30s and 100s. I would tell you that's probably irrelevant. But for your math, go back, you're using 18 million packets, and then you can look at standard single-source-type generic pricing relative to 505(b)(2). I would make the assumption that it's a single-sourced, highly genericized-type product. That's the way I would think that you should look at the powder. Now having said that, there are still pull-through of unapproved sources. So the unapproved sources were asked to exit the market back in the June time frame, and I believe that they had 2 months to produce product and 3 months to sell through product. So there's going to be a period of time where it's probably going to take us to Q1 before we see that conversion. So I think those are your levers in order to calculate the powder opportunity."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao of Barclays.",4,"Douglas Tsao of Barclays."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retai",110,"So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retaining 60-plus percent until these products have gone multi-sourced. So just curious in terms of your confidence that those will pick up traction as much as you want. And then also, just if you could provide some comment. If I look at the IMS data, didn't really get much traction with the Crestor product launch. Just curious if you have any sort of perspective on what might have happened there."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies f",296,"So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies followed on. So the reality is that while it was a large product, it was -- there was an awful lot of competition. And we had a short burst, and at the end of the day, pricing fell to probably somewhere around 98.5% to 99% off of brand wagon. And again, that's an area that we don't want to compete. That was a decision that was made many, many years ago when the market dynamics changed in that regard. On quetiapine, quetiapine launch is behaving as we expected, so I feel pretty confident about that product on a go-forward basis. The product launch came out on November 1, and we've already taken on around 96%, 97% of the market in terms of signing on accounts. So it's behaving as we expected. In the case of Zetia, the reference that you're making in terms of brand retention, we've taken our -- what we believe is an appropriate approach to the fact that perhaps the brand could retain some percentage based upon maybe some PBM contracts. So that's been taken into consideration. I think what may be important is in this particular product, about 88% of the product is handled through the retail chains. I think that's an important factor. So we feel pretty good about how this product's going to behave, and we've taken in generic conversion in terms of what I think is appropriate. So I feel good about where Zetia will head. No guarantees, but I feel good."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks.",24,"And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call.",20,"Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today",63,"And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today's call, and we will see you back at our February earnings call. Thank you all."
28071,405113130,1079505,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri M",53,"Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri Mattox, Senior Vice President in Investor Relations and Corporate Affairs. Please go ahead."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appoi",246,"Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appointed interim Chief Financial Officer; and Joe Ciaffoni, President of Endo Pharmaceuticals, our U.S. Branded business. We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Paul. Paul?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our third quarter 2016 earnings p",870,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our third quarter 2016 earnings presentation. To start, here's a brief agenda for today's call. Moving to Slide 3. As you know, the third quarter brought some changes and I believe, a sharpened focus on operational execution at Endo. Despite some headwinds for our Generics Base business, the overall diversity of our portfolio did enable us to deliver solid revenue and adjusted earnings per share results in the third quarter with revenue performance across all business units broadly in line or ahead of company expectations. 
I recently took on the role of CEO, and I am working to realize the potential for Endo moving forward. Our product-by-product assessment of the business and our portfolios is in progress, and we are working on the development of a strategic plan. Importantly, we are once again pleased to reaffirm our 2016 revenues and adjusted EPS guidance. 
On Slide 4. You will see a snapshot of our segment revenues for the third quarter. 
Moving to Slide 5. Let's discuss our branded business. Our branded performance in the third quarter was stronger than our expectations, which underlies our segment revenue and margin guidance provided earlier this year. We delivered solid XIAFLEX demand, particularly in Peyronie's disease, and our revenue growth expectation for XIAFLEX continues to be in the low double digits for the year. The BELBUCA launch is progressing, and we are evaluating how to maximize the value of this differentiated product within a challenging opioid market. We did see outperformance by select U.S. Branded products, including Voltaren Gel, LIDODERM and some products in our other branded portfolio. 
Moving to Slide 6. Let's talk about our international pharmaceuticals. Our results were in line with the expectations that underlied our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we drove solid performance across our base business, launched Nucynta and secured the Canadian rights for XIAFLEX. The additions of these products could provide a longer-term growth as we continue to manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our adjusted operating margins. 
Turning to Slide 7 and our generics business. We continued to deliver overall segment performance in line with our expectations. Our sterile injectables business continues to grow led by Vasostrict. In new launches and alternative dosages, we saw better-than-expected performance from alternative dosages, especially the LIDODERM authorized generic, and we have launched 15 products since the beginning of the year. We continue to file new ANDAs with the FDA while replenishing our R&D pipeline. 
Our base business declined approximately 20% sequentially from the second quarter 2016 driven by higher-than-expected consortium pricing pressures, a vast [ph] consortium structure and certain competitive generic entrants late in the quarter. Excluding stocking and onetime factors, this decline was approximately 15% from the second quarter 2016. We now expect full year base business decline to be in the low 30s percentage range. Given this deeper-than-expected erosion for our base business for the quarter and the year, our base business erosion rate in 2017 may be larger than our previous assumption of a return to historic Par annual erosion rates of 10% to 12%. We will update our assumptions on 2017 base erosion as part of our full year 2017 guidance on our year-end earnings call. It is important to note that Par's strategy is focused not on this base segment but on prioritizing growing higher-quality, higher barrier-to-entry products and continuing to advance and replenish our differentiating R&D pipeline. 
Moving on to Slide 8. You will see a chart tracking our new product launches. We have updated to show the 15 products that we have successfully launched so far in 2016. We've had a number of smaller product launches shift into early 2017 and others that we have rationalized due to commercialization assessments and our ongoing portfolio of prioritization but still anticipate that we will launch approximately 20 new products this year, including our first-to-file exclusive products, generic SEROQUEL XR and generic Zetia. 
Let's turn to Slide 9 to talk about those 2 key fourth quarter launches. Importantly, we've now launched our generic SEROQUEL XR product. The initial launch has gone smoothly, and all manufacturing, launch activities and product shipments are on track. Our expected December 2016 launch of generic Zetia is also progressing on track. We have received final approval from the FDA and have an agreement in place with Merck through our partner, Glenmark. This product is manufactured through that partnership with Glenmark, and we have a product in our warehouse and we're ready to launch with marketing exclusivity. Together, we expect these 2 first-to-file launches to contribute in line with our previously communicated projections. 
With that, let me turn the call over to Blaise Coleman to discuss the financial performance of the company and the quarter and our projected outlook. Blaise?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have",483,"Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have loss per share of $0.86 in the quarter versus a loss of $3.84 in the third quarter of 2015. GAAP net loss for continuing operations in the third quarter of 2016 decreased to $191 million compared to a GAAP net loss from continuing operations of $804 million during the same period in 2015, primarily due to goodwill and intangible asset impairment charges recorded during third quarter 2015. On an adjusted basis, overall third quarter results are better than previously guided. 
To summarize the points that Paul made, revenue was strong due to continued performance from XIAFLEX and better than expected due to outperformance by sterile injectables, alternative dosages and select other branded products. Adjusted net income and EPS are better than guided as a result of higher revenues, better gross margin percentage due to product mix and lower operating expenses primarily due to timing. 
On Slide 12, we are again reaffirming our revenue and adjusted EPS full year guidance. We expect revenues to be approximately $3.87 billion to $4.03 billion and adjusted EPS to be between $4.50 and $4.80. Given our overperformance in Q3 versus our expectations, we have increased confidence in our overall full year guidance range, which takes into account several moving parts, including the range of our launch forecast for our first-to-file generic versions of SEROQUEL XR and Zetia, projections around year-end timing of product sales and shipments and continued pricing pressure for our U.S. Generics Base business. 
Moving to cash and liquidity on Slide 13. On a year-to-date basis, cash flow from operations totaled approximately $443 million. We've also highlighted some of the material moving parts that have impacted our cash flow from operations on a quarterly and September year-to-date basis. 
On Slide 14, we are updating our view on estimated free cash flow in 2016. We now project debt paydown of approximately $330 million in 2016 and to exit the year in the high 4x range for our net debt to adjusted EBITDA leverage ratio. While we've provided some color in the past on potential free cash flow headwinds and tailwinds in 2017, given our dynamic sector environment and our ongoing strategic assessment, both of which could impact cash flows in 2017 versus previous expectations, we will wait to provide any details or updates for next year until we provide our full year 2017 financial guidance in late February. 
As noted in our press release, we ended the quarter with approximately $562 million in unrestricted cash, approximately $276 million in restricted cash and a net debt to adjusted EBITDA leverage ratio of approximately 4.9x. 
Now let me turn it back over to Paul."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper",539,"Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper-than-expected base erosion trends that we see and saw in the third quarter indicate stronger headwinds on the front as we exit the year. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid cycles that we expect to weigh on our generics business moving forward, could impact our adjusted gross margin profile. And our 505(b)(2) expectation and longer-term 505(b)(2) strategy has been impacted by the competitive landscape, regulatory actions and the pricing environment. We will provide more detail and insights into the expected impacts of these trends on our 2017 financial outlook when we provide full year guidance in late February 2017. I would like to note that deeper-than-expected erosion and demand for our products and/or changes to our resource allocation resulting from our strategic assessment could result in changes in the carrying values of assets across our segments. 
Next, XIAFLEX. We've identified XIAFLEX as a core U.S. Branded product and growth driver for Endo moving forward. We continue to put resources and efforts behind accelerating traction and growth in our Dupuytren's contracture and Peyronie's disease indications. We're also analyzing our R&D pipeline. Cellulite remains the primary focus there, and we look forward to reporting out on our Phase IIb data upon the completion of that trial. Other potential indications are currently undergoing a full commercial assessment and analysis so that we can best prioritize our R&D efforts and determine clinical trial time lines moving forward. 
The launch of BELBUCA is also progressing. We continue to believe that BELBUCA offers a compelling and differentiated product profile, and we want to ensure that we are best positioned moving forward. 
Finally, as the new CEO, I am spending a lot of time evaluating and working with our legal team to further develop and execute on our strategy with respect to the ongoing mesh litigation. 
On Slide 17, let's talk about my CEO assessment process. As I mentioned, we are pleased to reaffirm our revenue and adjusted EPS full year 2016 financial guidance. Overall, business performance continues to be broadly in line with our expectations. We are in the process of conducting a bottoms-up product-by-product assessment of all 3 of our business units. We expect that we'll be ready to communicate our evolved corporate strategy in the February 2017 time frame of our fourth quarter 2016 earnings announcement. As we've done in the past, we expect that we'll also communicate our full year 2017 financial guidance and expectations for our business at that time. 
In closing, Endo is sharpening its focus on operational execution, and I am excited to be leading the company. I want to take a moment to thank all of our dedicated employees whose hard work and commitment to the company make what we do possible. We continue to believe that this is a time of significant opportunity for Endo, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Now let me turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?",23,"Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our first question is from the line of Greg Gilbert of Deutsche Bank. Our next question is from Elliot Wilbur of Raymond James.",23,"Our first question is from the line of Greg Gilbert of Deutsche Bank. 
Our next question is from Elliot Wilbur of Raymond James."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepa",116,"Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepared commentary? Just trying to figure out, is this a result of a renewed bid cycle or some structural change on the consortiums with some of the recent movement? Or is it simply just existing competitors be a lot more aggressive in current product markets or the impact of new competition or maybe all 3? But if you could just maybe give a little bit more clarity behind that, it would be helpful."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks, Elliot, and I think that's right. I think you've kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real",277,"Yes. Thanks, Elliot, and I think that's right. I think you've kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real prudent approach here. But when we look at what's happening, we did have anticipated -- essentially higher-than-anticipated pressure from the consortiums, and we did, in essence, see a little more discounting for some of the more established generic competitors, so a little bit of that going on as well. When we see the 20% erosion factor that we talked about, in essence, if we exclude a couple of onetime events, we are more in the 15% erosion for the quarter. And specifically, when you look at the area in which we were -- effect that we had 2 products that were authorized generics, right? So these are products that you know that we -- that are revenue drivers. But in essence, they are large -- they're lower-margin contributors to the Par franchise. So metoprolol and budesonide were 2 products that -- we received additional competition from budesonide, and then we had a little heavier-than-expected competition at Red Oak from a competitor on the metoprolol aging. And structurally, we're seeing some changes at McKesson. As you know, they are moving away from their San Francisco operation, and you're going to start to see a shift in McKesson to their European operation that referred to Claris 1. So they're starting to kick in, and you'll see a change on a go-forward basis as they kind of unite with Walmart."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from the line of Louise Chen of Guggenheim.",12,"Our next question is from the line of Louise Chen of Guggenheim."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expecte",47,"It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expected to continue?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay, great. So I'm going to pass the first question over to Blaise.",13,"Okay, great. So I'm going to pass the first question over to Blaise."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our gr",173,"Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our growth rate sequentially for XIAFLEX at a total molecule level, we grew about 12%, and the majority of that was due to a stocking movement. At the end of Q2, we had about 6 days on hand. And at the end of Q3, we have about 8 days on hand. In terms of gross margin, we had favorable mix during the quarter, again a little bit stronger than the sterile injectables in some of the areas that Paul talked about. If you look at our full year guidance, we did change our assumption to be at the upper end of our gross margin range. So we would expect to see events that we've seen on a year-to-date basis playing through on a full year basis."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray. Our next question is from Jason Gerberry of Leerink Partners.",20,"Our next question is from David Amsellem of Piper Jaffray. 
Our next question is from Jason Gerberry of Leerink Partners."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that becaus",107,"I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that because fourth quarter is usually a little bit seasonally strong. And then second question. Paul, maybe -- can you provide a little bit of framework of this DOJ process? I mean, how do you think in general these processes play out from a time line perspective, how long before investors can get some visibility regarding how this process may evolve?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just",247,"Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just talk to the facts here. So this is a subpoena that we received over 2 years ago, and I think it's safe to say that we believe that we've cooperated with the DOJ and that there's -- in essence, there's no new information. And as it pertains specifically to Par, it was a focus around 2 products and one product of which we do not even sell. So from that standpoint, we're feeling reasonably confident in our position. At least that's what we believe. And to be specific, the issue deals with a product called doxycycline hyclate. It's a product we do not even sell. There may be some confusion at the DOJ, but we sell a product that was called doxycycline monohydrate. And then the second product is a product called digoxin. And in essence, what occurred there, Par came into an already established market with 2 generic competitors, plus the brand. We were the fourth entrant to an established market, and we never took our price -- there was never a price increase with respect to digoxin. So I think that's probably a statement of fact here by Par, and that's our position."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last y",68,"Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last year on a pro forma basis and saw on a pro forma basis were around $50 million."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Randall Stanicky of RBC Capital Markets.",11,"Our next question is from Randall Stanicky of RBC Capital Markets."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Paul, is this heightened generic erosion, is this cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the gene",92,"Paul, is this heightened generic erosion, is this cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the generic side could make sense if we're looking at a couple of years down the road. But I guess the question specifically, do you have visibility or comfort level that 2017 could get a low watermark for some of these challenges and headwinds? And then I have one quick follow-up."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, granted, the erosion factor here was greater than what we had originally assumed. An",235,"Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, granted, the erosion factor here was greater than what we had originally assumed. And we had communicated earlier that we thought we're going to be in the 10% to 12% range for 2017. The reality is that it'll be likely a little more steeper than that. And we just want to be a little bit mindful and thoughtful on how we communicate this. But when you look at the Par portfolio, the base is really not our focus. When you look at the products in our pipeline, products that we're launching, we're looking at more differentiated products. So we are -- as you know, as we call the portfolio out in some of the historical Qualitest products, we're now really moving to more technically challenging products that should be able to withstand pushback on either the trade or competitors. So we're shifting away from a highly commoditized portfolio as we move forward. So I feel we're going to have more erosion to deal with because the portfolio is still quite large. But over time, as we launch some more products, we should be in a better position to keep our margins at the historical 50 -- low-50 percentage on a go-forward basis."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think",68,"So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think about the near term relative to what we're seeing currently versus what you previously thought you would see?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you k",137,"Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you know, on the authorized generic side, Par is holding a small percentage on gross margin, yet we booked the sale. So when we get hit on competition, it's not all uncommon to see a higher erosion factor. Now as the portfolio swings away from AGs into more differentiated products, the likelihood is that we will be able to push back. But I just want to be a little mindful that there's still a fair number of commodities in the portfolio, and we'll come back and provide more color in 2017."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Marc Goodman of UBS.",9,"Our next question is from Marc Goodman of UBS."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or",83,"When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or is the FDA more against approving these 505(b)(2)s? Or basically, the pricing is going to get worse for these things? So is it all 3 of them? Or is it one versus the other? Just give us more color, I think."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When yo",410,"So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When you look at portfolios that are historically in either the injectable portfolio or even some of the legacy Par brands that have shifted over to Endo, those are pure 505(b)(2)s, and we have the resources and the R&D to continue to develop those products. But just to drill into specifically where I think you're headed is when Par undertakes a conversion of an unapproved drug to approved status, and those I break into 2 categories. I'll break those into a category whereby we will continue with our 505(b)(2) strategy of taking unapproved drugs and converting them, running the requisite clinical trials and putting a brand strategy behind that, where that may be detailed either through Joe's Endo team or Tony Pera's injectable team. That we will fight for intellectual property. That falls into one category. When we have intellectual property, it should be normal course. We'll launch the product. It will be priced appropriately for the work in which we've done to gain approval for. And then hopefully, our intellectual property will stick and we have something that we can build upon. Where we're getting some challenges is in the third category, where we develop a 505(b)(2) where we now have a brand we are working with the FDA to remove the unapproved sources, yet we don't have intellectual property. So now we have a timing issue. That's an area that we just need to pause a little bit because the window is a shorter period of time for contribution. So now in today's environment, there are pricing pressures, and we've got to be a little bit mindful of that. So we will continue with the strategy, understanding that when we can get intellectual property, that these 505(b)(2)s, in essence, will behave like a super generic, where we'll have the benefit and contribution driven by volume, but the pricing environment is going to be a little bit tighter and the likelihood is that we will see ANDAs coming at a quicker rate. But that's fine. That's still a meaningful product for the Par portfolio, and we will continue to do that. But that's where we will see a little pressure."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Chris Schott of JPMorgan.",9,"Our next question is from Chris Schott of JPMorgan."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just",97,"This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just how would you characterize replenishing the pipeline and expanding the alternative dosage form business? And then my second quick one, just on Vasostrict, the competitive landscape. Just any updates there. Or is this still status quo and you're feeling pretty confident on exclusivity for the next year or 2?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. T",293,"Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. The product is running. It's converted nicely. And in essence, there's no update, and I'll view that as a positive. Regarding the 2017 pipeline, we've kind of touched on this. We're not going to disclose specifically our products because we don't want to place ourselves at a competitive disadvantage. What I will call out is we don't have the 2 blockbusters that you're seeing right now in Zetia and quetiapine. That we don't have, but you need to remember that we are getting the benefit and the carryover of those 2 products from the fourth quarter of 2016 into the first quarter. So that's going to help us project into 2017. We've got a solid pipeline, but they are smaller products. Some of them contain Paragraph IVs. Some are first-to-market opportunities. At this point in time, we're not going to disclose them because we're not going to place ourselves at a competitive disadvantage. We're going to continue with our 505(b)(2) strategy. We're doing very nicely with our potassium liquid product. We're starting to build momentum with our potassium powder product. Vasostrict continues to perform. The injectable portfolio continuous to perform. And as I indicated before, our strategy, as we pick our R&D pipeline targets for the generic sector, we are going to continue to fund more opportunity into the injectable hard-to-manufacture category. And we're going to continue with our modified release solid oral dosage approach, whereby we are hoping that we will get less competition."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Donald Ellis of JMP Securities.",10,"Our next question is from Donald Ellis of JMP Securities."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it",70,"A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it looked like there was a drug down in -- over our corporate wholesale inventory in the quarter. Would you be able to quantify that?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA.",33,"Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally have",62,"Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally have broad availability in line to the label. And where we are working on improving the reimbursement is both in Medicare and Medicaid."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million.",44,"In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Liav Abraham of Citi.",9,"Our next question is from Liav Abraham of Citi."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?",36,"Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise.",19,"Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-lookin",129,"Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-looking comments for '17 either from a P&L or cash flow standpoint. In terms of your question on covenants, right now just to remind you, we do have 2 maintenance covenants on our secured debt, which is our term loans A and B in our revolver. And so our secured leverage covenant is less than 3.85x adjusted EBITDA, and we're currently at 2.1x. And we also have an interest coverage covenant, which -- that is -- the covenant is greater than 2.5x, and we're currently at 3.8x."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Stephan Stewart of Goldman Sachs.",5,"Stephan Stewart of Goldman Sachs."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just wanted to follow up on the pipeline question. And without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the gener",48,"Just wanted to follow up on the pipeline question. And without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics business beyond the first half of '17?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Again, I think right now, we're going to come back in February 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some ch",97,"Again, I think right now, we're going to come back in February 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some challenges. But ultimately, I'm going to point right back to the 505(b)(2)s, and products like Vasostrict and Adrenalin have served us well. But Stephan, I think right now what we're going to do is come back in the February time frame and provide a little bit more color."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just one follow-up on the DOJ investigation. I guess, how confident are you that it's ring-centered around the products mentioned versus just the start of something broader?",28,"Just one follow-up on the DOJ investigation. I guess, how confident are you that it's ring-centered around the products mentioned versus just the start of something broader?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I th",53,"Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I think that's our position."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Andrew Finkelstein of Susquehanna.",9,"Our next question is from Andrew Finkelstein of Susquehanna."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year.",21,"I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way we would be looking at this is that we have the product positioned where we needed to be, and anything that we consider on",77,"Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way we would be looking at this is that we have the product positioned where we needed to be, and anything that we consider on a go-forward basis would be more mindful and thoughtful of the current environment. I think that's probably the best way I would characterize our pricing strategy on Vasostrict."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?",18,"And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","I'm not sure I understand what you mean by unpressure.",11,"I'm not sure I understand what you mean by unpressure."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I mean, absent a competitor, you're not -- you would expect the gross to nets to be comparable to how they exist now.",23,"I mean, absent a competitor, you're not -- you would expect the gross to nets to be comparable to how they exist now."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, absolutely. Yes, right, the status quo.",7,"Yes, absolutely. Yes, right, the status quo."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Next question is from Gary Nachman of BMO Capital Markets.",10,"Next question is from Gary Nachman of BMO Capital Markets."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces.",43,"This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, okay, sure. So we'll pass it over to Blaise.",10,"Yes, okay, sure. So we'll pass it over to Blaise."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed w",53,"Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed well, and our FORTESTA franchise played -- performed well."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Annabel Samimy of Stifel.",9,"Our next question is from Annabel Samimy of Stifel."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?",28,"This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our bus",140,"Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our business, that includes the brand and international and the generics business. We're looking at all components and all our assets. And frankly, at this point in time, we're putting together a strategy plan, and we will come back. But at this point in time, there's been no decisions to divest any asset. And we're -- as we get closer to our February earnings call, we'll provide more color whether this is something that we will be considering. But at this point in time, there's been no movement on divesting any assets."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Sumant Kulkarni of Bank of America.",11,"Our next question is from Sumant Kulkarni of Bank of America."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile",94,"Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile injectables and alternate dosage forms? And secondly, given that Par does not have -- or Endo does not have a biosimilar strategy now, do you think your R&D spend is appropriately focused to get the best possible use of the opportunities that are out there on small molecule generics?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But",307,"Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But Sumant, I think one of our advantages, and I said this repeatedly, I think it is a good time for Endo to have sterile injectables facilities on U.S. soil. I think that separates us from the competition. So I'm seeing a lot of quality compliance issues with our competitors. I'm seeing a lot of back order issues. I think this gives us an advantage. And also, I think having a facility on U.S. soil with the R&D team and the manufacturing and quality teams that we have, I think that's an advantage for us. When I look at our product launches, we are always first-to-market in our categories in which we choose to play, and I think that provides a good set point for us as we move forward and ultimately, execute on our GPO contract. So once we do that, we're holding the contract and it's ours to defend. I think that differentiates us. Regarding the question on biosimilars, I know -- we'll come back, I've missed one. But the questions on the biosimilars, while maybe that's not a primary strategy of Par's today, an area that we have focused in on -- and I'm not going to get too deep into it, but we are focusing on polypeptides. That is challenging chemistry. I think that's going to start to set us apart, and that's going to leverage our capabilities both on the internal R&D side, partnerships that we've established and taking advantage of the Rochester facility. And I apologize. I think I missed maybe your first question."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or would that require any kind of bolstering going forward?",29,"It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or would that require any kind of bolstering going forward?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make pro",105,"So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make products, whether they're topicals, creams, ointments, ophthalmics, and things that may take smaller clinical trials. So that, to us, is an area that we have the skill set with our teams in place, and it's something that we're starting to do well. That, coupled with our Paragraph IV strategy, I think places us in a position to deliver higher-value generics on a go-forward basis."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Greg Gilbert of Deutsche Bank.",10,"Our next question is from Greg Gilbert of Deutsche Bank."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics",61,"It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics Base in 2015 that, that erosion would be off of?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that.",32,"So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes, the pro forma base business in 2015 is 17 52 [ph].",12,"Yes, the pro forma base business in 2015 is 17 52 [ph]."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?",24,"Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","For this year?",3,"For this year?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I'm sorry. Can you repeat that question?",8,"I'm sorry. Can you repeat that question?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance.",24,"Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Well, we have Zetia and quetiapine. So have we given that number?",12,"Well, we have Zetia and quetiapine. So have we given that number?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","We gave it for the second half.",7,"We gave it for the second half."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that, that's sort of the midpoint.",38,"Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that, that's sort of the midpoint."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. But the $425 million was the total.",8,"Okay. But the $425 million was the total."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","That's the total, all in, yes.",7,"That's the total, all in, yes."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?",40,"Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So i",147,"Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So it leaves about $900 million of the liability still to be serviced. We would expect about $300 million to be paid in Q4, and then the balance of that to be paid in 2017 fairly evenly over the first 3 quarters of 2017. In terms of modeling any sort of cash benefit or shield around that, we recommended and continue to do that from a modeling standpoint to model our cash tax rate as a percentage of adjusted income at the enterprise level. And our guidance previously still stands, which is in the low single digits"
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And with regards to BELBUCA, we booked low single digit millions.",11,"And with regards to BELBUCA, we booked low single digit millions."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray.",10,"Our next question is from David Amsellem of Piper Jaffray."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smalle",91,"So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smaller. But what's the right way of thinking about it in terms of orders of magnitude, smaller? And then how should we think about the competitive dynamics of that product? Just trying to get a sense of how important that's going to be in terms of a 2017 contributor."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calc",374,"All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calculate the units there. We have, in essence, converted the entire market. Maybe you might say the entire market is probably in the very high 90s. So what I'm politely saying is that we've executed, and all the unapproved sources have been off the market for a couple of months. So that, to me, is running nicely. But there's no barrier to entry, so you just have to be aware that an ANDA can be filed. And that product has been approved since, I believe, around 2014. So you just got to make an assumption. At some point, a company that has liquid capabilities can enter the market. The powder is the one that probably has created the most questions because there's so many different forms of powder. And I think in terms of sizing that -- and I think it's safe to say that we -- it's probably easier for us to communicate the number of packets in the market, and then you can go back and do the math. In essence, this is an 18-million-pack market, right? And they're broken into 30s and 100s. I would tell you that's probably irrelevant. But for your math, go back, you're using 18 million packets, and then you can look at standard single-source-type generic pricing. While it's a 505(b)(2), I would make the assumption that it's a single-sourced, highly genericized-type product. That's the way I would think that you should look at the powder. Now having said that, there are still pull-through of unapproved sources. So the unapproved sources were asked to exit the market back in the June time frame, and I believe that they had 2 months to produce product and 3 months to sell through product. So there's going to be a period of time where it's probably going to take us to Q1 before we see that conversion. So I think those are your levers in order to calculate the powder opportunity."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao of Barclays.",4,"Douglas Tsao of Barclays."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retai",110,"So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retaining 60-plus percent until these products have gone multi-sourced. So just curious in terms of your confidence that those will pick up traction as much as you want. And then also, just if you could provide some comments. If I look at the IMS data, didn't really get much traction with the Crestor product launch. Just curious if you have any sort of perspectives on what might have happened there."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies f",296,"So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies followed on. So the reality is that while it was a large product, it was -- there was an awful lot of competition. And we had a short burst, and at the end of the day, pricing fell to probably somewhere around 98.5% to 99% off of brand wagon. And again, that's an area that we don't want to compete. That was a decision that was made many, many years ago and the market dynamics changed in that regard. On quetiapine, quetiapine launch is behaving as we expected, so I feel pretty confident about that product on a go-forward basis. The product launch came out on November 1, and we've already taken on around 96%, 97% of the market in terms of signing on accounts. So it's behaving as we expected. In the case of Zetia, the reference that you're making in terms of brand retention, we've taken our -- what we believe is an appropriate approach to the fact that perhaps the brand could retain some percentage based upon maybe some PBM contracts. So that's been taken into consideration. I think what may be important is in this particular product, about 88% of the product is handled through the retail chains. I think that's an important factor. So we feel pretty good about how this product's going to behave, and we've taken in generic conversion in terms of what I think is appropriate. So I feel good about where Zetia will head. No guarantees, but I feel good."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks.",24,"And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call.",20,"Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today",63,"And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today's call, and we will see you back at our February earnings call. Thank you all."
28071,405113130,1080012,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day. .",26,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day. ."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri M",53,"Good day, ladies and gentlemen, and welcome to the Third Quarter 2016 Endo International plc Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Keri Mattox, Senior Vice President in Investor Relations and Corporate Affairs. Please go ahead."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appoi",246,"Thank you. Good morning, and thank you for joining us to discuss our third quarter 2016 financial results. With me on today's call are Paul Campanelli, President and CEO of Endo; Blaise Coleman, Senior Vice President of Global Finance Operations and appointed interim Chief Financial Officer; and Joe Ciaffoni, President of Endo Pharmaceuticals, our U.S. Branded business. We have prepared a slide presentation to accompany today's webcast, and that presentation as well as other materials are posted online in the Investors section at endo.com. 
I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and Canadian Securities Litigation Act and are subject to the changes, risks and uncertainties described in today's press release and in our U.S. and Canadian securities filings. 
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K furnished with the SEC today for Endo's reasons for including those non-GAAP financial measures in today's earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our earnings press release issued prior to today's call. 
With that, I would now like to turn the call over to Paul. Paul?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. Let me now turn to our third quarter 2016 earnings p",870,"Thank you, Keri. Good morning, everyone, and thank you for joining us for today's call. I hope that you've all had a chance to review the company's earnings press release that we issued earlier today. 
Let me now turn to our third quarter 2016 earnings presentation. To start, here's a brief agenda for today's call. Moving to Slide 3. As you know, the third quarter brought some changes and I believe, a sharpened focus on operational execution at Endo. Despite some headwinds for our Generics Base business, the overall diversity of our portfolio did enable us to deliver solid revenue and adjusted earnings per share results in the third quarter with revenue performance across all business units broadly in line or ahead of company expectations. 
I recently took on the role of CEO, and I am working to realize the potential for Endo moving forward. Our product-by-product assessment of the business and our portfolios is in progress, and we are working on the development of a strategic plan. Importantly, we are once again pleased to reaffirm our 2016 revenues and adjusted EPS guidance. 
On Slide 4. You will see a snapshot of our segment revenues for the third quarter. 
Moving to Slide 5. Let's discuss our branded business. Our branded performance in the third quarter was stronger than our expectations, which underlies our segment revenue and margin guidance provided earlier this year. We delivered solid XIAFLEX demand, particularly in Peyronie's disease, and our revenue growth expectation for XIAFLEX continues to be in the low double digits for the year. The BELBUCA launch is progressing, and we are evaluating how to maximize the value of this differentiated product within a challenging opioid market. We did see outperformance by select U.S. Branded products, including Voltaren Gel, LIDODERM and some products in our other branded portfolio. 
Moving to Slide 6. Let's talk about our international pharmaceuticals. Our results were in line with the expectations that underlied our revenue and margin guidance provided in May for Paladin, Litha and Somar. At Paladin, we drove solid performance across our base business, launched Nucynta and secured the Canadian rights for XIAFLEX. The additions of these products could provide a longer-term growth as we continue to manage the expected loss of exclusivity on select products in the Canadian market this year. In our Litha and Somar businesses, our underlying revenue growth is outpacing market growth rates, largely driven by volume, and we continue to improve our adjusted operating margins. 
Turning to Slide 7 and our generics business. We continued to deliver overall segment performance in line with our expectations. Our sterile injectables business continues to grow led by Vasostrict. In new launches and alternative dosages, we saw better-than-expected performance from alternative dosages, especially the LIDODERM authorized generic, and we have launched 15 products since the beginning of the year. We continue to file new ANDAs with the FDA while replenishing our R&D pipeline. 
Our base business declined approximately 20% sequentially from the second quarter 2016 driven by higher-than-expected consortium pricing pressures, a vast [ph] consortium structure and certain competitive generic entrants late in the quarter. Excluding stocking and onetime factors, this decline was approximately 15% from the second quarter 2016. We now expect full year base business decline to be in the low 30s percentage range. Given this deeper-than-expected erosion for our base business for the quarter and the year, our base business erosion rate in 2017 may be larger than our previous assumption of a return to historic Par annual erosion rates of 10% to 12%. We will update our assumptions on 2017 base erosion as part of our full year 2017 guidance on our year-end earnings call. It is important to note that Par's strategy is focused not on this base segment but on prioritizing growing higher-quality, higher barrier-to-entry products and continuing to advance and replenish our differentiating R&D pipeline. 
Moving on to Slide 8. You will see a chart tracking our new product launches. We have updated to show the 15 products that we have successfully launched so far in 2016. We've had a number of smaller product launches shift into early 2017 and others that we have rationalized due to commercialization assessments and our ongoing portfolio of prioritization but still anticipate that we will launch approximately 20 new products this year, including our first-to-file exclusive products, generic SEROQUEL XR and generic Zetia. 
Let's turn to Slide 9 to talk about those 2 key fourth quarter launches. Importantly, we've now launched our generic SEROQUEL XR product. The initial launch has gone smoothly, and all manufacturing, launch activities and product shipments are on track. Our expected December 2016 launch of generic Zetia is also progressing on track. We have received final approval from the FDA and have an agreement in place with Merck through our partner, Glenmark. This product is manufactured through that partnership with Glenmark, and we have a product in our warehouse and we're ready to launch with marketing exclusivity. Together, we expect these 2 first-to-file launches to contribute in line with our previously communicated projections. 
With that, let me turn the call over to Blaise Coleman to discuss the financial performance of the company and the quarter and our projected outlook. Blaise?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have",483,"Thank you, Paul, and good morning, everyone. First, on Slide 11, you will see a snapshot of the third quarter GAAP and non-GAAP financial results. Paul covered company and segment revenues earlier, so I will not review that here. On a GAAP basis, we have loss per share of $0.86 in the quarter versus a loss of $3.84 in the third quarter of 2015. GAAP net loss for continuing operations in the third quarter of 2016 decreased to $191 million compared to a GAAP net loss from continuing operations of $804 million during the same period in 2015, primarily due to goodwill and intangible asset impairment charges recorded during third quarter 2015. On an adjusted basis, overall third quarter results are better than previously guided. 
To summarize the points that Paul made, revenue was strong due to continued performance from XIAFLEX and better than expected due to outperformance by sterile injectables, alternative dosages and select other branded products. Adjusted net income and EPS are better than guided as a result of higher revenues, better gross margin percentage due to product mix and lower operating expenses primarily due to timing. 
On Slide 12, we are again reaffirming our revenue and adjusted EPS full year guidance. We expect revenues to be approximately $3.87 billion to $4.03 billion and adjusted EPS to be between $4.50 and $4.80. Given our overperformance in Q3 versus our expectations, we have increased confidence in our overall full year guidance range, which takes into account several moving parts, including the range of our launch forecast for our first-to-file generic versions of SEROQUEL XR and Zetia, projections around year-end timing of product sales and shipments and continued pricing pressure for our U.S. Generics Base business. 
Moving to cash and liquidity on Slide 13. On a year-to-date basis, cash flow from operations totaled approximately $443 million. We've also highlighted some of the material moving parts that have impacted our cash flow from operations on a quarterly and September year-to-date basis. 
On Slide 14, we are updating our view on estimated free cash flow in 2016. We now project debt paydown of approximately $330 million in 2016 and to exit the year in the high 4x range for our net debt to adjusted EBITDA leverage ratio. While we've provided some color in the past on potential free cash flow headwinds and tailwinds in 2017, given our dynamic sector environment and our ongoing strategic assessment, both of which could impact cash flows in 2017 versus previous expectations, we will wait to provide any details or updates for next year until we provide our full year 2017 financial guidance in late February. 
As noted in our press release, we ended the quarter with approximately $562 million in unrestricted cash, approximately $276 million in restricted cash and a net debt to adjusted EBITDA leverage ratio of approximately 4.9x. 
Now let me turn it back over to Paul."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper",539,"Thank you, Blaise. Moving to Slide 16. There are some strategic updates regarding the 2017 market environment that we believe are important to discuss. First, the U.S. Generics competitive landscape and pricing pressures continue to be challenging. Deeper-than-expected base erosion trends that we see and saw in the third quarter indicate stronger headwinds on the front as we exit the year. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid cycles that we expect to weigh on our generics business moving forward, could impact our adjusted gross margin profile. And our 505(b)(2) expectation and longer-term 505(b)(2) strategy has been impacted by the competitive landscape, regulatory actions and the pricing environment. We will provide more detail and insights into the expected impacts of these trends on our 2017 financial outlook when we provide full year guidance in late February 2017. I would like to note that deeper-than-expected erosion and demand for our products and/or changes to our resource allocation resulting from our strategic assessment could result in changes in the carrying values of assets across our segments. 
Next, XIAFLEX. We've identified XIAFLEX as a core U.S. Branded product and growth driver for Endo moving forward. We continue to put resources and efforts behind accelerating traction and growth in our Dupuytren's contracture and Peyronie's disease indications. We're also analyzing our R&D pipeline. Cellulite remains the primary focus there, and we look forward to reporting out on our Phase IIb data upon the completion of that trial. Other potential indications are currently undergoing a full commercial assessment and analysis so that we can best prioritize our R&D efforts and determine clinical trial time lines moving forward. 
The launch of BELBUCA is also progressing. We continue to believe that BELBUCA offers a compelling and differentiated product profile, and we want to ensure that we are best positioned moving forward. 
Finally, as the new CEO, I am spending a lot of time evaluating and working with our legal team to further develop and execute on our strategy with respect to the ongoing mesh litigation. 
On Slide 17, let's talk about my CEO assessment process. As I mentioned, we are pleased to reaffirm our revenue and adjusted EPS full year 2016 financial guidance. Overall, business performance continues to be broadly in line with our expectations. We are in the process of conducting a bottoms-up product-by-product assessment of all 3 of our business units. We expect that we'll be ready to communicate our evolved corporate strategy in the February 2017 time frame of our fourth quarter 2016 earnings announcement. As we've done in the past, we expect that we'll also communicate our full year 2017 financial guidance and expectations for our business at that time. 
In closing, Endo is sharpening its focus on operational execution, and I am excited to be leading the company. I want to take a moment to thank all of our dedicated employees whose hard work and commitment to the company make what we do possible. We continue to believe that this is a time of significant opportunity for Endo, our employees, the patients we serve and our shareholders. 
That concludes our prepared remarks. Now let me turn the call back over to Keri to manage our question-and-answer period. Keri?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?",23,"Thank you, Paul. We'd like now to open the line to your questions. [Operator Instructions] Christy, may we have the first question, please?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our first question is from the line of Greg Gilbert of Deutsche Bank. Our next question is from Elliot Wilbur of Raymond James.",23,"Our first question is from the line of Greg Gilbert of Deutsche Bank. 
Our next question is from Elliot Wilbur of Raymond James."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepa",116,"Just basically one question for you, Paul. Can you maybe just provide a little bit more color, go into a little bit more detail in terms of the evolving consortium pricing pressures that you've referenced several times in the release and during your prepared commentary? Just trying to figure out, is this a result of a renewed bid cycle or some structural change on the consortiums with some of the recent movement? Or is it simply just existing competitors be a lot more aggressive in current product markets or the impact of new competition or maybe all 3? But if you could just maybe give a little bit more clarity behind that, it would be helpful."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks, Elliot, and I think that's right. I think you've kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real",277,"Yes. Thanks, Elliot, and I think that's right. I think you've kind of hit the nail on the head. In essence, it's all 3 of those. So the starting point is, really, frankly, we want to start the tone and set the tone of credibility and really taking a real prudent approach here. But when we look at what's happening, we did have anticipated -- essentially higher-than-anticipated pressure from the consortiums, and we did, in essence, see a little more discounting for some of the more established generic competitors, so a little bit of that going on as well. When we see the 20% erosion factor that we talked about, in essence, if we exclude a couple of onetime events, we are more in the 15% erosion for the quarter. And specifically, when you look at the area in which we were -- effect that we had 2 products that were authorized generics, right? So these are products that you know that we -- that are revenue drivers. But in essence, they are large -- they're lower-margin contributors to the Par franchise. So metoprolol and budesonide were 2 products that -- we received additional competition from budesonide, and then we had a little heavier-than-expected competition at Red Oak from a competitor on the metoprolol aging. And structurally, we're seeing some changes at McKesson. As you know, they are moving away from their San Francisco operation, and you're going to start to see a shift in McKesson to their European operation that referred to Claris 1. So they're starting to kick in, and you'll see a change on a go-forward basis as they kind of unite with Walmart."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from the line of Louise Chen of Guggenheim.",12,"Our next question is from the line of Louise Chen of Guggenheim."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expecte",47,"It's Brandon Folkes on for Louise. Could you just talk about the magnitude of stocking benefit in the quarter for XIAFLEX? And then secondly, could you just talk about some of the drivers of gross margin strength in the quarter and whether they're expected to continue?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay, great. So I'm going to pass the first question over to Blaise.",13,"Okay, great. So I'm going to pass the first question over to Blaise."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our gr",173,"Yes, Brandon. So for the quarter, from a XIAFLEX perspective, we did see some stocking benefit. We saw a benefit in the quarter of about 2 days. So in absolute terms, that's about a little over $1 million of benefit in the quarter. When you look at our growth rate sequentially for XIAFLEX at a total molecule level, we grew about 12%, and the majority of that was due to a stocking movement. At the end of Q2, we had about 6 days on hand. And at the end of Q3, we have about 8 days on hand. In terms of gross margin, we had favorable mix during the quarter, again a little bit stronger than the sterile injectables in some of the areas that Paul talked about. If you look at our full year guidance, we did change our assumption to be at the upper end of our gross margin range. So we would expect to see events that we've seen on a year-to-date basis playing through on a full year basis."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray. Our next question is from Jason Gerberry of Leerink Partners.",20,"Our next question is from David Amsellem of Piper Jaffray. 
Our next question is from Jason Gerberry of Leerink Partners."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that becaus",107,"I just want to make sure I'm getting this right on XIAFLEX. So I mean, if you had a low double-digit full year growth, that would imply fourth quarter's down somewhere like 15% to 20% year-on-year. So I just want to make sure I'm understanding that because fourth quarter is usually a little bit seasonally strong. And then second question. Paul, maybe -- can you provide a little bit of framework of this DOJ process? I mean, how do you think in general these processes play out from a time line perspective, how long before investors can get some visibility regarding how this process may evolve?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just",247,"Yes. So Jason, I'm not going to really -- I'll start with the DOJ question, and I'll pass the XIAFLEX back to Blaise in a second. So we're not going to be able to comment a little bit specifically on the DOJ process, and maybe what we can do is maybe just talk to the facts here. So this is a subpoena that we received over 2 years ago, and I think it's safe to say that we believe that we've cooperated with the DOJ and that there's -- in essence, there's no new information. And as it pertains specifically to Par, it was a focus around 2 products and one product of which we do not even sell. So from that standpoint, we're feeling reasonably confident in our position. At least that's what we believe. And to be specific, the issue deals with a product called doxycycline hyclate. It's a product we do not even sell. There may be some confusion at the DOJ, but we sell a product that was called doxycycline monohydrate. And then the second product is a product called digoxin. And in essence, what occurred there, Par came into an already established market with 2 generic competitors, plus the brand. We were the fourth entrant to an established market, and we never took our price -- there was never a price increase with respect to digoxin. So I think that's probably a statement of fact here by Par, and that's our position."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last y",68,"Yes, Jason. And on the XIAFLEX question, so our guide, it's -- again, it's been low double digit for the year. We do anticipate that for Q4, what that implies is that we would see sales similar to Q3 of '16, so flat to slightly up. And our Q4 sales last year on a pro forma basis and saw on a pro forma basis were around $50 million."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Randall Stanicky of RBC Capital Markets.",11,"Our next question is from Randall Stanicky of RBC Capital Markets."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Paul, is this heightened generic erosion, is this cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the gene",92,"Paul, is this heightened generic erosion, is this cyclical or secular? And the reason I ask the question is because as you're looking at your asset base of branded generic assets, obviously, this is a shorter-term dynamic, and moving more towards the generic side could make sense if we're looking at a couple of years down the road. But I guess the question specifically, do you have visibility or comfort level that 2017 could get a low watermark for some of these challenges and headwinds? And then I have one quick follow-up."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, granted, the erosion factor here was greater than what we had originally assumed. An",235,"Yes. So Randall, I think right now, we're going to come back in our February earnings call and provide a little bit more insight. And I think the way we're looking at it, granted, the erosion factor here was greater than what we had originally assumed. And we had communicated earlier that we thought we're going to be in the 10% to 12% range for 2017. The reality is that it'll be likely a little more steeper than that. And we just want to be a little bit mindful and thoughtful on how we communicate this. But when you look at the Par portfolio, the base is really not our focus. When you look at the products in our pipeline, products that we're launching, we're looking at more differentiated products. So we are -- as you know, as we call the portfolio out in some of the historical Qualitest products, we're now really moving to more technically challenging products that should be able to withstand pushback on either the trade or competitors. So we're shifting away from a highly commoditized portfolio as we move forward. So I feel we're going to have more erosion to deal with because the portfolio is still quite large. But over time, as we launch some more products, we should be in a better position to keep our margins at the historical 50 -- low-50 percentage on a go-forward basis."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think",68,"So can we just narrow that cap a bit? So you were talking about a 15% erosion factor net of one-timers in 4Q. You've previously talked about 10% to 12% on an annual basis. That's a pretty big divide, right, from a sequential to an annual. How do we think about the near term relative to what we're seeing currently versus what you previously thought you would see?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you k",137,"Okay. So again, we'll come back. We'll come back in February, and we'll provide color with respect to that. But as we move forward and you look at the Par legacy portfolio, there has been a fair share of authorized generics in that portfolio. And as you know, on the authorized generic side, Par is holding a small percentage on gross margin, yet we booked the sale. So when we get hit on competition, it's not all uncommon to see a higher erosion factor. Now as the portfolio swings away from AGs into more differentiated products, the likelihood is that we will be able to push back. But I just want to be a little mindful that there's still a fair number of commodities in the portfolio, and we'll come back and provide more color in 2017."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Marc Goodman of UBS.",9,"Our next question is from Marc Goodman of UBS."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or",83,"When you were talking about 2017, you mentioned 505(b)(2) expectations. And can you put a little more color on that? You said the longer-term strategy could be impacted. So what does that mean? So competitively, are there more people doing 505(b)(2)s? Or is the FDA more against approving these 505(b)(2)s? Or basically, the pricing is going to get worse for these things? So is it all 3 of them? Or is it one versus the other? Just give us more color, I think."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When yo",410,"So -- sure. So Marc, when I look at 505(b)(2)s, I like to break them into 3 categories, right? And we got to be real specific here. So 505(b)(2)s has been and will continue to be a part of the Endo-Par strategy, but I break them into 2 categories. When you look at portfolios that are historically in either the injectable portfolio or even some of the legacy Par brands that have shifted over to Endo, those are pure 505(b)(2)s, and we have the resources and the R&D to continue to develop those products. But just to drill into specifically where I think you're headed is when Par undertakes a conversion of an unapproved drug to approved status, and those I break into 2 categories. I'll break those into a category whereby we will continue with our 505(b)(2) strategy of taking unapproved drugs and converting them, running the requisite clinical trials and putting a brand strategy behind that, where that may be detailed either through Joe's Endo team or Tony Pera's injectable team. That we will fight for intellectual property. That falls into one category. When we have intellectual property, it should be normal course. We'll launch the product. It will be priced appropriately for the work in which we've done to gain approval for. And then hopefully, our intellectual property will stick and we have something that we can build upon. Where we're getting some challenges is in the third category, where we develop a 505(b)(2) where we now have a brand we are working with the FDA to remove the unapproved sources, yet we don't have intellectual property. So now we have a timing issue. That's an area that we just need to pause a little bit because the window is a shorter period of time for contribution. So now in today's environment, there are pricing pressures, and we've got to be a little bit mindful of that. So we will continue with the strategy, understanding that when we can get intellectual property, that these 505(b)(2)s, in essence, will behave like a super generic, where we'll have the benefit and contribution driven by volume, but the pricing environment is going to be a little bit tighter and the likelihood is that we will see ANDAs coming at a quicker rate. But that's fine. That's still a meaningful product for the Par portfolio, and we will continue to do that. But that's where we will see a little pressure."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Chris Schott of JPMorgan.",9,"Our next question is from Chris Schott of JPMorgan."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just",97,"This is Dana Flanders on for Chris. Just my first one. Can you talk a little bit more about just the generic pipeline? And I know it's early, but any views on outlining key launches into 2017? And then if we are seeing greater base business declines, just how would you characterize replenishing the pipeline and expanding the alternative dosage form business? And then my second quick one, just on Vasostrict, the competitive landscape. Just any updates there. Or is this still status quo and you're feeling pretty confident on exclusivity for the next year or 2?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. T",293,"Great. So I'll take -- the first one on Vasostrict is pretty simple. As of today, we have not received any notification of a Paragraph IV. There's been no update to the FDA's Paragraph IV website. So at this point in time, there's really not much to do. The product is running. It's converted nicely. And in essence, there's no update, and I'll view that as a positive. Regarding the 2017 pipeline, we've kind of touched on this. We're not going to disclose specifically our products because we don't want to place ourselves at a competitive disadvantage. What I will call out is we don't have the 2 blockbusters that you're seeing right now in Zetia and quetiapine. That we don't have, but you need to remember that we are getting the benefit and the carryover of those 2 products from the fourth quarter of 2016 into the first quarter. So that's going to help us project into 2017. We've got a solid pipeline, but they are smaller products. Some of them contain Paragraph IVs. Some are first-to-market opportunities. At this point in time, we're not going to disclose them because we're not going to place ourselves at a competitive disadvantage. We're going to continue with our 505(b)(2) strategy. We're doing very nicely with our potassium liquid product. We're starting to build momentum with our potassium powder product. Vasostrict continues to perform. The injectable portfolio continuous to perform. And as I indicated before, our strategy, as we pick our R&D pipeline targets for the generic sector, we are going to continue to fund more opportunity into the injectable hard-to-manufacture category. And we're going to continue with our modified release solid oral dosage approach, whereby we are hoping that we will get less competition."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Donald Ellis of JMP Securities.",10,"Our next question is from Donald Ellis of JMP Securities."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it",70,"A couple of quickie questions. First of all, can you give us a breakdown in the quarter for Dupuytren's versus Peyronie's. And then can you also explain to us, are you getting -- are you -- is the reimbursement landscape improving for BELBUCA? And then it looked like there was a drug down in -- over our corporate wholesale inventory in the quarter. Would you be able to quantify that?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA.",33,"Okay. So Don, this is Paul. I'm going to pass the first question on XIAFLEX, the breakdown between PD and DC over to Joe. He also can talk a little bit about BELBUCA."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally have",62,"Yes. Thanks for the question, Donald. From a XIAFLEX perspective, the breakdown of Dupuytren's and Peyronie's is essentially 50-50. When you look at BELBUCA reimbursement, the best way to think about it is from a commercial perspective. We generally have broad availability in line to the label. And where we are working on improving the reimbursement is both in Medicare and Medicaid."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million.",44,"In terms of the inventory question, we already talked about XIAFLEX. From a generic standpoint, we did see some destocking in the quarter. So at the end of the quarter, we saw destocking of approximately 2 days, and that was worth about $10 million."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Liav Abraham of Citi.",9,"Our next question is from Liav Abraham of Citi."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?",36,"Can you just remind us of the pushes and pulls in cash flows -- in free cash flow outlook in 2017 versus 2016 and then also of your incremental debt capacity before you hit your covenants?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise.",19,"Yes. Liav, this is Paul. I'm going to pass that question on the free cash flow over to Blaise."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-lookin",129,"Yes, sure. So in '17, as we said in our scripted remarks, again, as we're conducting the strategic assessment that Paul is undertaking and for some of the other dynamic environment issues we talked about, we're not going to be providing any forward-looking comments for '17 either from a P&L or cash flow standpoint. In terms of your question on covenants, right now just to remind you, we do have 2 maintenance covenants on our secured debt, which is our term loans A and B in our revolver. And so our secured leverage covenant is less than 3.85x adjusted EBITDA, and we're currently at 2.1x. And we also have an interest coverage covenant, which -- that is -- the covenant is greater than 2.5x, and we're currently at 3.8x."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Stephan Stewart of Goldman Sachs.",5,"Stephan Stewart of Goldman Sachs."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just wanted to follow up on the pipeline question. And without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the gener",48,"Just wanted to follow up on the pipeline question. And without disclosing product opportunities, are you confident that the pipeline has enough to offset the base erosion and eventual competition on SEROQUEL and Zetia to drive overall growth for the generics business beyond the first half of '17?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Again, I think right now, we're going to come back in February 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some ch",97,"Again, I think right now, we're going to come back in February 2017, and we'll be able to add a little bit more color in that regard. Clearly, there are some headwinds on base erosion. We don't want to -- we do want to underscore that there's been some challenges. But ultimately, I'm going to point right back to the 505(b)(2)s, and products like Vasostrict and Adrenalin have served us well. But Stephan, I think right now what we're going to do is come back in the February time frame and provide a little bit more color."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Just one follow-up on the DOJ investigation. I guess, how confident are you that it's ring-centered around the products mentioned versus just the start of something broader?",28,"Just one follow-up on the DOJ investigation. I guess, how confident are you that it's ring-centered around the products mentioned versus just the start of something broader?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I th",53,"Yes. Again, Steve, I'm not going to comment on the DOJ and my opinion on the DOJ investigation. I think right now what we -- what I communicated earlier are statement of facts. We don't sell one product and we didn't take our price up on digoxin, and I think that's our position."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Andrew Finkelstein of Susquehanna.",9,"Our next question is from Andrew Finkelstein of Susquehanna."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year.",21,"I was just hoping, specifically on the outlook for Vasostrict, how you're thinking about pricing going forward over the next year."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way we would be looking at this is that we have the product positioned where we needed to be, and anything that we consider on",77,"Sure. I think our price -- we want to think of ourselves as rational players in the current pricing environment. So I think the way we would be looking at this is that we have the product positioned where we needed to be, and anything that we consider on a go-forward basis would be more mindful and thoughtful of the current environment. I think that's probably the best way I would characterize our pricing strategy on Vasostrict."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?",18,"And nothing to suggest unpressure relative to the kind of net pricing or volume you're seeing now?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","I'm not sure I understand what you mean by unpressure.",11,"I'm not sure I understand what you mean by unpressure."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","I mean, absent a competitor, you're not -- you would expect the gross to nets to be comparable to how they exist now.",23,"I mean, absent a competitor, you're not -- you would expect the gross to nets to be comparable to how they exist now."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, absolutely. Yes, right, the status quo.",7,"Yes, absolutely. Yes, right, the status quo."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Next question is from Gary Nachman of BMO Capital Markets.",10,"Next question is from Gary Nachman of BMO Capital Markets."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces.",43,"This is actually Chris¬†Wolpert on for Gary. I just wanted to maybe get a little bit more clarity around the other branded revenue. That was a pretty good percentage of U.S. brand, so if you could go into some of those pieces."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, okay, sure. So we'll pass it over to Blaise.",10,"Yes, okay, sure. So we'll pass it over to Blaise."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed w",53,"Yes. So Chris, just in terms of the other branded revenue, just in terms of the quarter again, we did have better expectation -- or performed better than our expectations. A couple of products in there that performed well. Testim and Testim AG performed well, and our FORTESTA franchise played -- performed well."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Annabel Samimy of Stifel.",9,"Our next question is from Annabel Samimy of Stifel."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?",28,"This is Esther in for Annabel. I just wanted to get your thoughts on divestments. Have you made any further decisions on the direction you're going to go?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our bus",140,"Yes, sure. Right now we've been -- we haven't made any clear decisions on monetizing any assets right now. I mean, what we're doing here -- in my first 30 days or so, what we are -- we're assessing our businesses, and we're assessing -- when I say our business, that includes the brand and international and the generics business. We're looking at all components and all our assets. And frankly, at this point in time, we're putting together a strategy plan, and we will come back. But at this point in time, there's been no decisions to divest any asset. And we're -- as we get closer to our February earnings call, we'll provide more color whether this is something that we will be considering. But at this point in time, there's been no movement on divesting any assets."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Sumant Kulkarni of Bank of America.",11,"Our next question is from Sumant Kulkarni of Bank of America."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile",94,"Both are fairly bigger picture, strategic ones for Paul. We know you have a base business, and the erosion in the base business seems to be trending higher than you had forecasted. At what point do you think that erosion could also start affecting sterile injectables and alternate dosage forms? And secondly, given that Par does not have -- or Endo does not have a biosimilar strategy now, do you think your R&D spend is appropriately focused to get the best possible use of the opportunities that are out there on small molecule generics?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But",307,"Yes. So the first question, in terms of the erosion, in terms of -- on the injectable side, so I think right now -- I'll start with erosion factor on injectables. So clearly, it's an area that other companies are starting -- are trying to break into. But Sumant, I think one of our advantages, and I said this repeatedly, I think it is a good time for Endo to have sterile injectables facilities on U.S. soil. I think that separates us from the competition. So I'm seeing a lot of quality compliance issues with our competitors. I'm seeing a lot of back order issues. I think this gives us an advantage. And also, I think having a facility on U.S. soil with the R&D team and the manufacturing and quality teams that we have, I think that's an advantage for us. When I look at our product launches, we are always first-to-market in our categories in which we choose to play, and I think that provides a good set point for us as we move forward and ultimately, execute on our GPO contract. So once we do that, we're holding the contract and it's ours to defend. I think that differentiates us. Regarding the question on biosimilars, I know -- we'll come back, I've missed one. But the questions on the biosimilars, while maybe that's not a primary strategy of Par's today, an area that we have focused in on -- and I'm not going to get too deep into it, but we are focusing on polypeptides. That is challenging chemistry. I think that's going to start to set us apart, and that's going to leverage our capabilities both on the internal R&D side, partnerships that we've established and taking advantage of the Rochester facility. And I apologize. I think I missed maybe your first question."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or would that require any kind of bolstering going forward?",29,"It was just on the R&D side on small molecules. Do you think you're appropriately funded right now? Or would that require any kind of bolstering going forward?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make pro",105,"So we are evaluating our capital allocation and putting some more resources behind generic R&D. So that's something that we are considering. And again, we'll communicate in the February time frame. What we are doing is focusing on those harder-to-make products, whether they're topicals, creams, ointments, ophthalmics, and things that may take smaller clinical trials. So that, to us, is an area that we have the skill set with our teams in place, and it's something that we're starting to do well. That, coupled with our Paragraph IV strategy, I think places us in a position to deliver higher-value generics on a go-forward basis."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from Greg Gilbert of Deutsche Bank.",10,"Our next question is from Greg Gilbert of Deutsche Bank."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics",61,"It's Greg Fraser on for Greg Gilbert. I think that you mentioned that you expect the Generics Base business to decline in the low 30% range for 2016. I just want to make sure that that's what you had said. And if so, what were pro forma sales for Generics Base in 2015 that, that erosion would be off of?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that.",32,"So what we said was our full year base erosion is now in the low 30s percentage. So that's what we've communicated. And just give us a second, we'll get you that."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes, the pro forma base business in 2015 is 17 52 [ph].",12,"Yes, the pro forma base business in 2015 is 17 52 [ph]."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?",24,"Great. That's helpful. Can you also give us a sense of how much contribution from generic launches is factored into the guidance for 4Q?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","For this year?",3,"For this year?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","I'm sorry. Can you repeat that question?",8,"I'm sorry. Can you repeat that question?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance.",24,"Yes. Just trying to get a sense of how much contribution from new generic launches in 4Q is factored into your full year guidance."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Well, we have Zetia and quetiapine. So have we given that number?",12,"Well, we have Zetia and quetiapine. So have we given that number?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","We gave it for the second half.",7,"We gave it for the second half."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that, that's sort of the midpoint.",38,"Yes. So that number stands. Sorry, Paul. The second half launches, there's a number we communicated before, which includes quetiapine and Zetia, and that's around $425 million. And there's a range around that, that's sort of the midpoint."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Okay. But the $425 million was the total.",8,"Okay. But the $425 million was the total."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","That's the total, all in, yes.",7,"That's the total, all in, yes."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?",40,"Okay. And just a couple quick ones. Did you book any sales for BELBUCA during the quarter? And on mesh, has your pretax cash call estimate for 2017, which I think was $550 million to $650 million, has that changed?"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So i",147,"Let me take the mesh question first. In terms of how we look at that for 2017. Let me just give you an update. So right now at the end of the quarter, we have $1.2 billion accrued from the balance sheet. We have about $300 million in restricted cash. So it leaves about $900 million of the liability still to be serviced. We would expect about $300 million to be paid in Q4, and then the balance of that to be paid in 2017 fairly evenly over the first 3 quarters of 2017. In terms of modeling any sort of cash benefit or shield around that, we recommended and continue to do that from a modeling standpoint to model our cash tax rate as a percentage of adjusted income at the enterprise level. And our guidance previously still stands, which is in the low single digits"
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And with regards to BELBUCA, we booked low single digit millions.",11,"And with regards to BELBUCA, we booked low single digit millions."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Our next question is from David Amsellem of Piper Jaffray.",10,"Our next question is from David Amsellem of Piper Jaffray."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smalle",91,"So just wanted to drill down on the potassium products and the opportunities there. And really specifically, a couple questions there is, how should we think about the size of the opportunity relative to Vasostrict? I know, Paul, that you said it's smaller. But what's the right way of thinking about it in terms of orders of magnitude, smaller? And then how should we think about the competitive dynamics of that product? Just trying to get a sense of how important that's going to be in terms of a 2017 contributor."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calc",374,"All right. So first of all, it is an important contributor for 2017. And I think the easier ones for you to understand is right now, there's 2 forms. There's a liquid form, and there's a powder form. The liquid form, you can easily go to IMS data and calculate the units there. We have, in essence, converted the entire market. Maybe you might say the entire market is probably in the very high 90s. So what I'm politely saying is that we've executed, and all the unapproved sources have been off the market for a couple of months. So that, to me, is running nicely. But there's no barrier to entry, so you just have to be aware that an ANDA can be filed. And that product has been approved since, I believe, around 2014. So you just got to make an assumption. At some point, a company that has liquid capabilities can enter the market. The powder is the one that probably has created the most questions because there's so many different forms of powder. And I think in terms of sizing that -- and I think it's safe to say that we -- it's probably easier for us to communicate the number of packets in the market, and then you can go back and do the math. In essence, this is an 18-million-pack market, right? And they're broken into 30s and 100s. I would tell you that's probably irrelevant. But for your math, go back, you're using 18 million packets, and then you can look at standard single-source-type generic pricing. While it's a 505(b)(2), I would make the assumption that it's a single-sourced, highly genericized-type product. That's the way I would think that you should look at the powder. Now having said that, there are still pull-through of unapproved sources. So the unapproved sources were asked to exit the market back in the June time frame, and I believe that they had 2 months to produce product and 3 months to sell through product. So there's going to be a period of time where it's probably going to take us to Q1 before we see that conversion. So I think those are your levers in order to calculate the powder opportunity."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Douglas Tsao of Barclays.",4,"Douglas Tsao of Barclays."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Analysts","So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retai",110,"So Paul, just curious. When you think about your expectations for Zetia and SEROQUEL, those launches, which are obviously very important for fourth quarter. If we just think about some of the generic conversions we've seen recently, brands have been retaining 60-plus percent until these products have gone multi-sourced. So just curious in terms of your confidence that those will pick up traction as much as you want. And then also, just if you could provide some comments. If I look at the IMS data, didn't really get much traction with the Crestor product launch. Just curious if you have any sort of perspectives on what might have happened there."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies f",296,"So Crestor is probably the easier one. I mean, I think there was about 11 approvals on, I would say, that second tranche. So I believe Actavis came in with maybe 5-week head start based upon a settlement agreement, and then about maybe 9 or 10 companies followed on. So the reality is that while it was a large product, it was -- there was an awful lot of competition. And we had a short burst, and at the end of the day, pricing fell to probably somewhere around 98.5% to 99% off of brand wagon. And again, that's an area that we don't want to compete. That was a decision that was made many, many years ago and the market dynamics changed in that regard. On quetiapine, quetiapine launch is behaving as we expected, so I feel pretty confident about that product on a go-forward basis. The product launch came out on November 1, and we've already taken on around 96%, 97% of the market in terms of signing on accounts. So it's behaving as we expected. In the case of Zetia, the reference that you're making in terms of brand retention, we've taken our -- what we believe is an appropriate approach to the fact that perhaps the brand could retain some percentage based upon maybe some PBM contracts. So that's been taken into consideration. I think what may be important is in this particular product, about 88% of the product is handled through the retail chains. I think that's an important factor. So we feel pretty good about how this product's going to behave, and we've taken in generic conversion in terms of what I think is appropriate. So I feel good about where Zetia will head. No guarantees, but I feel good."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks.",24,"And that concludes our Q&A session for today. I'd like to turn the call back over to Keri Mattox for any further remarks."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call.",20,"Thanks, Christy, and thank you all for joining us. I'll turn it over to Paul to close out the call."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Executives","And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today",63,"And thanks, Keri. I mean, as I said, this is really an important time for Endo. And we do appreciate your continued interest and support of the company, and we look forward to provide you with updates as we move forward. Thank you for joining us for today's call, and we will see you back at our February earnings call. Thank you all."
28071,405113130,1080903,"Endo International plc, Q3 2016 Earnings Call, Nov 08, 2016",2016-11-08,"Earnings Calls","Endo Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day."
